



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911



This is to certify that Ms. Anusha Mittal student of MBBS-II of Bharati Vidyapeeth University Medical College, Pune has been awarded the Short Term Studentship (STS) for a period of two months during 2019 under the guidance of Dr. Aarati B. Pokale for the project entitled, "Cervical cancer knowledge and human papilloma virus vaccination hesitancy in adolescent girls in Pune city- A quasi-experimental study" (Ref. No. 2019-03903) and the Report was found to be satisfactory.

Serving the nation since 1911

Dr. N.C Jain
Scientist G & Head, HRD
ICMR

Prof. (Dr.) Balram Bhargava
Secretary, Department of Health Research &
Director General, ICMR



Govt. of Maharashtra, Health Services
Jt. Director of Health Services (Leprosy & TB)

"AROGYA BHAVAN" Opp. Vishrantwadi Police Station,
 Alandi Road, Yerwada, Pune-411006.



Jt. Director - (020) 26686955
 Dy. Director - 26686951
 Office - 26686952-54
 Fax - 26686956



Section wise e-mail
 TB section- stomh@rntcp.org
 Lep section - jtlepnms@rediffmail.com
 Est section - jdhsest99@gmail.com

No. Jt. DHS/TB&L/ Desk- RNTCP/TB/ 16795-99 118
 Date 22/5/2018

To,
 The Dean
 Bharti Vidyapeeth University,
 Medical College,
 Pune

Sub:- Sanction of grant-in-aid for the Operational Research proposal under RNTCP.

Ref:- The State Operational Research Committee meeting held on 25th June, 2018 at Disha Hall, Parivartan Building, Arogya Bhavan, Pune.


The following Operational Research proposal submitted by the Principal Investigator (PI) of your institute was discussed in State Operational Research Committee Meeting held on 25th June, 2018 under RNTCP and it has been approved.

Sr. no	Name of the PI	Name of the Department & Medical College	Topic
Dr.	Dr. Prakash Doke, Professor,	Dept. of Community Medicine Bharti Vidyapeeth University Medical College, Pune	Death audit of registered tuberculosis patient in Pune MC area.

The Principal Investigator (PI) will sign a Memorandum of Undertaking (MOU) with the TB programme manager on behalf of the society for the release of funds. The MOU will include the objectives for which he will utilize the funds and the timeline for the study. It will also include the commitment from him to return the funds if the study cannot be taken up due to any reason, and other relevant causes. Funds will be released on the name of the institution of the Principal Investigator, so that the College / Department can ensure the completion of the study project / will return the funds in the event that the Principal Investigator is moved from the college during the course of the study.

A Grant-in-aid of **Rs. 1,99,500 (Rs. One Lac Ninety Nine Thousand Five Hundred only)** for the above OR proposal will be released under the "New FMR Code - 10.2.9 Research for Medical Colleges from RNTCP funds by CityTB Officer, Pune. 50% of the grant-in-aid will be

released initially and remaining 60% after receiving the report of data analysts and then released after receipt of the four hard copies of the final documents.


**Joint Director of Health Services
(Leprosy & TB) Pune**

Copy to –

1. The CTO Pune – To follow up with the respective medical college & Principal Investigator and release the grant-in-aid amount of Rs. 1,99,500 (Rs. One Lac Ninety Nine Thousand Five Hundred only) under the "FMR Code 10.2.9 Research for Medical Colleges from RNTCP funds as per the guidelines.

The additional budget of Rs. 1,99,500/- is sanctioned from state level approved PIP of Rs. 14.03 lac for the year 2019– 20.

2. Dr. Prakash Doke, Professor, Dept. of Community Medicine Bharti Vidyapeeth University Medical College, Pune
3. The RNTCP Medical Consultants by email – mhconsultants@rntcp.org
4. The OR Committee Members (All)

Copy with complements to –

Dr. Babaji Ghewade, Chairman State OR Committee, Maharashtra & Professor Respirator Medicine, Chief Medical Superintendent, Acharya Vinoba Bhave Rural Hospital and Jawaharlal Nehru Medical College, Wardha



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH

NIE
NATIONAL INSTITUTE OF
EPIDEMIOLOGY

ICMR - NATIONAL INSTITUTE OF EPIDEMIOLOGY

राष्ट्रीय जानपादिक रोग विज्ञान संस्थान

R-127, Second Main Road, Tamil Nadu Housing Board,
Ayapakkam, Chennai - 600 077, India

Phone: 91-44-26136204 / 26136201 / 26820469 (D)

Fax: +91-44-26820464 Website: www.nie.gov.in

directorne@dataone.in, director.nie@icmr.gov.in

manojmurhekar@nie.gov.in

Department of Health Research
Ministry of Health & Family Welfare
Government of India

Dr. Manoj Murhekar, M.D.
Director

NO.NIE/D/SNTBFC/21 **253**

1st February 2021

To

The Dean/ Principal/Director of Medical College/Institute _____

Sub: Participation by Community Medicine Department in verification of Sub-national claims for 'TB Free' status in India

Dear Sir/Madam,

Greetings from ICMR-NIE!

Government of India has resolved to end Tuberculosis (TB free) in India by 2025. To achieve that goal, the Ministry of Health & Family Welfare, Government of India has developed a sub-national TB free certification process. An important step in the sub-national TB free certification process is validation of claims of reduction in TB incidence at District/State/UT level.

As per the decision by Central TB Division, Govt. of India, National Institute of Epidemiology (NIE), ICMR has been identified as the independent verification agency for Sub-national certification of TB elimination efforts along with Indian Association of Preventive and Social Medicine (IAPSM) and World Health Organization (WHO). This year, TB free claims have been received from 67 districts, 1 state and 2 UTs.

Department of Community Medicine of your esteemed institute has been assigned this validation exercise along with other stakeholders in the district where the Medical College is located or the allotted nearby district (**list enclosed**). The faculties & PG students have to train field teams, undertake supervision of field work, verify secondary data, conduct qualitative interviews and submit a report. All expenditure will be borne out of the budget provided for this purpose by CTD to IAPSM.

You are requested to kindly consider the period of their engagement in the verification process in the month February & March 2021 as '**on duty**'.

Thank you and with regards,

Sincerely,

[Dr. Manoj Murhekar]

Copy to:

1. Professor and Head, Community Medicine, Medical College/Institute _____
2. Principal Investigator
3. District TB Officer

Copy for information to:

1. DDG (TB), CTD, MOHFW, Govt. of India Secretary, IAPSM
2. Secretary General, IAPSM
3. State Nodal Officer, IAPSM
4. State TB Officer

Enclosure: : List of identified Medical Colleges and assigned districts



WHO Collaborating Centre for Leprosy Research and Epidemiology

List of Districts and assigned Medical Colleges/Institutes for verification of Sub-national claims for 'TB Free' status in India

Sr	State	District	Medical College	Name	Contact	Email id
1	Madhya Pradesh	Betul	GMC, Bhopal	Dr. D.K. Pal	8962280240	paldkbpl@gmail.com
2	Madhya Pradesh	Sehore	GMC, Bhopal	Dr. Manju Toppo	9993113042	drmtoppo@gmail.com
3	Madhya Pradesh	Harda	Govt. Medical College Khandwa	Dr. Priyesh Marskole	9752325600	priyesh.marskole@gmail.com
4	Madhya Pradesh	Narsinghpur	NSCB Jabalpur	Dr. Prashant Verma	9827322824	drprashantv08@gmail.com
5	Madhya Pradesh	Umaria	NSCB Jabalpur	Dr. Neelam Toppo	9981598198	neelam.philips2011@gmail.com
6	Madhya Pradesh	Alirazpur	R.D. Gardi Medical College Ujjain	Dr. Dinesh Bhatnagar	7665851573	hodcm.rdgmc@gmail.com
7	Mizoram	Mamit	Zoram Medocal College, Falkawn	Dr Manoj B Patki	9920473981	drmbpatki@yahoo.co.in
				Dr Vanlalduhsaki	9862931101	vanlalduhsaki07@gmail.com
				Dr Andrew Lallawmzuala	6909488322	andrewlallawmzuala@gmail.com
8	Meghalaya	Jaintia	North Eastern Indira Gandhi Regional Institute of Health & Medical Sciences (NEIGRIHMS), Shillong Meghalaya	Dr Rikrak Ch Marak	8415930096	rikrakmarak.07@gmail.com
9	Meghalaya	EKH	North Eastern Indira Gandhi Regional Institute of Health & Medical Sciences (NEIGRIHMS), Shillong Meghalaya	Dr Ningombam Joenna Devi	7005622883	ningjoenna@gmail.com
10	Meghalaya	WKH	North Eastern Indira Gandhi Regional Institute of Health & Medical Sciences (NEIGRIHMS), Shillong Meghalaya	Dr Markordor Lyngdoh	9774668924	marsangriang@gmail.com
11	Lakshadweep	Lakshadweep	Amrita Institute of Medical Sciences, Kochi	Dr.Aswathy	9447294260	draswathygopan@gmail.com

List of Districts and assigned Medical College/Institute for verification of sub-national claims for 'TB free' status in India

			Amrita Institute of Medical Sciences, Kochi	Dr.Gayathri A V	8281733797	gayathriav88@gmail.com
12	Telangana	Khammam	Mamata Medical College, Khammam	Dr Nithesh	99855 31172	ramyanithesh@gmail.com
13	Telangana	Bhadadri Kothagudam	Mamata Medical College, Khammam			
14	Telangana	Nizamabad	Government Medical College, Siddipet	Dr Goutham	8825626482	thumatigoutham@gmail.com
15	Telangana	Kamareddy	Government Medical College, Siddipet	Dr Srinivas Gundala	9866870803	srini_25867@yahoo.co.in
				Dr Mamta	8826075160	drmamtagehlawat@gmail.com
16	Tamil Nadu	Thiruvannamalai	Tiruvannamalai MC	Dr Venkat	98945 97687	drvenkat90021@gmail.com
17	Arunachal Pradesh	Tirap	Tomo Riba Institute of Health & Medical Sciences, Naharlagun	Dr Debarshi Paul	9954526895	debarshipaul@gmail.com
18	Arunachal Pradesh	East Kameng	Tomo Riba Institute of Health & Medical Sciences, Naharlagun	Dr Anoop Dev	6901260770	dev_anoop@rediffmail.com
19	Arunachal Pradesh	East Siang	Tomo Riba Institute of Health & Medical Sciences, Naharlagun	Dr Pallavi Boro	9654817069/9	boropallavi@gmail.com
20	Arunachal Pradesh	West Siang	Tomo Riba Institute of Health & Medical Sciences, Naharlagun	Dr Amrita Sarkar	7002129302	dr.amrita.cm@gmail.com
21	Andhra Pradesh	Vizianagaram	Maharaja Institute of Medical Sciences	Dr Bikash Chandra Nayak Assistant Professor	8917331556	drbikash2013@gmail.com
				Dr D CH S VARA PRASAD RAO	9490950507	chandrashekarvaraprasadrao@gmail.com
22	Andhra Pradesh	Srikakulam	Government Medical College (RIMS)	Dr B Nagendra Naidu	9849846360	drnagnaidu@yahoo.co.in
23	Nagaland	Kiphire	Jorhat Medical College Assam	Dr.Bishnu Ram Das	9435020324	drbishnu07@yahoo.co.in

List of Districts and assigned Medical College/Institute for verification of sub-national claims for 'TB free' status in India

24	DNH & D&D	Dadra Nagar Haveli	NAMO Medical Education and Research Institute, Silvaasa	DR. Bhavesh Bariya	9537511598	baryabhavesh7@gmail.com
25	DNH & D&D	Daman	NAMO Medical Education and Research Institute, Silvaasa	Dr Paras Mehta	8460853214	drparasmehta7890@gmail.com
26	DNH & D&D	Diu	GMERS Medical College Junagadh	Dr.Jatin Chhaya	9978998810	dr.jatinchhaya@gmail.com
27	Odisha	Sonapur	Bhima Bhoi Medical College, Balangir	Dr Satyajit Sundar Ray	9861339499	dr.ssray@gmail.com
				Dr Gurukrushna Mohapatra	9861359857	gurukrushna@gmail.com
28	Odisha	Dhenkanal	Hi Tech Medical College, Bhubaneshwar	Dr. Lisa Sarangi	9437165488	sarangilisa@gmail.com
29	Gujarat	The Dangs	GMERS Medical College, Valsad	Dr. Ravikant Patel	9925046199	drravi909@yahoo.com
			GMERS Medical College, Valsad	Dr. Hinal Baria	9228895045	drbariag@gmail.com
30	Gujarat	Devbhumi Dwarka	M.P. Shah Medical College, Jamnagar	Dr Mithun Sanghavi	9428125190	drmmsanghavi@rediffmail.com
			M.P. Shah Medical College, Jamnagar	Dr Karansinh Sodha	8377995178	karansinh.s18@gmail.com
31	Gujarat	Porbandar	M.P. Shah Medical College, Jamnagar	Dr Rohit Ram	9099925720	rohit.ram84@yahoo.com
			M.P. Shah Medical College, Jamnagar	Dr Pradeep Pithadia	9909602670	pradeep280683@gmail.com
32	Gujarat	Botad	Government Medical College, Bhavnagar	Dr Ghanshyam Ahir	9687604104	ghanshyamahir@gmail.com
33	Gujarat	Mehsana	GMERS Medical College, Vadnagar	Dr Nilesh Thakor	9979846971	drnileshthakor@gmail.com
34	Gujarat	Rajkot	PDU Medical College, Rajkot	Dr Anupam Banerjee	9426783774	dranupamb@rediffmail.com
35	Jharkhand	Pashchimi Singhbhum				
36	Jharkhand	Dumka	P.J. Medical College, Dumka	Dr. Surinder Singh	7004147545	surendra.109@gmail.com

List of Districts and assigned Medical College/Institute for verification of sub-national claims for 'TB free' status in India

37	Jharkhand	Saraikela-Kharsawan	Manipal Tata Medical College, Jamshedpur	Dr. Ratnesh	9934115236	ratnesh2806@gmail.com
38	Jharkhand	Palamu	Palamu Medical College	Dr. Dilip Kumar	7488526734	dilipmyself09@gmail.com
39	Puducherry	Puducherry	Govt. Indira Gandhi Medical College & Research Institute (IGMC&RI)	Dr. Ananaraj R.	8105804642	anand2469@gmail.com
				Dr Vijay Chavada	9095316465	drchavada2000@gmail.com
40	Himachal Pradesh	Lahul-Spiti	IG Medical College SHIMLA	Dr. Anupam Parashar	9418035278	anupamvikrant@yahoo.co.in
41	Himachal Pradesh	Kinnaur	IG Medical College SHIMLA	Dr. Anmol Gupta	9418020160	dranmol1964@gmail.com
42	Himachal Pradesh	Kangra	Dr. RPGMC Tanda, Kangra	Dr. Sunil Raina	9418061066	ojarainasunil@yahoo.co.in
43	Himachal Pradesh	Una	Dr. RKGMC Hamirpur	Dr. Devender Kumar	9816334394	dev10121986@gmail.com
44	Himachal Pradesh	Hamirpur	Dr. RKGMC Hamirpur	Dr. Abhilash Sood	9418076890	abhilashsood@gmail.com
45	West Bengal	Nadia	AIIMS, Kalyani	Dr Ritesh Singh	9836444242	drriteshsingh@yahoo.com
				Dr Gandhari Basu	9007830561	gandhari.basu@gmail.com
46	West Bengal	Purba Medinipur	NRS Medical College, Kolkata	Dr. Chandra Shekhar Maity	9830838879	csmaity@gmail.com
				Dr. Niladri Shekhar Pal		niladrirockyfisher@gmail.com
47	Maharashtra	Kolhapur	Bharati Vidyapeeth Deemed to be University Medical College and Hospital, Sangli	Dr.Sanjay R. Quraishi	9822523362	sanjay4165@gmail.com
				Dr.Randhir V.Dhobale	9422396623	dr.randhirdhobale@gmail.com
48	Maharashtra	Nashik	Dr. Vasantrao Pawar Medical College Hospital and Research Centre, Nasik	Dr Sunil Panigrahi	8424017937	sunil1986panigrahi@gmail.com
				Dr Syed Meraj Ahmed	8056028572	merajahmed10@hotmail.com

List of Districts and assigned Medical College/Institute for verification of sub-national claims for 'TB free' status in India

49	Maharashtra	Ratnagiri	BKL Walawalkar Rural Medical College, Sawarde, Ratnagiri	Dr.R.P. Chauhan	7020609696	chauhanrambadan@gmail.com
50	Maharashtra	Satara	Bharati Vidyapeeth Deemed to be University Medical College and Hospital, Pune	Dr.Jayashree Gothankar	9423037645	jayashree.gothankar@bharativedyapeeth.edu, jayashreesg@rediffmail.com
				Dr Tejal Paratwar	9423953083	tejalnp14@gmail.com
51	Maharashtra	Sindhudurg	BKL Walawalkar Rural Medical College, Sawarde, Ratnagiri	Dr.R.P. Chauhan	7020609696	chauhanrambadan@gmail.com
52	Maharashtra	Bhiwandi Nizampur	Rajiv Gandhi Medical College, Kalwa, Thane	Dr.Swapnali S. Kadam	9820959095	faimerssk1@gmail.com
53	Maharashtra	Centenary	Lokmanya Tilak Medical College, Mumbai	Dr. Dasi Rao	9833348943	dhrao_2000@yahoo.com
54	Maharashtra	Ghatkopar	Lokmanya Tilak Medical College, Mumbai	Dr. Pallavi Shelke	8356945770	drpallavis@gmail.com
55	Maharashtra	Grant Road	National Institute of Public Health Training and Research, Mumbai	Dr.Sudhir Wanje	9920750333	swanje@rediffmail.com
56	Maharashtra	Parel	Grant Medical College, Mumbai	Dr.Lalit Sankhe	9820513651	lalit.sankhe@gmail.com
57	Maharashtra	Prabhadevi	Grant Medical College, Mumbai	Dr.Pallavi Uplap	9757017082	pallaviuplap@gmail.com
58	Punjab	Fatehgarh Sahib	DMCH, Ludhiana	Dr. Mahesh Satija	9876123916	maheshsatija@yahoo.com
59	Punjab	Kapurthala	GMC Amritsar	Dr Jasleen kaur	8146333011	drjasleen89@gmail.com
60	Punjab	Nawanshahr	DMCH, Ludhiana	Dr. Sarit Sharma	9815598162	sarit_sharma@yahoo.com
61	Tripura	North Tripura	Agartala Government Medical College, Tripura	Dr Chanda Mog	9436927950	drchandamog@gmail.com
62	Tripura	Dhalai	Agartala Government Medical College, Tripura	Dr Amar Tripura	7005565873	amartripura@ymail.com
63	Tripura	South Tripura	Agartala Government Medical College, Tripura	Dr Rituparna Das	8794030424	drrituparnad@gmail.com
64	Tripura	West Tripura	Agartala Government Medical College, Tripura	Dr Shampa Das	9436501217	drshampa777@gmail.com

List of Districts and assigned Medical College/Institute for verification of sub-national claims for 'TB free'status in India

65	Rajasthan	Bhilwara	RVRS Government Medical College, Bhilwara	Dr Mahesh Choudhary	8005799645	drmahesh2711@gmail.com
				Dr Sandeep Upadhyay	7597346403	u_sandeepkumar@yahoo.com
66	Rajasthan	Rajsamand	Ananta institute of medical sciences	Dr Mitin Parmar	800119207	mitin3112@gmail.com
				Dr Kalika Gupta	9868677619	kalikagupta007@gmail.com
67	Jammu	Kathua	GMC Kathua	Dr. Yangchen Dolma	7780823508	yangchendolma12@gmail.com
68	Jammu	Udhampur	GMC Jammu	Dr Rakesh Bahl	9419192166	rbrakeshbahl@gmail.com
69	Kashmir	Budgam	GMC Srinagar	Dr. S Mohammad Salim Khan	9419013699	smsalimkhan@gmail.com
70	Kerala	Kollam	GMC, Kollam	Dr. Zinia Nujum	7907862136	drzinia@gmail.com
71	Kerala	Ernakulam	Amrita Institute of Medical Sciences, Kochi	Dr.Aswathy	9447294260	draswathygopan@gmail.com
			Amrita Institute of Medical Sciences, Kochi	Dr.Gayathri A V	8281733797	gayathriav88@gmail.com
72	Kerala	Malappuram	MES Medical College, Perinthalmanna	Dr. Sheela P Haveri	8618629403	sheelaish@gmail.com
73	Kerala	Kasargod	GMC Kasargod	Dr Arun Bhat	9447062117	arunnbhatt.ch@gmail.com

CLINICAL STUDY AGREEMENT

among

Syneos Health UK Limited

and

Dr Vijay Raghunath Kalrao

and

Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital

Pfizer Protocol # C3591025

This Clinical Study Agreement (“Agreement”) among

Syneos Health UK Limited, with a place of business at Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire GU14 7BF United Kingdom and its clinical affiliates including but not limited to **inVentiv International Pharma Services Private Ltd.** Located at 3rd Floor, Tower A, The Presidency Towers, 46/4, MG Road, Sector – 14, Gurgaon – 122001, India (“CRO”)

and

Dr Vijay Raghunath Kalrao, with a place of business at Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, Department of Pediatrics Pune-Satara Road, Dhankawadi, Katraj, Pune-411043, Maharashtra, India
(“Principal Investigator”),

Pfizer 101258/18PFZ0017 C3591025 IND Tri Partite CSA
[Dr Vijay Raghunath Kalrao] [Bharati Vidyapeeth (Deemed to be University)
Medical College & Hospital Pune] [Site #1069]

Confidential

and

Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, with a place of business at Pune-Satara Road, Dhankawadi, Katraj, Pune-411043, Maharashtra, India ("**Institution**"),

when signed by all parties, is effective as of 01 Jun 2020.

Pfizer Inc. ("Pfizer") wishes to sponsor a clinical study trial/entitled "A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME-AVIBACTAM (CAS-AVI) IN CHILDREN FROM 3 MONTHS TO LESS THAN 18 YEARS OF AGE WHO ARE HOSPITALIZED AND RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR SUSPECTED OR CONFIRMED NOSOCOMIAL PNEUMONIA, INCLUDING VENTILATOR-ASSOCIATED PNEUMONIA" ("**Study**") to be conducted by Principal Investigator at Institution under the Pfizer protocol identified above ("**Protocol**"). Pfizer has delegated responsibility for management of this Study, including contracting and Study monitoring, to CRO, and has authorized CRO to bind Pfizer to all commitments within this Agreement identified as belonging to Pfizer.

The Principal Investigator as a signatory/confirming party to this Agreement acknowledges the liabilities and obligations as an 'investigator' under the provisions of the New Drugs and Clinical Trials Rules, 2019 ("**Rules**"). The parties agree as follows:

1. Responsibilities


1.1 Investigators and Research Staff. The Study will be conducted by Principal Investigator, namely **Dr Vijay Raghunath Kalrao** ("**Principal Investigator**") at a facility that is identified as a 'clinical trial site' under the Rules. Principal Investigator is not an employee of Institution. Principal Investigator is authorized by Institution to conduct the Study at Institution under a separate agreement between Principal Investigator and Institution. Principal Investigator will ensure that only individuals who are appropriately trained, experienced and qualified assist in the conduct of the Study as investigators, sub-investigators or research staff. The Principal Investigator shall sign an undertaking in the form prescribed in **Table 4** of the **Third Schedule** of the Rules.


1.2 Compliance Obligations. Principal Investigator and Institution are responsible to CRO and Pfizer for compliance by all Study personnel with the terms of this Agreement, the Protocol, the applicable provisions of the Drugs and Cosmetics Act, 1940 ("**Act**"), the Rules, and International Conference on Harmonization Good Clinical Practice ("**ICH GCP**") guidelines, ethical guidelines for Biomedical Research on Human Participants issued by the Indian Council of Medical Research, as well as applicable law, regulations, and governmental guidance, including without limitation, the laws of the Republic of India. The Institution and CRO shall be jointly responsible for obtaining requisite permissions and approvals for the conduct of the Study in terms of applicable laws, including permission from the Central Licensing Authority. The Institution also undertakes to abide by and

Agreed to and Accepted by:

Syenos Health UK Limited

Dr Vijay Raghunath Kalrao






Printed Name: John Michael Dominic Go

Date: 23 JUL 2020

Title: Associate Director, Site Start Up & Regulatory

Date: 20 Jul 2020

Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital


~~PRINCIPAL~~
Bharati Vidyapeeth
(Deemed to be University)
Medical College

Printed Name : (Brng.) Dr Narayanan Subramanian Mani
Pune - 411 043.

Title: Principal, Bharati Vidyapeeth (DTU) Medical College & Hospital

Date: 28 July 2020

Attachments

- Attachment A Study Budget and Payment Terms
- Attachment B Indemnification and Research Injury Policy
- Attachment C Equipment and Materials
- Attachment D Pfizer International Anti-Bribery and Anti-Corruption Principles

Pfizer 1012858/18PFZ0017 C3591025 IND Tri Partite CSA
[Dr Vijay Raghunath Kalrao] [Bharati Vidyapeeth (Deemed to be University)
Medical College & Hospital Pune] [Site #1069]

Confidential



Exhibit 1 to Attachment A Study Budget

SPONSOR		INVESTIGATOR									
Pfizer Inc.		Dr. Vijay Raghunath Kalrao									
Pfizer Inc. India		Bharati Vidyapeeth Medical College and Hospital									
Pfizer Inc. India		Pune									
Pfizer Inc. India		Vidya									
STUDY NUMBER		PROTOCOL NUMBER									
P18017		P18017									
TITLE		PROTOCOL TITLE									
P18017		P18017									
COUNTRY/CURRENCY		COUNTRY/CURRENCY									
INDIA / INR		INDIA / INR									
OVERHEAD		OVERHEAD									
30.00%		30.00%									
DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total No. of times a procedure may occur	Total PSC	Total Visit	Screening Day 1 to 1	Baseline IV infusion Day 1	84 Hour Assessment Day 3	48 Hour Assessment Day 3	Late Follow Up Day 28-35 Telephone Contact
Per Subject Cost											
Informed Consent	Includes informed consent	3,741.48	1.0	1.0	3,741.48	3,741.48	3,741.48	0.00	0.00	0.00	0.00
Physical Examination	Includes Physical Examination	3,736.02	2.0	2.0	7,472.04	7,472.04	7,472.04	0.00	0.00	3,736.02	0.00
Hematology	Includes Hematology	1,457.19	1.0	1.0	1,457.19	1,457.19	1,457.19	0.00	0.00	1,457.19	0.00
Urea Nitrogen	Includes Urea Nitrogen	278.18	1.0	1.0	278.18	278.18	278.18	0.00	0.00	278.18	0.00
CAZ-AVI Administration	Administration should be via either an appropriately sized sterile syringe and subcutaneous injection or by infusion bag and subcutaneous IV pump.	4,562.00	1.0	1.0	4,562.00	4,562.00	0.00	4,562.00	0.00	0.00	0.00
CAZ-AVI preparation	Includes CAZ-AVI preparation	1,930.02	1.0	1.0	1,930.02	1,930.02	0.00	1,930.02	0.00	0.00	0.00
Study Coordinator (hourly)	Includes Study Coordinator, Height, Weight, BMI if applicable, Vital Signs, Oxygen Saturation (if available), Adverse Events and Serious Adverse Events (if any), Contraception Procedures (if any), Contraception Check, Prior/Concomitant Treatment, Organ Results of Chest x-ray, CT Scan or other imaging tests.	1,777.26	0.5	0.5	11,552.19	11,552.19	5,331.78	1,777.26	1,777.26	1,777.26	0.50
Admin Data Entry	Includes Admin Data Entry	1,509.42	4.0	4.0	6,037.68	6,037.68	3,158.94	1,509.42	1,509.42	1,509.42	0.50
	PSC Subtotal w/out Overhead	37,791.29			37,791.29	37,791.29	16,000.02	9,058.09	2,676.07	8,447.97	1,688.34
	PSC Subtotal with Overhead	48,349.56			48,349.56	48,349.56	19,210.82	10,882.79	3,092.36	10,137.56	2,026.01
Additional Treatment Related Costs											
Additional Procedures that may not apply to all Patients	Includes consent, Spanish consent and assent as appropriate must be obtained for collection of BAL fluid for CAZ-AVI analysis.	2,269.74	1.0	1.0	2,269.74	2,269.74	0.00	2,269.74	0.00	0.00	0.00
Informed Consent	Includes consent	2,269.74	1.0	1.0	2,269.74	2,269.74	0.00	2,269.74	0.00	0.00	0.00
Hematology	Includes Hematology	584.62	1.0	1.0	584.62	584.62	584.62	0.00	0.00	0.00	0.00
Blood Chemistry	Includes Blood Chemistry	1,271.10	1.0	1.0	1,271.10	1,271.10	1,271.10	0.00	0.00	0.00	0.00
Urea Nitrogen	Includes Urea Nitrogen	278.18	1.0	1.0	278.18	278.18	278.18	0.00	0.00	0.00	0.00
Serum Pregnancy Test	Includes Serum Pregnancy Test	1,395.00	2.0	2.0	2,790.00	2,790.00	1,395.00	1,395.00	0.00	0.00	0.00
FOCBP	Includes FOCBP	343.00	2.0	2.0	686.00	686.00	343.00	343.00	0.00	0.00	0.00
Hematology Test	Includes Hematology Test	584.62	1.0	1.0	584.62	584.62	584.62	0.00	0.00	0.00	0.00
Blood Chemistry	Includes Blood Chemistry	1,271.10	1.0	1.0	1,271.10	1,271.10	1,271.10	0.00	0.00	0.00	0.00
Urea Nitrogen	Includes Urea Nitrogen	278.18	1.0	1.0	278.18	278.18	278.18	0.00	0.00	0.00	0.00
Sample Collection	Includes Sample Collection	737.58	1.0	1.0	737.58	737.58	0.00	737.58	0.00	0.00	0.00
PK Samples Cohort 1	All PK draws are applicable only 1 PK draw after CAZ-AVI infusion may be performed during the time of CAZ-AVI infusion.	737.58	7.0	7.0	5,163.06	5,163.06	0.00	5,163.06	0.00	0.00	0.00
PK Samples Cohort 2	All PK draws are applicable only 1 PK draw after CAZ-AVI infusion may be performed during the time of CAZ-AVI infusion.	737.58	6.0	6.0	4,425.48	4,425.48	0.00	4,425.48	0.00	0.00	0.00
PK Samples Cohorts 3 and 4	All PK draws are applicable only 1 PK draw after CAZ-AVI infusion may be performed during the time of CAZ-AVI infusion.	737.58	4.0	4.0	2,950.32	2,950.32	0.00	2,950.32	0.00	0.00	0.00
Processing BAL sample	Includes Processing BAL sample	5,470.98	1.0	1.0	5,470.98	5,470.98	0.00	5,470.98	0.00	0.00	0.00
Per Subject Cost Subtotal		37,791.29			37,791.29	37,791.29	16,000.02	9,058.09	2,676.07	8,447.97	1,688.34
Additional Cost Subtotal		66,473.81			66,473.81	66,473.81	28,692.52	19,041.70	30,086.15	2,676.07	1,688.34
Overhead		13,234.70			13,234.70	13,234.70	5,286.60	3,158.94	3,017.23	2,808.13	537.97
Total PSC		79,766.57			79,766.57	79,766.57	34,419.02	23,810.04	3,092.36	14,730.78	2,026.01

Other Study Level Costs	Procedure	Comments	Cost
	Local IRB/EC Fee - Initial Review	To be paid directly	
	Local IRB/EC Fee - Amendment	To be paid directly	
	Local IRB/EC Fee - Annual Review	To be paid directly	
	Pharmacy start-up fee		30,076.00
	Admin start-up fee		30,000.00
	Screen Fails	Applicable to subjects who BF at Visit 1. Max 4 SFs per site.	12,000.77
	Unscheduled visit	Reimbursed for actual procedures performed.	34,193.02
	Travel Allowance For Caregiver/Guardian	For Caregiver travel expenses for follow up visit. Budget 1 per 100% of subjects. Reimbursed for each site visit by paying the amount of INR 1000.00 OR amount of up to INR 3500.00 on submitting the actual receipt of the expenses.	Up to 3500.00



BHARATI VIDYAPEETH
(DEEMED TO BE UNIVERSITY)
MEDICAL COLLEGE & HOSPITAL, PUNE
Department of Pediatrics
Pediatric Research Cell

Pune-Satara Road, Dhankawadi, Pune - 411 043.
Phone : +91 20 24364308, Fax - +91 20 24375541
email - researchpedpune@gmail.com



Date: 8 June 2021

To,

The Chairman
Institutional Ethics Committee

Subject: Notification to Ethics Committee for Site Close-out for the E2007-G00-338 study

Protocol Number: E2007-G000-338

Protocol Title: "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial with an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age with Inadequately Controlled Seizures Associated with Lennox-Gastaut Syndrome"

Dear Sir,

Please be informed that the "Site Close-out Visit" (SCV) for the above referenced study was performed on 07 June 2021 at Bharati Hospital, Pune.

We can confirm that there are no active screened or randomized patients pertaining to the study at our site.

We request you to acknowledge the receipt of the document and provide the acknowledgment copy of the same at the earliest.

Thanking you,

Principal Investigator

DR. KAVITA SRIVASTAVA





BHARATI VIDYAPEETH
(DEEMED TO BE UNIVERSITY)
MEDICAL COLLEGE & HOSPITAL, PUNE
Department of Pediatrics
Pediatric Research Cell

Pune-Satara Road, Dhankawadi, Pune - 411 043.
Phone : +91 20 24364308, Fax - +91 20 24375541
email - researchpedpune@gmail.com



Date: 09 April 2021

To,

The Chairman
Institutional Ethics Committee
Bharati Vidyapeeth (Deemed to be University) Medical College
Pune

Ref: **Protocol Title:** "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial with an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age with Inadequately Controlled Seizures Associated with Lennox-Gastaut Syndrome"

Trial Code: E2007-G000-338

Subject: Notification to Ethics Committee for discontinuation of the E2007-G00-338 study

Dear Sir,

Please be informed that the Sponsor has taken decision to discontinue the E2007-G00-338 study. The Sponsor letter received for the study discontinuation has been enclosed herewith.

We had screened 1 patient on 01 Feb 2021 for this study, however, the patient was not randomized. Based on the sponsor decision, the patient has been termed as screened failure and discontinued from the study.

We can confirm that there are no active screened or randomized patients pertaining to the study at our site.

We request you to acknowledge the receipt of the document and provide the acknowledgment copy of the same at the earliest.

Thanking you,

Dr. Kavita Srivastava
Principal Investigator,
Bharati Hospital, Pune.



Received

12/04/2021.



March 30, 2021

Dear Investigator,

Re: E2007-G000-338 Suspension of Recruitment Activities

Protocol Title: "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial with an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age with Inadequately Controlled Seizures Associated with Lennox-Gastaut Syndrome"

We are writing to inform you that, regretfully, Eisai has taken the decision to discontinue the perampanel Phase 3 LGS study. Since study initiation in 2016, patient recruitment into this study has been challenging which is further impacted by the COVID-19 pandemic in the past year. This study discontinuation is not because of any safety concerns.

The last subject last visit date for the study is targeted to be 31 July 2021.

(Note: Please schedule the patient's study completion/early termination visit to take place by 23 July 2021 in order to allow for ~1 week of window shall unforeseen events require postponement of the last visit but no later than 31 July 2021.)

We understand that some of the study sites still have patients ongoing in the study. Please keep the following into consideration as you are making arrangements with the patients and their caregivers to schedule their remaining study visit(s):

- Patients currently in the Core Study can continue through the end of Core Study. If deemed by the investigator to be necessary, these patients will be allowed to enter Extension A (blinded conversion period only) provided the subject's last visit will be scheduled to take place by 23 July 2021 (and in any event no later than 31 July 2021 as detailed above).
- Patients currently in the Extension A or Extension B can continue in their respective extension phase; however, all patients should have their last study visit scheduled to take place by 23 July 2021 (and in any event no later than 31 July 2021 as detailed above).

In the coming days, your PPD CRA will be reaching to you with more detailed information about close out activities. Meanwhile, if you have any questions, please do not hesitate to contact your PPD CRA or Eisai's Study Director.

Yours Sincerely,

Stella Ngo, PhD
International Project Team Lead and Clinical
Lead for Fycompa
Neurology Business Unit
Eisai Inc.
Email: stella_ngo@eisai.com
Phone: +1-201-466-7398

Gleb Filippov, MD, PhD
Study Director and Medical Monitor for E2007-
G000-338
Neurology Business Unit
Eisai Inc.
Email: Gleb_Filippov@eisai.com
Phone: +1-551-264-6334

INSTITUTIONAL ETHICS COMMITTEE

BHARATI VIDYAPEETH DEEMED UNIVERSITY

Bharati Hospital & Research Centre, Pune-Satara Road, Dhankawadi, Pune 411043

Tel: 020 405555 55, Ext 265, Email: bvduiec@gmail.com

DCGI Regd. No. ECR/313/Inst/MH/2013/RR-19

NABH Accreditation No. EC-CT-2018-0016

IEC/2020/59

Date: 20 Jul 2020

To,

Dr. Kavita Srivastava,

Principal Investigator,

Professor, Pediatric Epilepsy & Neurology Unit,

Department of Pediatrics,

Bharati Vidyapeeth (Deemed to be University) Medical College,

Ref: **Protocol Title:** A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Trial Code: E2007-G000-338

Sub: Institutional Ethics Committee (IEC) **Approval** for conduct of the above referred study and study related documents.

Dear Dr. Srivastava,

The above referred study, submitted vide letter dated 05 Jun 2020 was reviewed and discussed in Institutional Ethics Committee meeting held on 08 Jul 2020, at 02:30 pm in the Conference Hall, ground floor, Bharati Vidyapeeth (Deemed To Be University) Medical College, Pune.

Following documents were submitted for review:

Sr. No.	Document/Language	Document Details/Versions
1.	Protocol No: E2007-G000-338	Version :1.0, Amendment 05, Version Date: 19 Nov 2018
2.	DCGI Submission Acknowledgment Letter	Dated 11 Mar 2020
3.	Investigator's Brochure	Investigator's Brochure Edition 19 Dated 26-Sep-2019
4.	Investigator's Brochure Addendum	Edition 19, Addendum 01, v1.0 dated 20 Jan 2020 Edition 19, Addendum 02, v1.0 dated 22 Apr 2020

5.	Insurance Certificate	Policy Period: Jan 28, 2020 to Jan 27, 2023 Policy No. 4067/192802706/00/000
6.	CRF Template	Dated March 5, 2019
7.	Draft CTA & Budget	NA
8.	English Adult ICF	India English Adult ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava
9.	Hindi Adult ICF	India Hindi Adult ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
10.	Hindi to English Adult ICF	India Hindi to English Adult ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
11.	Marathi Adult ICF	India Marathi Adult ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020
12.	Marathi to English Adult ICF	India Marathi to English Adult ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020
13.	English Parental ICF	India English Parental ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava
14.	Hindi Parental ICF	India Hindi Parental ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
15.	Hindi to English Parental ICF	India Hindi to English Parental ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
16.	Marathi Parental ICF	India Marathi Parental ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020
17.	Marathi to English Parental ICF	India Marathi to English Parental ICF v6.1.0_11 Mar 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020
18.	English Assent form Age 7-9 ICF	India English Assent 7-9 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava
19.	Hindi Assent form Age 7-9 ICF	India Hindi Assent 7-9 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
20.	Hindi to English Assent form Age 7-9 ICF	India Hindi to English Assent 7-9 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
21.	Marathi Assent form Age 7-9 ICF	India Marathi Assent 7-9 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020

22.	Marathi to English Assent form Age 7-9 ICF	India Marathi to English Assent 7-9 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020
23.	English Assent form Age 10-11 ICF	India English Assent 10-11 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava
24.	Hindi Assent form Age 10-11 ICF	India Hindi Assent 10-11 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01Jun2020
25.	Hindi to English Assent form Age 10-11 ICF	India Hindi to English Assent 10-11 ICF v4.1.0_18 Feb2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
26.	Marathi Assent form Age 10-11 ICF	India Marathi Assent 10-11 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020
27.	Marathi to English Assent form Age 10-11 ICF	India Marathi to English Assent 10-11 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020
28.	English Assent form Age 12-15 ICF	India English Assent 12-15 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava
29.	Hindi Assent form Age 12-15 ICF	India Hindi Assent 12-15 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
30.	Hindi to English Assent form Age 12-15 ICF	India Hindi to English Assent 12-15 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
31.	Marathi Assent form Age 12-15 ICF	India Marathi Assent 12-15 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020
32.	Marathi to English Assent form Age 12-15 ICF	India Marathi to English Assent 12-15 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020
33.	English Assent form Age 16-17 ICF	India English Assent 16-17 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava
34.	Hindi Assent form Age 16-17 ICF	India Hindi Assent 16-17 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
35.	Hindi to English Assent form Age 16-17 ICF	India Hindi to English Assent 16-17 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
36.	Marathi Assent form Age 16-17 ICF	India Marathi Assent 16-17 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020
37.	Marathi to English Assent form Age 16-17 ICF	India Marathi to English Assent 16-17 ICF v4.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020

38.	English Adult PG ICF	India English Adult PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava
39.	Hindi Adult PG ICF	India Hindi Adult PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
40.	Hindi to English Adult PG ICF	India Hindi to English Adult PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
41.	Marathi Adult PG ICF	India Marathi Adult PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020
42.	Marathi to English Adult PG ICF	India Marathi to English Adult PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020
43.	English Parental PG ICF	India English Parental PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava
44.	Hindi Parental PG ICF	India Hindi Parental PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
45.	Hindi to English Parental PG ICF	India Hindi to English Parental PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
46.	Marathi Parental PG ICF	India Marathi Parental PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020
47.	Marathi to English Parental PG ICF	India Marathi to English Parental PG ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020
48.	English Consent form for Audio Video Recording	India English AV ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava
49.	Hindi Consent form for Audio Video Recording	India Hindi AV ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
50.	Hindi to English Consent form for Audio Video Recording	India Hindi to English AV ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 01 Jun 2020
51.	Marathi Consent form for Audio Video Recording	India Marathi AV ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 12 May 2020
52.	Marathi to English Consent form for Audio Video Recording	India Marathi to English AV ICF v1.1.0_18 Feb 2020_Dr Kavita Srivastava Translation Certificate dated 02 Jun 2020
53.	English Patient Card	v1.0.0 dated 20 Nov 2019
54.	Hindi Patient Card	v1.0.0 dated 20 Nov 2019 Translation Certificate dated 29 Nov 2019

55.	Hindi to English Patient Card	v1.0.0 dated 20 Nov 2019 Translation Certificate dated 29 Nov 2019
56.	Marathi Patient Card	v1.0.0 dated 20 Nov 2019 Translation Certificate dated 29 Nov 2019
57.	Marathi to English Patient Card	v1.0.0 dated 20 Nov 2019 Translation Certificate dated 29 Nov 2019
58.	English Seizure Diary Book	Version 1.0_English-IN_Dated 20 Oct 2016
59.	Hindi Seizure Diary Book	Version 1.0_Hindi-IN_Dated 20 Oct 2016 Translation Certificate dated 19 Feb 2020
60.	Marathi Seizure Diary Book	Version 1.0_Marathi-IN_Dated 20 Oct 2016 Translation Certificate dated 19 Feb 2020
61.	English Patient Dosing Information	E2007-G00-338 Patient Dosing Information, v2.0, 07 Feb 2017
62.	Hindi Patient Dosing Information	E2007-G00-338 Patient Dosing Information_Hindi_ v2.0, 07 Feb 2017 Translation Certificate dated 07Jan2020
63.	Hindi to English Patient Dosing Information	E2007-G00-338 Patient Dosing Information_Hindi to English_ v2.0, 07 Feb 2017 Translation Certificate dated 07 Jan 2020
64.	Marathi Patient Dosing Information	E2007-G00-338 Patient Dosing Information_Marathi_ v2.0, 07 Feb 2017 Translation Certificate dated 07 Jan 2020
65.	Marathi to English Patient Dosing Information	E2007-G00-338 Patient Dosing Information_ Marathi to English_ v2.0, 07 Feb 2017 Translation Certificate dated 07 Jan 2020
66.	Investigator Undertaking Dr. Kavita Srivastava	Signed and dated on 04 Mar 2020
67.	CV & MRC for PI – Dr. Kavita Srivastava	CV dated 30 Dec 2019
68.	SRC approval letter	Dated 25 May 2020

Following members of the IEC attended the meeting to review and discuss the study proposal:

Sr. No.	Name	Qualification	Affiliation	Role in the IEC	External/Internal
1	Dr. Abhijeet Tilak	M.D. Pharmacology	Professor and Head, Department of Pharmacology, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune - 18	Medical Scientist/ Pharmacologist (Acting Chairperson)	External

Sr. No.	Name	Qualification	Affiliation	Role in the IEC	External/Internal
2	Dr. Priti Dave	MD Medicine	Professor Department of Medicine Bharati Vidyapeeth (Deemed to be University) Medical College, Pune	Clinician/ Physician	Internal
3	Dr. Sanjay Natu	MD DNB(Pediatrics) MNAMS FACEE (PEM)	Professor, Department of Pediatrics Smt. Kashibai Navale Medical College & General Hospital, Pune Consultant Pediatrician Shashwat Hospital, 22, Happy Colony, Kothrud, Pune	Clinician/ Pediatrician	External
4	Dr. Anand Deshpande	DNB (Pediatrics), DCH	Honorary Associate Professor, Department of Pediatrics, B. J. Medical College and Sassoon General Hospital, Pune Consultant Pediatrician, Deenanath Mangeshkar Hospital and Mai Mangeshkar Hospital, Pune	Clinician/ Pediatrician	External
5	Dr. Jayshree Dawane	MD Ph.D (Pharmacology)	Associate Professor, Department of Pharmacology Bharati Vidyapeeth (Deemed to be University) Medical College, Pune	Medical Scientist/ Pharmacologist	Internal
6	Adv. Ashwini Hogepatil	B.A., L.L.B.	Practicing Lawyer, Pune	Legal Expert	External
7	Mrs. Vidya Garkhedkar	M.A. (Philosophy) B. Ed	Assistant Teacher in Dept. of Philosophy & Logic at junior college, S.P. College, Pune 30	Philosopher	External
8	Mrs. Vijayalaxmi Bathe	B.A., B. Ed (Physical Education)	President of Jivhala Jeshth Nagrik Sangh, Astoniya Royale, Ambegaon BK, Pune 411046 Yoga Teacher	Lay Person	External

Sr. No.	Name	Qualification	Affiliation	Role in the IEC	External/Internal
9	Mrs. Sarika Deshmukh	B. Com	Housewife	Lay Person	External
10	Dr. Prasad Pore	MD (P&SM) D.N.B. (SPM)	Professor Department of Community Medicine Bharati Vidyapeeth (Deemed to be University) Medical College, Pune	Member Secretary	Internal

Adv. Sangeeni Pol and Dr. Swati Shirwadkar were unable to attend the meeting and had intimated about the same.

IEC composition was ICH - GCP and New Drugs and Clinical Trials Rules 2019 G.S.R. 227 (E) compliant. Required quorum was present for the meeting.

IEC reviewed the above mentioned documents and discussed the project in detail.

After reviewing all the study documents, IEC granted **Approval** for conduct of the study and study related documents for 1 year.

IEC suggested that after the 19 weeks of treatment period (Titration and Maintenance period), if the drug is beneficial, then those participants who are in control/ placebo arm, should also get the drug.

We approve the trial to be conducted in its presented form.

IEC expects to be informed about the progress of the study, any Serious Adverse Event (SAE) occurring in the course of the study, any changes in the protocol and patient information / informed consent, deviations, any new information that may affect adversely the safety of subjects or conduct of the study and asks to provide a copy of the final report.

Kindly submit a report on the progress of the study every six months. Annual study status report needs to be submitted for approval for continuation of the study.

With best wishes,

Yours truly,



Dr. Prasad Pore
Member Secretary




SRI T. ASHOK GOUD
S.V.L.NO.15-22-024/2000
R.L.NO. 15-22-015/2012
H.NO.2-31/6/A
TARA NAGAR, SERILINGAMPALLY
RANGA REDDY DISTRICT
92/20
LICENSE NO. 39/2012



96243
192420
DEC 10 2020
17:23
R.0000050 P87142
NON-JUDICIAL
STAMP DUTY
TELANGANA

CLINICAL TRIAL AGREEMENT

THIS AGREEMENT IS MADE AND ENTERED INTO AS OF THE 27th DAY OF
January 2021, 2020.

BETWEEN:

Indian Immunologicals Limited, a company duly incorporated under the Companies Act, and having its registered office at Road No. 44, Jubilee Hills, Hyderabad, Telangana- 500033 (hereinafter referred to as “IIL” or “Sponsor”) which expression shall be deemed to include its successors and administrators and assigns etc.

AND

Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital (BVDUMC), an institution incorporation under the laws of India, having its registered head office at Katraj-Dhankawadi, Pune-Satara Road, Pune-411043 India which expression shall be deemed to include its successors and administrators and assigns etc. (Hereinafter referred to as the ‘Institution’)

AND

Dr. Sonali Palkar, In-charge Pediatric Research, Department of Pediatrics and Associate Professor, Department of Community Medicine, Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, Katraj-Dhankawadi, Pune-Satara Road, Pune-411043 INDIA

(hereinafter referred to as the “Principal Investigator”) which expression shall be deemed to include its successors and administrators and assigns etc.

With each of the parties collectively or individually referred to as “Party” or “Parties”

AND RELATES TO THE CLINICAL TRIAL:

A Phase I Randomized Single Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of Chikungunya Vaccine (Inactivated) of HBI when administered by two different dosage schedules to Healthy Subjects of 19 to 49 Years of age.

Code: HBI/CG/I/2020/001.02.00 Version 02



[Signature]

[Signature]
Initial Here

OR INDIAN IMMUNOLOGICALS LTD.

FOR BHARATI VIDYAPEETH DEEMED UNIVERSITY MEDICAL COLLEGE & HOSPITAL, PUNE

Signature: _____



Name: Dr K. Anand Kumar
Title: Managing Director

Signature: _____

NSN

Name: (Brig.) Dr. Narayanan Subrahmanian Mani
Title: Principal

PRINCIPAL
Bharati Vidyapeeth
(Deemed to be University)
Medical College
Pune - 411 043.

Signature: _____

S. Sai Krishna

Name: Dr. S. Sai Krishna
Title: DGM- Medical & Veterinary Services

Signature: _____

S. Palkar

Name: Dr. Sonali Palkar
Title: Principal Investigator

PRINCIPAL INVESTIGATOR



m *SP* *N*
Initial Here

SCHEDULE A
- FINANCIAL CONDITIONS -

1-Clinical Trial Costs:

For sake of clarity, the Parties hereby agree that:

- (i) "Estimated Budget" shall mean the estimated total amount to be paid by the Sponsor considering INR 25,080 (Twenty Five Thousand and Eighty Rupees only) per completed subject. Assuming 66 subjects will complete the study, the estimated budget will be INR 16,55,280 (Rupees Sixteen lakhs Fifty Five Thousand Two hundred and Eighty only).
- (ii) "Actual Budget" shall mean the real amount to be paid by the Sponsor to the Institution, i.e. the Estimated Budget reviewed according to actual number of subjects who have completed the study.
- (iii) Study Completion: Subjects who have completed all the required visits as per the protocol and have given the final blood sample.
- (iv) Drop out cases will not be considered for payment.

2- Payments:

- a) The breakdown of the payment of INR 25,080 per completed subject is as follows:

Particulars	Rs.
Study Coordinator	3400
Co-Investigator Charges	5500
Investigator charges	8500
Travel Expenses for Subjects	3500
Institutional overhead charges (20%)	4180
TOTAL per Subject	25,080
Total for minium of 66 Subjects	16,55,280

(Exclusive of Taxes applicable)

- b) The charges for each screen failure subject (Subject who has given the first blood sample and is found to be screen failure) is 2500 /- (Rupees Two thousand and five hundred only).
- c) The Payment for the Screen failures will be made based on the actuals as per the invoices received every month till the required total number of subjects for the site have been enrolled.
- d) If the subject drops-out from the study for any reason after enrollment, the sponsor will pay 50% of the per subject cost of the Investigator, Co-investigator and study coordinator.





सत्यमेव जयते

INDIA NON JUDICIAL Government of Gujarat Certificate of Stamp Duty

Certificate No.	IN-GJ94955514007608T
Certificate Issued Date	12-Jan-2021 05:40 PM
Account Reference	IMPACC (AC)/ gj13023211/ GULBAI TEKRA/ GJ-AH
Unique Doc. Reference	SUBIN-GJGJ1302321126835903450718T
Purchased by	Cadila Healthcare Limited
Description of Document	Article 5(h) Agreement (not otherwise provided for)
Description	Agreement
Consideration Price (Rs.)	0 (Zero)
First Party	Cadila Healthcare Limited
Second Party	Dr Sanjay Lalwani
Stamp Duty Paid By	Cadila Healthcare Limited
Stamp Duty Amount(Rs.)	300 (Three Hundred only)

**Department of Pediatrics, Bharati Vidyapeeth
(Deemed To Be University)
Medical College & Hospital, Pune**



LB0012422180

Statutory Alert:

1. The authenticity of this Stamp certificate should be verified at www.shojestamp.com or using e-Stamp Mobile App of State Treasuries. Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.
2. The mode of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

CLINICAL STUDY AGREEMENT

Among

1. **CADILA HEALTHCARE LIMITED**, a multinational pharmaceutical company incorporated under the laws of India, having its Registered Office at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej-Gandhinagar Highway, Ahmedabad-382481, Gujarat, India (hereinafter referred to as **"the Sponsor"**)
2. **DR. SANJAY LALWANI**, (hereinafter referred to as **"Principal Investigator"**)
3. **BHARATI VIDYAPEETH (DEEMED TO BE UNIVERSITY) MEDICAL COLLEGE & HOSPITAL**, Pune-Satara Road, Dhankawadi, Katraj, Pune-411043 India (hereinafter referred to as **"the Institution"**)

CADILA PROJECT:

"A phase III, randomized, multi-centre, double blind, placebo controlled, study to evaluate efficacy, safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited. (Project No. NCOV.20.002)"

This Clinical Study Agreement ("Agreement") is executed on **29th day of January, 2021** ("Effective Date") among Cadila Healthcare Limited, Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej-Gandhinagar Highway, Ahmedabad-382481, Gujarat, India (**"Sponsor"**) India; **Dr. Sanjay Lalwani, Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital, Pune- Satara Road, Dhankawadi, Katraj, Pune-411043 India** for the study entitled **"A phase III, randomized, multi-center, double blind, placebo controlled, study to evaluate efficacy, safety and immunogenicity of Novel Corona Virus-2019-nCov vaccine candidate of M/s Cadila Healthcare Limited."** (Project No. NCOV.20.002)" (Hereinafter referred to as **"the study"**).

This Agreement also covers any companion protocol(s) later developed and approved by all the Parties that are conducted concurrently with the protocol identified herein (collectively **"Protocol"**) and that involve some or all the same subjects. The Sponsor and the Institution hereby declare that all the necessary permissions and licences required under the provisions of various acts and rules thereunder have been obtained for the performance of their respective obligations under this Agreement.

AND WHEREAS the Sponsor is desirous of engaging the said Principal Investigator and Institute for carrying out the Study.

NOW, THEREFORE, in consideration of the premises and the covenants and Agreements of the parties as hereinafter set forth, the parties have agreed and do hereby agree with each other to the following:

THE PARTIES AGREE AS FOLLOWS:

1. The Sponsor would like to test the vaccine namely **ZyCOV D** which will be used for Prevention of Corona Virus Disease - 2019 in healthy subjects. The Sponsor hereby declares that all the necessary permissions and licenses required under the provisions of relevant Acts and Rules

CLINICAL STUDY AGREEMENT


Executed by the parties:

SPONSOR:



(Mr. Mukund Thakkar)
SVP, Legal





(Dr. Balaji More)
Sr. GM, Clinical R&D

INSTITUTION:

Sign: 

Name: Brig. (Dr.) Narayanan Mani

Designation: Principal

Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital

PRINCIPAL
Bharati Vidyapeeth
(Deemed to be University)
Medical College
Pune - 411 043.

I have read and understand this Agreement and accept the terms as they relate to my activities as Principal Investigator. I further agree to ensure that all sub-investigators and research staff are informed of their obligations under this Agreement.

PRINCIPAL INVESTIGATOR:

Sign: 

Dr. Sanjay Lalwani
Principal Investigator

Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital

Department of Pediatrics, Bharati Vidyapeeth
(Deemed To Be University)
Medical College & Hospital, Pune

CLINICAL STUDY AGREEMENT

Clinical Trial Budget- For Category 1			
S. No.	Visits	Particulars	Rate per Visit
A	Visit Expenses		₹ 10,000.00
1	W-0	Site and Investigator Charges	₹ 2,000.00
2	W-4	Site and Investigator Charges	₹ 1,000.00
3	W-8	Site and Investigator Charges	₹ 1,000.00
4	W-12	Site and Investigator Charges	₹ 1,000.00
5	W-52	Site and Investigator Charges	₹ 1,000.00
6	Telephonic follow-ups (days 70, 84, 98, 112, 126, 140, 154, 168, 182, 196, 210, 224, 238, 252, 266, 280, 294, 308, 322, 336 and 350 (± 3days) after 1st dose.)	Telephonic follow-ups (20 time, @200 per call)	₹ 4,000.00
B	Other Expenses		₹ 3,000.00
7	Patient Travel Reimbursement (@500 Per Visit for 6 visits)		₹ 3,000.00
C	Total (A+B) = C		₹ 13,000.00
D	Approx. Budget for 500 enrolled subjects (@13000)		₹ 65,00,000.00

$$\begin{aligned}
 \text{Enrolled } 8 &= 8 \times 13000 = 1,04,000/- \\
 \text{4screened} &= 4 \times 2500 = 10,000/- \\
 & \underline{\hspace{10em}} \\
 & 1,14,000/-
 \end{aligned}$$



Department of Pediatrics, Bharati Vidyapeeth
(Deemed To Be University)
Medical College & Hospital, Pune



सत्यमेव जयते

INDIA NON JUDICIAL

Government of Karnataka

Rs. 200

e-Stamp

Certificate No. : IN-KA83095631302573R
Certificate Issued Date : 27-Mar-2019 03:38 PM
Account Reference : NONACC (FI)/ kaksfcl08/ UTTARHALLI1/ KA-BA
Unique Doc. Reference : SUBIN-KAKAKSFCL0896108670151704R
Purchased by : IQVIA RDS INDIA PRIVATE LIMITED
Description of Document : Article 12 Bond
Description : CLINICAL TRIAL AGREEMENT
Consideration Price (Rs.) : 0
(Zero)
First Party : IQVIA RDS INDIA PRIVATE LIMITED
Second Party : BVDU MEDICAL COLLEGE AND HOSPITAL
Stamp Duty Paid By : IQVIA RDS INDIA PRIVATE LIMITED
Stamp Duty Amount (Rs.) : 200
(Two Hundred only)

सत्यमेव जयते



Please write or type below this line

CLINICAL TRIAL AGREEMENT

The Clinical Trial Agreement ("Agreement") is made by and among:

- Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital, having a place of business at Pune - Satara Road, Dhankawadi, Pune- 411043, Maharashtra, India (the "Institution"), and;
- Dr. Jitendra Shankarlal Oswal, having a place of business at Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital, Pune - Satara Road, Dhankawadi, Pune- 411043, Maharashtra, India (the "Investigator"), and;

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at "www.shcilestamp.com". Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

- **IQVIA RDS (India) Private Limited**, (formerly **Quintiles Research (India) Private Limited**) a Company incorporated under the Companies Act, 1956 and having its registered office at 2nd Floor, Etamin Block, Prestige Technology Park II, Sarjapur-Marathahalli Outer Ring Road, Bangalore – 560 103, India (hereinafter “**CRO**”), acting on behalf of **Serum Institute of India Pvt. Ltd.**, and;
- **Serum Institute of India Pvt. Ltd.** a company incorporated under Companies Act, 1956 having its registered office at 212/2, off Soli Poonawalla Road, Hadapsar, Pune 411028, India. (hereinafter “**Sponsor**”).

Each a “**Party**” and together the “**Parties**”.

Protocol Number:	SII-aPENTA/IN-02
Protocol Title:	A Phase II/III, Multicentre, Randomized, Open-Label, Active-Controlled Study to Assess the Immunogenicity and Safety of DTaP-IPV+Hib Vaccine Manufactured by Serum Institute of India Pvt. Ltd. in Comparison with Pentaxim® in Indian Toddlers and Infants
Protocol Date:	03 Oct 2018
Sponsor:	Serum Institute of India Pvt. Ltd.
Country where Site is Conducting Study	India
Investigator:	Dr. Jitendra Shankarlal Oswal
Key Enrollment Date:	30 Calendar Days after Site Initiation Visit (being the date by which Site must enrol at least one (1) subject as more specifically set out in section 1.7 “Key Enrollment Date” below)
IRB/IEC	Institutional Ethics Committee Bharati Vidyapeeth Deemed University 4th floor, Bharati Hospital & Research Centre Pune - Satara Road, Dhankawadi, Pune- 411043, Maharashtra, India Phone No - 020 40555555, Ext. 265 Email ID - bvduiec@gmail.com

The following additional definitions shall apply to this Agreement:

- Affiliate:** means any entity that controls, is controlled by, or is under common control with the party being referred to. “control” means the ability to vote more than fifty (50) per cent of the issued voting shares of that entity or the legal power to direct or cause the direction of the general management and policies of the company, partnership or other entity in question, and “controlled” shall be construed accordingly.
- Protocol:** the clinical protocol referenced above as it may be modified from time to time by the Sponsor (defined below).
- Case Report Form or CRF:** case report form (paper or electronic) to be used by Site to record all of the Protocol-required information to be reported to Sponsor on each Study Subject (defined below).
- Study:** the clinical trial that is to be performed in accordance with this Agreement and the Protocol for purposes of gathering information about the compound/medical device identified in the Protocol.
- Study Subject:** an individual who participates in the Study, as a recipient of the Investigational Product (defined below).



INITIALS:
Sponsor

[Signature]
CRO

NSMam
Institution

[Signature]
Investigator

IN WITNESS WHEREOF, this Agreement has been executed by the Parties hereto through their duly authorized officers on the date(s) set forth below.

ACKNOWLEDGED AND AGREED BY SERUM INSTITUTE OF INDIA PVT. LTD.

Name: Dr. Hitt Sharma

Title : Study Director

Signature: [Signature]

Date: 05th August, 2019



**ACKNOWLEDGED AND AGREED BY IQVIA RDS (India) PRIVATE LIMITED
(formerly Quintiles Research (India) Private Limited)**

Name: Shweta Pradhan

Title: Director & Head Site Management

Signature: [Signature]

Date: 29/Jul/2019

ACKNOWLEDGED AND AGREED BY INSTITUTION

Name: (Brig.) Dr. Narayanan Subramanian Mani

Title: Principal, Bharati Vidyapeeth (Deemed To Be University) Medical College

Signature: [Signature]

Date: 26/08/2019

PRINCIPAL
Bharati Vidyapeeth
(Deemed to be University)
Medical College
Page - 42

ACKNOWLEDGED AND AGREED BY INVESTIGATOR

Name: Dr. Jitendra Shankarlal Oswal

Signature: [Signature]

Date: 17. Aug 2019

[Handwritten mark]



INITIALS:
Sponsor

[Signature]
CRO

[Signature]
Institution

[Signature]
Investigator

5. DISCONTINUED OR EARLY TERMINATION

Reimbursement for discontinued or early termination subjects will be prorated based on the number of confirmed completed visits.

6. SCREENING FAILURE

No payments is payable to for screen failures.

7. EC/IRB/IEC FEES

EC/IRB/IEC costs will be reimbursed on a pass-through basis upon receipt of a formal invoice issued by the EC/IRB/IEC and are not included in the attached Budget. Payment will be made directly to the EC/IRB/IEC. Any subsequent re-submissions or renewals, upon approval by CRO and Sponsor, will be reimbursed upon receipt of appropriate documentation.

8. Meeting Attendance:

Necessary travel and lodging expenses (including meals) incurred by the Site when attending Study start up meetings or other meetings necessary to provide information regarding the Study or Investigational Product will be reimbursed on a pass-through basis upon receipt of supporting invoices from a third party vendor.

9. BUDGET TABLE

SII-aPENTA_IN-02 (PART I)

Study visit	Grant	Institutional Overhead (20%)	Total
Visit 1	3600	720	11760
Visit 2	3100	620	
Visit 3	3100	620	
Budget	9800	1960	

SII-aPENTA_IN-02 (PART II)

Study visit	Grant	Institutional Overhead (20%)	Total
Visit 1	2000	400	15000
Visit 2	1500	300	
Visit 3	2000	400	
Visit 4	1500	300	
Visit 5	2000	400	
Visit 6	1500	300	
Visit 7	2000	400	
Budget	12500	2500	

Upon receipt of invoice, with adequate documentation, for the costs associated with a Study subject travel reimbursement up to a maximum amount of Rs 500/- per visit by will be reimbursed for the subject enrolled in the Study. This allowance per visit is intended to offset the Study subject's costs associated or incurred as a result of Study participation. This reimbursement shall be reflected in the Informed Consent Form as it will be provided to the Study subject.

NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED



INITIALS:
Sponsor

[Signature]
CRO

[Signature]
Institution

[Signature]
Investigator



icmr | **NIRT**
INDIAN COUNCIL OF
MEDICAL RESEARCH | NATIONAL INSTITUTE FOR
RESEARCH IN TUBERCULOSIS



आई सी एम आर - राष्ट्रीय खसमा अनुसंधान संस्थान
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार
कल्याण मंत्रालय, भारत सरकार

ICMR - National Institute for Research in Tuberculosis
Department of Health Research, Ministry of Health
and Family Welfare, Government of India

No.DIR/NIRT/Covid-19/BVMC/2020-21/1398

Date: 31.08.2020

To

The Director,
Bharati Vidyapeeth Medical College and Hospital,
Pune-Satara Road,
Dhankawadi, Katraj, Pune – 411 043.

Sub: Sanction and budget allotment for the Scheme Entitled, "A Phase 2/3,
Observer-blind, Randomized, Controlled Study to determine the Safety
and Immunogenicity of COVISHIELD (COVID-19 vaccine) in Healthy
Indian Adults"

Ref.: ICMR Lr.No.VIR/Covid-19/29/2020/ECD-I, dt.:25.08.2020

Sir,

With reference to ICMR letter under reference cited, the Director-in Charge, National Institute for Research in Tuberculosis, Chennai sanctions the above mentioned research scheme initially for a period of 8 months from 25.08.2020 to 24.04.2021 subject to extension upto the total duration specified in para 3(3) below:

The Director-in-Charge of NIRT also sanctions the Budget allotment of **Rs.62,60,250/-** (Rupees Sixty Two Lakhs Sixty Thousand Two Hundred and Fifty only) as detailed in the attached budget statement for the period from **25.08.2020** to **24.04.2021**.

The grant in aid will be given subject to the following conditions:

1. The payment of the grant will be made in two instalments (1st instalment – 60%, 2nd & final instalment – 40% respectively) to the Head of the Institution. The first instalment of the grant will be paid as soon as a report regarding the commencement of the project is received by NIRT.
2. The staff appointed in the project should be paid as indicated in the Budget Statement attached.
3. The approved duration of the research scheme is 8 months. The extension will be given after review of the work done on the scheme during the previous months.

Cont..2..

नं. 1, मेयर सत्यमूर्ति रोड, चेटपुट, चेन्नई - 600 031, भारत
No.1, Mayor Sathiyamoorthy Road, Chetpet, Chennai - 600 031, India

Tel: +91-44-28369500
Fax: +91-44-28362528, 28262529
www.nirt.res.in



BVMC Pune site:

29, 22, 145

Sr.No	BUDGET HEAD	Quantity	AMOUNT	DURATION	Total
	Manpower <i>Dr. Vaishali</i>				
	Junior Medical officer (Medical) Rs. 60,000/-	1	60,000	8	4,80,000
	Staff Nurse @Rs. 31500/- p/m <i>Pritya Khan</i>		31,500	8	5,04,000
<i>Savita</i>	Lab technician @Rs. 18000/- p/m <i>Savitri</i>	1	18,000	8	1,44,000
<i>Sampada</i>	Field Investigator / CRC @Rs. 31000/- p/m <i>Sampada</i>	1	31,000	8	2,48,000
<i>Krutika</i>	Research Assistant @Rs. 31000/- p/m <i>Krutika</i>	1	31,000	2	62,000
<i>Deepali</i>	Data entry operator (Grade C) @Rs. 31000/- <i>Deepali</i>	1	31,000	8	2,48,000
	Sub-Total-1				16,86,000
	Patient Management				
	Volunteer Reimbursement –I screening	320	500	1	160000
	Volunteer Reimbursement enrollemnt and follow up	250	500	4	5,00,000
	Communication & Stationery				6,60,000/-
	Communication	1	10000	6	60,000
	(Stationaries) Printing of forms, Registers, Protocol, SOPs	-	60000	1	60,000 →
	Archival charges	1	100000	1	1,00,000
	Laboratory Consumables				2,20,000/-
	CoVID swab testing	320	3000	1	960000
	Antibody Test (IgG)	320	600	1	192000 X
<i>42,000/-</i>	CoVID swab testing	100	3000	1	300000
	Additional Labs for symptomatics if needed	100	5000	1	500000
	Urine Pregnancy test	100	120	2	24000
	Vacutainer needles	400	15	1	6000
	Blood collection tubes	400	20	1	8000
	Disposable syringes	400	20	1	8000
	Urine containers	200	15	1	3000
	Test tub & Pipettes	400	10	3	12000
	Surgical mask	20	20	40	16000
	Hand sanitizer	20	250	10	50000
	N95 mask, Gloves, face shield	20	500	20	200000
	PPE suit	5	1500	100	750000
	Contingency/Miscellaneous				28,37,000
	Placing of recruitment advertise in Newspaper		10000	1	10000
	Conducting interviews		10000	1	10000
	Sub-total-2				39,29,000
	Overhead @5%				2,80,750
	Equipments				
	Pharmacy Grade Refrigerator	1	40,000	-	40,000
	Data logger	2	15,000	-	30,000
	Filing Cabinet	1	30,000	-	30,000
	Pen drive - 16GB	1	500	-	500
	Vaccine Carrier (Tropicool)	2	12,000	-	24,000
	Sub-Total-3				1,24,500
	Travel				
	Hiring of vehicles (1 no)	1	30000	8	240000
	Grand total = Rs. 62,60,250/-				

25

70

59

SRI T. ASHOK GOUD
S.V.L.NO.15-22-024/2000
RL.NO. 15-22-015/2012
H.NO.2-31/6/A
TARA NAGAR, SERTINGAMPALLY
RANGA REDDY DISTRICT
LICENSE NO. 39/2012



79587

136428

తెలంగాణ

JUN 18 2020

200 200 200 200 200 200 200 200

11:47

R.0000050

PB7142

NON-JUDICIAL
STAMP DUTY

TELANGANA

CLINICAL TRIAL AGREEMENT

THIS AGREEMENT IS MADE AND ENTERED INTO AS OF THE 27th DAY OF
October, 2020.

BETWEEN:

Indian Immunologicals Limited, a company duly incorporated under the Companies Act, and having its registered office at Road No. 44, Jubilee Hills, Hyderabad, Telangana- 500033 (hereinafter referred to as “IIL” or “Sponsor”) which expression shall be deemed to include its successors and administrators and assigns etc.

AND

Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital (BVDUMC), an institution incorporation under the laws of India, having its registered head office at Katraj, Dhankawadi, Pune-411043 India which expression shall be deemed to include its successors and administrators and assigns etc. (Hereinafter referred to as the ‘Institution’)

AND

Dr. Rahul Jahagirdar, Professor in Pediatrics, Department of Pediatrics, Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital, Katraj, Dhankawadi, Pune-411043 INDIA

(hereinafter referred to as the “Principal Investigator”) which expression shall be deemed to include its successors and administrators and assigns etc.

With each of the parties collectively or individually referred to as “Party” or “Parties”

AND RELATES TO THE CLINICAL TRIAL:

A Phase II/III Multicentric Randomized Single Blind Study to Compare the Immunogenicity and Safety of Measles and Rubella Vaccine (Live) of HBI with MR-VAC® Vaccine in Healthy Subjects

Code: HBI/MR/II/III/2019/001.02.00 Version 02



FOR INDIAN IMMUNOLOGICALS LTD.

FOR BHARATI VIDYAPEETH (DEEMED TO BE UNIVERSITY) MEDICAL COLLEGE & HOSPITAL (BVDUMC), PUNE

Signature: _____

Name: Dr. Prasanna Deshpande

Title: Deputy Managing Director



Signature: _____

Name: Dr. S. Sai Krishna

Title: DGM- Medical & Veterinary Services

Signature: _____

Name: (Brig.) Dr. Narayan Mani

Title: Principal

19/10/2020

Bharati Vidyapeeth
(Deemed to be University)
Medical College
PUNE 411 043.

PRINCIPAL INVESTIGATOR

Signature: _____

Name: Dr. Rahul Jahagirdar

Title: Principal Investigator

15/10/20



SCHEDULE A
- FINANCIAL CONDITIONS -

1-Clinical Trial Costs:

For sake of clarity, the Parties hereby agree that:

- (i) "Estimated Budget" shall mean the estimated total amount to be paid by the Sponsor considering INR 11,040 (Eleven thousand rupees only) per completed subject. Assuming 100 subjects will complete the study, the estimated budget will be INR 1104,000 (Rupees Eleven lakhs Four Thousand only).
- (ii) "Actual Budget" shall mean the real amount to be paid by the Sponsor to the Institution, i.e. the Estimated Budget reviewed according to actual number of subjects who have completed the study.
- (iii) Study Completion: Subjects who have completed all the required visits as per the protocol and have given the final blood sample.
- (iv) Drop out cases will not be considered for payment.

2- Payments:

a) The breakdown of the payment of INR 11,040 per completed subject is as follows:

Particulars	Rs.
Study Coordinator	1200
Travel Expenses for Subjects	1000
Co-Investigator Charges	2000
Investigator charges	5000
Institutional overhead charges (20%)	1840
TOTAL per Subject	11,040
Total for minium of 100 Subjects	11,04,000

(Exclusive of Taxes applicable)

For NAAC 20 sub. \approx 2,20,800

Enrolled 31 \rightarrow $31 \times 11040 = 3,42,240/-$





महाराष्ट्र MAHARASHTRA

2018

AR 284800

5 MAR 2019

98203

500 L

वस्तु प्रकार Agreement

दस्तावेज प्रकार अज्ञेय

भिकृतीये वर्णन

मुद्रांक विकल वेणान्नाची नं. सिरम इंस्टिट्यूट ऑफ

पत्ता ७७५८८ पुणे

दुसऱ्या पक्षकाचा नांव

हस्ता घटकतीये नांव व पत्ता राजेश कांबळे

विक्रय वेळापत्रक

नसयानांक, २२०९२२५

मुद्रांक विकल वेणान्नाची नं. जि.प. अंडर प्रॉटेक्ट, पोलीस स्टेशन, पुणे - १९

या कारणासाठी जहाती मुद्रांक खोबी वेळ, स्वामी खांबे वाचनालयी मुद्रांक खरेदी वेळापत्रक ६ महिन्यात यापुढे देयकमान आहे.



Initial

CLINICAL TRIAL AGREEMENT

THIS CLINICAL TRIAL AGREEMENT ("Agreement") is made and entered into as of _____ day of _____ (hereinafter "Effective Date") by and between:

DiagnoSearch Life Sciences Pvt. Ltd. a company incorporated under Companies Act, 1956 having its registered office at 702, Dosti Pinnacle, Plot No. E-7, Road No. 22, Wagle Industrial Estate, Thane- 400604, Maharashtra, India (hereinafter "CRO"), acting on behalf of **Serum Institute of India Pvt. Ltd.** a company incorporated under Companies Act, 1956 having its registered office at 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028, India. (hereinafter "Sponsor");

NS/NSA

Dr. Sanjay K Lalwani, Professor & Head, Department of Pediatrics, Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital, Pune 411043; hereinafter referred to as Investigator; AND

Bharati Vidyapeeth (Deemed To Be University) Medical College & Hospital, Pune 411043 an institution functioning as per the provisions of the Societies Registration Act, 1860 having its Registered Office at - Katraj-Dhankwadi, Pune-Satara Road, Pune 411043, India; represented by its Principal, **Bharati Vidyapeeth (Deemed To Be University) Medical College, Brig. (Dr.) Narayanan Subramanian Mani** (which expression shall where the context so admits include its successors and permitted assigns) hereinafter referred to as Institution.

WHEREAS CRO is engaged in the business of managing and providing clinical research services and related activities and has been appointed by Sponsor to arrange and administer a clinical Study entitled: **"Phase 3, Randomized, Double-Blind Study to Evaluate the Immunogenicity, Safety and Tolerability of Serum Institute of India's 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) in Healthy Indian Infants."** Protocol no. – PCV-10-003, Version 4.0, dated 25-JAN-2019 ("the Protocol") and has entered into an agreement with Sponsor or one of its affiliates concerning the management, funding and administration of the Study;

AND WHEREAS Sponsor intends to appoint Investigator relating to the said **PCV-10-003**, Clinical Study and requires CRO to supervise the services / activities to be undertaken by Investigator along with the services provided by CRO to Sponsor.

AND WHEREAS Institution and Investigator have each reviewed sufficient information regarding Sponsor's vaccine (the "Study Vaccine"), the Protocol for the Study and the Investigator Brochure to evaluate their interest in participating in the Study and each desires to participate in the Study as more particularly described in this Agreement.

NOW, THEREFORE, subject to the terms, conditions and covenants hereinafter set forth CRO, Investigator and Institution agree as follows.

CRO, Investigator and Institution are sometimes hereinafter individually referred to as a Party and collectively as Parties.

Article 1 – The Study


1.1 The Institution and the Investigator undertake to conduct the Study in strict accordance with various guidelines and applicable regulatory requirements including but not limited to (a) the current World Medical Association Declaration of Helsinki titled, "Ethical Principles for Medical Research Involving Human Subjects;" (b) the current ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95); (c) the current Indian Ministry of Health and Family Welfare guideline for good clinical practice titled, "Good Clinical Practices for Clinical Research in India;" (d) the current Indian Council of Medical Research ethical guideline for clinical research titled, "Ethical Guidelines for Biomedical Research on Human Subjects;" (e) the written requirements of all reviewing Institutional Ethics Committees and institutional review boards (collectively, the Institutional Ethics Committees) and subsequent amendments if any, to the above guidelines and such other regulations that may be pronounced by a competent authority from time to time. It is understood and agreed that, in the event of a conflict among any of the Standards, the most stringent Standard shall apply.

Project: Protocol No. PCV-10-003

Or to such other address and any Party may designate in writing from time to time to the other. Any notice shall be effective as of its date of receipt.



IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed in multiple counterparts by their duly authorized representatives.

FOR Principal Investigator:


By:  Date 01/04/2019
Name: Dr. Sanjay Lalwani
Title: Principal Investigator

full signature


FOR AND ON BEHALF OF:
Bharati Vidyapeeth (Deemed To Be University) Medical College, And Hospital Pune

By:  Date 01 APR 2019
Name: Brigid Narayanan Subramanian Mani
Title: Principal Investigator


FOR AND ON BEHALF OF:
DiagnoSearch Life Sciences Pvt. Ltd.

By:  Date 20/MARCH/2019
Name: Mandar Vaidya
Title: Director-Operations

FOR AND ON BEHALF OF:
Serum Institute of India Pvt. Ltd.

By:  Date 11/3/2019
Name: Dr. Vistasp Sethna
Title: Head - Conjugate Vaccines and Monoclonals

SCHEDULE B DRAFT STUDY BUDGET

PNEUMOSIL Phase 3 Study - Site Budget							
Heading	Visit 1	Visit 2	Visit 3	Visit 4	Total	No. of Subjects randomized	Total per study
Informed Consent	1,200				1,200		36,000
Medical History, Reviews of AE/SAE/Concomitant Medications	700	700	700	700	2,800		84,000
Physical Examination /E Criteria	700	700	700	700	2,800		84,000
Randomization	700				700		21,000
Study Vaccination	1,000	1,000	1,000		3,000	30	90,000
Review of Diary Cards		700	700	700	2,100		63,000
Blood Sample for Immunogenicity		800	800	800	2,400		72,000
Follow-up FRA Contact	5,000	3,900	3,900	3,900	16,700		501,000
Screen Failure (Assumption: 10% of randomized, hence 3)							
Screening Process (B)	3,000						
Total (A+B)						3	9,000
Institute Overhead 20% (C)							510,000
Patient Travel Cost (D)	500	500	500	500	2,000		102,000
Screen Failure travel Reimbursement (E)	500				500	30	60,000
Total (A+B+C+D+E)						3	1,500
Infrastructure set up cost* (F)							673,500
* One time payment							
Heading	Unit Cost in INR	Quantity	Unit				
Operational and administrative cost (G)	15,000	8	month				120,000.00
Archival Charges* (H)	10,000						10,000.00
* One time charges							
Total Project Cost (A+B+C+D+E+F+G+H)							843,500.00
Per Subject Cost (Project cost/no. of subjects assumed to be randomized)							28,116.67

Notes:

- Period of recruitment is assumed as 4-6 weeks.
- Maximum number of screen failures for which Investigator to be compensated shall not exceed 10% of total randomized subjects at the site.
- INR 500/- will be paid as a screening visit travel reimbursement for screen failures not exceeding 10% of the total randomized subject at the site.
- The study recruitment will be a competitive, and there will be no upper limit to actual number of subjects enrolled. The final calculation will be based on the actual number of subjects enrolled and actual number of visits completed. The final calculation will be done on prorated basis.
- Outpatient cost, if occur, would be reimbursed at actuals.

Inst. → Overhead charges will given in final invoice
→ Pending
→ End of study

NSM

Project: Protocol No. PCV-10-003

SCHEDULE E

FORM OF FINANCIAL REPORT TO SPONSOR

Investigator Name: Dr. Sanjay Lalwani Institutional Name: BVMURC, Pune		PAN number of Payee:	
Particulars	Rate / unit	Number of Units	Total
Investigator's subject Grant *			
Visit 1	5,000	-	-
Visit 2	3,900	-	-
Visit 3	3,900	-	-
Visit 4	3,900	-	-
Total (A)			-
Screen Failure (B)	3,000	-	-
Institute Overhead @ 20% (C)	-----	-----	-
Subject Grant Total (A+B+C)			-
Subject Travel Cost^			
Subject Travel Cost (D)	500	-	-
Screen Failure Travel Cost (E)	500	-	-
Other			
Infrastructure set up cost* (F) * One time payment	—	—	-
Operational and administrative cost (G)			
Month(s)	Unit Cost	Number of Units	
Mar-19	15,000.00	-	-
Archival (H)			
Archival Charges	10,000.00	-	-
Total Cost (A+B+C+D+E+F+G+H)			-
Notes			
• For timely release of payment please submit the invoice monthly			
* Please attached an annexure to the Invoice with visit wise break-up for each subject			
^ Please provide visit-wise break-up of travel cost along with signed receipt for each subject			
• Institutional overheads are to be claimed in the final invoice over the actual cost of A+B.			



महाराष्ट्र MAHARASHTRA

2018

UM 650574

E-Track Number : 116566
Center Number : 203769
Reference for Payment : PO.....

प्रधान मुद्रांक कार्यालय, मुंबई
प.म.वि.क्र. ८०००००९
20 FEB 2019
सक्षम अधिकारी

श्री. प्र. ना. चिंचघरे

AGREEMENT FOR CLINICAL TRIALS

This Agreement for Clinical Trials (the "Agreement") is effective on 22-Mar-2019, (the "Effective Date") between

Bharati Vidyapeeth Deemed University and Medical College, Bharati Hospital and Research Centre, Department of Pediatrics, Katraj - Dhankawadi, Pune - 411043, Maharashtra, India (hereinafter referred to as "**Institution**")

And

Dr. Sanjay Lalwani, Bharati Vidyapeeth Deemed University and Medical College, Bharati Hospital and Research Centre, Department of Pediatrics, Katraj - Dhankawadi, Pune - 411043, Maharashtra, India (herein referred as the "**Principal Investigator**" or "**Investigator**")

And

GLAXOSMITHKLINE PHARMACEUTICALS LIMITED, a company registered under the Companies Act, 1956 and having its registered office at at Dr. Annie Besant Road, Worli, Mumbai 400030 (hereinafter referred to as "**GSK**").



NSNaw

WHEREAS GSK is a pharmaceutical company involved in the research, distribution and sale of vaccines for use in humans;

WHEREAS GlaxoSmithKline Biologicals S.A., rue de l'Institut 89, B - 1330 Rixensart, Belgium (hereinafter referred to as "**GSK Bio**" or "**Sponsor**") is the sponsor of the Study (as defined below) and has subcontracted the conduct of the Study to its affiliated local company, GSK;

WHEREAS Institution is concerned with the diagnosis, treatment and prevention of disease and clinical research for the improvement of healthcare

WHEREAS GSK is willing to contract with Institution to undertake the conduct of a sponsored study on the investigational Vaccine (as defined later) entitled "A phase **III**, randomized, open study to assess the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, *Rotarix*, when given as a two-dose primary vaccination, in healthy infants with no previous history of rotavirus illness or vaccination." (hereinafter referred to as the "**Study**"). Such Study will be conducted under the oversight and responsibility of Investigator at Institution; and

WHEREAS Investigator shall conduct the Study and Institution is willing to provide certain resources in furtherance thereof.

NOW, THEREFORE, in consideration of the promises and the mutual covenants and conditions hereinafter recited, the parties do hereby agree as follows:

I. INSTITUTION AND PRINCIPAL INVESTIGATOR

- a) Institution represents and warrants that it holds the necessary registrations and authorisations to perform the Study under this Agreement.
- b) Save as may be agreed from time to time by GSK and Institution, Principal Investigator shall take primary responsibility for the conduct of the Study at the Study site on behalf of Institution.
- c) The Institution represents that it is entitled to procure the services of Dr. Sanjay Lalwani to act as principal investigator for the Study ("**Principal Investigator**" or "**Investigator**") and shall be responsible for the performance of the obligations of the Principal Investigator and other Study staff set out in this Agreement. Institution represents that Investigator and other Study staff holds the necessary registration and has the necessary expertise, time and resources to perform the Study.
- d) Institution shall procure and shall ensure that Principal Investigator procures the performance of the obligations of the Study staff as set out in this Agreement with all due skill, care and diligence. Institution shall provide qualified personnel, facilities and resources, as required, to perform this Agreement.
- e) Where Institution is not the principal employer of Principal Investigator, Investigator represents that Principal Investigator has notified his/her principal employer of his/her proposed participation in the Study and, where relevant, his/her supervision of the Study staff and that his/her principal employer has



NSN

Investigator's breach, negligence, gross negligence or wilful misconduct or a breach by Institution or any of its agents, contractors or subcontractors of this Agreement.

X. COMPENSATION

- a) GSK agrees to pay for up to a maximum of 90 subjects included in the screening sequence, (at a cost of 11400/- per screened subject).
- b) GSK also agrees to pay, for each subject enrolled and properly documented as detailed in the Protocol, the following fees, in INR and this up to a maximum of 90 subjects included in the Study:

Total study budget	Unit cost	No. of subjects	Amount
Study assessments	6300	90 ⁹⁷	567000
Investigator's fees	3600	90	324000
Study personnel's fees	1500	90	135000
Total			1026000 → 1073,8
Overheads (to specify)	20%		205200 214,-
Travel reimbursement	1500	90	135000
Others (to specify)	100000		100000
Archival costs (for 25 years)			
Miscellaneous	20000		20000
Total study budget			1486200

(hereinafter referred to as the "Study Budget")

visit 1
5500 x 97
visit 2
3100 x 93
visit 3
2800 x 90

Visit Activities	Cost in INR		
	Visit 1	2	3
Informed consent	800 ⁹⁷	0 ⁹³	0 ⁹⁴
Check Inclusion/Exclusion Criteria	700	0	0
Physical Examination - General	800	700	0
Vaccine/Treatment Administration	400	400	0
Record, Concomitant Medication/Vaccine	300	300	300
Blood Draw, Complex	800	0	800
Study Coordinator, Complex - per visit	500	500	500
Physician, Complex - per visit	1200	1200	1200

5500 3100 2800 = 11

- c) The maximum Study Budget assigned to the Principal Investigator amounts to 1486200 (Study costs). The Principal Investigator shall be responsible for allocating and paying all costs of Study within the limit of the Study Budget to all co-investigators and sub-investigators working for the Study.

Payment of this Study Budget will be made upon achieving the following milestones:

Milestone payment	
I	First Payment: post site initiation visit: An amount of Rs.20000 will be released after site initiation visit.
II	Subsequent payments:
1	Towards subject visit: once in every two months based on subjects visits shown in eTRACK
2	Screen failure travel reimbursement payment: 10% of screen failures will be provided travel reimbursement.



[Handwritten signature]

NSN...

3	Cost involved in medical management and additional costs: once in every two months; shall be made on the receipt of the invoice and supporting documents
III	Post query resolution: An amount of Rs.50000 will be put on hold from the second last invoice. The said payment will be made after post query resolution.
IV	Post close out: archival payment will be made.

- d) Payments shall be remitted by GSK in INR on a milestone-completion basis, within thirty (30) days after receipt of duly documented invoice or supporting documentation demonstrating completion of the milestone. If the number of the subjects is less than the then-current target number set forth in Section XI a), the Study Budget and the installments will be reduced accordingly.

The Study Budget shall cover all Study expenditure such as, but not limited to investigators fees, GE/IP surveillance fees, Study personnel's fees, laboratory costs, (including personal and material), travel costs linked to public disclosure activities (if and to the extent requested by GSK) such as Publication Steering Committee meetings, core writing team meetings and presentations of Study results at conferences or congresses, overheads and others (including but not limited to administrative costs, taxes, insurances, ERC submission costs, etc).

Such Study Budget has been agreed upon by the parties prior to start the Study, therefore GSK shall in no event accept any overspending and the Principal Investigator and the Institution undertakes to complete the Study within such Study Budget.

Payment instructions shall be specified in Schedule B attached hereto (please fill in the Schedule B - Payment Instructions Sheet).

Bank transfer costs shall be supported by GSK.

- e) The Institution will receive the fees mentioned in sub-paragraphs (a) and (b) above for every subject evaluable according to the Protocol. The fee mentioned under (b) above shall be paid only with respect to evaluable subject and when the vaccination's calendar as foreseen in the Protocol has been scrupulously respected. In the event of non-evaluable subject(s), only the screening costs specified in sub-paragraph (a) will be paid. The non-evaluable subject's criteria are defined in the Protocol and include, but are not limited to, the following events:
- i) subject or vaccine number not allocated;
 - ii) Study vaccine dose not administered but subject number allocated;
 - iii) administration of vaccine forbidden in the Protocol;
 - iv) wrong vaccine vial given;
 - v) deliberately breaking the randomization code at investigator site, violating the allowable reasons for breaking the code (i.e. SAE, etc.);




[Handwritten signature]

[Handwritten signature]

IN WITNESS WHEREOF, the parties caused this Agreement to be executed, as of the date first written above, in multiple counterparts (each of which will be deemed to be an original, and all of which together will constitute one and the same Agreement) by their duly authorized representatives who, by signing, confirm their authority to bind their respective party.

For and on behalf of
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED


By : 
Name : Dr. Sanjay Gandhi
Title : Vice President - Vaccines Area Medical
Lead (Gavi, Asia) & Lead LML (Clinical
R&D, EM)


By :
Name :
Title :

For and on behalf of

By my signature I indicate my agreement to fulfill the role and obligations of Principal Investigator under this Agreement and consent to the disclosure of my name and Institution(s) with which I am affiliated as well as the details of any payment or benefit in kind made to me or for my benefit under this Agreement in publicly accessible worldwide registers.

Bharati Vidyapeeth (Deemed To be University) and Medical College, Pune **Principal Investigator**

By : 
Name : **PRINCIPAL**
Bharati Vidyapeeth
Title : (Deemed to be University)
Medical College
Pune - 43

By : 
Name : Dr. Sanjay Lalwani
Title : **Dr S K. Lalwani**
Vice Principal
Professor and Head
Department of Pediatrics
Bharati Vidyapeeth Deemed University
Medical College
Pune-Satara Road, Pune-411 043

Attachments to the present Agreement :

Schedule A : Protocol

Schedule B : Payment instructions sheet

Schedule C : Statement of Investigator Financial Interest Form



Juhi Suhanda <juhi.x.suhanda@gsk.com>

Tue, Oct 13, 2020 at 5:09 PM

To: BVDUMC Pedresearch <researchpedpune@gmail.com>

Cc: "sampadaransubhe@gmail.com" <sampadaransubhe@gmail.com>, Hitesh Bharucha <hitesh.x.bharucha@gsk.com>,
Jagdish Jamgade <jagdish.c.jamgade@gsk.com>, "sanjaylalwani2007@rediffmail.com"

<sanjaylalwani2007@rediffmail.com>

Dear Dr Sonali,

Good Evening!

Please see below the Subject Visit Payments made so far. The payments marked in Green are already made to the site and those marked in yellow are pending.

<i>Upto 31st May 2019</i>	Subjects	Amount	Total
Visit 1	13	5500	71500
Visit 2	4	3100	12400
			83900
20 % Overhead			16780
			100680
Travel reimbursement	17	500	8500
			109180
<i>Upto 31st Jul 2019</i>	Subjects	Amount	Total
Visit 1	36	5500	198000
Visit 2	20	3100	62000
Visit 3	12	2800	33600
			293600
20 % Overhead			58720
			352320
Travel reimbursement	68	500	34000
			386320
<i>Upto 30th Sep 2019</i>	Subjects	Amount	Total
Visit 1	39	5500	214500
Visit 2	42	3100	130200
Visit 3	31	2800	86800
			431500
20 % Overhead			86300
			517800
Travel reimbursement	112	500	56000
			573800
<i>As of 26th Nov 2019</i>	Subjects	Amount	Total
Visit 1	9	5500	49500
Visit 2	27	3100	83700
Visit 3	20	2800	56000
			189200
20 % Overhead			37840
			227040
Travel reimbursement	56	500	28000
			255040

As of 13th Feb 2020	Subjects	Amount	Total
Visit 3	27	2800	75600
20 % Overhead			15120
			90720
Travel reimbursement	27	500	13500
Miscellaneous			20000
			124220
Retainage			50000
			74220
Last Payment			Amount (INR)
Archival Fees			100000
Retainage release			50000
			150000

Below is the calculation mentioning the payments deducted for subject withdrawals.

Subject Withdrawals(NOT PAID)			
Visit Type	No of subject withdrawn	Amount (INR)	Total
Visit 2	4	3100	12400
Visit 3	7	2800	19600
			32000
Overhead 20%			6400
Travel	11	500	5500
Total			43900

Also attached are the previous signed invoices for Subject Visit Payments received from site and cheques that were generated from GSK for your reference.

Do let me know in case of any further queries. Also kindly send the last invoice and online banking details so i can initiate the payment process.

Thank you! Stay Safe!
Best Regards
Juhi Suhandra
 Clinical Trial Assistant
 Clinical Operations
 GSK Vaccines
 252, Dr. Annie Besant Road, Worli,
 Mumbai - 400030, India.
 Email -juhi.x.suhandra@gsk.com
 Mob - 9987810153

31st may - 1,09,180
 31 July - 3,86,320
 30 Sep - 5,73,800
 26 Nov - 2,55,040
~~13,24,340~~
 13,24,340

gsk.com | Twitter | YouTube | Facebook | Flickr



224220 - Remaining Bal. awarded
 19/04/2020



सत्यमेव जयते

Government of Karnataka

Rs. 100

e-Stamp

Certificate No. : IN-KA88909563250360T
Certificate Issued Date : 30-Aug-2021 11:41 AM
Account Reference : NONACC (FI)/ kagcsl08/ KORAMANGALA1/ KA-BA
Unique Doc. Reference : SUBIN-KAKAGCSL0837726249773340T
Purchased by : CBCI SOCIETY FOR MEDICAL EDUCATION CBCI
Description of Document : Article 12 Bond
Description : CLINICAL TRIAL AGREEMENT ACT
Consideration Price (Rs.) : 0
 (Zero)
First Party : HAMILTON HEALTH SCIENCES CORPORATION
Second Party : CBCI SOCIETY FOR MEDICAL EDUCATION CBCI
Stamp Duty Paid By : CBCI SOCIETY FOR MEDICAL EDUCATION CBCI
Stamp Duty Amount(Rs.) : 100
 (One Hundred only)

सत्यमेव जयते



Please write or type below this line

**AMENDMENT 1
TO THE CLINICAL TRIAL AGREEMENT - ACT**

This amendment ("Amendment 1") is effective as of August 16, 2021 (the "Amendment 1 Effective Date"), between:

Hamilton Health Sciences Corporation ("HHSC"), through its Population Health Research Institute ("PHRI"), at 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada represented by Ms. Tanya Chow, Director of Contracts, PHRI (which expression shall, where the context so permits include his successors in office and assigns)

2021-0997-PHRI v3

Page 1 of 8

DS
DS

-and-

CBCI Society for Medical Education, ("CBCI") established and registered under the Karnataka Societies Registration Act, 1980, having its address at St. John's National Academy of Health Sciences, John Nagar, Sarjapur Road, Koramangala, Bengaluru -560034, Karnataka, India, represented by its Secretary (which expression shall, where the context so permits include his successors in office and assigns) hereafter referred as the "**Society**"

-and-

St. John's Research Institute, ("SJRI") a unit of the Society, having its address at St. John's National Academy of Health Sciences, John Nagar, Sarjapur Road, Koramangala, Bengaluru-560034, Karnataka, India, represented by its Dean (which expression shall, where the context so permits include his successors in office and assigns) hereafter referred as "**Institute**"

-and-

Division of Clinical Research and Training ("DCRT"), a Division of SJRI, with its administrative office at St. John's Research Institute, St. John's National Academy of Health Sciences, Bengaluru-560 034 Karnataka; India, represented by, Dr. Denis Xavier, Professor, Dept. of Pharmacology, St. John's Medical College and Head DCRT and Dr Prem Pais, Adjunct Professor, Medicine Department, St. Johns Research Institute (hereafter called "**National Leaders**")

-and-

Bharati Vidyapeeth (Deemed to Be University) Medical College, at Pune - Satara Rd, Bharati Vidyapeeth Campus, Dhankawadi, Pune, Maharashtra, 411043, India ("**Institution**")

-and-

Dr. Purwa Doke, at Pune - Satara Rd, Bharati Vidyapeeth Campus, Dhankawadi, Pune, Maharashtra, 411043, India ("**Investigator**")

Capitalized terms used in this Amendment 1 but not defined herein shall have the meanings set forth in the Agreement, as hereinafter defined.

WHEREAS, the parties entered into an Agreement for the clinical trial entitled **Anti-Coronavirus Therapies to prevent progression of COVID-19 (ACT)** ("**Project**") on October 26, 2020 (hereinafter the "**Agreement**");

AND WHEREAS, the parties have agreed to amend the Agreement, subject to the terms and conditions outlined herein.

NOW THEREFORE, in consideration of the mutual promises and covenants contained herein and other good and valuable consideration, the sufficiency of which is hereby recognized, the parties hereby agree as follows:

1. The following is deleted in the Agreement:

Hamilton Health Sciences Corporation ("HHSC"), through its **Population Health Research Institute** ("PHRI"), at 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada represented by Ms. Tanya Chow, Director of Contracts, PHRI (which expression shall, where the context so permits include his successors in office and assigns)

and replaced with:

Hamilton Health Sciences Corporation ("HHSC"), through its **Population Health Research Institute** ("PHRI"), at 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada represented by the Director of Contracts, PHRI (which expression shall, where the context so permits include such successors in office and assigns)

2. The following is deleted in the Agreement:

Division of Clinical Research and Training ("DCRT"), a Division of SJRI, with its administrative office at St. John's Research Institute, St. John's National Academy of Health Sciences, Bengaluru-

PD



Handwritten signature



560 034 Karnataka; India, represented by, Dr. Denis Xavier, Professor, Dept. of Pharmacology, St. John's Medical College and Head DCRT Dr Prem Pais, Adjunct Professor, Medicine Department, St. Johns Research Institute (hereafter called "**National Leaders**")

and replaced with:

Division of Clinical Research and Training ("DCRT"), a Division of SJRI, with its administrative office at St. John's Research Institute, St. John's National Academy of Health Sciences, Bengaluru-560 034 Karnataka; India, represented by, Dr. Denis Xavier, Professor, Dept. of Pharmacology, St. John's Medical College and Head DCRT and Dr. Prem Pais, Adjunct Professor of Medicine, DCRT, St. Johns Research Institute (hereafter called "**National Leaders**")

3. The following Whereas: paragraph is deleted in the Agreement:

D. DCRT, SJRI will be the National Leader Office ("**NLO**") Dr. Denis Xavier, Professor Dept. of Pharmacology, St. John's Medical College as its Head and Dr Prem Pais, Adjunct Professor, Medicine Department, St. Johns Research Institute.

and replaced with:

D. DCRT, SJRI will be the National Leader Office ("**NLO**") Dr. Denis Xavier, Professor Dept. of Pharmacology, St. John's Medical College as its Head and Dr. Prem Pais, Adjunct Professor of Medicine, DCRT, St. Johns Research Institute.

4. The following Section 2.1 is deleted in the Agreement:

2.1 This Agreement shall commence on the Effective Date specified above, and continue until approximately August 31st 2021, or until PHRI receives all completed and corrected forms, reports and other documentation from the Institution as required by the Protocol and final payment is sent by PHRI or upon written notice from PHRI of early termination of the Project, whichever occurs first, unless otherwise terminated earlier in accordance with **ARTICLE 9 (Termination) ("Term")**.

and replaced with:

2.1 This Agreement shall commence on the Effective Date specified above, and continue until approximately August 31, 2023, or until PHRI receives all completed and corrected forms, reports and other documentation from the Institution as required by the Protocol and final payment is sent by PHRI or upon written notice from PHRI of early termination of the Project, whichever occurs first, unless otherwise terminated earlier in accordance with **ARTICLE 9 (Termination) ("Term")**.

5. The following in Section 10.1 is deleted in the Agreement:

And to:

Dr. Prem Pais
Adjunct Professor-Medicine Department
St. John's Research Institute
St. John's National Academy of Health Sciences
Johnnagar, Bengaluru -560 034, India
Tel: +91 80 49467005
Email: Prempais@sjri.res.in

and replaced with:

And to:

Dr. Prem Pais
Adjunct Professor of Medicine
DCRT, St. John's Research Institute
St. John's National Academy of Health Sciences
Johnnagar, Bengaluru -560 034, India
Tel: +91 80 49467005
Email: Prempais@sjri.res.in



6. The Payment Schedule, Exhibit 1, in the Agreement shall be replaced with the new and revised Exhibit 1-A appended to this Amendment 1. The new and revised Exhibit 1-A shall be retroactively effective as of the Effective Date of the Agreement.
7. The Payment Rule Form, Exhibit 2, in the Agreement shall be replaced with the new and revised Exhibit 2-A appended to this Amendment 1.
8. Except as set forth in this Amendment 1, the Agreement is unaffected and shall continue in full force and effect in accordance with its terms. If there is a conflict between this Amendment 1 and the Agreement, the terms of this Amendment 1 shall prevail to the extent of such conflict.
9. This Amendment 1 may be executed in two or more identical counterparts, facsimile counterparts or electronic counterparts, each of which when executed by a party shall be deemed to be an original and such counterparts shall together constitute one and the same Amendment 1. This Amendment 1 shall be binding and take full force and effect as of the Amendment 1 Effective Date.

- signature page to follow -

PD



[Handwritten signature]



IN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed this Amendment 1.

Hamilton Health Sciences Corporation

DocuSigned by:

Janette Panhuis

8F2C807FD562413

Signature

Name: Janette Panhuis

Position: Chief Operating Officer, Population Health Research Institute

Date: 2021-Aug-16 | 14:56 EDT

(YYYY-MMM-DD)

INSTITUTION: Bharati Vidyapeeth (Deemed to Be University) Medical College

Signature

Name: _____

Title: _____

Date: _____

(YYYY-MMM-DD)

INVESTIGATOR: Dr. Purwa Doke

Purwa D.

Signature

Date: 2021-Sept-15

(YYYY-MMM-DD)

CBCI Society for Medical Education

Paul Parathazham

Signature

Name: Rev. Dr. Paul Parathazham

Title: Secretary

SECRETARY

C.B.C.I. SOCIETY FOR MEDICAL EDUCATION
ST. JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES
SARJAPUR ROAD, BANGALORE - 560 034

Date: 2021 Sept. 08

(YYYY-MMM-DD)

St. John's Research Institute

Tony D.S. Raj

Signature

Name: Dr. Tony D.S. Raj

Title: Dean

DEAN

St. John's Research Institute
St. John's National Academy of Health Sciences
Koramangala, Bangalore - 560 034, INDIA


Date: 2021 Sept 01

(YYYY-MMM-DD)

PD




National Leader Office



Signature
Name: Dr. Denis Xavier
Title: Head, Division of Clinical Research & Training

Date: 2021 Aug 28
(YYYY-MMM-DD)



Signature
Name: Dr. Prem Pais
Title: Adjunct Professor of Medicine, DCRT

Date: 2021 Aug 21
(YYYY-MMM-DD)



PD



EXHIBIT 1-A – PAYMENT SCHEDULE

Payments will be processed on a **bi-monthly** basis with the payment run cut-offs February 28th, April 30th, June 30th, August 30th, October 31st and December 31st of each year. Payments will be issued within 25 days from the processing/run date (i.e., Payment for run date February 28th will be sent on or prior to March 25th). Payments shall be according to the following schedule, and will be made for all CRFs received and validated as clean prior to the applicable cut-off date.

Visit Type	Amount in CAD per Subject, per visit, including receipt by PHRI of the required CRF for such visit(s)
Baseline/Randomization	260
8 day follow up visit	162.50
45 day follow up visit	162.50
Final Visit	65
Total Per Subject Amount **	650

** Amount per completed Subject, including all costs (i.e., recruitment and follow-up including events reporting, overheads, coordinators time, investigators time, PPE, translation, pharmacists, drug storage costs, creatinine tests, monitoring visits, archiving, all applicable taxes, Subject expenses such as travel and parking, etc., if applicable). All relevant forms are to be completed at each visit, including all prior events and related documentation.

Additional payment:

Site coordinator insurance will be provided to each site as a one time payment of \$95 CAD with the first payment.

PD



EXHIBIT 2-A - PAYMENT RULE FORM

COUNTRY:	INDIA
SITE #:	459-0
INSTITUTION:	Bharati Vidyapeeth (Deemed To Be University) Medical College Pune
INVESTIGATOR:	Dr. Purwa Doke

Payment will be in CAD. Payments will be processed on a **bi-monthly** basis with the payment run cut-offs on February 28th, April 30th, June 30th, August 30th, October 31st and December 31st of each year. Payments will be issued and sent out within 25 days from the processing/run date (i.e., payment for run date February 28th will be sent on or prior to March 25th) provided that a minimum of **500CAD** has been earned within such payment period. Payments will be made for all CRFs received and validated to be clean prior to this date, according to the attached payment schedule.

Payments will be made to only one party. **(ALL INFORMATION BELOW MUST BE LEGIBLE)**

The following information is required in order to generate payment by wire transfer. Incomplete information will result in no payment.

Bank Name:	State Bank of India, Katraj, Pune
Bank Address:	Sr No. 133/2 Near Bharati Vidyapeeth Satara Road Dist: Pune, Maharashtra, INDIA (411046) Tel No (020-24371861)
Bank SWIFT code:	-
Beneficiary (Account Holder) Name:	Principal, BVDU Medical College
Beneficiary Address:	Bharati Vidyapeeth (Deemed To Be University) Medical College Satara Road, Pune-411043
Beneficiary IBAN or Account number:	10277606023
IFSC Code (India only):	SBIN0008752
Reference (if applicable):	-
Contact name and email for payment notification:	Dr. Juilee Surve (icutrials@gmail.com)
Tax ID # / GST Registration # / VAT #:	-
PAN card #:	AAATB1836D
For HHSC use only - Vendor ID #:	



PD

INSTITUTIONAL ETHICS COMMITTEE

BHARATI VIDYAPEETH DEEMED UNIVERSITY

Bharati Hospital & Research Centre, Pune-Satara Road, Dhankawadi, Pune 411043

Tel: 020 40555555, Ext 265, Email: bvduicc@gmail.com

DCGI Regd. No. ECR/313/Inst/MH/2013/RR-19

NABH Accreditation No. EC-CT-2018-0016

IEC/2020/129

Date: 06 Nov 2020

To,

Dr. Prachee Makashir

Principal Investigator,

Professor of Medicine,

Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital,
Pune.

Ref: **Protocol Title:** A phase 2 evaluation of the efficacy of homeopathic remedy Zincum Muriaticum as an adjuvant therapy to standard of care in adult subjects with moderate to severe COVID-19: Randomised, double blind, parallel group, placebo controlled, multicenter trial (ZIMCOV)

Sub: Institutional Ethics Committee (IEC) **Approval** for conduct of the above referred study and study related documents

Dear Dr. Makashir,

The above referred study was reviewed and discussed in Institutional Ethics Committee meeting held online, on Friday, 16 Oct 2020 and IEC had provided Conditional approval vide letter IEC/2020/119 dated 26 Oct 2020.

IEC has received responses to IEC queries vide letter dated 29 Oct 2020 as follows:

Q1. Only one formulation of medication (either tablet or liquid formulation) to be used for all patients.

Response:

1) Zincum muriaticum 200 C liquid potency is to be used in the trial. It's essentially a liquid potency drug as most of the homeopathic medicines are. The liquid potency drugs are impregnated on sucrose globules for ease of administration. The sucrose globules are just vehicle for the liquid drug. So essentially there is no change in the liquid formulation whether it is impregnated on sucrose globules or given in liquid form as such (for patients on ventilator). Then for ease of administration the liquid potency will be given per orally in diluted form as per details outlined in the protocol. This information is endorsed by Dr. Mrs. Anita Patil, Dean, Homeopathy Medical College, BVDU, a Co Investigator for the trial. So essentially it is the same formulation of drug.

2) Moderately severe Covid-19 is a medical condition that is known to deteriorate and some patients may need mechanical ventilation. As the patient may take time to show a response to the homeopathic medicine and since it is highly safe, the protocol proposes to continue the trial even if such an eventuality were to occur.

3) Submitted protocol has been approved by IEC Smt Kashibai Navale Medical College and General Hospital and the trial has been registered on CTRI and has recruited over 25 patients already at Navale hospital.

After reviewing responses to IEC queries, IEC found them satisfactory. CTRI number and Clinical Trial Agreement (CTA) need to be submitted.

IEC granted **Approval** for the conduct of the study and study related documents for 1 year.

We approve the trial to be conducted in its presented form.

IEC expects to be informed about the progress of the study, any Serious Adverse Event (SAE) occurring in the course of the study, any changes in the protocol and patient information / informed consent, deviations, any new information that may affect adversely the safety of subjects or conduct of the study and asks to provide a copy of the final report.

Kindly submit a report on the progress of the study every six months. Annual study status report needs to be submitted for approval for continuation of the study.

With best wishes,

Yours truly,



Dr. Prasad Pore
Member Secretary



INSTITUTIONAL ETHICS COMMITTEE

BHARATI VIDYAPEETH DEEMED UNIVERSITY

Bharati Hospital & Research Centre, Pune-Satara Road, Dhankawadi, Pune 411043

Tel: 020 40555555, Ext 265, Email: bvduiec@gmail.com

DCGI Regd. No. ECR/313/Inst/MH/2013/RR-19

NABH Accreditation No. EC-CT-2018-0016

IEC/2020/70

Date: 29 Jul 2020

To,

Dr. Vishwanath Patil

Principal Investigator,

Associate Professor,

Department of Critical Care Medicine,

Bharati Vidyapeeth (Deemed to be University) Medical College,
Pune

Ref: **Protocol Title:** An Open Label, Randomized, Multicenter, Controlled Clinical Study to Evaluate the Efficacy and Safety of Nafamostat Mesilate in the Treatment of Moderate COVID-19 disease
Protocol Version No. Version 2.0, Dated 30 May/2020

Sub: Institutional Ethics Committee (IEC) **Conditional Approval** for conduct of the above referred study and study related documents.

Dear Dr. Patil,

The above referred study, submitted for expedited review and approval vide letter dated 11 Jul 2020 was reviewed and discussed in Institutional Ethics Committee online meeting held on 22 Jul 2020, at 02:30 pm.

IEC has received SRC approval letter vide letter dated 24 Jul 2020.

Following documents were submitted for review:

Sr. No.	Details of document	Version No. and date
1	SRC approval letter	SRC/2020/25 dated 22 Jul 2020
2	Investigator's Brochure	Version 1.0, Dated 21/APR/2020
3	Clinical Study Protocol and Appendices (Appendix I, II, III, IV, V, VI) (Along with List of Changes)	Version 2.0, Dated 30/MAY/2020

4	Case Report Form (CRF)	Version Final 2.0, Dated 09/JUL/2020
5	Center Specific Patient Information Sheet and Informed Consent Form (PIS +ICF) in English	Version No. 2.0.1; Dated 02/JUN/2020
6	Translation & Back translation of Center Specific Patient Information Sheet and Informed Consent Form (PIS +ICF) in Hindi language	Version No. 2.0.1; Dated 02/JUN/2020
7	Translation & Back translation of Center Specific Patient Information Sheet and Informed Consent Form (PIS +ICF) in Marathi language	Version No. 2.0.1; Dated 02/JUN/2020
8	Translation & Back translation certificate for Center Specific PIS +ICF in Hindi language	06/JUN/2020
9	Translation & Back translation certificate for Center Specific PIS +ICF in Marathi language	06/JUN/2020
10	Draft Clinical Trial Agreement	-
11	CTRI	CTRI/2020/06/026220
12	Insurance (Policy No. 4067/119274809/04/000)	From 01 July 2020 to 30 June 2021
13	Investigator Undertaking & PSP	Dated 03/JUN/2020
14	CV and MRC certificate of PI	-
15	DCGI CT NOC (CT-ND/41/2020)	Dated 25/MAY/2020
16	DCGI notification letter	Dated 05/JUN/2020
17	DCGI notification letter	Dated 24/JUN/2020
18	DCGI notification letter	Dated 10/JUL/2020

Following members of the IEC attended the online meeting to review and discuss the study proposal:

Sr. No.	Name	Qualification	Affiliation	Role in the IEC	External/Internal
1	Dr. Abhijeet Tilak	M.D. Pharmacology	Professor and Head, Department of Pharmacology, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune - 18	Medical Scientist/ Pharmacologist (Acting Chairperson)	External
2	Dr. Priti Dave	MD Medicine	Professor Department of Medicine Bharati Vidyapeeth (Deemed to be University) Medical College, Pune	Clinician/ Physician	Internal

Sr. No.	Name	Qualification	Affiliation	Role in the IEC	External/Internal
3	Dr. Sanjay Natu	MD DNB(Pediatrics) MNAMS FACEE (PEM)	Professor, Department of Pediatrics Smt. Kashibai Navale Medical College & General Hospital, Pune Consultant Pediatrician Shashwat Hospital, 22, Happy Colony, Kothrud, Pune	Clinician/ Pediatrician	External
4	Dr. Anand Deshpande	DNB (Pediatrics), DCH	Honorary Associate Professor, Department of Pediatrics, B. J. Medical College and Sassoon General Hospital, Pune Consultant Pediatrician, Deenanath Mangeshkar Hospital and Mai Mangeshkar Hospital, Pune	Clinician/ Pediatrician	External
5	Dr. Jayshree Dawane	MD (Pharmacology) Ph.D (Pharmacology)	Associate Professor, Department of Pharmacology Bharati Vidyapeeth (Deemed to be University) Medical College, Pune	Medical Scientist/ Pharmacologist	Internal
6	Adv. Sangeeni Pol	L.L.B., B.S.L.	Practicing Lawyer, Pune	Legal Expert	External
7	Adv. Ashwini Hogeptil	B.A., L.L.B.	Practicing Lawyer, Pune	Legal Expert	External
8	Mrs. Vidya Garkhedkar	M.A. (Philosophy) B. Ed	Assistant Teacher in Dept. of Philosophy & Logic at junior college, S.P. College, Pune 30	Philosopher	External
9	Dr. Swati Shirwadkar	M.A., Ph.D (Sociology) D. Litt. (honoris causa)	Retired Professor from Savitribai Phule Pune University (SPPU)	Social Scientist	External
10	Mrs. Vijayalaxmi Bathe	B.A., B. Ed (Physical Education)	President of Jivhala Jeshth Nagrik Sangh, Astoniya Royale, Ambegaon BK, Pune 411046 Yoga Teacher	Lay Person	External

Sr. No.	Name	Qualification	Affiliation	Role in the IEC	External/Internal
11	Mrs. Sarika Deshmukh	B. Com	Housewife	Lay Person	External
12	Dr. Prasad Pore	MD (P&SM) D.N.B. (SPM)	Professor Department of Community Medicine Bharati Vidyapeeth (Deemed to be University) Medical College, Pune	Member Secretary	Internal

IEC composition was ICH - GCP and New Drugs and Clinical Trials Rules 2019 G.S.R. 227 (E) compliant. Required quorum was present for the meeting.

IEC reviewed the above mentioned documents and discussed the project in detail.

IEC had following suggestions/ recommendations:


1. IEC seeks clarification for the continuous infusion of study drug for 10 days, as it is given for 5 days for other indications such as Pancreatitis and Disseminated Intravascular Coagulation (DIC). IEC suggested that as it is a first clinical trial, the study drug should be tried for 5 days first, if it is not successful, then it should be tried for further days.

2. IEC suggested that one more arm with the reduced time may be added in the study so that unnecessary exposure may be avoided.

After reviewing all the study documents, IEC granted **Conditional Approval** for the study related documents and conduct of the study and seeks clarifications to the above mentioned suggestions/ recommendations.

With best wishes,

Yours truly,



Dr. Prasad Pore
Member Secretary





icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Established in 1950

भारतीय आयुर्विज्ञान अनुसंधान परिषद्
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार
कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research
Department of Health Research, Ministry of Health
and Family Welfare, Government of India

Dated: 31/08/2020

NO. 54/3/GER/Indo-Sweden /17-NCD-II

To

Mrs. Santa De
Professor,
Medical Surgical Nursing,
Bharati Vidyapeeth Deemed University college of Nursing,
Dhankawadi, Pune-411043

Sub: "Multi-cultural aspects of active ageing: a cooperative study between Sweden and India. Under Mrs. Santa De.

Madam,

This is with reference to your above mentioned research proposal.

The Competent Authority of the ICMR has sanctioned the continuation of the above mentioned project in the 3rd year w.e.f. 16.07.2020 to 15.07.2021 with the budget allotment of Rs. 11,72,142/- (Eleven lakh seventy two thousand one hundred forty two only) subject to the same terms & conditions as mentioned vide this office letter of even number dated 22.11.2017. The budget statement is enclosed herewith for ready reference.

It is also requested that statement of accounts and utilization certificate up to 15.07.2020 as per ICMR format may be sent to this office immediately. 3rd year grant will be released only after receipt of the same.

Yours faithfully,

(Ishwar Likhar)
Admn. Officer
For Director-General

Copy to

1. Principal, Bharati Vidyapeeth Deemed University, College of Nursing, Dhankawadi, Pune-411043
2. Accounts Section ICMR (RFC No. (P-60)NCD/NTF/13/2017-18 dated 13.11.2017)
3. A.O. (NCD) 4) Mr. Hemant Kumar, Sr. TO, NCD,
4. IRIS Section 2017-0053

TSB
For Director-General

वी. रामलिंगस्वामी भवन, पोस्ट बॉक्स नं. 4911,
अंसारी नगर, नई दिल्ली - 110 029, भारत
V. Ramalingaswami Bhawan, P.O. Box No. 4911,
Ansari Nagar, New Delhi - 110 029, India

Tel: +91-11-26588895 / 26588980 / 26589794
+91-11-26589336 / 26588707
Fax: +91-11-26588662 | icmr.nic.in

Utilization Certificate (Annual/~~Final~~)


Certified that out of Rs.1241260/- of grants-in-aid sanctioned during the year ...2018-19.... in favour of ...Bharati Vidyapeeth Deemed University, College of Nursing, Pune under ICMR Letter No54/3/GER/Indo-Sweden/17/NCD-II and Rs...27067/- on account of interest earned from Bank Savings Account for the year, a sum of Rs 912235.00 has been utilized for the purpose of Active ageing project for which it was sanctioned and that the balance of Rs. 356092.00 remaining unutilized at the end of the year will be adjusted towards the grants-in-aid payable during the next year i.e. 2019-20.

Santosh
16.9.2019
Signature of
Principal Investigator
with date

G. Anandharan
Signature of Registrar/
of the Institute with date

[Signature] 16.9.2019
Signature of Accounts Officer
Finance & Accounts Officer
of the Institute with date
Bharati Vidyapeeth Deemed University
Pune-411 030.

[Signature]
For M/s. V.A. Dudhedia & Co.
Chartered Accountants



Utilization Certificate (Annual/Final)

Certified that out of Rs.11,05,396/- of grants-in-aid sanctioned during the year 2019-20 in favour of Bharati Vidyapeeth Deemed University, College of Nursing, Pune under ICMR Letter No54/3/GER/Indo-Sweden/17/NCD-II and Rs. 6165/- on account of interest earned from Bank Savings Account for the year, a sum of Rs 765892/- has been utilized for the purpose of Active ageing project for which it was sanctioned and that the balance of Rs.3,45,669.00 remaining unutilized at the end of the year will be adjusted towards the grants-in-aid payable during the next year i.e. 2020-21.

SRM
A.O.
Acc
Pu
Pr

20

Santosh 22.9.2020
Signature of
Principal Investigator
with date

G. Rajakumar
Signature of Registrar/
of the Institute with date

[Signature] 22.9.2020
Signature of Accounts Officer
of the Institute with date

Finance & Accounts Officer
Bharati Vidyapeeth
(Deemed to be University)
Pune-411 030

[Signature]
For M/s. V.A. Dudhedia & Co.
Chartered Accountants



VIJAYKUMAR A. DUDHEDIA
CHARTERED ACCOUNTANTS
M. No. 13889

SR/NM/NT-1029/2015 (C)
Government of India
Ministry of Science & Technology
Department of Science & Technology
(Nano Mission)

Technology Bhavan
New Mehrauli Road
New Delhi -110 016
Dated: **13.03.2018**

ORDER

Sub: **Financial assistance for the research project entitled "Charged graphite nanoplateletes anchored ultrafiltration membrances for separation of heavy metals" under the guidance of Dr. Yogesh Jayasingh Chendake, Department of Chemical Engineering, Bharati Vidyapeeth University, College of Engineering, Pune-411 043 (Maharashtra).**

With reference to the sanction order No. **SR/NM/NT-1029/2015 (G)** dated **13.03.2018**, sanction of the President is accorded to the release of **Rs. 11,00,000/-** (Rupees eleven lakh only) to the "**Principal, Bharati Vidyapeeth University, College of Engineering, Pune-411 043 (Maharashtra)**" being the grant under 'Grants-in-aid Capital' for implementation of above mentioned project.

2. This sanction is subject to the condition that the grantee organisation will furnish to the Department of Science & Technology, financial year wise Utilization Certificate (UC) in the proforma prescribed as per GFR 2017 and audited statement of expenditure (SE) along with up to date progress report at the end of each financial year duly reflecting the interest earned/accrued on the grants received under the project. This is also subject to the condition of submission of the final statement of expenditure, utilization certificate and project completion report within one year from the scheduled date of completion of the project.
3. The grantee organisation will have to enter & upload the Utilization Certificate in the PFMS portal besides sending it in physical form to this Division. The subsequent/final instalment will be released only after confirmation of the acceptance of the UC by the Division and entry of previous Utilization Certificate in the PFMS.
4. If the grant has been released under capital head through separate sanction order under the same project for purchase of equipment(s), separate SE/UC has to be furnished for the released Capital head grant.
5. The grant-in-aid being released is subject to the condition that
 - a) A transparent procurement procedure in line with the provisions of General financial Rules 2017 will be followed by the university/institute under the appropriate rules of the grantee organization while procuring capital assets sanctioned for the project and a certificate to this effect will be submitted by the university/institute immediately on receipt of the grant.
 - b) While submitting Utilization Certificate/Statement of Expenditure, the university/institute has to ensure submission of supporting documentary evidences with regard to purchase of equipment/capital assets as per the provisions of GFR 2017. Subsequent releases of grants under the project shall be considered only on receipt of the said documents.
6. The grantee organization will maintain separate audited account for the project and the entire amount of grant will be kept in an interest bearing bank account. The interest earned/accrued should be reported to DST (financial year wise) while submitting the Statement of Expenditure/Utilization Certificate. The interest thus earned will be treated as a credit to the grantee organization, which will be adjusted towards future release of grant.


7. The Unique ID of Bharati Vidyapeeth University, Pune under NGO DARPAN portal is MH/2017/0153828.
8. DST reserves sole rights on the assets created out of grants. Assets acquired wholly or substantially out of government grants (except those declared as obsolete and unserviceable or condemned in accordance with the procedure laid down in GFR 2017), shall not be disposed of without obtaining the prior approval of DST.
9. The account of the grantee organization shall be open to inspection by the sanctioning authority and audit(both by C&AG of India and Internal Audit by Principal Accounts Office of the DST), whenever the organization is called upon to do so on, as laid down under Rule 236(1) of General Financial Rules 2017.
10. Due acknowledgement of technical support/ financial assistance resulting from this project grant should mandatorily be highlighted by the grantee organization in bold letters in all publications/ media releases as well as in the opening paragraphs of their Annual Reports during and after the completion of the project.
11. Failure to comply with the terms and condition of the Bond will entail full refund with interest in terms of Rule 231(2) of GFR 2017.
12. The expenditure involved is debitable to Demand No.84, Department of Science & Technology for the year 2017-18:

Demand No. 84	Department of Science & Technology
3425	Other Scientific Research (Major Head)
60.	Others: (Sub-Major Head)
60.200	Assistance to other Scientific Bodies (Minor Head)
69.	Research & Development (National Mission on Nano Science & Nano Technology)
69.00.35	Grants-in-aid Capital for 2017-2018 (Previous: Nano Mission: 3425.60.200.36.01.35)
This release is being made under Nano Mission .	

13. The amount of **11,00,000/-** (Rupees eleven lakh only) will be disbursed to the "Principal, Bharati Vidyapeeth University, College of Engineering, Pune-411 043(Maharashtra)". The bank details for electronic transfer of funds through RTGS are given below:-

Saving Bank account number	32929906172
Name of the bank and branch	State Bank of India, Near Bharati Vidyapeeth, Pune-411043
RTGS/IFSC Code	SBIN0008752
MICR Code	411002018

14. As per rule 234 of GFR 2017, this sanction has been entered at S. No. **234 NMD** in the register of grants maintained in the Division for the scheme Research & Development (National Mission on Nano Science & Nano Technology).
15. The issues with the concurrence of IFD Vide their Concurrence Dy. No. C/5426/IFD/2017-18 dated **13.03.2018**.



(G.V RAGHUNATH REDDY)
 Scientist-E

To

Pay & Accounts Office,
Department of Science & Technology
New Delhi

Copy forwarded for information and necessary action to:

1. The Principal Director of Audit, Scientific Department
IIIrd floor, AGCR Building, I.P. Estate
New Delhi
2. Drawing and Disbursing Officer, DST, Cash Section.
(Copy with two spare copies)
3. **Dr. Yogesh Jayasingh Chendake**
Department of Chemical Engineering
Bharati Vidyapeeth University
College of Engineering
Pune-411 043(Maharashtra)
4. The Principal
Bharati Vidyapeeth University
College of Engineering
Pune-411 043(Maharashtra)
5. The Pay & Accounts Officer, DST.
6. Sanction folder (Nano Mission).
7. File copy.


(G.V RAGHUNATH REDDY)
Scientist-E

REQUEST FOR ANNUAL INSTALMENT WITH UP-TO-DATE STATEMENT OF EXPENDITURE

1. Sanction Order No and date: SR-NM-NT-1029-2015; Dated 13/03/2018
2. Total Project Cost Rs. 33,72,000/- (Rs. 29,51,000/- General grant)
3. Revised Project Cost: NA
(If applicable)
4. Date of Commencement: 02/05/2018
5. Statement of Expenditure: for financial year 2019-2020 (Ending on 1 Sep 2020)
(month wise expenditure incurred during current financial year)

Month & year	Expenditure incurred / committed
May 2019	Rs. 18,000/-
June 2019	Rs. 18,000/-
July 2019	Rs. 18,000/-
August 2019	Rs. 40,258/-
September 2019	Rs. 18,000/-
October 2019	Rs. 18,000/-
November 2019	Rs. 18,000/-
December 2019	Rs. 18,000/-
January 2020	Rs. 75,348/-
February 2020	Rs. 18000/-
March 2020	Rs. 18000/-
April 2020	Rs. 18000/-
May 2020	Rs. 18000/-
June 2020	Rs. 18000/-
July 2020	Rs. 18000/-
August 2020	Rs. 4,79,051/-

6. Grant received in each year:
 - a. 1st Year: 2018-19 [Recurring (General): Rs. 13,51,000/-]
 - b. 2nd Year: 2019-2020 [Recurring (General): Rs. 8,28,128/- (Sanctioned Rs. 5,00,000/-
+ Remaining Balance Rs. 3,28,128/-]
 - c. 3rd Year:
 - d. Interest, if any: Rs. 3,942/- (Rs. 529/- expenditure incurred)
 - e. Total (a+b+c+d): Rs. 21,83,070/-

Statement of Expenditure

(to be submitted financial year wise ie. DOS* to 1st September of that financial year say 2020, 01-04-2019 till 01.09.2020+2year and so on)

Sr No	Sanctioned Heads	Funds Allocated (indicate sanctioned or revised)	1 st Year (DOS to 31 st March next year) (IV)	Expenditure Incurred 2 nd Year (1 st April to 31 st March 2019) (V)	3 rd Year & so on (1 st April to 30 th August 2020) (VI)	Total Expenditure IV + V + VI (VII)	Balance as on (date) (VIII) = III - (IV+V+VII)	Requirement of Funds upto 31 st March next year	Remarks (if any)**
1.	Manpower costs	4,32,000.00		1,73,400.00	2,70,000.00	4,43,400.00	-11,400.00	-11,400.00	2,70,000.00
2.	Consumables	7,50,000.00		5,50,000.00	1,93,491.00	7,43,491.00	6,509.00	6,509.00	1,93,491.00
3.	Travel	1,00,000.00		-	22,258.00	22,258.00	77,742.00	77,742.00	22,258.00
4.	Contingencies	3,00,000.00		88,641.00	77,408.00	1,66,049.00	1,33,951.00	1,33,951.00	77,408.00
5.	Others, if any	4,40,000.00		89,378.00	2,65,500.00	3,54,878.00	85,122.00	85,122.00	2,65,500.00
6.	Equipment	-		-	-	-	-	-	-
7.	Overhead expenses	2,50,000.00		1,25,000.00		1,25,000.00	1,25,000.00	1,25,000.00	
8.	Total	22,72,000.00		10,26,419.00	8,28,657.00	18,55,076.00	4,16,924.00	4,16,924.00	8,28,657.00

Name and Signature of Principal Investigator:
Date: 02/09/2020

(Signature)
Dr. Yogesh Chavdakar

Signature of Competent financial authority
(with seal)

(Signature)

PRINCIPAL
Bharati Vidyapeeth
Deemed to be University
College of Engineering

* DOS - Date of Start of project (02/05/2018), ** Considering the release of Rs. 5.00 lakh instead of sanctioned Rs. 9.21 lakh for second installment and Rs. 3,28,128/- remaining from earlier year and an extension of four months due to Covid 19 situation following allocation was considered for second year

Note :

- Expenditure under the sanctioned heads, at any point of time, should not exceed funds allocated under that head, without prior approval of DST i.e. Figures in Column (VIII) should not exceed corresponding figures in Column (III)
- Utilisation Certificate (Annexure III) for each financial year ending 31st March has to be enclosed along with request for carry-forward permission to the next financial year



(Signature)
V. A. DUDHEDIA
ACCOUNTANTS
CHARTERED
M. No. 13389



REQUEST FOR ANNUAL INSTALMENT WITH UP-TO-DATE STATEMENT OF EXPENDITURE

1. Sanction Order No and date: SR-NM-NT-1029-2015; Dated 13/03/2018
2. Total Project Cost: Rs. 33,72,000/- (Non Recurring - Capital): Rs. 11, 00,000/-)
3. Revised Project Cost:
(If applicable)
4. Date of Commencement: 02/05/2018
5. Statement of Expenditure:
(Month wise expenditure incurred during current financial year 2018-19)

Month & year	Expenditure incurred/ committed
August 2018	Rs. 8,28,407/-
October 2018	Rs. 69,473/-
November 2018	Rs. 6,823/-
March 2019	Rs. 1,91,750/-

6. Grant received in each year:
 - a. 1st Year: Non Recurring (Capital): Rs. 11,00,000/-
 - b. 2nd Year: NIL
 - b. 3rd Year:
 - c. Interest, if any:
 - d. Total (a+b+c+d): Rs. 11,00,000/-

Statement of Expenditure

(to be submitted financial yearwise ie. DOS* to 31st March of that financial year say 20XX, 01-04-20XX till 31.03.20XX+1 year and so on)

Sr No	Sanctioned Heads	Funds Allocated (indicate sanctioned or revised)	1 st Year (DOS to 31 st March next year) (IV)	2 nd Year (1 st April to 31 st March 2019) (V)	3 rd Year & so on (1 st April to 30 th August 2020) (VI)	Total Expenditure IV + V + VI (VII)	Balance as on (date) (VIII) = III - (IV+V+VII)	Requirement of Funds upto 31 st March next year	Remarks (if any) **
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)		
1.	Manpower costs								
2.	Consumables								
3.	Travel								
4.	Contingencies								
5.	Others, if any								
6.	Equipment	11,00,000.00		10,96,453.00	NIL	10,96,453.00	3,547.00		
7.	Overhead expenses								
8.	Total	11,00,000.00		10,96,453.00	NIL	10,96,453.00	3,547.00		

Name and Signature of Principal Investigator:

[Signature]

Date: 02/09/2020

[Signature]

Signature of Competent financial authority
(with seal)

PRINCIPAL
Bharati Vidyapeeth
(Deemed to be University)
College of Engineering
Pune-Satara Road, Pune-411 043

* DOS - Date of Start of project ** Considering the release of Rs. 5.00 lakh instead of sanctioned Rs. 9.21 lakh for second installment and Rs. 3,28,128/- remaining from earlier year and an extension of four months due to Covid 19 situation, there was no allocation for non-recurring for second year, hence the total amount of Rs. 8,28,128/- was utilized as part of recurring grant.


Note:

- Expenditure under the sanctioned heads, at any point of time, should not exceed funds allocated under that head, without prior approval of DST i.e. Figures in Column (VIII) should not exceed corresponding figures in Column (III)
- Utilisation Certificate (Annexure III) for each financial year ending 31st March has to be enclosed along with request for carry-forward permission to the next financial year.



[Signature]

VIJAYKUMAR A. DUDHEDIA
CHARTERED ACCOUNTANTS
M. No. 13889



GFR 12 – A
[(See Rule 238 (1))]
FORM OF UTILIZATION CERTIFICATE

UTILIZATION CERTIFICATE FOR THE YEAR (2019-20) in respect
of recurring/non-recurring
GRANTS-IN-AID/SALARIES/CREATION OF CAPITAL ASSETS

1. Name of the Scheme: DST Nanomission
2. Whether recurring or non-recurring grants: Both recurring and non-recurring grants
3. Grants position at the beginning of the financial year: Rs. 3,28,128/- Remaining from last year
+ Rs. 5,00,000/- received from DST-NM, Dated: 07/07/2020
(i) Cash in Hand/Bank: Rs. 8,28,128/-
(ii) Unadjusted advances: Nil
(iii) Total = Rs. 8,28,128/-

4. Details of grants received, expenditure incurred and closing balances: (Actuals)

Unspent balances of Grants received years [figure as at Sl. No. (iii)]	Interest earned thereon	Interest deposited back to the Government	Grants received during the year			Total available funds (1+2-3+4)	Expenditure incurred	Closing balances (5-6)
			Sanction No (i)	Date (ii)	Amount			
1	2	3	4			5	6	7
3,28,128.00	3,942.00	NA	SR-NM-NT-1029-2015	07/07/2020	5,00,000/-	8,32,070.00	8,28,657.00	3,413.00

Component wise utilization of grants:

Grant-in-aid-General	Grant-in-aid-Salary	Grant-in-aid-creation of capital assets	Total
5,58,657.00	2,70,000.00	-	8,28,657.00

Details of grants position at the end of the year

- (i) Cash in Hand/Bank: Rs. 3,413/-
- (ii) Unadjusted Advances: Nil
- (iii) Total: Rs. 3,413/-

Certified that I have satisfied myself that the conditions on which grants were sanctioned have been duly fulfilled/are being fulfilled and that I have exercised following checks to see that the money has been actually utilized for the purpose for which it was sanctioned:

- (i) The main accounts and other subsidiary accounts and registers (including assets registers) are maintained as prescribed in the relevant Act/Rules/Standing instructions (mention Act/Rules) and have been duly audited by designated auditors. The figures depicted above tally with the audited figures mentioned in financial statement/accounts.

- (ii) There exists internal controls for safeguarding public funds/assets, watching outcomes and achievements of physically targets against financial inputs, ensuring quality in asset creation etc. & the periodic evaluation of internal controls is exercised to ensure their effectiveness.
- (iii) To the best of our knowledge and belief, no transactions have been entered that are in violation of relevant Act/rules/Standing instructions and scheme guidelines.
- (iv) The responsibilities among the key functionaries for execution of the scheme have been assigned in clear terms and are not general in nature.
- (v) The benefits were extended to the intended beneficiaries and only such areas/districts were covered where the scheme was intended to operate.
- (vi) The expenditure on various components of the scheme was in the proportions authorized as per the scheme guidelines and terms and conditions of grant-in-aid.
- (vii) It has been ensured that the physical and financial performance under DST Nanomission has been according to the requirements, as prescribed in the guidelines issued by Govt. of India and the performance/targets achieved statement for the year to which utilization of fund resulted in outcomes given in Annexure-I duly enclosed.
- (viii) The utilization of the fund resulted in outcomes given at Annexure – II duly enclosed.
- (ix) Details of various schemes executed by the agency through grants-in-aid from same Ministry or other Ministries is enclosed at Annexure – II

Date:
Place:

Signature

Name:
Chief Finance Officer
(Head of Finance)

(Strike out inapplicable term)

Signature

Name: Dr. Anand Bhalerao
Head of Organisation

PRINCIPAL
Bharati Vidyapeeth
(Deemed to be University)
College of Engineering
Pune-Satara Road, Pune-411 045



VIJAYKUMAR A. DUDHEDIA
CHARTERED ACCOUNTANTS
M. No. 13989



GFR 12 – A
 [(See Rule 238 (1))]
FORM OF UTILIZATION CERTIFICATE

UTILIZATION CERTIFICATE FOR THE YEAR (2019-20) in respect
 of recurring/non-recurring
 GRANTS-IN-AID/SALARIES/CREATION OF CAPITAL ASSETS

1. Name of the Scheme: DST Nanomission
2. Whether recurring or non-recurring grants: Both recurring and non-recurring grants
3. Grants position at the beginning of the financial year: Rs. 3,547/-
 - (i) Cash in Hand/Bank: Rs. 3,547/-
 - (ii) Unadjusted advances: Nil
 - (iii) Total = Rs. 3,547/- **

4. Details of grants received, expenditure incurred and closing balances: (Actuals)

Unspent balances of Grants received years [figure as at Sl. No. (iii)]	Interest earned thereon	Interest deposited back to the Government	Grants received during the year			Total available funds (1+2-3+4)	Expenditure incurred	Closing balances (5-6)
			Sanction No (i)	Date (ii)	Amount			
1	2	3	4			5	6	7
3,547.00	NA	NA	-	-	-	-	-	3,547/-

Component wise utilization of grants:

Grant-in-aid-General	Grant-in-aid-Salary	Grant-in-aid-creation of capital assets	Total
Nil	Nil	Nil	Nil

**Considering the release of Rs. 5.00 lakh instead of sanctioned Rs. 9.21 lakh for second installment and Rs. 3,28,128/- remaining from earlier year and an extension of four months due to Covid 19 situation, there was no allocation for non-recurring for second year, hence the total amount of Rs. 8,28,128/- was utilized as part of recurring grant.

Details of grants position at the end of the year

- (i) Cash in Hand/Bank: Nil
- (ii) Unadjusted Advances: Nil
- (iii) Total: Nil

Certified that I have satisfied myself that the conditions on which grants were sanctioned have been duly fulfilled/are being fulfilled and that I have exercised following checks to see that the money has been actually utilized for the purpose for which it was sanctioned:


- (i) The main accounts and other subsidiary accounts and registers (including assets registers) are maintained as prescribed in the relevant Act/Rules/Standing instructions (mention Act/Rules) and have been duly audited by designated auditors. The figures depicted above tally with the audited figures mentioned in financial statement/accounts.

- (ii) There exists internal controls for safeguarding public funds/assets, watching outcomes and achievements of physically targets against financial inputs, ensuring quality in asset creation etc. & the periodic evaluation of internal controls is exercised to ensure their effectiveness.
- (iii) To the best of our knowledge and belief, no transactions have been entered that are in violation of relevant Act/rules/Standing instructions and scheme guidelines.
- (iv) The responsibilities among the key functionaries for execution of the scheme have been assigned in clear terms and are not general in nature.
- (v) The benefits were extended to the intended beneficiaries and only such areas/districts were covered where the scheme was intended to operate.
- (vi) The expenditure on various components of the scheme was in the proportions authorized as per the scheme guidelines and terms and conditions of grant-in-aid.
- (vii) It has been ensured that the physical and financial performance under DST Nanomission has been according to the requirements, as prescribed in the guidelines issued by Govt. of India and the performance/targets achieved statement for the year to which utilization of fund resulted in outcomes given in Annexure-I duly enclosed.
- (viii) The utilization of the fund resulted in outcomes given at Annexure – II duly enclosed.
- (ix) Details of various schemes executed by the agency through grants-in-aid from same Ministry or other Ministries is enclosed at Annexure – II

Date:
Place:


Signature

Name:
Chief Finance Officer
(Head of Finance)



Signature

Name: Dr. Anand Bhalerao
Head of Organisation


(Strike out inapplicable term)



PRINCIPAL
Bharati Vidyapeeth
(Deemed to be University)
College of Engineering
Pune-Satara Road, Pune-411 043



VIJAYKUMAR A. DUDHEDIA
CHARTERED ACCOUNTANT'S
M. No. 13989




3.1.6 Number of departments with UGC-SAP, CAS, DST-FIST, DBT, ICSSR and other recognitions by national and international agencies during the year						
Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Government/Non-Government)	Department	Year of Award	Funds provided (INR in lakhs)
Fund for Improvement of Science and Technology	Dr K R Mahadik	DST-FIST	Government	Pharmaceutics	18 th Feb 2021	32
3.2.1 Extramural funding for Research (Grants sponsored by the non-government sources such as industry, corporate houses, international bodies for research projects) in Lakhs)						
Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Government/Non-Government)	Department	Year of Award	Funds provided (INR in lakhs)
Effect of SAVA-1 on Cyclophosphamide induced neutropenia.	Dr. Arulmozhi. S	SAVA Health Care Limited-R & D, Plot No. 17/6, Block DI, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	12/14/2020	0.7485
In-vivo Studies on the Antidiabetic activity and toxicity of copper oxide nanoparticles using Wistar Rats	Dr. Urmila M.Aswar	Dr Anirudh Vasant Pethkar, Department of Microbiology, Institute of Science, Aurangabad	Non-Government	Pharmacology	28-Jan-21	0.5
Investigation of immunomodulatory activity of SAVA3 in experimental animal models of immunity.	Dr. Arulmozhi. S and Dr. Deepa Mandlik	SAVA Health Care Limited-R & D, Plot No. 17/6, Block DI, MIDC, Chinchwad, Pune-411019, Maharashtra.	Non-Government	Pharmacology	4/1/2021	0.5209
E.Tect of SAVA-4 and SAVA-5 on Cyclophosphamide induced neutropenia in mice.	Dr. Arulmozhi. S and Dr. Amol Muthal	SAVA Health Care Limited-R & D, Plot No. 17/6, Block DI, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	5/2/2021	0.60168

Effect of SAVA 3, SAVA 5 and SAVA 6 on Cyclophosphamide induced Neutropenia	Dr. Arulmozhi S and Dr. Amol Shinde	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	non-Government	Pharmacology	6/18/2021	0.75498
Effect of SAVA ED on Paroxetine-induced erectile dysfunction in rats	Dr. Arulmozhi S and Dr. Deepa Mandlik	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	7/2/2021	1.57416
Ocular pharmacokinetics study of SAVA 7 in Wistar rats	Dr. Arulmozhi S and Dr. Deepa Mandlik	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	7/2/2021	0.3649
Screening of Hepatic Profile of animals treated with SAVA 8	Dr. Arulmozhi S and Dr. Deepa Mandlik	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	6/28/2021	0.70805
Effect of SAVA V0001979 on streptozotocin nicotinamide induced diabetes mellitus in rats.	Dr. Arulmozhi. S	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	3/20/2021	1.03984
Formulation Lab	Sangram Patil	Poona College of Pharmacy,	Non-Government	Insitute	4/3/2021	1.18
PTL	Upendra Pendse	Poona College of Pharmacy,	Non-Government	Quality Assurance	28/11/20	0.984

3.2.2 Grants for research projects sponsored by the government agencies during the year (INR in Lakhs)

62.6927



Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Government/Non-Government)	Department	Year	Funds provided (INR in lakhs)
Nil	Nil	Nil	Nil	Nil	Nil	Nil


3.2.3 Number of research projects per teacher funded by government and non-government agencies during the year

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Government/Non-Government)	Department	Year	Funds provided (INR in lakhs)
Fund for Improvement of Science and Technology	Dr K R Mahadik	DST-FIST	Government	Pharmaceutics	18 th Feb 2021	32
Effect of SRV0001908 on Cyclophosphamide induced neutropenia.	Dr. Arulmozhi. S	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	12/14/2020	0.7485
In-vivo Studies on the Antidiabetic activity and toxicity of Copper oxide nanoparticles using Wistar Rats	Dr. Urmila M.Aswar	Dr Anirudh Vasant Pethkar, Department of Microbiology, Institute of Science, Aurangabad	Non-Government	Pharmacology	28-Jan-21	0.5
Investigation of immunomodulatory activity of SAVA3 in experimental animal models of immunity.	Dr. Arulmozhi. S and Dr. Deepa Mandlik	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	4/1/2021	0.5209
Effect of SAVA-4 and SAVA-5 on Cyclophosphamide induced neutropenia in mice.	Dr. Arulmozhi. S and Dr. Anol Muthal	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	4/5/2021	0.60168



Effect of SAVA 3, SAVA 5 and SAVA 6 on Cyclophosphamide induced Neutropenia	Dr. Arulmozhi S and Dr. Amol Shinde	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	non-Government	Pharmacology	6/24/2021	0.75498
Effect of SAVA ED on Paroxetine-induced erectile dysfunction in rats	Dr. Arulmozhi S and Dr. Deepa Mandlik	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	7/5/2021	1.57416
Ocular pharmacokinetics study of SAVA 7 in Wistar rats	Dr. Arulmozhi S and Dr. Deepa Mandlik	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019.	Non-Government	Pharmacology	7/5/2021	0.3649
Screening of Hepatic Profile of animals treated with SAVA 8	Dr. Arulmozhi S and Dr. Deepa Mandlik	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	7/5/2021	0.70805
Effect of SRV0001979 on streptozotocin nicotinamide induced diabetes mellitus in rats.	Dr. Arulmozhi S	SAVA Health Care Limited-R & D, Plot No. 17/6, Block D1, MIDC, Chinchwad, Pune 411019, Maharashtra.	Non-Government	Pharmacology	4/12/2021	1.03984
	Sangram Patil	Poona College of Pharmacy,	Non-Government	Insitute	4/3/2021	1.18 62.6927
	Upendra Pendse	Sahayadri Hospital Ltd 30C Erandwane Pune	Non-Government	Quality Assurance	28/11/20	0.984

Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.



No SR/FST/College-2019-526 (C)
 GOVERNMENT OF INDIA
 MINISTRY OF SCIENCE & TECHNOLOGY
 DEPARTMENT OF SCIENCE & TECHNOLOGY
 R & D (Infrastructure) DIVISION

Technology Bhawan,
 New Mehrauli Road,
 New Delhi -110016

18th February, 2021

ORDER

Subject: Financial assistance (1st installment) to the **POONA COLLEGE OF PHARMACY, BHARATI VIDYAPEETH UNIVERSITY, PAUD ROAD, ERANDWANE PUNE, MAHARASHTRA - 411038** under FIST Program.

Sanction of the President is hereby accorded to the approval of the aforesaid project at a total cost of **Rs.72,00,000/- (Rupees Seventy two lakh only)** for 5 years. The detailed breakup of the grant for General as well as Capital Components are given below:

To strengthen the research facilities in the College (Being Govt. Aided College the amount would be shared on 50:50 ratio)
Capital Assets: Rs.69.0 L

E-Rs. 64.0 L [Flow Through cell apparatus - Rs 45.0 L, FT Raman Spectrometer - Rs. 19.0L]

NW-Rs. 5.0L. Setting up computer lab (15 Desktop PCs, 1 server and UPS)]

General Components: Rs.3.0L

M- Rs.3.0 L

Total : Rs. 72.00 Lakh

[DST's contribution Rs.36.0 lakh & College's Share-Rs.36.0 lakh]

2 The total budget recommended for 5 years has been phased as below: (Rs. In lakh)

Budget Heads	1 st year	2 nd year	3 rd year	4 th year	5 th year	Total
Equipment	64.0	-	-	-	-	64.0 (DST- 32.0L, College- 32.0L)
NW	-	5.0	-	-	-	5.0 (DST- 2.5L, College- 2.5L)
Maintenance	-	0.75	0.75	0.75	0.75	3.0 (DST- 1.5L, College- 1.5L)
Total	64.0	15.75	0.75	0.75	0.75	72.0 (DST- 36.0L, College- 36.0L)

3 The sanction of the President is also accorded to the release of **Rs 32,00,000/- (Rupees Thirty two lakh only)** to the **Principal, POONA COLLEGE OF PHARMACY, BHARATI VIDYAPEETH UNIVERSITY, PAUD ROAD, ERANDWANE PUNE, MAHARASHTRA - 411038** under FIST Program as a 1st installment of the grant in 2020-2021 under 'creation of capital assets' head for the maximum cost of the aforesaid Equipment including (9.4%) Custom Duty & other duties under the 'Equipment'. The break-up of the 1st installment grant released now would be **Equipment: Rs. 32.0 lakh for procurement of the equipments mentioned above [Equipments of Foreign Origin to be acquired on FE Terms only and should not include charges for any comprehensive Maintenance and training personnel from the vendors during procurement process].**


4 **The Department/Institute will appropriately limit the expenditure within the sanctioned amount in case of any expected excess expenditure.** The Department is requested to utilize the released funds in first one year from the date of sanction order.

5 This sanction is subject to the condition that the grantee organisation will furnish to the Department of Science & Technology, financial year wise Utilization Certificate (UC) in the proforma prescribed as per GFR 2017 and audited statement of expenditure (SE) along with up to date progress report at the end of each financial year duly reflecting the interest earned / accrued on the grants received under the project. This is also subject to the condition of submission of the final statement of expenditure, utilization certificate and project completion report within one year from the scheduled date of completion of the project.

6 The aforesaid concurrence is subject to the stipulation that continuation beyond the first year shall be subject to appraisal and approval of the continuation of the Schemes(FIST) under which this project is funded, as approved by DoE's vide their OM No 42(02)/PF-II/2014, dated 06.08.2020.

7 The grantee organisation will have to enter & upload the Utilization Certificate in the PFMS portal besides sending it in physical form to this Division with UC id generated in PFMS Portal. The subsequent/final installment will be released only after confirmation of the acceptance of the UC by the Division and entry of previous Utilization Certificate in the PFMS.

Bhattacharya



Incharge Principal

Bharati Vidyapeeth Deemed University
 POONA COLLEGE OF PHARMACY

If the grant has been released under Capital head/General through separate sanction order(s) under the same project for purchase of equipment, separate SE/UC has to be furnished for the released Capital head/General grant.

9. There is no pending SE/UC on this Project as per details in the PFMS also. This is the first release of this project under FIST Program, which has been initiated, in this financial year so no previous UC is attached with this sanction order.

10. The grant-in-aid being released is subject to the condition that:

(a) a transparent procurement procedure in line with the provisions of General Financial Rules 2017 will be followed by the University/Institute under the appropriate rules of the grantee organisation while procuring capital assets sanctioned for the above mentioned project and a certificate to this effect will be submitted by the University/Institute immediately on receipt of the grant, and

(b) while submitting Utilization Certificate/Statement of Expenditure, the University/Institute has to ensure submission of supporting documentary evidences with regard to the purchase of equipment/capital assets as per the provisions of GFR 2017. Subsequent release of grants under the project shall be considered only on receipt of the said documents.

c) Grantee Institute may furnish copy of invoice in respect of equipments worth Rs. 5.0 L and above along with customs clearance certification (in case of imported equipments) after procurement of the equipments

d) Goods (consumables/equipment/Networking items) available in GeM portal may be procured through GeM (Government E-Market) platform only and the University/ Institute will also follow DOE's DoE's guidelines for incurring expenditure under the different sub-head.

e) The Grantee Institution is advised to start using EAT module and next release will be made only after mapping and following EAT modules by the grantee institutions

f) Grantee Institute will furnish copy of bills showing expenditure incur on maintenance of the equipments after warranty period of respective equipments are over

11. In terms of Rule 230(8) of GFR 2017, the grantee organization will maintain separate audited account for the project and the entire amount of grant will be kept in an interest bearing bank account. For Grants released during F.Y. 2017-18 and onwards, all interests and other earnings, generated against released Grant shall be remitted to Consolidated Fund of India.

12. DST reserves sole rights on the assets created out of grants. Assets acquired wholly or substantially out of government grants (except those declared as obsolete and unserviceable or condemned in accordance with the procedure laid down in GFR 2017), shall not be disposed of without obtaining the prior approval of DST. The ownership of the equipment/facilities created will vest with DST.


13. The account of the grantee organisation shall be open to inspection by the sanctioning authority and audit (both by C&AG of India and Internal Audit by the Principal Accounts Office of the DST), whenever the organisation is called upon to do so, as laid down under Rule 236(1) of General Financial Rules 2017.

14. Due acknowledgement of technical support / financial assistance resulting from this project grant should mandatorily be highlighted by the grantee organisation in bold letters in all publications / media releases as well as in the opening paragraphs of their Annual Reports during and after the completion of the project

15. Failure to comply with the terms and conditions of the scheme will entail full refund with interest in terms of Rule 231 (2) of GFR 2017.

16. The expenditure involved is to be debited to

- Demand No -87 Department of Science & Technology
 - "3425" -Other Scientific Research (Major Head)
 - 60-Others (Sub-Major Head)
 - 60 200-Assistance to other Scientific Bodies (Major Head)
 - 68- Science and Technology Institutional and Human Capacity Building
 - 68 04 35-Grants for creation of capital assets for the (Voted)
 - [Previous: R&D Support: 3425.60.200.68.00.35]
- The above release is made under 'R&D' Scheme



Handwritten signature


Incharge Principal
 Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
 Eraodwane, Pune - 411 038.

The amount of Rs. 20,00,000/- (Rupees Twenty lakh only) will be drawn by the Drawing and Disbursing Officer, DST and will be disbursed to the Principal, POONA COLLEGE OF PHARMACY, BHARATI VIDYAPEETH UNIVERSITY, PAUD ROAD, ERANDWANE PUNE, MAHARASHTRA - 411038. The bank details for electronic transfer of funds through RTGS are given below:-

1. Name of the Account Holder: Principal, POONA COLLEGE OF PHARMACY, BHARATI VIDYAPEETH UNIVERSITY
2. Name of the Bank: IDBI Bank
3. Bank Account Number: 0653104000125093
4. IFSC Code: IBKL0000653
5. MICR Code: 411259015

18. As per Rule 234 of GFR 2017, this sanction has been entered at S. No. 190 in the register of grants maintained in the Division for the scheme (R&D Support).

19. This issues with the concurrence of IFD Vide their Concurrence Dy.No.5123 dated the 17.02.2021.


(Arindam Bhattacharyya)
Scientist 'E'

Email: a.bhattacharyya@nic.in


To
The Pay and Accounts Officer,
Department of Science & Technology,
New Delhi.

Copy forwarded for information and necessary action to

1. Cash Section (with two spare copies)


1. **Principal**
POONA COLLEGE OF PHARMACY,
BHARATI VIDYAPEETH UNIVERSITY,
PAUD ROAD, ERANDWANE PUNE,
MAHARASHTRA - 411038


2. Office of the Director & Audit, Scientific Department, AGCR Bldg, 3rd Floor, IP Estate, New Delhi - 110002
3. Office of Account General, Maharashtra, Mumbai
4. FIST-Secretariat
5. CoA / IFD, DST, New Delhi.
6. Head, R & D (Infrastructure), DST New Delhi.
7. Sanction Folder.


(Arindam Bhattacharyya)
Scientist 'E'

Email: a.bhattacharyya@nic.in


Ah




Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

1) Effect of SRV0001908 on Cyclophosphamide induced neutropenia.

SAVA HEALTHCARE LTD																									
Billing Address: Sava Healthcare Ltd - R & D, PLOT NO-176, BLOCK-D1, MIDC, CHIRCHWAD, PUNE - 411019, MAHARASHTRA, INDIA Insurance Policy No.: CRI No: 1U51397033659PLC074903 GSTIN: 27AAEC4345AD12M PAN No: 1AAEAS469E Mfg Lic No: Drug Lic No:																									
PURCHASE ORDER																									
Kind Attention: Mobile No:																									
Vendor: Principal Poona College of Pharmacy, Bharati Vidyapeeth Educational Complex, Erandwane, Pune - 411038, MAHARASHTRA, INDIA Tel No: GSTIN: 27AAA1B1934D522	Delivery Address: Sava Healthcare Ltd, Sava Healthcare Ltd - R & D, PLOT NO-176, BLOCK-D1, MIDC, CHIRCHWAD, PUNE - 411019 Tel No: 2038001241 Fax No: Email: purchase@savahc.com																								
	P.O. No.: SRD/2021/PO5/WOC/100106 Date: 14/12/2020 PR No.: BRD/2021/PR/QE/WOC/00113 Quotation Ref: Place of Supply: 27 - MAHARASHTRA, India State																								
Kindly deliver material as per terms and conditions mentioned below in purchase order.																									
<table border="1"> <thead> <tr> <th>Sl.</th> <th>Item Code & Description</th> <th>Quantity</th> <th>UOM</th> <th>Basic Rate (RS)</th> <th>Basic Value (RS)</th> <th>Tax/Charges</th> <th>Total (RS)</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>SRV0001908 - Cyclophosphamide induced neutropenia SCOPE OF WORK: 1. SWISS ALBINO MICE, TOTAL 40 ANIMALS & TRANSPORTATION OF ANIMALS 2. COST OF CYCLOPHOSPHAMIDE TOTAL AND DIFFERENTIAL WBC COUNT, NO. OF OBSERVATION - 3 (DAY 0, DAY 3 & DAY 10), ALSO DDST OF GCSF INCLUDED 3. MISCELLANEOUS (ANAESTHETICS, BLOOD COLLECTION KITS AND VACUOTAINER, IAEC STATIONERY ETC) 4. OVERHEAD CHARGES (20% OF TOTAL COST) 5. CONSULTANCY CHARGES (20% OF TOTAL COST) Manufacturer: HSN/SAC Code: 385346 Delivery: 14/12/2020</td> <td>1,000</td> <td>NOB</td> <td>63432.00</td> <td>63432.00</td> <td>CUST @ 0.00 - 6160.00 1.1 SGST @ 9.00 - 5709.36</td> <td>74850.36</td> </tr> <tr> <td colspan="5"></td> <td>63432.00</td> <td>11417.36</td> <td>74849.36</td> </tr> </tbody> </table>	Sl.	Item Code & Description	Quantity	UOM	Basic Rate (RS)	Basic Value (RS)	Tax/Charges	Total (RS)	1	SRV0001908 - Cyclophosphamide induced neutropenia SCOPE OF WORK: 1. SWISS ALBINO MICE, TOTAL 40 ANIMALS & TRANSPORTATION OF ANIMALS 2. COST OF CYCLOPHOSPHAMIDE TOTAL AND DIFFERENTIAL WBC COUNT, NO. OF OBSERVATION - 3 (DAY 0, DAY 3 & DAY 10), ALSO DDST OF GCSF INCLUDED 3. MISCELLANEOUS (ANAESTHETICS, BLOOD COLLECTION KITS AND VACUOTAINER, IAEC STATIONERY ETC) 4. OVERHEAD CHARGES (20% OF TOTAL COST) 5. CONSULTANCY CHARGES (20% OF TOTAL COST) Manufacturer: HSN/SAC Code: 385346 Delivery: 14/12/2020	1,000	NOB	63432.00	63432.00	CUST @ 0.00 - 6160.00 1.1 SGST @ 9.00 - 5709.36	74850.36						63432.00	11417.36	74849.36	
Sl.	Item Code & Description	Quantity	UOM	Basic Rate (RS)	Basic Value (RS)	Tax/Charges	Total (RS)																		
1	SRV0001908 - Cyclophosphamide induced neutropenia SCOPE OF WORK: 1. SWISS ALBINO MICE, TOTAL 40 ANIMALS & TRANSPORTATION OF ANIMALS 2. COST OF CYCLOPHOSPHAMIDE TOTAL AND DIFFERENTIAL WBC COUNT, NO. OF OBSERVATION - 3 (DAY 0, DAY 3 & DAY 10), ALSO DDST OF GCSF INCLUDED 3. MISCELLANEOUS (ANAESTHETICS, BLOOD COLLECTION KITS AND VACUOTAINER, IAEC STATIONERY ETC) 4. OVERHEAD CHARGES (20% OF TOTAL COST) 5. CONSULTANCY CHARGES (20% OF TOTAL COST) Manufacturer: HSN/SAC Code: 385346 Delivery: 14/12/2020	1,000	NOB	63432.00	63432.00	CUST @ 0.00 - 6160.00 1.1 SGST @ 9.00 - 5709.36	74850.36																		
					63432.00	11417.36	74849.36																		
Amount in Words: (INR - Seventy Four Thousand Eight Hundred Fifty Only) Payment Terms: PAYMENT : 80% PAYMENT TO BE RELEASED BEFORE START OF THE PROJECT & REMAINING PAYMENT TO BE RELEASED AFTER APPROVAL OF DRAFT REPORT																									
<table border="1"> <tr> <td>Discount</td> <td>0.000</td> </tr> <tr> <td>Round-Off</td> <td>0.24</td> </tr> <tr> <td>Total Value</td> <td>74850.30</td> </tr> </table>		Discount	0.000	Round-Off	0.24	Total Value	74850.30																		
Discount	0.000																								
Round-Off	0.24																								
Total Value	74850.30																								
Prepared By: <i>D.S.</i>	Checked By: <i>Amisha</i>																								
Authorized By: <i>[Signature]</i>																									



Incharge Principal
 Bharati Vidyapeeth Deemed University
 POONA COLLEGE OF PHARMACY
 Erandwane, Pune - 411 038.

2) In-vivo Studies on the Antidiabetic activity and toxicity of Copper oxide nanoparticles using Wistar Rats



Prof. Dr. Shivajirao Kadam
M.Sc., Ph.D.
Chancellor

DR. ATMARAM PAWAR
M.Pharm., Ph.D.
IN-CHARGE PRINCIPAL

Bharati Vidyapeeth
(Deemed to be University)
Founder Chancellor : Dr. Patangrao Kadam

- Accredited with 'A+' Grade (2017) by NAAC
- Accredited (2004) & Reaccredited (2011) with 'A' Grade by NAAC
- Category-I University Status by UGC

POONA COLLEGE OF PHARMACY

- Reaccredited by NBA & NAAC
- ISO-9001:2015 Certified Institute



Bharati Vidyapeeth Education Trust
Erandwane, Pune - 411 004 (M.S.) India
Tel: 020-25443251 Fax: 020-25443252
E-mail: pcp@bharativedu.com
Website: www.bharativedu.edu
www.pcp.bharativedu.com

Date: 28th Jan 2021


Quotation for the study- 'Evaluation of anti-diabetic potential of Copper oxide nanoparticles in Wistar Rats'

Budget parameters	Cost (Rs.)	Total
1. Cost of animals: Wistar rats @Rs. 300/-per animal Total 42 animals & Transportation of Animals	12,600/ 1000/	13,600/
2. IAEC approval and Maintenance of animals during study: Rs. 2/ per day per rat with 42 rats for 60 days	2000/ 5040	7040
3. Drugs and Chemicals Streptozotocin, Metformin, miscellaneous for experiment- sample collection tubing's, eppendorf's, containers, markers etc.	30,000/	30,000/
4. Biochemical estimation kits- Biochemical kits- Blood glucose, SGOT, ALT, SOD, Cholesterol, Creatine, total protein, HbA1C.	25,000	25,000
4. Cost of histopathological studies of diabetic rats Rs. 300 per sample	3900	3900
Total		79540
4. Overhead Charges (15 % of the Total Cost)		11930
5. Consultancy Charges (15 % of the Total Cost)		11930
Grand Total		1,03,400

* At actual





Dr. Urmila M. Aswar
(Principal Investigator)


Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.




Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

3) Investigation of immunomodulatory activity of SAVA3 in experimental animal models of immunity.

SAVA HEALTHCARE LTD		SAVA HEALTHCARE LTD					
		Billing Address Sava Healthcare Ltd - R & D, PLOT NO-17/6, BLOCK-D1, MIDC, CHINCHWAD PUNE - 411019 MAHARASHTRA, INDIA Tel No : Fax :					
PURCHASE ORDER		Insurance Policy No. : CIN No : U51397GJ2004PLC074963 GSTIN : 27AAECA9456D1ZM PAN No : AAECA9456D Mfg Lic No : Drug Lic No :					
Kind Attention : Mobile No :		P.O. No. : SRD/2122/POS/WOC/00001 Date : 01/04/2021 PR No. : SRD/2122/PRO/PWO/00001 Quotation Ref: Place of Supply : 27 - MAHARASHTRA Intra State					
Vendor Principal Ponna College of Pharmacy Bharati Vidyapeeth Educational Complex Erandwane Pune - 411038 MAHARASHTRA, INDIA TelNo.: Email : GSTIN: 27AAATB1836D5Z2		Delivery Address Sava Healthcare Ltd., Sava Healthcare Ltd - R & D, PLOT NO-17/6, BLOCK-D1, MIDC, CHINCHWAD PUNE - 411019 Tel No.: 2030601241 Fax No.: Email id: purchase@savaglobal.com					
Kindly deliver material as per terms and conditions mentioned below in purchase order.							
Sr.	Item Code & Description	Quantity	UOM	Basic Rate (RS)	Basic Value (RS)	Tax/Charges	Total (RS)
1	SRV0001979 - Testing Charges To Investigate the immunomodulatory activity of SAVA-3 in experimental animal models of immunity. 1. Cost of animals: Swiss Albino mice @Rs. 140/-per animal. Total 60animals RS. 8400 & amp Transportation of Animals RS 1000 Feed and maintenance of animals (Rs. 2 per animal per day for 60 animals x 35 days) RS 4200 IAFC Approval Charges RS 10000 2. Cost of the experimentation: Cost of Cyclophosphamide RS 9352 Cost of SRBC's RS 9600 Miscellaneous (Anaesthetics, Blood collection kits and vacoutainer, 96 well plates, Stationery) RS 10000 3. Contingency (5 % of Total expenditure) RS 2628 4. Consultancy Charges (20 % of Total expenditure) RS 16511 5. Overhead Charges (15 % of Total expenditure) RS 7883 Manufacturer : HSN/SAC Code 998346 Delivery 01/04/2021	1.000	NOS	73574.00	73574.00	CGST @ 9.00 6621.60 SGST @ 9.00 5621.60	86817.32
 Prepared By		 Checked By		 Authorised By		Corporate office: SAVA House, Off New Airport Road, Viman Nagar, Pune -411014 INDIA Tel: +91 20 30516100 Fax No: +91 20 30516161	




 Incharge Principal
 Bharati Vidyapeeth Deemed University
 POONA COLLEGE OF PHARMACY
 Erandwane, Pune - 411 038.

4) Effect of SAVA-4 and SAVA-5 on Cyclophosphamide induced neutropenia in mice.



Prof. Dr. Shivajiroo Kadam
M.Sc., Ph.D.
Chancellor
DR. ATMARAM PAWAR
M.Pharm., Ph.D.
IN-CHARGE PRINCIPAL

Bharati Vidyapeeth
(Deemed to be University)
Founder Chancellor: Dr. Patangrao Kadam

- Accredited with 'A+' Grade (2017) by NAAC
- Accredited (2004) & Reaccredited (2011) with 'A' Grade by NAAC
- Category I University Status by UGC

POONA COLLEGE OF PHARMACY

- Reaccredited by NBA & NAAC
- ISO-9001:2015 Certified Institute



Bharati Vidyapeeth Educational Complex,
Erandwane, Pune - 411 038 (M.S.) INDIA
Tel: (020) 25437737 Fax: (020) 25437383
E-mail: pcp.bv@gmail.com
Website: pcp.bharativedyapeeth.edu
www.bharativedyapeeth.edu

Date: 2/05/2021

To
SAVA Healthcare Ltd - R & D,
Plot No. 17/6, Block D1, MIDC,
Chinchwad Pune-411019.
GSTIN: 27AAECA9456D1ZM
Quotation for screening "Effect of SAVA 3 and SAVA 4 on cyclophosphamide induced neutropenia in mice"



1. Cost of animals - Swiss albino mice @ Rs. 140/- per animal Total 24 animals and Transportation charges Feed and maintenance of animals (Rs. 2 per animal per day for 17 days) IAEC Approval Charges	Rs. 3360/- Rs. 1000/- Rs. 816 /- Rs. 10,000/-	Rs. 15,176/-
2. Cost of Experimentation - i. Cost of cyclophosphamide ii. Total and Differential WBC count No. of observations - 3 (Day 0, Day 3 and Day 10) 3 x 24x 150 iii. Cost of C-GSF iv. Cost of AST,ALT v. Miscellaneous (Anaesthetics, Blood collection Kits, Vacoutainer, 96 well plates, stationery)	Rs. 9352/- Rs. 10,800/- Rs. 1800/- Rs. 3400/- Rs. 5000/-	Rs. 30,352/-
3. Contingency (5% of total Expenditure)		Rs. 2,276
4. Consultancy Charges (20% of total Expenditure)		Rs. 9,105
5. Overhead Charges (15% of total Expenditure)		Rs. 6,829
	Total	Rs. 63,738
	18% GST	Rs. 11,473
	Grand Total	Rs. 75,210

80 % of the cost to be released before the start of the project. Remaining 20 % of the cost to be released after approval of the draft report.

Payment mode: Cheque or NEFT in favour of Principal, Poona College of Pharmacy, Pune

Sava Health care Limited will provide with test substance 1 week prior to the start of the study.

Dr. Arulmozhi S
Head,
Department of Pharmacology



Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

5) Effect of SAVA 3, SAVA 5 and SAVA 6 on Cyclophosphamide induced Neutropenia



Prof. Dr. Shivajiroo Kadam
M.Sc., Ph.D.
Chancellor
DR. ATMARAM PAWAR
M.Pharm., Ph.D.,
IN-CHARGE PRINCIPAL

Bharati Vidyapeeth
(Deemed to be University)
Founder Chancellor : Dr. Patangrao Kadam

- Accredited with 'A+' Grade (2017) by NAAC
- Accredited (2004) & Reaccredited (2011) with 'A' Grade by NAAC
- Category-I University Status by UGC

POONA COLLEGE OF PHARMACY

- Reaccredited by NBA & NAAC
- ISO-9001-2015 Certified Institute



Bharati Vidyapeeth Educational Complex,
Erandwane, Pune - 411 038. (P.A.S) 9804
Tel. : (020) 25437237 Fax : (020) 25439383
E-mail - pcph.bvu@gmail.com
Website - pcph.bharativedyapeeth.edu,
www.bvuuniversity.edu.in

18/06/2021

To
SAVA Healthcare Ltd - R & D,
Plot No. 17/6, Block D1, MIDC,
Chinchwad Pune 411019.
GSTIN: 27AAECA9456D1ZM


Quotation for Screening "Effect of SAVA 3, SAVA 5 and SAVA 6 on cyclophosphamide induced neutropenia in mice"



1. Cost of animals: Swiss Albino mice @Rs. 140/- per animal		Rs. 20,264
Total 36 animals &	Rs. 5040	
1 Rabbit	Rs. 3000	
Transportation charges	Rs. 1000	
Feed and maintenance of animals (Rs. 2 per animal per day for 17 days)	Rs. 1224	
IAEC Approval Charges	Rs. 10000	
2. Cost of the experimentation:		Rs. 29,152
Cost of Cyclophosphamide	Rs. 9352	
Total and Differential WBC count, blood platelet counts	Rs. 16,200	
No. of observations - 3 (Day 0, Day 3 and Day 10) 3 x 36 x 150	Rs. 3600	
Cost of AST, ALT		
3. Miscellaneous (Anaesthetics, Blood collection kits and vacoutainer, Stationery etc.)	Rs. 13000	Rs. 13000
4. Overhead Charges (20% of the Total Cost)		Rs. 12,483
5. Consultancy Charges (20% of the Total Cost)		Rs. 12,483
Total		Rs. 87382
18% GST		Rs. 15729
Grand Total		Rs. 1,03,111


80% of the cost to be released before the start of the project. Remaining 20% of the cost to be released after approval of the draft report.

Payment mode: Cheque or NEFT in favour of Principal, Poona College of Pharmacy, Pune

Sava Health care Limited will provide with test substance 1 week prior to the start of the study.


Dr. Arulmozhi, S
Head,
Department of Pharmacology




Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

6) Effect of SAVA ED on Paroxetine-induced erectile dysfunction in rats



Prof. Dr. Shivejrao Kadam
M.Sc., Ph.D.
Chancellor
DR. ATMARAM PAWAR
M.Pharm., Ph.D.
IN-CHARGE PRINCIPAL

Bharati Vidyapeeth
(Deemed to be University)
Founder Chancellor : Dr. Patangrao Kadam

Accredited with 'A+' Grade (2017) by NAAC
Accredited (2004) & Reaccredited (2011) with 'A' Grade by NAAC
Category 3 University Status by UGC

POONA COLLEGE OF PHARMACY

Reaccredited by NBA & NAAC • ISO 9001:2015 Certified Institute



Bharati Vidyapeeth Educational Complex,
Erandwane, Pune - 411 008. 28.51.9284
M: 9228 3543/3237 Fax: 4228 2542/2822
E-mail: pco@bharati.ac.in
Website: www.bharati.ac.in
www.poona.edu.in

Date: 26/7/2021


To
SAVA Healthcare Ltd - R & D,
Plot No. 17/B, Block DI, MIDC,
Chinchwad Pune 411019.
GSTIN: 27AAECA9456D12M
Effect of SAVA ED on Paroxetine-induced erectile dysfunction in rats

*1. Cost of animals: Wistar rats @Rs. 300/-per animal		
Total 20 animals &	Rs. 9000	Rs. 21,800
Transportation charges	Rs.1000	
Feed and maintenance of animals (Rs. 2 per animal per day for 30 days)	Rs.1800	
IAEC Approval Charges	Rs.10000	
2. Cost of the experimentation:		Rs. 63,488
Sildenafil citrate, Paroxetine		
Vanadium chloride, Sulphanilamide		
Ethylenediaminedihydrochloride, Progesterone, estradiol benzoate	Rs. 63,488	
3. Miscellaneous (Anaesthetics, Blood collection kit, Travel, vacutainer, Stationery etc.)	Rs. 10000	Rs. 10,000
5. Manpower (10% of the Total Cost)		Rs. 9,529
4. Overhead Charges (15 % of the Total Cost)		Rs. 14,293
5. Consultancy Charges (15 % of the Total Cost)		Rs. 14,293
Total		Rs. 1,33,403
18 % GST		Rs. 24,013
Grand Total		Rs. 1,57,416

80 % of the cost to be released before the start of the project. Remaining 20 % of the cost to be released after approval of the draft report.
Payment mode: Cheque or NEFT in favour of Principal, Poona College of Pharmacy, Pune

Sava Health care Limited will provide with test substance 1 week prior to the start of the study

Dr. Arulmozhi S.
Head,
Department of Pharmacology



Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

7) Ocular pharmacokinetics study of SAVA 7 in Wistar rat
 r) Ocular pharmacokinetics study of SAVA 7 in Wistar rat



Prof. Dr. Shivajirao Kadam
 M.Sc., Ph.D.

Chancellor

DR. ATMARAM PAWAR
 M.Pharm., Ph.D.,
 IN-CHARGE PRINCIPAL

Bharati Vidyapeeth
 (Deemed to be University)

Founder Chancellor : Dr. Patangrao Kadam

- Accredited with 'A+' Grade (2017) by NAAC
- Accredited (2004) & Reaccredited (2011) with 'A' Grade by NAAC
- Category-I University Status by UGC

POONA COLLEGE OF PHARMACY

- Reaccredited by NBA & NAAC
- ISO-9001-2015 Certified Institute



Bharati Vidyapeeth Educational Complex,
 Erandwane, Pune - 411 038. (M.S.) INDIA
 Tel : (020) 25437237 Fax : (020) 25439383
 E-mail : pcp.bvu@gmail.com
 Website : pcp.bharativedyapeeth.edu
 www.bvuuniversity.edu.in

Date: 2/7/2021


To
 SAVA Healthcare Ltd - R & D,
 Plot No. 17/6, Block D1, MIDC,
 Chinchwad Pune-411019.
 GSTIN: 27AAECA9456D1ZM
 Quotation for "Pharmacokinetics of SAVA 7 in wistar rats"



1. Cost of animals: Wistar rats @Rs. 300/-per animal		
Total 12 animals & Transportation charges	Rs. 3600 Rs.1000	Rs. 15,088
Feed and maintenance of animals (Rs. 2 per rat per day for 17 days and Rs. 4 per rabbit for 10 days)	Rs. 488	
IAEC Approval Charges	Rs.10000	
2. Miscellaneous (Anaesthetics, analgesics, Blood collection kit, solvent, vacoutainer, Stationery etc.)	Rs. 7000	Rs. 7000
3. Manpower (10 % of the Total cost)		Rs. 2209
4. Overhead Charges (15 % of the Total Cost)		Rs.3313
5. Consultancy Charges(15 % of the Total Cost)		Rs.3313
Total		Rs. 30,923
18 % GST		Rs. 5,567
Grand Total		Rs. 36,490


80 % of the cost to be released before the start of the project. Remaining 20 % of the cost to be released after approval of the draft report.

Payment mode: Cheque or NEFT in favour of Principal, Poona College of Pharmacy, Pune


Sava Health care Limited will provide with test substance 1 week prior to the start of the study.


 Dr. Arulmozhi. S
 Head,
 Department of Pharmacology




 Incharge Principal
 Bharati Vidyapeeth Deemed University
 POONA COLLEGE OF PHARMACY
 Erandwane, Pune - 411 038.

8) Screening of Hepatic Profile of animals treated with SAVA



Prof. Dr. Shivajirao Kadam
M.Sc., Ph.D.
Chancellor

DR. ATMARAM PAWAR
M.Pharm., Ph.D.
IN-CHARGE PRINCIPAL

Bharati Vidyapeeth
(Deemed to be University)
Founder Chancellor : Dr. Patangrao Kadam

• Accredited with 'A+' Grade (2017) by NAAC
• Accredited (2004) & Reaccredited (2011) with 'A' Grade by HAAC
• Category-2 University Status by UGC

POONA COLLEGE OF PHARMACY

• Reaccredited by NBA & NAAC • ISO-9001:2015 Certified Institute

Celebrating
50
and Beyond
1961-2011

Bharati Vidyapeeth Educational Campus,
Erandwane, Pune - 411 008, 25, 17, 28, 29
Tel. : 020-25437234 Fax : 020-25426003
E-mail : pcc@bvidyapeeth.com
Website : www.bharativedyapeeth.edu
www.poonacollegepharmacy.in

28/06/2023


To
SAVA Healthcare Ltd – R & D,
Plot No. 17/6, Block D1, MIDC,
Chinchwad Pune 411019.
GSTIN: 27AAECA94S6D1ZM
Quotation for "Screening of Hepatic Profile of animals treated with SAVA 8"


1. Cost of animals: Wistar rats @Rs. 300/-per animal		
Total 26 animals & Transportation charges	Rs. 7800	Rs. 20,360
Feed and maintenance of animals (Rs. 2 per animal per day for 30 days)	Rs.1000	
IAEC Approval Charges	Rs.1560	
	Rs.10000	
2. Cost of the experimentation:		Rs. 14,500
SGPT, SGGT, ALP and Bilirubin kits	Rs. 7000	
Histopathology (15 Samples)	Rs.7500	
3. Miscellaneous (Anaesthetics, Blood collection kit, Travel, vacoutainer, Stationery etc.)	Rs. 8000	Rs. 8000
4. Manpower (10 % of the total cost)		Rs.4286
5. Overhead Charges (15 % of the Total Cost)		Rs.6429
5. Consultancy Charges (15 % of the Total Cost)		Rs. 6429
Total		Rs. 60,004
18 % GST		Rs. 10,801
Grand Total		Rs. 70805


80 % of the cost to be released before the start of the project. Remaining 20 % of the cost to be released after approval of the draft report.

Payment mode: Cheque or NEFT in favour of Principal, Poona College of Pharmacy, Pune

Sava Health care Limited will provide with test substance 1 week prior to the start of the study.


Dr. Arulmozhi S
Head,
Department of Pharmacology




Incumbent Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

9) Effect of SRV0001979 on streptozotocin nicotinamide induced diabetes mellitus in



Prof. Dr. Shivajirao Kadam
M.Sc., Ph.D.
Chancellor

DR. ATMARAM PAWAR
M.Pharm., Ph.D.,
IN-CHARGE PRINCIPAL

Bharati Vidyapeeth
(Deemed to be University)
Founder Chancellor : Dr. Patangrao Kadam

- Accredited with 'A+' Grade (2017) by NAAC
- Accredited (2004) & Reaccredited (2011) with 'A' Grade by NAAC
- Category-I University Status by UGC

POONA COLLEGE OF PHARMACY

- Reaccredited by NBA & NAAC
- ISO-9001-2015 Certified Institute



Bharati Vidyapeeth Educational Complex,
Erandwane, Pune - 411 038, (M.S.) INDIA
Tel. : (020) 25437237 Fax : (020) 25439383
E-mail : pcp.bvu@gmail.com
Website : pcp.bharativedyapeeth.edu
www.bvuniversity.edu.in

TAX INVOICE

20/03/2021

PCP/M.Pharm/141/2020-21

Invoice No. 33/2020/21

To
SAVA Healthcare Ltd - R & D,
Plot No. 17/6, Block D1, MIDC,
Chinchwad Pune-411019.
GSTIN: 27AAECA9456D1ZM
PO Reference Number: SRD/2021/POS/WOC/00127

"Effect of SAVA1(SRV0001979) on Streptozotocin-Nicotinamide induced diabetes mellitus in rats"


1. Cost of animals: Albino Wistar rats @Rs. 300/- per animal	Rs. 7200	Rs. 9544
Total 24 animals & Transportation of Animals	Rs. 1000	
Feed and maintenance of animals (Rs. 2 per animal per day for 24 animals x 28 days)	Rs. 1344	
2. Cost of the experimentation:	Rs. 36500	Rs. 41,400
Cost of Streptozotocin	Rs. 3500	
Cost of Nicotinamide	Rs. 1400	
Blood Glucose Kits	Rs. 12000	
3. Miscellaneous (Anaesthetics, Blood collection kits and vacoutainer, 96 well plates, Histopathology containers IAEC Stationary etc.)		Rs. 12000
4. Overhead Charges (20 % of the Cost)		Rs. 12,589
5. Consultancy Charges (20 % of the Cost)		Rs. 12,589
Total		Rs. 88,122
18 % GST		Rs. 15,862
Grand Total		Rs. 1,03,984

GST No. 27AAATB1836D522
PAN No. AAATB1836D
TIN No. PNEB00400B

[Signature]
Signature of Study Director
Dr. Arulmozhi.S

[Signature]
Signature of Head of the Institution
Dr. A.P. Pawar
Incharge Principal

rats.



[Signature]
Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

10) Food Testing Laboratory (PTL)

11) PTL

Bharati Vidyapeeth (Deemed to be University), Pune (India)

Name of College / Institute : - Poona College of Pharmacy, Pune - 411038 (PTL)

Receipt and Payment 2020-2021

Receipt	Amount	Payment	Amount
		Salary & Allowances	65,394
Chemical Testing Charges	1,77,206	Salary	
		Honorarium	14,979
		Administrative Expenditure	
		III) Educational Expenses	
		Labrotary/Chemical Exps	18,601
		Bank Charges	
		Telephona Exp	
		Miscellenous	
Sub-Total	1,77,206	Sub-Total	98,974

Janle

Mrs. Upendra S. Pendte

22/09/2021


Head

Poona College Of Pharmacy
Public Testing Laborat
Pune

ABHIS

ACCOUNTANT

Bharati Vidyapeeth (Deemed to be University)
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.



ABHIS
Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

BVDU Centre for Food Testing Laboratory, Pune 2021-22


LBS Road
Pune

Income and Expenditure Statement

1-Apr-2020 to 31-Mar-2021

Particulars	1-Apr-2020 to 31-Mar-2021	Particulars	1-Apr-2020 to 31-Mar-2021
Purchase Accounts		Sales Accounts	41,88,536.92
Indirect Expenses		Sample Testing Fees	41,88,536.92
Administrative Expenditure	4,98,470.55	Bank Interest	16,163.00
Application/ Registration Fee Charge	34,000.00	Bank Interest	16,163.00
Audit Fee Charges	5,000.00	Other Receipts	
Bank Charges	820.40	Excess of expenditure over income	20,64,570.69
Cleaning & Maintenance Expenses	23,200.00		
Computer Repairs & Maintenance	23,196.57		
Conveyance Expenses	10,996.00		
Electrical Repairs & Maintenance	22,302.00		
Generator (Diesel) Expenses	4,000.00		
Insurance Charges (Machinery)	76,088.00		
Miscellaneous Expenses	30,720.58		
Postage & Courier Expenses	1,04,965.00		
Printing & Stationary	26,312.00		
Professional Fee Charges	60,760.00		
Repairs & Maintenance	48,987.00		
Telephone Expenses	2,406.00		
Transport Charges	2,400.00		
Travelling Expenses	22,317.00		
Depreciation	6,68,160.00		
Depreciation	6,68,160.00		
Laboratory Expenditure	26,24,440.06		
Equipments Repair & Maintenance	7,31,942.47		
GST Expenses (SGST & CGST)	30,076.00		
Internet /Website Expenses	2,497.00		
Journals & Reading Room Expenses	10,000.00		
Lab Consumable Material	14,04,879.59		
Laboratory Expenses	1,575.00		
Sample Collection Charges	1,80,370.00		
Sample Testing Charges	2,63,100.00		
Salaries & Allowance	24,78,200.00		
Provident Fund- Mangt Share	93,241.00		
Salary & Allowances	23,00,971.00		
Honorarium	83,988.00		
Total	62,69,270.61	Total	62,69,270.61

Handwritten signature



Bharati Vidyapeeth (Deemed to be University), Pune (India)

Name of College / Institute : - Poona College of Pharmacy, Pune - 411038 (PTL)

Receipt and Payment 2020-2021


Receipt	Amount	Payment	Amount
		Salary & Allowances	
Chemical Testing Charges	1,77,206	Salary	65,394
		Honorarium	
		Administrative Expenditure	14,979
		III) Educational Expenses	
		Labrotary/Chemical Exps	18,601
		Bank Charges	
		Telephone Exp	
		Miscellenous	
Sub-Total	1,77,206	Sub-Total	98,974

Jante

Mr. Upendra S. pendte

22/09/2021

Head
Poona College Of Pharmacy
Public Testing Laboratory
Pune



[Signature]
Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

[Signature]
ACCOUNTANT

Bharati Vidyapeeth (Deemed to be University)
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

BVDU Centre for Food Testing Laboratory, Pune 2021-22


LBS Road
Pune

Income and Expenditure Statement

1-Apr-2020 to 31-Mar-2021

Particulars	1-Apr-2020 to 31-Mar-2021	Particulars	1-Apr-2020 to 31-Mar-2021
Purchase Accounts		Sales Accounts	<u>41,88,536.92</u>
Indirect Expenses		Sample Testing Fees	41,88,536.92
Adminstrative Expenditure	4,98,470.55	Bank Interest	16,163.00
Application/ Registration Fee Charge	34,000.00	Bank Interest	<u>16,163.00</u>
Audit Fee Charges	5,000.00	Other Receipts	
Bank Charges	820.40	Excess of expenditure over income	20,64,570.69
Cleaning & Maintenance Expenses	23,200.00		
Computer Repairs & Maintainance	23,196.57		
Conveyance Expenses	10,996.00		
Electrical Repairs & Maitenance	22,302.00		
Ganerator (Diesel) Expenses	4,000.00		
Insurance Charges (Machinery)	76,088.00		
Miscellaneous Expenses	30,720.58		
Postage & Courier Expenses	1,04,965.00		
Printing & Stationary	26,312.00		
Professional Fee Charges	60,760.00		
Repairs & Maintenance	48,987.00		
Telephone Expenses	2,406.00		
Transport Charges	2,400.00		
Travelling Expenses	<u>22,317.00</u>		
Depreciation	6,68,160.00		
Depreciation	6,68,160.00		
Laboratory Expenditure	26,24,440.06		
Equipments Repair & Maintainance	7,31,942.47		
GST Expenses (SGST & CGST)	30,076.00		
Internet /Website Expenses	2,497.00		
Journals & Reading Room Expenses	10,000.00		
Lab Consumable Material	14,04,879.59		
Laboratory Expenses	1,575.00		
Sample Collection Charges	1,80,370.00		
Sample Testing Charges	<u>2,63,100.00</u>		
Salaries & Allowance	24,78,200.00		
Provident Fund- Mangt Share	93,241.00		
Salary & Allowances	23,00,971.00		
Honorarium	<u>83,988.00</u>		
Total	62,69,270.61	Total	62,69,270.61

Handwritten signature



Handwritten signature
Incharge Principal
Bharati Vidyapeeth Deemed University
POONA COLLEGE OF PHARMACY
Erandwane, Pune - 411 038.

Release of third installment (2021)

Z. 28015/72/2016-HPC (EMR)-AYUSH-C

Government of India
Ministry of AYUSH

AYUSH BHAWAN,
B-Block, GPO Complex,
INA, New Delhi
Dated: 17.03.2021

To,
The Pay & Accounts Officer (Secretariat),
Ministry of Health & Family Welfare,
Nirman Bhawan,
New Delhi - 110001.


Sub: Release of 3rd installment of Rs. 10,17,536/- (Rupees Ten Lakhs Seventeen Thousand Five Hundred Thirty Six only) of recurring grants-in-aid during the financial year 2020-21 under Revenue-regarding

Sir,

In exercise of power delegated under Rule DFPR-1978. I am directed to convey the sanction of the President to the payment of Rs. 10,17,536/- (Rupees Ten Lakhs Seventeen Thousand Five Hundred Thirty Six only) to Bharati Vidyapeeth University, Pune as 3rd installment of recurring grants-in-aid for research project under EMR Scheme (Extra Mural Research Projects through Research Institutes etc. [3121]) of Ministry of AYUSH during the financial year 2020-21 as detailed below:

S. No	Name of the Organization	Title of the Project	Heads	Amount to be released 3 rd Instt (In Rs.)
1.	Bharati Vidyapeeth University, Pune	Validation of Traditional Unani Plant Products and Their Ingredients for anticancer effect on Hepatocellular Carcinoma	Salary	511800
			Other Non-Recurring Exp. Analysis software	50000
			Recurring Expenditure chemicals, glassware for animal In vivo and cell based in vitro study	330736
			Expenses for product development and standardization	50000
			TA/DA	25000
			Miscellaneous Exp	50000
			Total	10,17,536/-

1. The grant will be subjected to the terms & condition for grants in aid under the scheme for Extra Mural Research in AYUSH and further subject to the relevant conditions prescribed under General Financial Rules of Govt. of India.
2. The grant in aid will also be subject to the conditions that no amount or part thereof shall be delivered to any purpose other than the one for which it has been sanctioned.
3. **It is certified that the Grant in aid is being released as 3rd installment in respect of above project to the said Institute.**
4. The Grants-in-aid as per provision of Rule 228 to 230 of General Financial Rules - 2017 and will be subjected to the conditions laid down in GFR-2017.
5. The accounts of the Grantee institutions/ organizations shall be open to inspection by the sanctioning authority and audit both by the CAG of India under the provision of CAG (DPC) Act, 1971 and internal audit wing of the O/o CCA of the Ministry, whenever the institutions or organization is called upon to do so.


कुन्दन भा. सिन्हा/KUNDAN B. SINHA
अवर सचिव/Under Secretary
आयुष मंत्रालय, भारत सरकार
Ministry of AYUSH Govt. of India
आयुष भवन, बी-ब्लॉक, गुप्तोपकरण, इना, नई दिल्ली-23
AYUSH Bhawan, B-Block, GPO Complex, INA, New Delhi-23

Bharati Vidyapeeth
(Deemed to be University)
Rajiv Gandhi Institute of
I.T. & B.T., Katraj, Pune-46
Inward No.: 109.....
Date: 22/3/21 Sign: [Signature]

6. It is certified that the amount of grant sanctioned is within the budget provision as accepted in the Budget Estimate for financial year 2020-21. It is also certified that the pattern of assistance has been approved by the Ministry of Finance.
7. It is further certified that the payee is not a defaulter in submission of the utilization certificate in past and has no UC as due for rendition under the rules under the scheme of the Ministry.
8. The expenditure on the account will be debit to the Budget Head under Demand No. 04, Ministry of AYUSH, 2210- Medical and Public Health (Major Head), 02 200- Other Systems (minor Head), 07- Grants for Extra Mural Research Project through Research institutions (Pvt / Semi Govt. /Govt./ Universities/NGO) etc, 070 031- Grants in aid during the year 2020-21 (Revenue).

S.No.	Description	(Amount In Rs.)
1.	Budget allotment (B.E)	Rs.7,98,00,000/-
2.	Net amount of the bill	Rs. 10,17,536/-
3.	Total expenditure from 1 st April to date (excluding the present bill)	Rs. 7,10,78,544 /-
4.	Balance left after the present bill.	Rs. 77,03,920/-

9. **It is recurring expenditure and it is the 3rd installment**
10. This sanction issues with the approval of AS & FA vide the Integrated Finance Division Concurrence Dy. No. C-586 dated 09.03.2021.
11. This sanction is subject to condition that the grantee institute will disburse this grant-in-aid through EAT (Expenditure, Advance and Transfer) Module of PFMS as per the guidelines issued by Ministry of Finance. Further, the grantee institution is also insisted to provide the Utilization Certificate in form 12 A as prescribed under GFR 2017.
12. The sanction is issued subject to condition that information/details in respect of Direct Benefit Transfer (DBT) under the budget heads Salary/Manpower, TA/DA & Fee of PI and Co-I as per notification of the scheme under section 7/57 of Aadhaar Act 2016 will be provided/uploaded to Ministry on monthly basis as per DBT App/format by the Principal Investigator/Organization.


Yours faithfully,

कुन्दन भा. सिन्हा / KUNDAN B. SINHA
 अवर सचिव / Under Secretary
 आयुष मंत्रालय, भारत सरकार
 Ministry of AYUSH, Govt. of India
 Under Secretary to the Govt. of India
 AYUSH Bhawan, B-Block, GPO Complex, INA, New Delhi-23

Copy to:

1. The Director General of Audit, Central Revenues, New Delhi
2. US (Finance), Ministry of Health & Family Welfare, Nirman Bhawan, New Delhi
3. Cash (Health) Section, AYUSH BHAWAN, B-Block, GPO Complex, INA, Ministry of AYUSH
4. Director General, Central Council for Research in Unani Medicine (CCRUM), New Delhi
5. Head of Institution, Rajiv Gandhi Institute of IT and Biotechnology, Bharati Vidyapeeth Deemed University, Pune-Satara Road, Dhankawadi, Pune - 411046
6. Dr. Alpana S. Moghe, Associate Professor & HOD, Department of Cell & Molecular Biology, Rajiv Gandhi Institute of IT and Biotechnology, Bharati Vidyapeeth Deemed University, Pune-Satara Road, Dhankawadi, Pune - 411046
7. Finance Desk - II/ AYUSH (E-III)
8. Sanction Folder

कुन्दन भा. सिन्हा / KUNDAN B. SINHA
 अवर सचिव / Under Secretary
 आयुष मंत्रालय, भारत सरकार
 Ministry of AYUSH, Govt. of India
 Under Secretary to the Govt. of India
 आयुष भवन, बी-ब्लॉक, जीपीओ कॉम्प्लेक्स, आईएनए, नई दिल्ली-23
 AYUSH Bhawan, B-Block, GPO Complex, INA, New Delhi-23





icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911

भारतीय आयुर्विज्ञान अनुसंधान परिषद
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार
कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research
Department of Health Research, Ministry of Health
and Family Welfare, Government of India

File No. 5/3/8/57/2020-ITR

Dated: 11.03.2021

To,

The Director,
Bharati Vidyapeeth,
Rajiv Gandhi Institute of Information Technology and Biotechnology,
Pune Satara Road,
Pune - 411046

Subject: Sanction of Budget allotment for the ICMR Ad-hoc Project entitled "Development of Genetically Tailored Organotypic Model for Study of Enteroviruses" under **Dr. Alpna Subodh Moghe (PI), Associate Professor**, Bharati Vidyapeeth, Rajiv Gandhi Institute of Information Technology and Biotechnology, Pune-411046 & **Dr. Shyam Sundar Nandi, (Co-PI) Scientist 'D'**, National Institute of Virology (ICMR), Parel, Mumbai-400012.

Sir/Madam,

The Director General of the Council sanctions the above mentioned project initially for a period of **one year** i.e. from **29th March, 2021 to 28th March, 2022** subject to extension up-to total duration specified in para (3) below.

The Director General of the ICMR also sanctions the budget allotment of **Rs. 26,02,660/- (Rupees Twenty Six Lakh Two Thousand Six Hundred and Sixty Only)** as detailed in the attached statement for the period ending, **29th March, 2021 to 28th March, 2022**.

First Installment of grant-in-aid of **Rs. 26,02,660/-** for the 1st year will be released out of the first year budget of **Rs. 26,02,660/-**. The payment of the grant will be made in one installment in the name of **BHARATI VIDYAPEETH-RAJIV GANDHI INST OF IT&BT ICMR RESEARCH GRANT** through RTGS Bank Account Number: **39351034850**, IFSC Code: **SBIN0008752**, MICR code of bank: **411002018**, State Bank of India, Katraj Branch, S.No.133/2, Near Bharati Vidyapeeth Deemed Univ., Katraj, Pune-411046. (A copy of Mandate Form & cancelled cheque are enclosed).

1. The first year grant will be paid generally as soon as report regarding the commencement of the project and appointment of the staff is received by the Council. The demand for payment of the subsequent installment of the grant should be placed with the Council in advance.
2. The staff appointed on the project should be paid as indicated in the attached budget statement.
3. The approved duration of the research scheme is **Two years**. The annual extension will be given after review of the work done on the research scheme during the previous year.
4. Five copies of the annual progress report of work done be submitted to the Council every year after completion of ten months of the project. Failure to submit the report in time may lead to termination of the project.

Contd.....2/-

5. The Institute will maintain a separate saving bank account of the receipts and the expenditure incurred on the research scheme and will furnish a utilization certificate and an audited statement of the account pertaining to the grant.
6. The grant shall be utilized after following the provisions laid down in GFR-2017 and TA rules.
7. The other terms and conditions are indicated in Annexure-1.

The receipt of this letter may please be acknowledged.

Yours faithfully,

(A. Wason)
15/3/21

(A. Wason)

Administrative Officer

Copy together with a copy of the budget statement forwarded for information to:

- ✓ 1. **Dr. Alpana Subodh Moghe**, Associate Professor, Bharati Vidyapeeth, Rajiv Gandhi Institute of IT and Biotechnology, Pune-411046.
2. Copy together with copy of the budget statement forwarded to **Accounts Section-V**, ICMR for information and necessary action. The expenditure on the account may be met from the provision made for **Division of ITR for Ad-hoc project** on grant-in-aid basis in the budget of the Council for the financial year **2020-21**.
3. Copy together with copy of the budget statement forwarded to budget section (**Finance**) ICMR for completion of the Council's budget.
4. **IRIS cell, ICMR, ID.No. 2020-3034**
RFC No. (P-18) ITR/Ad-hoc/53/2020-21 dt.09.03.2021

File No. 5/3/8/57/2020-ITR

Date of start: 29.03.2021

Duration: 2 Years

IRIS cell, ICMR, ID.No. 2020-3034

RFC No. (P-18) ITR/Ad-hoc/53/2020-21 dt.09.03.2021

Project entitled "Development of Genetically Tailored Organotypic Model for Study of Enteroviruses" under **Dr. Alpana Subodh Moghe (PI), Associate Professor,** Bharati Vidyapeeth, Rajiv Gandhi Institute of Information Technology and Biotechnology, Pune-411046 & **Dr. Shyam Sundar Nandi, (Co-PI) Scientist 'D',** National Institute of Virology (ICMR), Parel, Mumbai-400012.

BUDGET ESTIMATE (1st year)
29.03.2021 to 28.03.2022

S.No	Particular	1 st Year
I	Staff Technical Assistant(1) @ Rs. 31,000 p.m. (Corresponding to PB-2 Rs.9300-34800+GradePay Rs.4200)	3,72,000
II	Consumables (Cell culture reagents/CRISPR Cas9 Reagents/Sequencing reagents/Chemicals/Plastic ware)	7,00,000
III	Contingency	50,000
	Total	11,22,000
	Overhead charges @ 3%	33,660
IV	Equipment RWV Bioreactor Required for growing 3D culture using cell lines and matrix proteins	13,50,000
	2 Laptop	75,000
V	Travel	22,000
	Grand Total	26,02,660

(Rupees Twenty Six Lakh Two Thousand Six Hundred and Sixty Only)

A. Wason
15/3/21
(A. Wason)

Administrative Officer



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911

भारतीय आयुर्विज्ञान अनुसंधान परिषद
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार
कल्याण मंत्रालय, भारत सरकार
Indian Council of Medical Research
Department of Health Research, Ministry of Health
and Family Welfare, Government of India

File No. 5/3/8/57/2020-ITR

Dated: 11.03.2021

Subject: 1st & final installment of First Year grant-in-aid of ICMR Ad-hoc Project entitled "Development of Genetically Tailored Organotypic Model for Study of Enteroviruses" under **Dr. Alpana Subodh Moghe (PI)**, Associate Professor, Bharati Vidyapeeth, Rajiv Gandhi Institute of Information Technology and Biotechnology, Pune-411046 & **Dr. Shyam Sundar Nandi, (Co-PI) Scientist 'D'**, National Institute of Virology (ICMR), Parel, Mumbai-400012.

MEMORANDUM:

Reference this office letter of even number dated

The Director General, ICMR sanctions the payment of **Rs. 26,02,660/- (Rupees Twenty Six Lakh Two Thousand Six Hundred and Sixty Only)** as the 1st & final installment of First year grant-in-aid for incurring expenditure in this connection with the above mentioned Research scheme. The amount of **Rs. 26,02,660/-** may be debited in the provision of **Rs. 26,02,660/-** made for the above mentioned research scheme for the 1st year i.e. from **29.03.2021 to 28.03.2022**.

A formal bill for **Rs. 26,02,660/-** is sent herewith for payment to **BHARATI VIDYAPEETH-RAJIV GANDHI INST OF IT&BT ICMR RESEARCH GRANT** through RTGS **Bank Account Number: 39351034850, IFSC Code: SBIN0008752, MICR code of bank: 411002018, State Bank of India, Katraj Branch, S.No.133/2, Near Bharati Vidyapeeth Deemed Univ., Katraj, Pune-411046. (A copy of Mandate Form & cancelled cheque are enclosed).**

RFC No. (P-18) ITR/Ad-hoc/53/2020-21 dt.09.03.2021

A. Wason
15/3/21
(A. Wason)

Administrative Officer

Accounts Section - V, ICMR

1. The Director, Bharati Vidyapeeth, Rajiv Gandhi Institute of Information Technology and Biotechnology, Pune Satara Road, Pune – 411046. An amount of **Rs. 26,02,660/-** of **1st Year grant-in-aid** is being credited to your account as per detailed submitted by you. The grant has been sanctioned on the condition laid down in our letter referred to above.
2. **Dr. Alpana Subodh Moghe**, Associate Professor, Rajiv Gandhi Institute of Information Technology and Biotechnology, Pune-411046.
3. **IRIS cell, ICMR, ID. No. 2020-3034**



Grant-in-Aid Agreement

This **Grant-in-Aid Agreement ("GIA Agreement")** is made and entered into on this **15** day of **June**, 2020 ("**Effective Date**"),

BETWEEN

Tata Power Community Development Trust, a Trust duly registered under the Bombay Public Trusts Act 1950, vide Registration number E - 25632 with its registered office at Bombay House, 24, Homi Mody Street, Mumbai 400001(hereinafter referred to as **TPCDT** which expression shall unless repugnant to the context thereof be deemed to mean and include its successors and assigns), of the ONE PART;

AND

Bharati Vidyapeeth (Pune), a non-profit organization registered as **Registered with Charities Commissioner** , registration number **90186** under the **Societies Registration Act 1860** with its registered office **BVDU Social Sciences Centre, New Law College Building, Erandwane Campus, Pune 411 038**India, represented by its Trustee/Authorised Signatory **Dr. Ganesh R Rathod**having current and valid Income tax 12AA registration certificate for tax exemption and 80G tax Deduction certificate, hereinafter referred to as **Bharati Vidyapeeth (Pune)** which expression shall unless repugnant to the context thereof be deemed to mean and include its successors and permitted assigns), of the OTHER PART.

(Hereinafter **TPCDT** and **Bharati Vidyapeeth (Pune)** shall be individually referred to as "**the Party**" and collectively as "**the Parties**")

WHEREAS:

- a) TPCDT is, inter alia, engaged in non-profit & community development initiatives **under 5 thrust areas namely Education, Health & Sanitation, Livelihood & Employability, Water and Financial Inclusion**, and is a key facilitator that supports developmental projects across identified locations to create and offer sustainable solutions to the diverse challenges faced by local communities.
- b) **Bharati Vidyapeeth (Pune)** is a non-profit organization based out of **Pune** working in the field of **Health & Sanitation**. The NGO works in the states of **Maharashtra**The mission is to **To be world class university for social transmission through dynamic education linkages with employability on entrepreneurship especially women and adolescent girls**..The average annual gross contribution received by the NGO for last three years amount Rs5Cr. The NGO operates at locations such as

Pune, Solapur, Sangli District of Maharashtra. in the thrust areas of Education, Health, Livelihood, Women Empowerment and Employability.

- c) ***Bharati Vidyapeeth(Pune)*** has submitted a proposal dated 15-May-2020 to TPCDT for conducting ***Integrated Community Health Care : Promote and sensitize preventive health care – Anemia, Malnutrition, Breast Feeding, Health Behavior Change Communication*** and same forms part of GIA Agreement and is marked as **Annex- 3**
- d) TPCDT is desirous of being partner in the Intervention to be implemented by Bharati Vidyapeeth (Pune)The scope of the intervention and funding are as detailed and forms part of this GIA Agreement
- e) ***Bharati Vidyapeeth (Pune)***would not sublet or delegate any of the project activities as part of this GIA Agreement.
- f) Believing the aforesaid to be true, and in furtherance of its Mission & Objectives, TPCDT has agreed to engage ***Bharati Vidyapeeth (Pune)***, **through this GIA Agreement**, as the implementing agency to ***Integrated Community Health Care : Promote and sensitize preventive health care – Anemia, Malnutrition, Breast Feeding, Health Behavior Change Communication***

NOW THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, agree as follows:

1. INTERVENTION & ADMINISTRATION

- a) **Intervention Title:** ***Integrated Community Health Care : Promote and sensitize preventive health care – Anemia, Malnutrition, Breast Feeding, Health Behavior Change Communication***
- b) **Scope:** ***To improve technical knowledge and counseling skill on Nutrition and Health from AWW & ANM/ASHA and Peer Educators from Mulshi and Mangaon Taluka of Pune and Raigad Districts.***
- c) **Project Objectives:** ***To create awareness about COVID-19 virus, Anemia , Malnutrition and Health as well as Nutrition among 8500 villagers and Govt. Service providers. (Refer Annex-3, Sec-B,4)***
- d) **Project Timelines:** ***From 01-Jun-2020 to 31-Mar-2021***
- e) **Name of Collaborating Organizations:**
- f) ***Bharati Vidyapeeth (Pune)*** is the implementing organization for this Project.
- g) TPCDT is the non-profit organization, which would be funding this Project, by way of Grant-in-Aid in furtherance of developmental objects.

2. PROJECT LOCATION:

- a) State & District ***Maharashtra & Pune***
- b) Revenue Block ***Mulshi***
- c) Gram Panchayat or Ward ***Mulshi (Kh)***
- d) No of Villages or Ward Mohallas ***20*** covered
- e) Beneficiaries potentially covered through this project ***8500 (Refer Annex-3,Sec-B-6)***
- f) SC & ST Beneficiaries as ***20*** % of above (No.), covered through this intervention.

3. THE WORKING RELATIONSHIP:

The bipartite collaboration would be guided by the following mutually agreed principles:

- a) All the parties shall ensure transparency and accountability in all activities undertaken as a part of the intervention.

- b) The parties shall encourage adoption of a scientific, rational, democratic, bottoms-up, community needs-based approach to the issues addressed.
- c) The parties shall encourage the use of technology-based interventions for higher impacts, outreach and outcomes.
- d) Each stakeholder to designate Single Point of Contact (SPoC) for effective coordination during the project execution.

4. INTERVENTION TERM AND WORKPLAN

- a) The intervention shall be implemented in accordance with GIA Agreement and the intervention proposal set out in Annexure-3.
- b) **Bharati Vidyapeeth (Pune)** shall forthwith notify TPCDT in writing in the event of the occurrence of any event that may cause delay in achieving the intervention delivery milestone.
- c) The terms of the intervention under this GIA Agreement of FY-19.
- d) The work plan in terms of (NGO name) deliverables with timelines mentioned in (Annexure-3, Sec B-8)

5. INTERVENTION BUDGET/PARTNERS NAME & PAYMENT TERMS:

- a) TPCDT has sanctioned to **Bharati Vidyapeeth (Pune)** a Grant-in-Aid of **600000.0** (Indian Rupees **Six Lakhs** for the Project to be undertaken by **Bharati Vidyapeeth (Pune)** in relation to Integrated Community Health Care : Promote and sensitize preventive health care – Anemia, Malnutrition, Breast Feeding, Health Behavior Change Communication as "Authorized/Approved Activities")
- b) TPCDT shall deploy financial resources for the Term of this GIA Agreement up to a total cost of INR **600000.0** (Indian Rupees **Six Lakhs** only). (**Annex-3 Sec-B-8**) The **Bharati Vidyapeeth (Pune)** agrees that the project management charges shall not exceed 10% of the total Grant-in-Aid (INR) Amount, and to that effect satisfies TPCDT.
- c) It is understood and agreed between the Parties that TPCDT's Grant-in-Aid to **Bharati Vidyapeeth (Pune)**, is with respect to the intervention as per KPIs mentioned in (**Annex-2**)
- d) Compliances & Schedule of Payments for Total Grant Amount of Rs: **600000.0**

Installment number	Installment payment (in %)	Installment Amount	Key Milestone (Annex-1)
1	25%	150000.0	On signing of GIA Agreement
2	30%	180000.0	On completion of agreed key deliverables mentioned in Annexure-1 and 80% utilization of 1st installment.
3	35%	210000.0	On Completion of 50% of Key performance indicators [Midline study] (Refer KPIs annex-2) and 80% utilization of 2nd installment.
4	10%	60000.0	Completion of all initiatives, 80% utilization of 3rd installment, achieving 100% KPIs and submission of end line report.

- a) **Bharati Vidyapeeth (Pune)** shall submit expenditure statements, indicating usage of 80% of first and consequent Grant installments, during course of the project based on actuals.
- b) Any cost escalation of the Project beyond the Grant in Aid Amount, committed hereinabove shall be borne by **Bharati Vidyapeeth (Pune)**
- c) The pre-commissioning process shall start immediately after accepting and signing of the GIA Agreement between the Parties. Work shall be completed as per milestones and timelines defined in "Scope" part of this document jointly planned and agreed by both parties.
- d) **Bharati Vidyapeeth (Pune)** shall submit program report for the immediate previous month in the reporting cycle by 5th of the month, along with relevant supporting documents to TPCDT.
- e) **Bharati Vidyapeeth (Pune)** shall submit financial report including expenses incurred for the immediate previous month in the reporting cycle of 1st to 31st calendar month, along with relevant supporting documents to TPCDT
- f) If TPCDT does not receive two consecutive progress reports (both programmatic and financial) it shall be at liberty to hold the project or hold further release of Grant-in-Aid Assistance agreed by TPCDT
- g) **Bharati Vidyapeeth (Pune)** shall refund any unutilized Grant, to TPCDT at the end of a Project. Both Parties may discuss possibility of, and TPCDT may approve appropriate utilization of unutilized grants in a manner agreed by both Parties, with set timelines
- h) TPCDT has the sole authority to hold, stop or extend the Project timeline and Grant-in-Aid Amount.
- i) TPCDT provides Grants based on funding received annually from its Funders. In cases of multiyear programs, where the payments cross a financial year (31 March), the Grant Amounts made post this period may vary, depending on changes in funds and program directions/focus.

6. **REPRESENTATIONS & WARRANTIES:**

- a) **Mutual Representations and Warranties** - Each Party represents and warrants to the other Party that:
 - i. It has the full right, power and authority to enter into this GIA Agreement, to Grant-in-Aid the rights Grant-in-Aided hereunder and to perform its obligations hereunder;
 - ii. The execution of this GIA Agreement by its representative whose signature is set forth at the end hereof has been duly authorized by all necessary action of the Party; and
 - iii. When executed and delivered by such Party, this GIA Agreement will constitute the legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms.
 - iv. For hardware and software, **Bharati Vidyapeeth (Pune)** is solely responsible and accountable owner of the same.
 - v. The product warranties, any maintenance, repair or damage will be tracked by **Bharati Vidyapeeth (Pune)**
- b) **Representations and Warranties of Bharati Vidyapeeth (Pune)**

Bharati Vidyapeeth (Pune) represents and warrants to TPCDT that: The execution, delivery and performance of this GIA Agreement do not and shall not be inconsistent and violate any agreed obligation of **Bharati Vidyapeeth (Pune)**;
 - i. The Grant-in-Aid shall be directed only towards Authorized/ Approved Activities as set out;

- ii. From time to time, Mr./Ms. ***Dilip Kawade*** or any other nominee of TPCDT shall be invited to respective field locations or project locations, to undertake field visits, along with employees/representative of ***Bharati Vidyapeeth (Pune)*** engaged in the Project
- iii. It shall furnish to TPCDT, copies of all necessary permissions and other necessary documents received from relevant government authorities and departments, conveying permission/ no-objection for covering the selected Project;
- iv. The resources received for this project shall be used for the Project objectives only and not for any commercial use. The resources shall be used, maintained and treated as a value to the respective projects;

7. USE OF TATA POWER LOGO FOR BRANDING:

- g) This Intervention is being deployed under Tata Power Health & Sanitation CSR Intervention. The logo of Tata Power and brand name of intervention can be used appropriately by ***Bharati Vidyapeeth (Pune)*** within the scope of this intervention with mutual consent of both parties.

8. NO LIABILITY

- a) ***Bharati Vidyapeeth (Pune)*** shall comply with all laws, regulations and also arrange to provide all the necessary approvals for carrying out all the plans agreed between the parties, for ensuring compliance of all applicable law, statutes for deployment as mentioned in this GIA Agreement. TPCDT shall not be liable in any manner whatsoever for any non-compliance in respect of the applicable laws, regulations and in the event of any adverse claim of whatsoever nature arising thereof, the entire burden shall be strictly borne by ***Bharati Vidyapeeth (Pune)***.
- b) Nothing in this GIA Agreement is intended or shall be construed to authorize either Party to create or assume any liability or indebtedness of any kind in the name of, or on behalf of the other Party or to act for or be responsible for the performance of the other Party in any manner except and to the extent expressly provided in this GIA Agreement. Notwithstanding anything contrary contained herein the parties shall not be obliged to incur any liability in case of any of the parties shall without prior specific approval/ consent of the other parties' credit or accept any contract binding upon the parties other than as envisaged in this GIAA.

9. CONFIDENTIALITY

The parties agree that all data which is transmitted or communicated by either party to the other party shall in all cases be held in confidence by the Receiving Party and not disclosed to any third party unless written consent of Disclosing Party is first obtained, except that, Receiving Party has the right to disclose such information to its own employees, consultants and representatives who are bound by an obligation of confidentiality and who need to know such information for the purposes specified hereinabove. The Receiving Party agrees that it shall not use the confidential data for any purpose(s) other than the ones specified herein. However, the Receiving Party shall not be required to maintain confidential or be restricted in its use of any data which,

- i. Was in public domain at the date of disclosure to Receiving Party
- ii. Becomes public knowledge during the term of this GIA Agreement without breach of this GIA Agreement
- iii. Receiving Party can show that it was in its possession prior to disclosure by Disclosing Party, and

- iv. Disclosure of which is required by law or by order of a court of competent jurisdiction. The obligation as to confidentiality shall survive for 5 years post termination/ expiry of this GIA Agreement.

10. INTELLECTUAL PROPERTY RIGHTS (IPR)

With respect to the services rendered under this GIA Agreement, the Parties agree that:

- a) All IPR arising out of this GIA Agreement and the data, information or activities therein shall solely vest with TPCDT. Usage of any such data or information that involves the IPR for TPCDT shall amount to an infringement if such usage is not authorized in writing.
- b) **Bharati Vidyapeeth (Pune)** agrees that it shall comply with all the relevant laws and shall not infringe in any IPR in the course of performing its obligations under this GIA Agreement.
- c) **Bharati Vidyapeeth (Pune)** agreed to indemnify/ keep indemnified TPCDT from all claims, suits, actions, losses, penalties or liabilities arising out of a breach of the clauses above.

11. ETHICAL BEHAVIOUR:

- a) **Bharati Vidyapeeth (Pune)** represent and warrant that it has conducted and shall conduct its business in accordance with the highest ethical standards and it shall comply with all applicable laws in the performance of its obligations under this **GIA Agreement**, including but not limited to, laws dealing with ethical business practices.
- b) If, at any time during the term of this **GIA Agreement**, **Bharati Vidyapeeth (Pune)** is informed or information comes to its attention that it or any of its affiliates is or may be in violation of any applicable law (or if it is so determined by any court, tribunal or governmental agency or authority), **Bharati Vidyapeeth (Pune)** shall immediately take all appropriate steps (including any reasonable requests by TPCDT) to remedy such violation and comply with such a law in all respects. Where such violation occurs and is not remedied TPCDT may terminate this GIA Agreement with immediate effect.
- c) **Bharati Vidyapeeth (Pune)** shall establish and maintain all proper records (including accounting records) required by applicable law and shall make such records available to TPCDT, if requested to do so. A certified utilization certificate shall be issued at the end of any project.
- d) **Bharati Vidyapeeth (Pune)** acknowledges of having read Tata Code of Conduct, accessed from Tata Power company website URL: <https://www.tatapower.com/pdf/aboutus/Tata-Code-Power-of-Conduct.pdf>
Bharati Vidyapeeth (Pune), as CSR Partner of Tata Power, acknowledges to comply with the guidelines given therein as part of upholding highest ethical standards during the deployment of this Project.

12. TERM, EXTENSION&TERMINATION/EXPIRY:

- a) This GIA Agreement shall commence as of the Effective date and shall remain in force until **31-Mar-2021**. Unless terminated earlier in accordance with the terms of this GIA Agreement. The Parties may renew this GIA Agreement on 'no cost to TPCDT' basis for a mutually agreed period if the situation so warrants, and the extension of period of agreement envisaged herein occasioned for the reasons not attributable to **Bharati Vidyapeeth (Pune)**, for its non-performance or delay in performance.
- b) TPCDT shall have the right to terminate this GIA Agreement immediately, for any reason whatsoever without assigning any reason thereof.

- c) In the event of termination, the ***Bharati Vidyapeeth (Pune)*** shall refund the unspent residual amount to TPCDT.

13. WAIVER:

No failure or delay by a party to exercise any right or remedy provided under this GIA Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.

14. VARIATION:

Both the Parties agree and confirm that the terms and conditions contained in this GIA Agreement may be changed / altered through written mutual consent; at any point, during course of the Agreement.

No variation of this GIA Agreement shall be effective unless it is in writing and signed by the Parties (or their authorised representatives).

15. SEVERANCE:

If any court or competent authority finds that any provision of this GIA Agreement (or part of any provision) is invalid, illegal or unenforceable, that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this GIA Agreement shall not be affected.

16. THIRD PARTY RIGHTS:

No person other than a Party to this GIA Agreements shall have any rights to enforce any term of this GIA Agreement.

17. NO PARTNERSHIP OR AGENCY:

Nothing in this GIA Agreement is intended to, or shall be deemed to, establish any partnership or joint venture between the Parties, constitute either Party the agent of the other Party, nor authorise either Party to make or enter into any commitments for or on behalf of the other Party.

18. NOTICES:

All notices related to this GIA Agreement which are permitted hereunder shall be in writing and deemed to have been duly given/served if delivered personally or sent by facsimile transmission (with answerback received) or overnight express or by registered mail or certified mail, postage prepaid. All notices shall be sent to the addresses mentioned in the title clause or to such other address as the Parties may designate from time to time in writing.

19. FORCEMAJURE:

- a) Neither Party shall be liable to the other for any delay or failure in the performance by it of any obligation under this GIA Agreement to the extent affected, delayed or prevented by an event of Force Majeure, provided that the Party that is affected by the Force Majeure shall provide notice thereof to the other Party as soon as practicable, but in any event not later than 7 [seven] days from the time which the affected Party knew or should reasonably have known of the commencement of the event of Force Majeure.
- b) The affected Party shall use its reasonable endeavours to mitigate the adverse effects of the Force Majeure event affecting it and shall seek reasonable alternative means to resume the Services, to the extent not affected by the event of Force Majeure. The affected Party shall provide to the other Party reasonable details as requested by the other Party regarding the nature of the Force Majeure event.

Neither Party shall be entitled to make any claim on the other for any fees, costs, expenses, losses or damages incurred or suffered as a result of an event of Force Majeure.

- c) If any event of Force Majeure continues beyond a period of one month, either Party may terminate this GIA Agreement.

20. ASSIGNMENT AND OTHER DEALINGS PROHIBITED:

This GIA Agreement is personal to the Parties and no Party shall, without the prior written consent of the other Party (such consent not to be unreasonably conditioned, withheld or delayed), assign, transfer, or deal in any other manner with this GIA Agreement or any of its rights and obligations under or arising out of this GIA Agreement, or purport to do any of the same. No Party shall sub-contract or delegate in any manner any or all of its obligations under this GIA Agreement to any third party or agent. Each Party that has rights under this GIA Agreement is acting on its own behalf and not for the benefit of another person.

21. ARBITRATION:

Any dispute or differences arising out of or in connection with this GIA Agreement (including the validity or interpretation hereof) shall be referred to the sole arbitrator to be nominated by Parties and the arbitration shall be governed by the provisions of the Indian Arbitration & Conciliation Act, 1996 or any law relating to arbitration in force at the time of such reference. The venue of the arbitration shall be Mumbai. The parties submit to the exclusive jurisdiction of the Courts of Mumbai.

22. GOVERNING LAW AND JURISDICTION:

This GIA Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the laws of India. The parties irrevocably agree that the courts of Mumbai shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this GIA Agreement or its subject matter or formation (including non-contractual disputes or claims).

23. COUNTERPARTS:

This GIA Agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original of this GIA Agreement, but all the counterparts shall together constitute the same GIA Agreement. No counterpart shall be effective until each party has executed at least one counterpart.

24. ENTIRE AGREEMENT:

This GIA Agreement constitutes the entire agreement between the parties and supersedes all previous agreements between the parties relating to its subject matter.

IN WITNESS WHEREOF the Parties hereto have caused this GIA Agreement to be executed, in duplicate, by their duly authorized representatives on the date first written above.

<p>For TPCDT</p> <p>Approved On: 25-Jun-2020 07:34:43 PM</p> <p>Name: <i>Nagori Forum</i></p> <p>Designation: <i>Head - Corporate Social Responsibility</i></p>	<p>For Bharati Vidyapeeth (Pune)</p> <p>Signature: <i>Dr. G. R. Rathod</i></p> <p>Name: DIRECTOR Bharati Vidyapeeth (Deemed to be University) Social Science Centre (M.S.W) Erandwane, Pune - 411 038.</p>
--	--



Grant-in-Aid Agreement

This **Grant-in-Aid Agreement ("GIA Agreement")** is made and entered into on this **30** day of **June**, 2020 ("**Effective Date**"),

BETWEEN

Tata Power Community Development Trust, a Trust duly registered under the Bombay Public Trusts Act 1950, vide Registration number E - 25632 with its registered office at Bombay House, 24, Homi Mody Street, Mumbai 400001(hereinafter referred to as **TPCDT** which expression shall unless repugnant to the context thereof be deemed to mean and include its successors and assigns), of the ONE PART;

AND

Bharati Vidyapeth(Pune), a non-profit organization registered as **Registered with Charities Commissioner**, registration number **90186** under the **Societies Registration Act 1860** with its registered office **Social Sciences Centre, FIELDS Dr. G. R. Rathod** having current and valid Income tax 12AA registration certificate for tax exemption and 80G tax Deduction certificate, hereinafter referred to as **Bharati Vidyapeth(Pune)** which expression shall unless repugnant to the context thereof be deemed to mean and include its successors and permitted assigns), of the OTHER PART.

(Hereinafter **TPCDT** and **Bharati Vidyapeth(Pune)** shall be individually referred to as "**the Party**" and collectively as "**the Parties**")

WHEREAS:

- a) TPCDT is, inter alia, engaged in non-profit & community development initiatives **under 5 thrust areas namely Education, Health & Sanitation, Livelihood & Employability, Water and Financial Inclusion**, and is a key facilitator that supports developmental projects across identified locations to create and offer sustainable solutions to the diverse challenges faced by local communities.
- b) **Bharati Vidyapeth(Pune)** is a non-profit organization based out of **Pune (Maharashtra)** working in the field of **Livelihood & Skill Building**. The NGO works in the states of **Maharashtra**. The mission is to **Social transmission through dynamic education**. The average annual gross contribution received by the NGO for last three years amount Rs 5Cr. The NGO operates at locations such as Social Sciences Centre, BharatiVidyapeeth Deemed University, Erandawane, Pune-411038 in the thrust areas of Education, Health and livelihood and employability.

GNT202100000023

- c) ***Bharati Vidyapeth(Pune)*** has submitted a proposal dated 14-May-2020 to TPCDT for conducting ***Micro Enterprises for Women (DHAAGA)*** and same forms part of GIA Agreement and is marked as **Annex - 3**
- d) TPCDT is desirous of being partner in the Intervention to be implemented by ***Bharati Vidyapeth(Pune)*** The scope of the intervention and funding are as detailed and forms part of this GIA Agreement
- e) ***Bharati Vidyapeth(Pune)*** would not sublet or delegate any of the project activities as part of this GIA Agreement.
- f) Believing the aforesaid to be true, and in furtherance of its Mission & Objectives, TPCDT has agreed to engage ***Bharati Vidyapeth(Pune)***, through this GIA Agreement, as the implementing agency to ***Micro Enterprises for Women (DHAAGA)***

NOW THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, agree as follows:

1. INTERVENTION & ADMINISTRATION

- a) **Intervention Title:** *Micro Enterprises for Women (DHAAGA)*
- b) **Scope:** *Women will be linkages for financial resources with Government scheme.*
- c) **Project Objectives:** *400 women from Mulshi block will be financially independent FIELD 15 , Sec-B,4)*
- d) **Project Timelines:** *From 01-Apr-2020 to 31-Mar-2021*
- e) **Name of Collaborating Organizations:**
- f) ***Bharati Vidyapeth(Pune)*** is the implementing organization for this Project.
- g) TPCDT is the non-profit organization, which would be funding this Project, by way of Grant-in-Aid in furtherance of developmental objects.

2. PROJECT LOCATION:

- a) State & District ***Maharashtra & Pune***
- b) Revenue Block ***Mulshi***
- c) Gram Panchayat or Ward ***Maley***
- d) No of Villages or Ward Mohallas **15** covered
- e) Beneficiaries potentially covered through this project **400 (Refer Annex-3,Sec-B-6)**
- f) SC & ST Beneficiaries as **20 %** of above (No.), covered through this intervention.

3. THE WORKING RELATIONSHIP:

The bipartite collaboration would be guided by the following mutually agreed principles:

- a) All the parties shall ensure transparency and accountability in all activities undertaken as a part of the intervention.
- b) The parties shall encourage adoption of a scientific, rational, democratic, bottoms-up, community needs-based approach to the issues addressed.
- c) The parties shall encourage the use of technology-based interventions for higher impacts, outreach and outcomes.
- d) Each stakeholder to designate Single Point of Contact (SPoC) for effective coordination during the project execution.

4. **INTERVENTION TERM AND WORKPLAN**

- a) The intervention shall be implemented in accordance with GIA Agreement and the intervention proposal set out in Annexure-3.
- b) **Bharati Vidyapeth(Pune)** shall forthwith notify TPCDT in writing in the event of the occurrence of any event that may cause delay in achieving the intervention delivery milestone.
- c) The terms of the intervention under this GIA Agreement of FY-19.
- d) The work plan in terms of (NGO name) deliverables with timelines mentioned in (Annexure-3, Sec B-8)

5. **INTERVENTION BUDGET/PARTNERS NAME & PAYMENT TERMS:**

- a) TPCDT has sanction to **Bharati Vidyapeth(Pune)** a Grant-in-Aid of **1300000.0** (Indian Rupees **Thirteen Lakhs only** for the Project to be undertaken by **Bharati Vidyapeth(Pune)** in relation to Micro Enterprises for Women (DHAAGA) as "Authorized/Approved Activities")
- b) TPCDT shall deploy financial resources for the Term of this GIA Agreement up to a total cost of INR **1300000.0** (Indian Rupees **Thirteen Lakhs only** only). (**Annex-3 Sec-B-8**) The **Bharati Vidyapeth(Pune)** agrees that the project management charges shall not exceed 10% of the total Grant-in-Aid (INR) Amount, and to that effect satisfies TPCDT.
- c) It is understood and agreed between the Parties that TPCDT's Grant-in-Aid to **Bharati Vidyapeth(Pune)**, is with respect to the intervention as per KPIs mentioned in (**Annex-2**)
- d) Compliances & Schedule of Payments for Total Grant Amount of Rs: **1300000.0**

Installment number	Installment payment (in ₹)	Installment Amount	Key Milestone (Annex-1)
1	25%	325000.0	On signing of GIA Agreement
2	30%	390000.0	On completion of agreed key deliverables mentioned in Annexure-1 and 80% utilization of 1st installment.
3	35%	455000.0	On Completion of 50% of Key performance indicators [Midline study] (Refer KPIs annex-2) and 80% utilization of 2nd installment.
4	10%	130000.0	Completion of all initiatives, 80% utilization of 3rd installment, achieving 100% KPIs and submission of end line report.

- a) **Bharati Vidyapeth(Pune)** shall submit expenditure statements, indicating usage of 80% of first and consequent Grant installments, during course of the project based on actuals.
- b) Any cost escalation of the Project beyond the Grant in Aid Amount, committed hereinabove shall be borne by **Bharati Vidyapeth(Pune)**
- c) The pre-commissioning process shall start immediately after accepting and signing of the GIA Agreement between the Parties. Work shall be completed as per milestones and timelines defined in "Scope" part of this document jointly planned and agreed by both parties.
- d) **Bharati Vidyapeth(Pune)** shall submit program report for the immediate previous month in the reporting cycle by 5th of the month, along with relevant supporting documents to TPCDT.

GNT202100000023

- e) **Bharati Vidyapeth(Pune)** shall submit financial report including expenses incurred for the immediate previous month in the reporting cycle of 1st to 31st calendar month, along with relevant supporting documents to TPCDT
- f) If TPCDT does not receive two consecutive progress reports (both programmatic and financial)it shall be at liberty to hold the project or hold further release of Grant-in-Aid Assistance agreed by TPCDT
- g) **Bharati Vidyapeth(Pune)** shall refund any unutilized Grant, to TPCDT at the end of a Project. Both Parties may discuss possibility of, and TPCDT may approve appropriate utilization of unutilized grants in a manner agreed by both Parties, with set timelines
- h) TPCDT has the sole authority to hold, stop or extend the Project timeline and Grant-in-Aid Amount.
- i) TPCDT provides Grants based on funding received annually from its Funders. In cases of multiyear programs, where the payments cross a financial year (31 March), the Grant Amounts made post this period may vary, depending on changes in funds and program directions/focus.

6. **REPRESENTATIONS & WARRANTIES:**

- a) **Mutual Representations and Warranties** - Each Party represents and warrants to the other Party that:
 - i. It has the full right, power and authority to enter into this GIA Agreement, to Grant-in-Aid the rights Grant-in-Aided hereunder and to perform its obligations hereunder;
 - ii. The execution of this GIA Agreement by its representative whose signature is set forth at the end hereof has been duly authorized by all necessary action of the Party; and
 - iii. When executed and delivered by such Party, this GIA Agreement will constitute the legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms.
 - iv. For hardware and software, ***Bharati Vidyapeth(Pune)*** is solely responsible and accountable owner of the same.
 - v. The product warranties, any maintenance, repair or damage will be tracked by ***Bharati Vidyapeth(Pune)***
- b) **Representations and Warranties of *Bharati Vidyapeth(Pune)***

Bharati Vidyapeth(Pune) represents and warrants to TPCDT that: The execution, delivery and performance of this GIA Agreement do not and shall not be inconsistent and violate any agreed obligation of ***Bharati Vidyapeth(Pune)*** ;

- i. The Grant-in-Aid shall be directed only towards Authorized/ Approved Activities as set out;
- ii. From time to time, Mr./Ms. **Dilip Kawade** or any other nominee of TPCDT shall be invited to respective field locations or project locations, to undertake field visits, along with employees/representative of ***Bharati Vidyapeth(Pune)*** engaged in the Project
- iii. It shall furnish to TPCDT, copies of all necessary permissions and other necessary documents received from relevant government authorities and departments, conveying permission/ no-objection for covering the selected Project;
- iv. The resources received for this project shall be used for the Project objectives only and not for any commercial use. The resources shall be used, maintained and treated as a value to the respective projects;

7. **USE OF TATA POWER LOGO FOR BRANDING:**

- g) This Intervention is being deployed under Tata Power Livelihood & Skill Building

CSR Intervention. The logo of Tata Power and brand name of intervention can be used appropriately by **Bharati Vidyapeth(Pune)** within the scope of this intervention with mutual consent of both parties.

8. NO LIABILITY

- a) **Bharati Vidyapeth(Pune)** shall comply with all laws, regulations and also arrange to provide all the necessary approvals for carrying out all the plans agreed between the parties, for ensuring compliance of all applicable law, statutes for deployment as mentioned in this GIA Agreement. TPCDT shall not be liable in any manner whatsoever for any non-compliance in respect of the applicable laws, regulations and in the event of any adverse claim of whatsoever nature arising thereof, the entire burden shall be strictly borne by **Bharati Vidyapeth(Pune)**.
- b) Nothing in this GIA Agreement is intended or shall be construed to authorize either Party to create or assume any liability or indebtedness of any kind in the name of, or on behalf of the other Party or to act for or be responsible for the performance of the other Party in any manner except and to the extent expressly provided in this GIA Agreement. Notwithstanding anything contrary contained herein the parties shall not be obliged to incur any liability in case of any of the parties shall without prior specific approval/ consent of the other parties' credit or accept any contract binding upon the parties other than as envisaged in this GIAA.

9. CONFIDENTIALITY

The parties agree that all data which is transmitted or communicated by either party to the other party shall in all cases be held in confidence by the Receiving Party and not disclosed to any third party unless written consent of Disclosing Party is first obtained, except that, Receiving Party has the right to disclose such information to its own employees, consultants and representatives who are bound by an obligation of confidentiality and who need to know such information for the purposes specified hereinabove. The Receiving Party agrees that it shall not use the confidential data for any purpose(s) other than the ones specified herein. However, the Receiving Party shall not be required to maintain confidential or be restricted in its use of any data which,

- i. Was in public domain at the date of disclosure to Receiving Party
- ii. Becomes public knowledge during the term of this GIA Agreement without breach of this GIA Agreement
- iii. Receiving Party can show that it was in its possession prior to disclosure by Disclosing Party, and
- iv. Disclosure of which is required by law or by order of a court of competent jurisdiction. The obligation as to confidentiality shall survive for 5 years post termination/ expiry of this GIA Agreement.

10. INTELLECTUAL PROPERTY RIGHTS (IPR)

With respect to the services rendered under this GIA Agreement, the Parties agree that:

- a) All IPR arising out of this GIA Agreement and the data, information or activities therein shall solely vest with TPCDT. Usage of any such data or information that involves the IPR for TPCDT shall amount to an infringement if such usage is not authorized in writing.
- b) **Bharati Vidyapeth(Pune)** agrees that it shall comply with all the relevant laws and shall not infringe in any IPR in the course of performing its obligations under this GIA Agreement.

GNT202100000023

- c) **Bharati Vidyapeth(Pune)** agreed to indemnify/ keep indemnified **TPCDT** from all claims, suits, actions, losses, penalties or liabilities arising out of a breach of the clauses above.

11. ETHICAL BEHAVIOUR:

- a) **Bharati Vidyapeth(Pune)** represent and warrant that it has conducted and shall conduct its business in accordance with the highest ethical standards and it shall comply with all applicable laws in the performance of its obligations under this **GIA Agreement**, including but not limited to, laws dealing with ethical business practices.
- b) If, at any time during the term of this **GIA Agreement**, **Bharati Vidyapeth(Pune)** is informed or information comes to its attention that it or any of its affiliates is or may be in violation of any applicable law (or if it is so determined by any court, tribunal or governmental agency or authority), **Bharati Vidyapeth(Pune)** shall immediately take all appropriate steps (including any reasonable requests by **TPCDT**) to remedy such violation and comply with such a law in all respects. Where such violation occurs and is not remedied **TPCDT** may terminate this GIA Agreement with immediate effect.
- c) **Bharati Vidyapeth(Pune)** shall establish and maintain all proper records (including accounting records) required by applicable law and shall make such records available to **TPCDT**, if requested to do so. A certified utilization certificate shall be issued at the end of any project.
- d) **Bharati Vidyapeth(Pune)** acknowledges of having read Tata Code of Conduct, accessed from Tata Power company website URL: <https://www.tatapower.com/pdf/aboutus/Tata-Code-Power-of-Conduct.pdf> **Bharati Vidyapeth(Pune)**, as CSR Partner of Tata Power, acknowledges to comply with the guidelines given therein as part of upholding highest ethical standards during the deployment of this Project.

12. TERM, EXTENSION&TERMINATION/EXPIRY:

- a) This GIA Agreement shall commence as of the Effective date and shall remain in force until **31-Mar-2021**. Unless terminated earlier in accordance with the terms of this GIA Agreement. The Parties may renew this GIA Agreement on 'no cost to **TPCDT**' basis for a mutually agreed period if the situation so warrants, and the extension of period of agreement envisaged herein occasioned for the reasons not attributable to **Bharati Vidyapeth(Pune)**, for its non-performance or delay in performance.
- b) **TPCDT** shall have the right to terminate this GIA Agreement immediately, for any reason whatsoever without assigning any reason thereof.
- c) In the event of termination, the **Bharati Vidyapeth(Pune)** shall refund the unspent residual amount to **TPCDT**.

13. WAIVER:

No failure or delay by a party to exercise any right or remedy provided under this GIA Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.

14. VARIATION:

Both the Parties agree and confirm that the terms and conditions contained in this GIA Agreement may be changed / altered through written mutual consent; at any point, during course of the Agreement.

No variation of this GIA Agreement shall be effective unless it is in writing and signed by the Parties (or their

authorised representatives).

GNT20210000023

15. SEVERANCE:

If any court or competent authority finds that any provision of this GIA Agreement (or part of any provision) is invalid, illegal or unenforceable, that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this GIA Agreement shall not be affected.

16. THIRD PARTY RIGHTS:

No person other than a Party to this GIA Agreements shall have any rights to enforce any term of this GIA Agreement.

17. NO PARTNERSHIP OR AGENCY:

Nothing in this GIA Agreement is intended to, or shall be deemed to, establish any partnership or joint venture between the Parties, constitute either Party the agent of the other Party, nor authorise either Party to make or enter into any commitments for or on behalf of the other Party.

18. NOTICES:

All notices related to this GIA Agreement which are permitted hereunder shall be in writing and deemed to have been duly given/served if delivered personally or sent by facsimile transmission (with answerback received) or overnight express or by registered mail or certified mail, postage prepaid. All notices shall be sent to the addresses mentioned in the title clause or to such other address as the Parties may designate from time to time in writing.

19. FORCEMAJURE:

- a) Neither Party shall be liable to the other for any delay or failure in the performance by it of any obligation under this GIA Agreement to the extent affected, delayed or prevented by an event of Force Majeure, provided that the Party that is affected by the Force Majeure shall provide notice thereof to the other Party as soon as practicable, but in any event not later than 7 [seven] days from the time which the affected Party knew or should reasonably have known of the commencement of the event of Force Majeure.
- b) The affected Party shall use its reasonable endeavours to mitigate the adverse effects of the Force Majeure event affecting it and shall seek reasonable alternative means to resume the Services, to the extent not affected by the event of Force Majeure. The affected Party shall provide to the other Party reasonable details as requested by the other Party regarding the nature of the Force Majeure event. Neither Party shall be entitled to make any claim on the other for any fees, costs, expenses, losses or damages incurred or suffered as a result of an event of Force Majeure.
- c) If any event of Force Majeure continues beyond a period of one month, either Party may terminate this GIA Agreement.

20. ASSIGNMENT AND OTHER DEALINGS PROHIBITED:

This GIA Agreement is personal to the Parties and no Party shall, without the prior written consent of the other Party (such consent not to be unreasonably conditioned, withheld or delayed), assign, transfer, or deal in any other manner with this GIA Agreement or any of its rights and obligations under or arising out of this GIA Agreement, or purport to do any of the same. No Party shall sub-contract or delegate in any manner any

or all of its obligations under this GIA Agreement to any third party or agent. Each Party that has rights under this GIA Agreement is acting on its own behalf and not for the benefit of another person.

21. ARBITRATION:

Page 7 of 10

GNT202100000023

Any dispute or differences arising out of or in connection with this GIA Agreement (including the validity or interpretation hereof) shall be referred to the sole arbitrator to be nominated by Parties and the arbitration shall be governed by the provisions of the Indian Arbitration & Conciliation Act, 1996 or any law relating to arbitration in force at the time of such reference. The venue of the arbitration shall be Mumbai. The parties submit to the exclusive jurisdiction of the Courts of Mumbai.

22. GOVERNING LAW AND JURISDICTION:

This GIA Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the laws of India. The parties irrevocably agree that the courts of Mumbai shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this GIA Agreement or its subject matter or formation (including non-contractual disputes or claims).



23. COUNTERPARTS:

This GIA Agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original of this GIA Agreement, but all the counterparts shall together constitute the same GIA Agreement. No counterpart shall be effective until each party has executed at least one counterpart.

24. ENTIRE AGREEMENT:

This GIA Agreement constitutes the entire agreement between the parties and supersedes all previous agreements between the parties relating to its subject matter.

IN WITNESS WHEREOF the Parties hereto have caused this GIA Agreement to be executed, in duplicate, by their duly authorized representatives on the date first written above.

<p>For TPCDT</p> <p>Approved On: 14-Jul-2020 02:09:08 AM</p> <p>Name: <i>Nagori Forum</i></p> <p>Designation:</p>	<p>For Bharati Vidyapeeth(Pune)</p> <p>Signature: </p> <p>Name: Dr. G. R. Rathod</p> <p>Designation: DIRECTOR</p> <p>Bharati Vidyapeeth (Deemed to be University) Social Science Centre(M.S.W) Erandwane, Pune - 411 038.</p>
<p>Approved On:</p> <p>Name:</p> <p>Designation:</p>	<p>Witness:</p> <p>Signature: </p> <p>Name: Dr. Vijay Kulkarni</p> <p>(Associate Professor)</p>



No. BT/PR22677/MED/97/366/2017
GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY

Block 2, (6-8th Floors)
CGO Complex, Lodhi Road,
New Delhi- 110 003
Date: **13.10.2020**

RELEASE ORDER

In continuation of this Department's sanction order of even number dated Mar 15, 2018 sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rule, 1978, for the release of Rs. **1042795.00** (Rupees Ten Lakhs Forty Two Thousand Seven Hundred and Ninety Five Only) being the third year release for the project entitled "**Influence of Maternal One-Carbon (1C) Metabolism in Placental Function, Fetal Growth and Programming**", being implemented by

1. Dr. Chittaranjan Yajnik, King Edward VII Memorial Hospital, Pune - 411011, Maharashtra,
2. Dr. Sadhana Joshi, Interactive Research School for Health Affairs, Pune Satara Road, Katraj, Pune - 411043, Maharashtra,

The detailed break-up is as given below:

SNo	Institute Name	Recurring						Total Release Amount (Rs)
		Manpower	Consumable	Travel	Contingency	Others	Overhead	
1	Interactive Research School for Health Affairs	520461.00	155314.00	20071.00	24672.00	0.00	0.00	720518.00
The Interest earned amount Rs.0.05642 lakhs has been re-appropriated to Consumable head.								
2	King Edward VII Memorial Hospital	271020.00	0.00	21775.00	29482.00	0.00	0.00	322277.00
The Interest earned amount Rs. 0.02587 lakhs has been re-appropriated to travel head								

2. The amount of Rs. **1042795.00** (Rupees Ten Lakhs Forty Two Thousand Seven Hundred and Ninety Five Only) will be directly credited by the Pay & Accounts Officer, DBT in the account as detailed below:

1. Rs. **322277.00** (Rupees Three Lakhs Twenty Two Thousand Two Hundred and Seventy Seven Only) to The Director, King Edward VII Memorial Hospital, Pune - 400012, Maharashtra

Bank Name : Bank of Maharashtra
Branch Name : Somwar Peth, Pune
A/c No. : 20117879976
IFSC Code : MAHB0000040
MICR Code : 411014051


2. Rs. **720518.00** (Rupees Seven Lakhs Twenty Thousand Five Hundred and Eighteen Only) to The Director, Interactive Research School for Health Affairs, Pune Satara Road, Dhankawadi, Pune - 411043, Maharashtra

Bank Name : State Bank of India
Branch Name : State Bank of India, Katraj Branch
A/c No. : 30808434608
IFSC Code : SBIN0008752
MICR Code : 411002018

3. The expenditure involved is debitable to:

Demand No. 88	Department of Biotechnology
3425	Other Scientific Research 2020-2021
3425.60	Others (Sub Major Head)
3425.60.200	Assistance to other Scientific Bodies (Minor Head)
3425.60.200.29	Biotechnology Research and Development
3425.60.200.29.17	Assistance for Research and Development
3425.60.200.29.17.31	Grants -in-Aid General

4. The Director, King Edward VII Memorial Hospital, Pune, Maharashtra and The Director, Interactive Research School for Health Affairs, Pune, Maharashtra will submit audited utilization certificates and statements of expenditure in respect of the above-mentioned amount.
5. As per Rule 236 (1) of GFR 2017, the accounts of all Grantee Institutions or Organisations shall be open to inspection by the sanctioning authority and audit, both by the Comptroller and Auditor General of India under the provision of CAG(DPC) Act 1971 and internal audit by the Principal Accounts Office of the Ministry or Department, whenever the Institution or Organisation is called upon to do so.
6. No International Travel will be undertaken from the sanctioned project grant unless specified otherwise.
7. The Institute/Agency will keep the whole of the grant in a Bank Account earning interest, and the interest so earned should be reported to DBT in the Utilisation Certificate and Statement of Expenditure. The Interest so earned will be treated as created to the institute/Agency and shall be adjusted towards further instalment of the grant and or at the time of Final Settlement of Accounts.
8. i) In case the whole or a part of the amount of the grant-in-aid is being refunded, an interest rate at the rate of ten percent thereon shall be recovered.
ii) Grantee Institutions are a private organization and the MoA has been signed.
iii) The Competent Authority has allowed a sum of Rs. 0.06777 lakhs for IRSHA Pune and Rs. 0.06549 lakhs for KEM, Pune to be carried forward to the current financial year 2020-21.
iv) The expenditure to be made as per the EAT module of the Government of India.
The other terms and conditions governing the financial sanction will remain unaltered.
9. The utilization certificate for the financial year 2019-20 is enclosed herewith.
10. This issues under the powers delegated to this Department and with the concurrence of IFD, DBT, vide their SAN No. **102/IFD/SAN/670/2020-2021** dated **August, 17 2020**.
11. This sanction order has been noted at serial no. 11 in the Register of Grants.


 डॉ. नेहा बंसल (Dr. NEHA BANSAL)
 वैज्ञानिक सी / Scientist 'C'
 बायोटेक्नोलॉजी विभाग / Department of Biotechnology
 विज्ञान और प्रौद्योगिकी मंत्रालय
 Ministry of Science & Technology
 भारत सरकार / Govt. of India
 एक्स, लोधी रोड, नई दिल्ली - 110003
 Ex. Lodi Road, New Delhi-110003

To,

The Pay & Accounts Officer,
Department of Biotechnology,
New Delhi - 110 003.

Copy to:

- 1 The Principal Director of Audit (Scientific Departments), DACR Building, New Delhi- 110 002.
- 2 Dr. Chittaranjan S Yajnik (Project Co-ordinator), King Edward Memorial Hospital, Sardar Moodliar Road, Rasta Peth, Pune-400012.
- 3 The Director, Interactive Research School for Health Affairs, Pune Satara Road, Dhankawadi, Pune - 411043, Maharashtra
- 4 The Director, King Edward Vii Memorial Hospital, Pune - 400012, Maharashtra
- 5 Dr. Chittaranjan Yajnik, PI, Diabetes Unit, King Edward Vii Memorial Hospital, Pune - 411011, Maharashtra
- 6 Dr. Sadhana Joshi, Professor, Nutritional Medicine, Interactive Research School for Health Affairs, Pune Satara road, Katraj, Pune - 411043, Maharashtra
- 7 Cash Section, DBT (2 copies).
- 8 Sanction Folder.
- 9 File Copy.

डॉ. नेहा बंसल / Dr. NEHA BANSAL
वैज्ञानिक (Dr. Neha Bansal)
Scientist - 'C'
Biotecnología
G.O. Complet, 19/03/2003

No. BT/PR22677/MED/97/366/2017
GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY

Block 2, 6-8th Floors
CGO Complex, Lodhi Road,
New Delhi- 110 003
Dated: 15/03/2018

ORDER

Sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rules, 1978, for the implementation of the project entitled: "Influence of Maternal One-Carbon (1C) Metabolism in Placental Function, Fetal Growth and Programming" for a period of 3 Year 0 Month at a total cost of Rs. 16198362 (Rupees One Crores Sixty One Lakhs Ninety Eight Thousand Three Hundred and Sixty Two Only) on the terms and conditions detailed here under:-

2 The Project :

2.1 Title : "Influence of Maternal One-Carbon (1C) Metabolism in Placental Function, Fetal Growth and Programming"

2.2 Details of the Investigators:

Project Co-ordinator

Dr. Chittaranjan Yajnik
PI
Diabetes Unit
King Edward VII Memorial Hospital
Pune, Pune, Maharashtra, 411011

Principal Investigators:

Dr. Chittaranjan Yajnik
PI
Diabetes Unit
King Edward VII Memorial Hospital
Pune, Pune, Maharashtra, 411011

Dr. Arnab Mukhopadhyay
Staff Scientist V
Molecular Aging Laboratory
National Institute of Immunology
Aruna Asaf Ali Marg, New Delhi, Delhi, 110067

Dr. Giriraj Ratan Chandak
Scientist
Genomic Research on Complex Diseases (GRC) Group
Centre For Cellular And Molecular Biology
CSIR- Centre for Cellular and Molecular Biology
(CSIR-CCMB), Habsiguda, Hyderabad,
Hyderabad, Andhra Pradesh, 500007

AW

Hoshi

Head
Bharati Vidyapeeth
(Deemed to be University)
Mother and Child Health
Interactive Research School for Health Affairs (IRSHA)
Pune-Satara Road, Pune - 411 043.

No. BT/PR30592/BIC/101/1081/2018
 GOVERNMENT OF INDIA
 MINISTRY OF SCIENCE & TECHNOLOGY
 DEPARTMENT OF BIOTECHNOLOGY

Block 2, (6-8th Floors)
 CGO Complex, Lodhi Road,
 New Delhi- 110 003
 Date: 28-05-2021

RELEASE ORDER

In continuation of this Department's sanction order of even number dated 26-04-2019, sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rule, 1978, for the release of Rs. **1263185.00** (Rupees Twelve Lakhs Sixty-Three Thousand One Hundred and Eighty-Five Only) being the second year release for the project entitled "**Epigenetic regulation of placental peroxisome proliferator activated receptor (PPAR) in women delivering low birth weight babies**", being implemented by:

Dr. Deepali Prakash Sundrani, Interactive Research School for Health Affairs, Interactive Research School for Health Affairs, Bharati Vidyapeeth University, Pune-Satara Road, Katraj-Dhanakwadi, Pune, Pune - 411043, Maharashtra

The detailed break-up is as given below:

SN	Institute Name	Recurring						Total Release Amount (Rs)
		Manpower	Consumable	Travel	Contingency	Others	Overhead	
1	Interactive Research School for Health Affairs Pune	454347.00	699740.00	10000.00	24598.00	0.00	74500.00	1263185.00

Interest earned of Rs. 17,855/- has been remitted by the institute to the Consolidated Fund of India through Bharatkosh vide receipt no.1401210001143. Carry forward of unspent balance of Rs 1001/- (excluding Rs 1063 interest earned during 2020-21) from FY 2020-21 to FY 2021-22 permitted. The interest earned in 2020-21 would be remitted to Bharatkosh.

Table-2: Details of revised total cost of project* (Amount in Rs)

Head	Year-I	Year-II	Year-III	Total
Equipment	4,14,183	00	00	4,14,183
Manpower	3,36,000	5,00,333	4,17,600	1,253,933
Consumables	4,00,000	7,00,000	7,00,000	18,00,000
Travel	20,000	20,000	20,000	60,000
Contingency	25,000	25,000	25,000	75,000
Overhead	44,500	74,500	74,500	1,93,500
Total	12,73,283	13,19,833	12,37,100	37,96,616

* Project cost increased due to revision of salary of Project assistant from Rs 18000/- pm to Rs 20000/- pm + HRA. The revision of total cost has approval of Competent Authority.

2. The amount of Rs. **1263185.00** /-(**Rupees Twelve Lakhs Sixty Three Thousand One Hundred and Eighty Five Only**) will be directly credited by the Pay & Accounts Officer, DBT in the account as detailed below:

The Director, Interactive Research School for Health Affairs, Pune Satara Road, Dhankawadi, Pune - 411043, Maharashtra

Bank Name : State Bank of India
Branch Name : Katraj Pune
A/c No. : 30808434608
IFSC Code : SBIN0008752
MICR Code : 411002018

3. The expenditure involved is debitable to:

Demand No. 89	Department of Biotechnology
3425	Other Scientific Research 2021-2022
3425.60	Others (Sub Major Head)
3425.60.200	Assistance to other Scientific Bodies (Minor Head)
3425.60.200.29	Biotechnology Research and Development
3425.60.200.29.17	Assistance to Research and Development
3425.60.200.29.17.31	Grants -in-Aid General

4. The Director, Interactive Research School for Health Affairs, Pune, Maharashtra will submit audited utilization certificates and statements of expenditure in respect of the above-mentioned amount.
5. As per Rule 236 (1) of GFR 2017, the accounts of all Grantee Institutions or Organisations shall be open to inspection by the sanctioning authority and audit, both by the Comptroller and Auditor General of India under the provision of CAG(DPC) Act 1971 and internal audit by the Principal Accounts Office of the Ministry or Department, whenever the Institution or Organisation is called upon to do so.
6. No International Travel will be undertaken from the sanctioned project grant unless specified otherwise.
7. The Institute/Agency will keep the whole of the grant in a Bank Account earning interest, and the interest so earned should be reported to DBT in the Utilisation Certificate and Statement of Expenditure. The Interest so earned shall be remitted to Consolidated Fund of India.
8. The other terms and conditions governing the financial sanction will remain unaltered.
9. The utilization certificate for the financial year 2020-21 is enclosed herewith.
10. This issues under the powers delegated to Divisional Heads vide IFD Order No. G-17012/1/2020-IFD-DBT dated 29.12.2020. This has been noted in IFD Dy. No.102/IFD/SAN/103/2021-22 dated 28.05.2021.
11. This sanction order has been noted at serial no. **2 (2021-22)** in the Register of Grants.

(Dr. Abhishek Kumar Mehta)
Scientist-C

To,

The Pay & Accounts Officer,
Department of Biotechnology,
New Delhi – 110 003.

Copy to:

- 1 The Principal Director of Audit (Scientific Departments), DACR Building, New Delhi- 110 002.
- 2 The Director, Interactive Research School for Health Affairs, Pune Satara Road, Dhankawadi, Pune - 411043, Maharashtra
- 3 Dr. Deepali Prakash Sundrani, Assistant Professor, Mother and Child Health, Interactive Research School for Health Affairs, Interactive Research School for Health Affairs, Bharati Vidyapeeth University, Pune-Satara Road, Katraj-Dhanakwadi, Pune, Pune - 411043, Maharashtra
- 4 Dr. Sadhana Joshi, Professor and Head, Mother and Child Health, Interactive Research School for Health Affairs, Bharati Vidyapeeth (Deemed to be) University, Pune Satara Road, Pune, Pune - 411043, Maharashtra
- 5 Dr. Tushar Panchanadikar, Professor & Head, Department of Obstetrics & Gynaecology, Bharati Vidyapeeth University Medical College, Pune, Bharati Vidyapeeth University, Pune Satara Road, Pune, Pune - 411043, Maharashtra
- 6 Cash Section, DBT (2 copies).
- 7 Sanction Folder.
- 8 File Copy.

(Dr. Abhishek Kumar Mehta)
Scientist-C

No. BT/PR30830/MED/97/441/2018
GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY

Block 2, (6-8th Floors)
CGO Complex, Lodhi Road,
New Delhi- 110 003
Date: **16.02.2021**

RELEASE ORDER

In continuation of this Department's sanction order of even number dated Jul 18, 2019 sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rule, 1978, for the release of Rs. **2020577.00** (Rupees Twenty Lakhs Twenty Thousand Five Hundred and Seventy Seven Only) being the second year release for the project entitled "**Epigenetic regulation of angiogenic factors in assisted reproductive technology (ART) and non-ART derived placenta**", being implemented by

Dr. Deepali Prakash Sundrani, Interactive Research School for Health Affairs, Bharati Vidyapeeth University, Pune-Satara Road, Katraj-Dhanakwadi, Pune - 411043, Maharashtra,

The detailed break-up is as given below:

SNo	Institute Name	Recurring					Total Release Amount (Rs)
		Manpower	Consumable	Travel	Contingency	Overhead	
1	Interactive Research School for Health Affairs, Pune	191613.00	1683128.00	25000.00	23286.00	97550.00	2020577.00

2. The amount of Rs. **2020577.00** (Rupees Twenty Lakhs Twenty Thousand Five Hundred and Seventy Seven Only) will be directly credited by the Pay & Accounts Officer, DBT in the account as detailed below:

The Director, Interactive Research School for Health Affairs, Pune Satara Road, Dhankawadi, Pune - 411043, Maharashtra


Bank Name : State Bank of India
Branch Name : Katraj Pune
A/c No. : 30808434608
IFSC Code : SBIN0008752
MICR Code : 411002018

3. The expenditure involved is debit to:

Demand No. 88	Department of Biotechnology
3425	Other Scientific Research 2020-2021
3425.60	Others (Sub Major Head)
3425.60.200	Assistance to other Scientific Bodies (Minor Head)
3425.60.200.29	Biotechnology Research and Development
3425.60.200.29.17	Assistance for Research and Development
3425.60.200.29.17.31	Grants -in-Aid General

4. The Director, Interactive Research School for Health Affairs, Pune, Maharashtra will submit audited utilization certificates and statements of expenditure in respect of the above-mentioned amount.
5. As per Rule 236 (1) of GFR 2017, the accounts of all Grantee Institutions or Organisations shall be open to inspection by the sanctioning authority and audit, both by the Comptroller and Auditor General of India under the provision of CAG(DPC) Act 1971 and internal audit by the Principal Accounts Office of the Ministry or Department, whenever the Institution or Organisation is called upon to do so.

6. No International Travel will be undertaken from the sanctioned project grant unless specified otherwise.
7. The Institute/Agency will keep the whole of the grant in a Bank Account earning interest, and the interest so earned should be reported to DBT in the Utilisation Certificate and Statement of Expenditure. The Interest so earned will be treated as created to the institute/Agency and shall be adjusted towards further instalment of the grant and or at the time of Final Settlement of Accounts.
8. i. In case the whole or a part of the amount of the grant-in-aid is being refunded, an interest rate at the rate of ten percent thereon shall be recovered.
 ii. Grantee Institution is a private organization and the MoA has been signed.
 iii. The Competent Authority has allowed a sum of Rs. 6.16905 lakhs to be carried forward to the current financial year 2020-21 (However interest earned amount Rs. 0.34505 lakhs has been remitted to CFI, receipt is enclosed)
 iv. The expenditure to be made as per the EAT module of the Government of India.
 The other terms and conditions governing the financial sanction will remain unaltered.
9. The utilization certificate for the financial year **2019-20** is enclosed herewith.
10. This issues under the powers delegated to Divisional Heads wide IFD order No. BT/04/2015-IFD dated 1.4.2019 and subsequently modified vide order of even number dated 10.05.2019 This has been noted in IFD at SAN No. **102/IFD/SAN/2435/2020-2021** dated **February, 16 2021**.
11. This sanction order has been noted at serial no **43** dated **16.02.2021** in the Register of Grants.



(Dr. Neha Bansal)
Scientist 'C'


To,

The Pay & Accounts Officer,
Department of Biotechnology,
New Delhi - 110 003.

डॉ. नेहा बंसल / Dr. NEHA BANSAL
वैज्ञानिक 'सी' / Scientist 'C'
बायोटेक्नोलॉजी विभाग / Department of Biotechnology
विज्ञान और प्रौद्योगिकी मंत्रालय
Ministry of Science & Technology
भारत सरकार / Govt. of India
सी.जी.ओ. कॉम्प्लेक्स, लोधी रोड, नई दिल्ली-110003
C.G.O. Complex, Lodhi Road, New Delhi-110003

Copy to:

- 1 The Principal Director of Audit (Scientific Departments), DACR Building, New Delhi- 110 002.
- 2 The Director, Interactive Research School for Health Affairs, Pune Satara Road, Dhankawadi, Pune - 411043, Maharashtra
- 3 Dr. Deepali Prakash Sundrani, Assistant Professor, Mother and Child Health, Interactive Research School for Health Affairs, Bharati Vidyapeeth University, Pune-Satara Road, Katraj-Dhanakwadi, Pune - 411043, Maharashtra
- 4 Dr. Sadhana Joshi, Professor and Head, Mother and Child Health, Interactive Research School for Health Affairs, Bharati Vidyapeeth (Deemed to be) University, Pune Satara Road, Pune - 411043, Maharashtra
- 5 Dr. Sanjay Gupte, Director, Gupte Hospital and Research Center, Interactive Research School for Health Affairs, Gupte Hospital and Research Center, Bhandarkar Road, Pune - 411004, Maharashtra
- 6 Cash Section, DBT (2 copies).
- 7 Sanction Folder.
- 8 File Copy.



(Dr. Neha Bansal)
Scientist 'C'

डॉ. नेहा बंसल / Dr. NEHA BANSAL
वैज्ञानिक 'सी' / Scientist 'C'
बायोटेक्नोलॉजी विभाग / Department of Biotechnology
विज्ञान और प्रौद्योगिकी मंत्रालय
Ministry of Science & Technology
भारत सरकार / Govt. of India
सी.जी.ओ. कॉम्प्लेक्स, लोधी रोड, नई दिल्ली-110003
C.G.O. Complex, Lodhi Road, New Delhi-110003

No. BT/PR30830/MED/97/441/2018
GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY

Block 2, 6-8th Floors
CGO Complex, Lodhi Road,
New Delhi- 110 003
Dated: **18/07/2019**

ORDER

Sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rules, 1978, for the implementation of the project entitled "**Epigenetic regulation of angiogenic factors in assisted reproductive technology (ART) and non-ART derived placentae**" for a period of 3 Years at a total cost of Rs. **5991300** (Rupees Fifty Nine Lakhs Ninety One Thousand Three Hundred Only) on the terms and conditions detailed here under :-

2 The Project :

2.1 Title : "Epigenetic regulation of angiogenic factors in assisted reproductive technology (ART) and non-ART derived placentae"

Details of the Investigators:

2.2

Dr. Deepali Prakash Sundrani

Assistant Professor
Mother and Child Health
Interactive Research School for Health Affairs
Bharati Vidyapeeth University, Pune-Satara
Road, Katraj-Dhanakwadi, Pune-411043,
Maharashtra,

CO-PI:

Dr. Sanjay Gupte

Director
Gupte Hospital and Research Center
Interactive Research School for Health
Affairs, Bhandarkar Road, Pune -
411004, Maharashtra

Dr. Sadhana Joshi

Professor and Head
Mother and CHild Health
Interactive Research School for Health Affairs (IRSHA),
Bharati Vidyapeeth University, Satara Road,
Pune - 411043, Maharashtra

2.3 Objectives:

1. To compare the DNA methylation and mRNA expression patterns of angiogenic factors [vascular endothelial growth factor (VEGF), placental growth factor (PIGF), fms-like tyrosine kinase-1 (FLT-1) and kinase insert domain receptor (KDR)] in ART and non-ART derived placentae
2. To compare the expression of microRNAs targeting the above-mentioned factors in ART and non-ART derived placentae
3. To examine the association of ART procedures with maternal one carbon metabolites (folate, vitamin B12, and homocysteine) and fatty acids in the above women
4. To examine the association of epigenetic changes in the placenta with birth outcome

2.4 Time Schedule:

The duration of the project is 3 Years from the date of this sanction order.

2.5 Project Cost:

The total cost of the project is Rs. **5991300** (Rupees Fifty Nine Lakhs Ninety One Thousand Three Hundred Only) as per details given below :

Budget Head	Year I	Year II	Year III	Total(Rs.)
Equipment	1194900.00			1194900.00
Manpower	216000.00	216000.00	216000.00	648000.00
Overhead	38300.00	97550.00	92550.00	228400.00
Travel	25000.00	25000.00	25000.00	75000.00
Consumables	500000.00	1685000.00	1585000.00	3770000.00
Contingency	25000.00	25000.00	25000.00	75000.00
Total (Rs.)	1999200.00	2048550.00	1943550.00	5991300.00

2.6 Equipment:

The details of the equipment sanctioned for the implementation of the project at **Annexure-I**

2.7 Manpower:

The details of the manpower sanctioned for the implementation of the project at **Annexure-II**

3. Head of Account:

The **Non-Recurring** expenditure involved is debitable to:

Demand No. 85	Department of Biotechnology
3425	Other Scientific Research 2019-2020
3425.60	Others (Sub Major Head)
3425.60.200	Assistance to other Scientific Bodies (Minor Head)
3425.60.200.29	Biotechnology Research and Development
3425.60.200.29.17	Assistance for Research and Development
3425.60.200.29.17.35	Grants for creation of capital assets

The **Recurring** expenditure involved is debitable to:

Demand No. 85	Department of Biotechnology
3425	Other Scientific Research 2019-2020
3425.60	Others (Sub Major Head)
3425.60.200	Assistance to other Scientific Bodies (Minor Head)
3425.60.200.29	Biotechnology Research and Development
3425.60.200.29.17	Assistance for Research and Development
3425.60.200.29.17.31	Grants -in-Aid General

4. Terms & Conditions:

- In case the whole or a part of the amount of the grant-in-aid is being refunded, an interest at the rate of ten percent thereon shall be recovered.
- Grantee Institution is a private organization
- The equipment sanctioned under the project should be purchased within 18 months from the date of the release of the grant.
- The expenditure to be made as per the EAT module of the Government of India.

4.1 The other terms and conditions governing this sanction are attached at Annexure- III.

- 4.2A Memorandum of Agreement (MoA) will be signed between the Department of Biotechnology and the grantee institution on Non-Judicial stamp paper Rs. 100/- in the enclosed format and the second release/installment will be made only after signing of MoA between the grantee institutions and DBT. In case of NGO's and Private Institution's, execution of MOA is mandatory before first release. A format of the MoA is enclosed in Annexure-IV
- 4.3 The Institute/Agency will keep the whole of the grant in a Bank Account earning interest, and the interest so earned should be reported to DBT in the Utilization Certificate and Statement of Expenditure. The Interest so earned will be treated as created to the institute/Agency and shall be adjusted towards further installment of the grant and or at the time of Final Settlement of Accounts.
- 5.No International Travel will be undertaken from the sanctioned project grant unless specified otherwise.
- 6.The Director, Interactive Research School for Health Affairs, Pune, Maharashtra would be responsible for submission of Statements of Expenditure (SoE), utilization certificates (UC), Assets Certificates, Manpower staffing & expenditure details in prescribed DBT formats to DBT in respect of grants released in this project from time to time.
- 7.PI's of DBT sponsored projects can consider appointment of JRF from Category-II merit list of DBT-BET exam so that candidates can be paid fellowships at par with NET/GATE/BET qualified candidates as per DST OM No. A.SR/S9/Z-08/2018 dated on 30 Jan 2019. However, there is no compulsion on PI's to select candidates for JRF in their projects from Category-II of DBT-BET.
- 8.As per Rule 236 (1) of GFR 2017, the accounts of all Grantee Institutions or Organizations shall be open to inspection by the sanctioning authority and audit, both by the Comptroller and Auditor General of India under the provision of CAG(DPC) Act 1971 and internal audit by the Principal Accounts Office of the Ministry or Department, whenever the Institution or Organization is called upon to do so.
- 9.If the Research Project involves biological resources, the obligations under the Biological Diversity Act 2002 as applicable shall be complied with by the Project Investigator, the details of such obligations can be accessed at www.nbaindia.org
- 10.If this project works requires any Statutory Clearance (such as Ethical Committee Clearance, Informed Consent, Animal Ethics Committee Clearance, Institutional Bio-safety Committee Clearance, National Biodiversity Authority approval etc.), Project investigator(s) and Host Institution(s) shall compulsory comply the same before undertaking such activities.
- 11.This issues under the power delegated to this Department and with the concurrence of IFD vide their SAN No. **102/IFD/SAN/1016/2019-2020** dated **July, 18 2019**.
- 12.This sanction order has been noted at serial no. 08 in the Register of Grants.



(Dr. Anamika Gambhir)
Scientist - 'F'

To,
The Pay & Accounts Officer,
Department of Biotechnology,
New Delhi - 110 003.

Copy to:

- 1 The Principal Director of Audit (Scientific Departments), DACR Building, New Delhi- 110 002.
- 2 The Director, Interactive Research School for Health Affairs, Pune Satara Road, Dhankawadi, Pune - 411043, Maharashtra
- 3 Dr. Deepali Prakash Sundrani, Assistant Professor, Mother and Child Health, Interactive Research School for Health Affairs, Interactive Research School for Health Affairs, Bharati Vidyapeeth University, Pune-Satara Road, Katraj-Dhanakwadi, Pune - 411043, Maharashtra
- 4 Dr. Sadhana Joshi, Professor and Head, Mother and Child Health, Interactive Research School for Health Affairs, Bharati Vidyapeeth University, Pune Satara Road, Pune - 411043, Maharashtra
- 5 Dr. Sanjay Gupte, Director, Gupte Hospital and Research Center, Interactive Research School for Health Affairs, Gupte Hospital and Research Center, Bhandarkar Road, Pune, 411004, Maharashtra
- 6 Cash Section, DBT (2 copies).
- 7 Sanction Folder.
- 8 File Copy.

Dr. ANAMIKA GAMBHIR
वैज्ञानिक 'एफ' / Scientist 'F'
बायोटेक्नोलॉजी विभाग / Deptt. of Biotechnology
विज्ञान और प्रौद्योगिकी मंत्रालय / M/o Science & Tech.
भारत सरकार, नई दिल्ली / Govt. of India, N. Delhi



(Dr. Anamika Gambhir)
Scientist - 'F'

Annexure -I

Details of the Equipment sanctioned for the implementation of the project entitled "**Epigenetic regulation of angiogenic factors in assisted reproductive technology (ART) and non-ART derived placentae**":

Interactive Research School for Health Affairs			
SNo.	Name of Equipment	No.	Cost(Rs.)
1.	Deep Freezer (-80 deg C)	1	564900.00
2.	Nanodrop	1	630000.00
Total			1194900.00

डॉ. अनामिका गम्भीर / Dr. ANAMIKA GAMBHIR
वैज्ञानिक 'एफ' / Scientist - 'F'
बायोटेक्नोलॉजी विभाग / Biotechnology
विज्ञान और प्रौद्योगिकी मंत्रालय / M/o Science
भारत सरकार, नई दिल्ली / Govt. of India, N. Delhi

Annexure -II

Details of the manpower sanctioned for the implementation of the project entitled "**Epigenetic regulation of angiogenic factors in assisted reproductive technology (ART) and non-ART derived placentae**":

Head	No. of Position	Year I	Year II	Year III	Total (Rs.)
Technician (Project Technician III)	1	216000	216000	216000	648000
Total(Rs.)		216000	216000	216000	648000

Emoluments detail of research personal(s) mentioned in table(s) of Annexure-II shall be applicable only if candidate(s) met educational qualification and eligibility criteria as per DST OM No. SR/S9/Z-08/2018 dated 30.01.2019.

डॉ. अनामिका गंभीर / Dr. ANAMIKA GAMBHIR
वैज्ञानिक / Scientist 'F'
बायोटेक्नोलॉजी विभाग / Deptt. of Biotechnology
विज्ञान और प्रौद्योगिकी मंत्रालय / M/o Science & Tech.
भारत सरकार, नई दिल्ली / Govt. of India, N. Delhi



जैव प्रौद्योगिकी उद्योग अनुसंधान सहायता परिषद
(भारत सरकार का उपक्रम)
Biotechnology Industry Research Assistance Council
(A Government of India Enterprise)

Ref. No. - BT/CS0006/CS/02/20

Dated : 11th February, 2021

Subject: Funding of Project entitled "Capacity enhancement of National Immunogenicity and Biologics Evaluation Center for assessing the immunogenicity of SARS-CoV-2 vaccines" for funding under **Mission COVID Suraksha**

GRANT-IN-AID LETTER AGREEMENT

This Grant-in-aid Letter Agreement (hereinafter called as "GLA") is between Biotechnology Industry Research Assistance Council, a Government of India enterprise, incorporated under the Companies Act, 2013 having its office at 1st Floor, MTNL Building, 9, CGO Complex, Lodhi Road, New Delhi- 110003 (the "BIRAC") and the entities mentioned below for the research proposal entitled "Capacity enhancement of National Immunogenicity and Biologics Evaluation Center for assessing the immunogenicity of SARS-CoV-2 vaccines" under **Mission COVID Suraksha**

1. Recipient(s) and Designated Project Investigator(s):

S. No.	Recipient(s)	Designated Project Investigator
1	Interactive Research School for Health Affairs, Pune, an Institute, having its registered office at Bharativedyapeeth Medical college Campus, Satara Road, Dhankavadi, Pune, Maharashtra, 411043 , hereinafter referred to as the "Institute" (which expression shall wherever the context so admits include its successors in interest, liquidators, administrators and permitted assignees).	Dr. Akhilesh Chandra Mishra, Director, Interactive Research School for Health Affairs, Bharativedyapeeth Medical college Campus, Satara Road, Dhankavadi, Pune, MAHARSHTRA-411043 Email: acm1750@gmail.com Mobile: 91-9970178555

2. Aims & Objectives:

The detailed aims and the objectives that are to be executed by the aforesaid are as per the detailed Project document, submitted including revisions / modifications incorporated therein (hereinafter called as "Project") and appended herein as **Schedule 3**.

The main objectives proposed to be achieved from the project are enumerated hereunder:

- (1) **Facility Augmentation and Upgradation of technology for existing key tests**
- (2) **Pseudo virus technology transfer and standardization of surrogate neutralization assay**
- (3) **Development of tests for CMI responses to natural COVID-19 infections and to the vaccines**
- (4) **Manpower training, ILC activities and develop and share standardized reagents and protocols for testing;**



MTNL Building, 9, CGO Complex, Lodhi Road, New Delhi - 110003, India

Phone: +91-11-24389600 Fax: +91-11-24389611 Website: www.birac.nic.in E-mail: birac.dbt@nic.in

सीआईएन सं./CIN No. : U73100DL2012NPL233152



Additional Objective may consist of effective management of health disasters or undertaking research connected therewith such as COVID-19 using the Project resources and through the implementing measures of the supported Project as may be identified in National interest and governed by a specific BIRAC Order.

3. **Project Duration:** The Recipient shall complete the Project within the stipulated period of 12 months from the date of issue of Provisional Funding Letter dated 25th January, 2021 ("Effective Date").

4. **Project Implementation Site:**

IRSHA, Bharatividyaapeeth, Medical college Campus,
Satara Road, Katraj Dhankavadi
Pune, MAHARASHTRA-411043
91-020-24366929
91-09823437353
<http://irsha.bharatividyaapeeth.edu>


5. **Project Cost and Contribution:** The total estimated cost of the Project is **Rs. 1341.58 Lakhs** (Rupees One Thousand Three Hundred Forty-One Lakhs and Fifty-Eight Thousand only). The contribution of BIRAC is **Rs. 1341.58 Lakhs** (Rupees One Thousand Three Hundred Forty-One Lakhs and Fifty-Eight Thousand only) as Grant-in-aid to the **Interactive Research School for Health Affairs, Pune**. Initially the first release is **Rs 670.79 Lakhs** and further releases will be based on the specific Order of BIRAC.

6. **BIRAC Budget break-up :**


Budget Head	Support under strategic funding for Mission COVID Suraksha	Grand Total
Non-recurring	802.99	802.99
Recurring	538.59	538.59
Total	1341.58	1341.58

Details of Equipment Proposed To Be Acquired Through BIRAC Contribution For Applicant Institute

S. No	Infrastructure/ Equipment	Capacity	Quantity	Specific Requirement In the Project	Estimated Value (Rs. In Lakhs)
1.	Automated cell culture workstation	45	1	For execution of cell culture assays such as pseudovirus or PRNT or micro-neutralization and ELISAs with minimal human intervention and high throughput manner	281.46
2	Plate Stacker	25	2	To minimize human	41.82



				intervention in plaque counting and ELISA execution of test in high-throughput manner	
3	CO2 incubator	100	3	High demand of vaccine immunogenicity testing and limited CO2 capacity is hampering turn around time. CO2 incubator are need to increase the productivity	13.85
4	Electronic pipette	1200	9	Manual pipetting increases the probability of error during execution of assays. Moreover, it limits the number of samples to be tested. Electronic pipette with broad range will help in execution of more samples within the same time period	13.85
5	Minus 80 deep freezers	500	3	Storage of samples from SARS-CoV-2 clinical trials and back-up as per GCLP norms. Current capacity of minus 80 deep freezers at NIBEC is not sufficient to store samples from various clinical trials viz. Chikungunya, dengue, SARS-CoV-2. Moreover, one freezer will be devoted for central reagent to other institutions	19.31
6	MesoScale Discovery instrument	25	1	Newly introduced novel technological system already being used in large global clinical trials. Required for execution of assays for detecting proteins such as cytokines, antibodies in high throughput manner with high sensitivity and short turnaround time.	157.67



Handwritten signature

Handwritten mark

				ACE2 neutralization assay is available as an alternative to live virus neutralization test .	
7	Dry ice storage canister	50	1	Dryice storage for longer period	1.99
8	Waste aspiration system for biosafety cabinets	5	13	Aspiration of bio-hazardous liquid waste in close system to minimize aerosol generation, prevent spillage and to ensure safety of staff.	24.70
9	Automated cell counter	2	2	For counting the cells accurately without human intervention	7.99
10	Ultracentrifuge	1	1	For concentration and purification of live or inactivated viruses.	86.99
				Concentrated virus is required as a stimulant for flow cytometry based assays. Density gradient ultracentrifugation could be performed to ensure production	
11	Minus 20 deep freezer	500	3	Storage of samples from SARS-CoV-2 clinical trials and back-up as per GCLP norms. Current capacity of minus 80 deep freezers at NIBEC is not sufficient to store samples from various clinical trials viz. Chikungunya, dengue, SARS-CoV-2. Moreover, one freezer will be devoted for central reagent to other institutions	15.23
12	Pipettes sets	5	7	Decrease turnaround time for various SARS-CoV-2 related assay. Moreover, standardization and validation of assays. Pipettes include 2-20 ul, 20-200 ul, 100-1000	6.98




9

				ul, 8channel 5-50 ul, 8 channel30-300 ul pipettes	
13	Cooling centrifuge	4	9	Currently all BSL2 cell culture laboratories are not equipment with cooling centrifuge. High number of washing steps in flow cytometry limits use of centrifuge for other activities. In addition, GCLP compliance requires restricted moment of infectious material. Cooling centrifuge are necessary for maximum GCLP compliance	24.09
14	Microscope	4	3	Currently all BSL2 cell culture laboratories are not equipment with microscope. GCLP compliance requires minimal moment within facility with infected cells. Microscope are necessary for maximum GCLP compliance	10.71
15	Fluorescence microscope	4	1	For pseudovirus based neutralization assay	11.88
16	Flow cytometer software	1	1	Analysis of flow-based data by multiple users to decrease turnaround time	3.88
17	Automated cell seeding system	1	1	To decrease turn-around time, increase accuracy, make facility available for other assays	27.27
18	ELISA reader	1	96	Manpower training, ILC activities, develop and share standardized reagents	13.67
19	ELISA washer	1	8	Manpower training, ILC activities, develop and share standardized reagents	2.94
20	Biosafety cabinet	2	2	Manpower training, ILC activities, develop and	13.74



Handwritten signature or initials in blue ink.




Handwritten signature or initials in blue ink.

				share standardized reagents	
21	Conference system	1	1	Manpower training, ILC activities, develop and share standardized reagents	12.97
				Total	792.99
				Accessories to be Acquired (Rs. in lakhs)	10.00
				Grant Total	802.99

7. Milestones/Timelines

Sr. No.	Milestone(s)	Month of end of activity	Required financial input (Rs. In Lakhs)
1	Acceptance of Undertaking under GLA And Fulfilment of fund release requirements	1	670.79 (50% of BIRAC contribution)
2	Status report on Procurement, installation and validation of high-throughput equipment. Validation of ACE2 based neutralization assay on high-throughput systems. And Submission of SOE for the corresponding milestone certified by internal finance.	2	536.632 (40% of BIRAC contribution)
3	Status report on NABL accreditation of the CMI assays developed and providing services for the COVID assays to Vaccine companies And Submission of SOE for the corresponding milestone certified by internal finance.	3	0.00
4	Status report on Manpower training, ILC activities and develop and share standardized reagents and protocols for testing And Submission of SOE for the corresponding milestone certified by internal finance.	12	0.00
5	Submission of final completion report and consolidated Statement of Expenses (SOE) duly certified by Chartered Accountant (CA)/Auditor.	12	134.158 (10% of BIRAC contribution)

Note:- Statements of Expenses (SOE) duly audited by a chartered accountant for the expenditure incurred towards the Project every half quarterly, ending 31st March, 30th June, 30th September, and 31st December, to BIRAC, within a month of closure of the



(Handwritten signature)

accounts for the respective quarter should be submitted till completion of Project Duration.

The Institute shall submit audited Annual reports along with the audited balance sheets and profit & loss accounts to BIRAC within six months of the completion of the financial year ending 31st March till the Project duration.

***Regulatory Requirements : None**

8. Specific conditions of Implementation

- Sale of products out of this project in India will be subjected to negotiation of pricing by BIRAC/Government of India to promote affordability on account of the grant-in-assistance under BIRAC.
- Government orders will be given preference over private orders for all products coming out of this project.

9. Periodic Payment/Release Arrangements of the project support based on milestones

Instal-ment	Contribution by BIRAC to Interactive Research School for Health Affairs, Pune	Total(Rs. in Lakhs)
1	670.79	670.79
2	536.632	536.632
3	0.00	0.00
4	0.00	0.00
5	134.158	134.158
Total	1341.58	1341.58

The total estimated cost of the Project is **Rs. 1341.58 Lakhs** (Rupees One Thousand Three Hundred Forty-One Lakhs and Fifty-Eight Thousand only)

10. *The recipient of the fund should convey their acceptance to the terms and conditions of this GLA within four (4) weeks of the issue of GLA failing which the present offer of the funding support will be considered as infructuous and the project will be treated as withdrawn.*

11. Inclusion by Reference:

This GLA includes and incorporates by this reference:	- Terms and Conditions (Schedule 1) - Acceptance and Undertaking (Schedule 2) - Project document (Schedule 3) - Intellectual Property Governing Framework (Schedule 4)
---	---

12. The Expenditure is debitable to **K.01 - Head of Accounts for the financial year 2020-21.**



[Handwritten signature]

13. This issue with the approval of competent authority vides BFD No. BFD/AO/K.01/03/2020-2021 dated 11.02.2021

14. The GLA has been noted at Serial No. 03 in the Register of Grant/Cost.







[Handwritten signature]



[Handwritten signature]

THIS GLA is between Biotechnology Industry Research Assistance Council ("BIRAC") and "Interactive Research School for Health Affairs, Pune", and is effective as of the date of last signature. Each party to this GLA may be referred to individually as a "Party", "Interactive Research School for Health Affairs, Pune" as "Fund Recipient" and all Party together as the "Parties." As a condition of this grant, the Parties enter into this GLA by having their authorized representatives sign below:

1) For and on behalf of BIRAC	
Name: Dr. Kavita Singh	
Designation: Mission Director, National Biopharma Mission	
Signature: 	
Official Seal	

2) For and on behalf of Interactive Research School for Health Affairs, Pune , the Fund Recipient duly authorized vide duly authorized vide letter dated 11th Feb 2021 by its concerned authority dated 12th Feb 2021	
Name DR. A. C. MISHRA	
Designation DIRECTOR	
Signature 	
Institute official Seal	
Director Bharati Vidyapeeth (Deemed to be University) Interactive Research School for Health Affairs (IRSHA) Pune-Satara Road, Pune - 411 043.	

Schedule I

Terms and Conditions


The terms and conditions for Project support under Grant-in-aid Letter Agreement (hereinafter called as "GLA") are as follows:

1. FUND DISBURSEMENT

i. First instalment of the Grant-in-aid will be released after issue of the GLA subject to fulfilment of the terms and conditions for such release by the relevant Parties. Further release of funds shall be subject to satisfactory progress against the objectives, outputs, milestones and targets specified in the Project which progress shall be determined by BIRAC and on submission of audited/certified statements of accounts as provided for in Point 2 (a).

2. FUND UTILISATION AND ACCOUNTING

- a. The Fund Recipient shall submit the Statements of Expenses (SoE) duly audited by a Chartered Accountant (CA) as required for the project under the GLA.
- b. The Fund Recipient shall submit final consolidated SoE duly certified by a CA/Auditor to BIRAC in the format provided on the completion of the project.
- c. The input credit for the expenditures incurred under the project out of Grant-in-aid shall be reported to BIRAC as a part of utilization certificate against the corresponding entry-Amount of GST Input credit. Such amount, if any, will be considered accordingly at the time of the release of the next installment.
- d. The Fund Recipient shall submit audited Annual reports along with the audited balance sheets and profit & loss accounts to BIRAC within six months of the completion of the financial year ending 31st March till the completion of the Project Duration.
- e. The Fund Recipient shall keep the Grant-in-aid assistance and their project contribution in a separate no-lien account in the name of the Fund Recipient with a Scheduled Bank (as defined under the RBI Act, 1934), the withdrawals and payments from which account shall be subject to verification by BIRAC. It shall also obtain and furnish to BIRAC a letter from the concerned bank foregoing the right of set off or lien in respect of such account. Further, the interest earned on the Grant-in-aid if any should be reported to BIRAC. The interest thus earned will be adjusted towards further installment of the fund. The interest earned on the Grant-in-aid should be reported to BIRAC. The interest thus earned on the grant in aid will be adjusted towards further installment of the fund.
- f. The Fund Recipient shall ensure that the funds released for the Project are actually utilized only for the purposes of the Project and as expressly provided for in this GLA. Re-appropriation of BIRAC funds from one budget head to another shall not be effected without the specific written approval of BIRAC.
- g. The Fund Recipient shall refund such part of Grant-in-aid funds disbursed to it that



remains unutilized with it upon completion of all the responsibilities, duties and functions specified in connection with the Project, within one month of such completion, to BIRAC along with consolidated accounts of the funds received and utilized and of the unutilized balance returned (SOE).

- h. The Fund Recipient at their own cost shall take adequate care to maintain the capital assets acquired for the Project through BIRAC Grant-in-aid. The capital assets acquired through BIRAC Grant-in-aid shall not be disposed of or hypothecated without the specific approval of BIRAC till full and final settlement of all dues to the satisfaction of BIRAC.
- i. The Procurements for the Project shall be in accordance with the best commercial practices if the fund recipient is a Company/LLP and shall be in accordance with the procurement framework prescribed by BIRAC if the fund recipient is a Government/ public Institution.
- j. The Fund Recipient shall give prior information to BIRAC about additional funding from any other government/ private source (National/ International) for the same project objectives availed at any time before the project completion.

3. NATIONALLY IMPORTANT PROJECTS:

If certain Projects are determined as nationally important Projects, then BIRAC will issue a specific Order to make the following provisions applicable:

A. In such cases of national importance BIRAC shall retain a royalty-free, non-exclusive, irrevocable license to the Product developed with the funding support of BIRAC with right to sub-license for the purposes of public interest/Government of India and/or as decided by the committee. The licensor of such Product will ensure that where the Product has been produced in collaboration with entities not in receipt of BIRAC Grant-in-aid, such partnering entities will also grant license to BIRAC in the same way.


B. Nationally Important Projects shall mean such Projects that will serve specific purposes notified by Government of India in public interest.

C. In cases of national importance, if BIRAC determines that such -

- a) Action is necessary because the Fund Recipient or licensee/s has not taken, within the period of four (4) years from the date of completion of the Project, effective steps to commercialize the Product in such field of use.
- b) Action is necessary to meet requirements for public use or national interest and such requirements are not reasonably satisfied by the Fund Recipient or licensee/s.

Then, March-in-rights are applicable whereby

- i. BIRAC along with retention of royalty-free, non-exclusive, irrevocable license to the Product, after taking into consideration the fund recipient(s) requirement for reasonable



Handwritten signature or mark.

expansion and the demand supply gap at the appropriate time, shall have the right to require the Fund Recipient to transfer the technical know-how of the Product developed under the Project to other entrepreneur(s) and train them, on such terms and conditions as may be mutually agreed among BIRAC, the fund recipient and such other entrepreneur(s). Provided, BIRAC shall reserve its right to require that the Product must be manufactured and sold in India.

ii. If the fund recipient(s) does not agree with the terms of above sub section (i), then BIRAC shall require that all rights and interests associated with the Product including Intellectual Property (IP) Rights to be assigned to BIRAC. The Fund Recipient(s) and co-owners of the IP shall undertake all necessary actions to affect the assignment.

4. PROJECT MONITORING

A Project Monitoring and Review Committee (PMRC) comprising of eminent experts from the respective field(s)/Internal BIRAC and NBM members will be constituted to monitor the progress of the objective(s) of the Project. The functions of the PMRC shall be as follows:

- a. To monitor the progress of the Project in conformity with the outputs, milestones, targets objectives and other terms and conditions as contained in the GLA
- b. To keep track of funding from any other source for the Project.
- c. To assess the global developments impacting the domain of the Project.
- d. Based on the foregoing, to assess and recommend:
 - i. the release of next installment or part release thereof by the BIRAC,
 - ii. revision of Project Duration,
 - iii. closing, dropping or modifying any of the components of the Project, within the overall approved objectives, budget and time-frame,
 - iv. inclusion of additional industrial/institutional partner(s), if the Fund Recipient and the Institutes requests involvement of such partner(s), in the overall interest of the Project; and
 - v. revision of the financial assistance.
- e. To advise on issues related to securing of IPR and mentor to overcome any technological problem faced in the Project implementation; and
- f. To advise on any other matter as referred to it by BIRAC and/or otherwise reasonably necessary for effective discharge of its duties and/or achievement of aims and objectives of the Schemes.

5. INDEMNIFICATION

- a. The Fund Recipient shall, at all times, indemnify and keep indemnified BIRAC against



any claims or suits in respect of any losses, damages or compensation payable in consequences of any accident, death or injury sustained by their employees or by any other third party resulting from or by any act, omission or operation conducted by or on their behalf.

- b. The Fund Recipient shall, at all times, indemnify and keep indemnified BIRAC against all claims/damages etc. by any infringement of any Intellectual Property Rights (IPR) while carrying out their responsibilities/work under the Project and this GLA.
- c. The provision of Grant-in-aid funds by BIRAC does not create any liability, explicit or implicit, on BIRAC in respect of the manpower engaged in the Project.
- d. The Parties shall not be held responsible for non-fulfillment of their respective obligations in successful completion of the Project under this GLA due to the exigency of one or more force majeure events such as but not limited to acts of God, war, flood, earthquakes etc.
- e. BIRAC through the Project funding shall not be held as a **Sponsor** in terms of the Clinical Trial statutes and the Fund Recipient are entirely responsible for abiding by the relevant laws, Rules and Regulations of the land if any Phase of the Clinical Trial is a Project Component.



6. CHANGE OF CONTROL:

BIRAC shall reserve the right to reconsider further funding assistance, governance of the New Intellectual Property and consider refund of the amount of Grant-in-aid in such circumstances of change of control as mentioned the following paragraphs:

- a. The Fund Recipient shall inform BIRAC if it proposes to undertake or permit any merger, consolidation, reorganization scheme of arrangement or compromise with its creditors or shareholders or effect any scheme of amalgamation or reconstitution or substantial expansion. The word substantial expansion shall have the same meaning as under the Industries (development and Regulation) Act, 1951.
- b. The Fund Recipient shall inform BIRAC within 30 (thirty) days, if it has notice of any application for winding up having been made or any statutory notice of winding up under the provisions of the Companies Act, 2013, or any other notice under any other Act or otherwise of any suit or other legal process intended to be filed or initiated against the Fund Recipient and affecting the title to the properties of the Fund Recipient or if a receiver is appointed of any of its properties or business or undertaking.
- c. The Fund Recipient shall notify BIRAC of any material change in its shareholding pattern, entity status, entity name, Project Coordinator, implementation site, registered office or any such change that would impact on performance of its obligations under the Project and this GLA.

7. FORECLOSURE AND TERMINATION

- a. In case, during the Project Duration, it is found that the Project or any Project component is not likely to lead to successful completion, BIRAC may decide to foreclose the Project



AP

or the Project component as warranted. The decision of the BIRAC shall be final in all respects. The Fund Recipient shall immediately refund any Grant-in-aid unutilized out of BIRAC disbursements to BIRAC. BIRAC, at its discretion can allow deduction of the future committed expenses to third party vendors on pro-rata basis according to the quantum of BIRAC funding. The Fund Recipient shall submit consolidated accounts of funds received, utilized and unutilized (SOE). If the Fund Recipient likes to continue the Project at its own cost, it would be able to do so without restrictions from BIRAC after complying with these provisions.

- b. The Fund Recipient may, before the completion of the Project, terminate this GLA by giving three months notice in writing to BIRAC. BIRAC may also terminate this GLA by written notice in the event of committing breach of any term of this GLA and either not rectifying it to the satisfaction of BIRAC or not satisfying BIRAC about its inevitability within a specified period. In the event of termination of the GLA, no further disbursement shall be made by BIRAC. The Company as Fund Recipient shall be liable to return immediately the amount of Grant-in-aid already availed of from BIRAC with additional simple interest at the rate of 12 (twelve) per cent per annum within 30 (thirty) days of termination of the GLA. Interest on the quantum of funding assistance shall accrue from the date of release of the grant in aid assistance. The Institute as Fund Recipient(s) shall immediately refund any funds unutilized out of BIRAC disbursements, to BIRAC, along with consolidated accounts of funds received, utilized and unutilized (SOE). In case of failure to repay, without prejudice to any other rights under this GLA, the amount can be recovered by initiating any procedure available in Law.


8. DISPUTE RESOLUTION AND ARBITRATION

In the event of any dispute or difference between the Parties hereto upon or in relation to or in connection with this GLA, such dispute or difference, shall be resolved amicably and in good faith by mutual consultation.

If such resolution is not possible, then the unresolved dispute or difference whatsoever arising between the Parties out of or relation to the construction, meaning, scope, operation or effect of this GLA or the validity the breach thereof or in respect of any defined legal relationship associated therewith or derived there from dispute shall be submitted for arbitration to International Center for Alternate Dispute Resolution (ICADR), an autonomous organization working under the aegis of the Ministry of Law & Justice, Department of Legal Affairs, Government of India. The Authority to appoint the arbitrator(s) shall be the ICADR. The Arbitration under this Clause and provision of administrative services by ICADR shall be in accordance with the ICADR Arbitration Rules, 1996 read with The New Delhi International Arbitration Centre Act 2019. The award made in pursuance thereof shall be binding on the Parties. The venue of arbitration shall be New Delhi and the arbitration proceedings shall be conducted in English Language. The provision of this Clause shall not become inoperative notwithstanding the GLA expiring or ceasing to exist or being terminated or foreclosed.

9. EFFECT AND AMENDMENTS TO THE GLA

- a. GLA shall remain in force whichever of these is the longest time unless suspended sooner:



- b. For 12 Months (Project duration) months from the above Effective Date;
- c. As long as any part of the amount disbursed for the Project remains unspent; or
- d. For as long as any monitoring or recording or IP governance is required under any relevant laws and regulations.
- e. No amendment or modification of this GLA shall be valid unless the same is made in writing by the Parties or their authorized representatives specifically stating the same to be an amendment of this GLA. The modifications / changes shall be effective from the date on which they are made / executed unless otherwise agreed to.
- f. No extension to the project duration will be considered.

10. SEVERABILITY

In case any one or more of the provisions or parts of a provision contained in this GLA shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this GLA; and this GLA shall, to the fullest extent lawful, be construed as if such invalid or illegal or unenforceable provision, or part of a provision, had never been contained herein.

11. GOVERNING LAW

This GLA and the associated undertaking shall be governed and interpreted in accordance with the laws of India subject to the exclusive jurisdiction of the Courts at New Delhi.



Acceptance & Undertaking

In consideration of the foregoing, the Fund Recipient, intending to be admittedly bound by the terms set forth above, undertake as stated below:

The Fund Recipient shall:

1. Execute the activities as set out in the Project document and shall conform to the specified objectives, outputs, milestones, and targets therein at Schedule 3.
2. Submit periodic Progress report to BIRAC as per the Project milestones, details of activities involved in performing the Project activities
3. Submit Statements of Accounts Expenses (SOE) as per Schedule 1.
4. Comply with the fund utilization and accounting requirements as per Schedule 1.
5. Obtain all the necessary requisite approvals, clearance certificates, permissions and licenses from the Government/local authorities for conducting its activities/operations in connection with the Project.
6. Abide by the decisions of BIRAC to modify the objectives, outputs, milestones, targets, Project Grant-in-aid as also the foreclosure of the Project or any of its components as may be arrived at after mutual discussion.
7. Subject itself to Project monitoring of the Project Monitoring and Review Committee (PMRC).
8. Maintain strict confidentiality and refrain from disclosure thereof, of all or any part of such information and data exchanged/generated from the Project which is not in the public domain by use and/or publication at the time of its disclosure except for purposes in accordance with this Project or is required by public authority, by law or decree.
9. Complete the Project within the stipulated period subject to the Change Order(s) issued by the BIRAC from time to time.
10. Not sub-delegate or outsource the obligations under this GLA without express permission of BIRAC except as provided for in the Project Document.
11. Manage the Intellectual Property developed through the funding Assistance of BIRAC in a manner that ascertains Global Access, regardless of whether this GLA expires, foreclosed or terminated as per Schedule 4.
12. Adhere to this GLA and the Conditions of Grant, as, violation of any provision of which shall be the reason for suspension of the Grant.
13. Consider any changes to the provisions of this GLA when made in writing only and shall consider any notice duly served if the same shall have been delivered electronically through the official mail of the Project Coordinator or delivered by post at the addresses mentioned in the GLA.
14. Acknowledge the assistance of BIRAC while publishing or presenting in any manner the details of the Project, its progress or its success or commercialization of the Project.



A

Project Document including Project Risk Management Plan

PROPOSAL OBJECTIVES

Objective1: Facility Augmentation and Upgradation of technology for existing key tests

Methodology/Experimental Design To Accomplish The Stated Objective:

Procurement, installation and validation of MSD machines Standardization of tests for evaluation of different antibodies, cytokines and Chemokines assessing advantages and disadvantages of the suitability of the system

Procurement, installation and validation of automated liquid handling systems for ELISA and cell culture work

Alternate Strategies: Not Applicable

Process Indicators for Measuring Success:

Procurement, installation and validation of electrochemiluminescence machine

Objective2: Pseudo virus technology transfer and standardization of surrogate neutralization assay

Methodology/Experimental Design To Accomplish The Stated Objective:

Production of vesicular stomatitis virus based Pseudo-viruses VSV-SARS-S/ TFP bearing coronavirus SARS-CoV-2 S Protein

Determining Infectivity of VSV-SARS-S/TFP by measuring fluorescence at 488-510 nm in microplate reader

Micro-neutralization assay to determine Coronavirus SARS-CoV-2 specific neutralizing antibody titers in Serum samples

Standardization of neutralization assay of COVID 19

Comparison of standardized assay with existing classical standard neutralization assay of COVID-19

NABL accreditation of in-house standardized neutralization assay and providing services to vaccine companies

Alternate Strategies:

Flow cytometry based detection of positive cells may be standardized

Process Indicators for Measuring Success:

Fluorescence detection as measure of production and infectivity of pseudo-virus



Handwritten signature or mark in blue ink.

Micro-neutralization assay should yield comparable results with classical micro-neutralization

Objective3: Development of tests for CMI responses to natural Covid-19 infections and to the vaccines

Methodology/Experimental Design To Accomplish The Stated Objective:

Assessment of the frequency and functional profile of diverse lymphocyte subsets T and B cells by flow cytometry including intracellular cytokine secretion assays.

In-vitro stimulation of PBMCs by inactivated whole virus and different proteins/peptide arrays of SARS CoV-2 is planned

Alternate Strategies: Not Applicable

Process Indicators for Measuring Success:

Standardized and part validated assays

Objective4: Manpower training, ILC activities and develop and share standardized reagents and protocols for testing

Methodology/Experimental Design To Accomplish The Stated Objective:

Supply secondary standardized reagents to other laboratories which get funded under this mission

Develop and share protocols and SOPs for T-cell, B-cell and antibody response assays as per international standards with all institutions funded under this Mission.

Manpower training, ILC activities and develop and share standardized reagents and protocols for testing

Alternate Strategies: Not applicable


Process Indicators for Measuring Success:

Training and supply of reagents as per schedule

OBJECTIVE WISE ACTIVITIES & TIMELINES

Objective 1: Facility Augmentation and Upgradation of technology for existing key tests

Activities	Month of Start Activity	Month of End Activity	Deliverables
Procurement, installation and validation of high throughput Validation of 2 based	0	2	Good co-relation between results from the assays with gold standard assays



Handwritten signature or initials.

neutralization assay on high-throughput systems			
IQ/OQ/PQ completed for all equipment	0	2	Q/OQ/PQ completed for all equipment
Preparation of SOPs	0	2	Preparation of SOPs completed

Objective 2: Pseudo virus technology transfer and standardization of surrogate neutralization assay

Activities	Month Start of Activity	Month of End of Activity	Deliverables
Transfer Pseudo virus production Technology developed at IIT, Indore to NIBEC	0	2	Absorbance of pseudo virus production technology
Standardization of neutralization assay of COVID 19	0	2	Fluorescence detection as measure of production and infectivity of pseudo-virus Micro-neutralization assay should yield comparable results with classical micro-neutralization
Comparison of standardized assay with existing classical (standard) neutralization assay of Covid-19	0	3	Comparison of standardized assay with existing classical standard neutralization assay of Covid-19 completed
NABL accreditation of in-house standardized neutralization assay and providing services to vaccine companies.	0	3	NABL accreditation of in-house standardized neutralization assay under progress or completed

Objective 3: Development of tests for CMI responses to natural COVID-19 infections and to the vaccines


Activities	Month Start of Activity	Month of End of Activity	Deliverables



Standardization and validation of CMI Assays: Enumeration of virus-specific T-cells CD4/CD8, Intracellular cytokine staining, Memory T-cell phenotyping, Cytotoxicity T-cell assay and Virus-specific Cytokine profiling	0	2	Standardized and part validated assays
Inter-Laboratory comparison of developed CMI assays. Alternately split sample approach can be used for validation of assays.	0	3	ILC for CMI assays in progress
NABL accreditation of the CMI assays developed and providing services for the COVID assays to Vaccine companies.	0	3	Providing services of CMI assays to vaccine companies

Objective 4: Manpower training, ILC activities and develop and share standardized reagents and protocols for testing

Activities	Month Start of Activity	Month of End of Activity	Deliverables
Supply secondary standardized reagents to other laboratories which get funded under this mission.	3	12	Inventory preparation for reagents completed
Develop and share protocols and SOPs for T-cell, B-cell and antibody response assays as per international standards with all institutions funded under this Mission.	3	12	SOP development completed
Manpower training, ILC activities and standardized reagents	3	12	Facility for manpower training and ILC activities completed.



Handwritten signature in blue ink.

reagents and protocols for testing		Standardized reagents prepared
------------------------------------	--	--------------------------------

Milestones	Month of End of Activity
Signing of the GLA	0
Procurement, installation and validation of high-throughput equipment. Validation of ACE2 based neutralization assay on high-throughput systems.	02
NABL accreditation of the CMI assays developed and providing services for the COVID assays to Vaccine companies.	03
Manpower training, ILC activities and develop and share standardized reagents and protocols for testing	12
Submission of Report	12



INTELLECTUAL PROPERTY GOVERNING FRAMEWORK**1. SCOPE OF IP GENERATED DURING THE CONDUCT OF THE PROJECT**

- a) The New Intellectual Property (IP) rights belong to Fund Recipient (s) unless agreed otherwise.

Provided, this Project is not determined as a "Nationally Important Project" to be governed through specific 'Order of BIRAC'. Such cases of "Nationally Important Project" shall have specific terms of licensing, pricing or March-in-rights for the purposes of public interest/ demand of Government of India.

- b) It is the responsibility of the Fund Recipient to protect the New Intellectual Property (New IP). They shall bear the expenditure involved in protecting the New IP.

2. GLOBAL ACCESS

The Fund Recipient agrees to conduct and manage the Project and the resulting products, services, processes, technologies, materials, software, data or other innovations (collectively, "Product") and any IP that arises (New IP) in the manner that ensures "Global Access."

Global Access requires that

- a) The knowledge and information gained from the Project be promptly and broadly disseminated or published.
- b) Project Developments and/or New IP are made available and accessible at an affordable price to people most in need within developing countries.
- c) In this regard, ensure Global Access in all present and future research and development agreements in a suitable form.

NOTE: For the purpose of this GLA, New IP means intellectual property generated during the conduct of the Project by the Company, but excluding the intellectual property generated by the Fund Recipient before execution of this GLA and any IP generated outside the scope of this GLA even during the term of this GLA.

1. The background Intellectual Property (IP) generated by the Fund Recipient(s) before execution of this GLA are as provided hereunder:

I.	Background IP of the Institute
The applicant does not own any IP related to the proposal	





icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
serving the nation since 1911

भारतीय आयुर्विज्ञान अनुसंधान परिषद
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार
कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research
Department of Health Research, Ministry of Health
and Family Welfare, Government of India

VIR/8/2019/ECD-I

Dated: 10.12.2019

Subject:- Payment of 1st **Installment** of 1st year of grant-in-aid for the research scheme entitled, "Evaluation of circulatory biomarkers for disease severity in hepatitis E"

MEMORANDUM

Reference this office letter No.VIR/8/2019/ECD-I dated

The Director-General, ICMR sanctions the payment of **Rs. 21,81,700/- (Rupees twenty one lakh eighty one thousand and seven hundred only)** as the 1st installment of 1st year of the grant for incurring expenditure in connection with the above mentioned research scheme. The amount of **Rs. 21,81,700/-** may be debited in the provision of **Rs. 43,63,399/-** made for the above mentioned research scheme for the current financial year 2019-20.

A formal bill for **Rs. 21,81,700/-** is sent herewith for payment by RTGS to **The Director, Bharati Vidyapeeth, Interactive Research School for Health Affairs, Pune-411043.**

Yours faithfully,

(Ishwar Likhari)
Administrative Officer,
for Director General


Accounts Section-V (Mandate form, cancelled cheque, vendor form and e-bill Enclosed)

The Director, Bharati Vidyapeeth, Interactive Research School for Health Affairs, Pune-411043. A bank RTGS for the amount of **Rs. 21,81,700/- 1st installment** of 1st year will be sent to you in due course. The grant has been sanctioned on the conditions laid down in our letter dated 10.12.2019.

Dr. Shubham Shrivastava, Associate Professor, IRSHA, BVDU Pune-411043. It is requested that an audited statement of accounts together with utilization certificate --N/A-- for the grant received and utilized in may be sent to this office in due course.

Online Team, ICMR.

Sr. T.O (2)


For Director General

वी.सुब्रह्मण्यम् भवन, पोस्ट बॉक्स नं. 4911,
अम्बाला नगर, नई दिल्ली - 110 029, भारत
V. Subrahmanyam Bhawan, P.O. Box No. 4911,
Ambala Nagar, New Delhi - 110 029, India

Tel: +91-11-26588895 / 26588980 / 26589794
+91-11-26589336 / 26588707
Fax: +91-11-26588662 | icmr.nic.in



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911

भारतीय आयुर्विज्ञान अनुसंधान परिषद
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार
कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research
Department of Health Research, Ministry of Health
and Family Welfare, Government of India

No.VIR/8/2019/ECD-I

Dated: 10.12.2019

To

The Director
Bharati Vidyapeeth,
Interactive Research School for Health Affairs,
Pune-411043

Subject: - Sanction and budget allotment for the New Schemes Entitled, "Evaluation of circulatory biomarkers for disease severity in hepatitis E"

Sir,

The Director General of the Council sanctions the above mentioned research scheme initially for a period of one year from **01.01.2020** to **31.12.2020** subject to extension upto the total duration specified in para 3(3) below.

The Director General of the Council also sanctions the budget allotment of **Rs. 43,63,399/- (Rupees forty three lakh sixty three thousand three hundred and ninety nine only)** as detailed in the attached budget statement for the year 2019-2020.

The grant-in-aid will be given subject to the following conditions:

The payment of the grant will be made in lump-sum to the Head of the Institution. The first installment of the grant will be paid generally as soon as a report regarding the commencement of the project and appointment of the staff is received by the Council.

The staff appointed on the project should be paid as indicated in the budget statement attached.

The approved duration of the scheme **Two years**. The annual extension will be given after review of the work done on the scheme during the previous year.

A report on the progress made will be submitted to the Council as and when called for.

वी. रामलिंगस्वामी भवन, पोस्ट बॉक्स नं. 4911,
अंसारी नगर, नई दिल्ली - 110 029, भारत
V. Ramalingaswami Bhawan, P.O. Box No. 4911,
Ansari Nagar, New Delhi - 110 029, India

Tel: +91-11-26588895 / 26588980 / 26589794
+91-11-26589336 / 26588707
Fax: +91-11-26588662 | icmr.nic.in

Budget Statement
(01.01.2020 to 31.12.2020)

The new Project entitled, "Evaluation of circulatory biomarkers for disease severity in hepatitis E" under Dr. Shubham Shrivastava, Associate Professor, IRSHA, BVDU Pune-411043.

Head	Year 1
Staff	
Scientist B (non-medical) @48000/- pm + 30% HRA (one post)	6,51,600
JRF @31000/- p.m. + 24% HRA (one post)	4,61,280
Research Assistant @31000/- p.m (3 post)	11,16,000
Sub-Total	22,28,880
Contingency (recurring)	
Traveling for collection of samples	1,92,000
ELISA kits for diagnosis of viral hepatitis	6,19,500
ELISA kits (S100 and alpha-defensins)	2,70,000
miRNA isolation kit	-
miRNA specific primer and probe	-
PBMC and monocyte isolation	5,00,000
Antibodies for flow cytometry	-
Consumables (plasticwares)	2,00,000
Contingency	50,000
Overhead charges @5%	2,03,019
Travel (for attending meetings and conferences)	1,00,000
Total	43,63,399

Shubham

(Rupees forty three lakh sixty three thousand three hundred and ninety nine only)

No. VIR/8/2019/ECD-I

REC No. ECD/Adhoc/73/2019-20

Dated 05.12.2019

Date: 18.02.2019

Interactive Research School for Health Affairs
Pune-Satara Road,
Katraj Dhankawadi, Pune,
MAHARASHTRA, India - 411043

Ref: Proposal No. BT/NBM/0095/02/18 Project Title "Establishment of National Centre for Immunogenicity Testing NCIT to evaluate vaccines in clinical trials" under Industry-Academia Collaborative Mission For Accelerating Discovery Research To Early Development For Biopharmaceuticals - "Innovate in India (i3) Empowering biotech entrepreneurs & accelerating inclusive innovation."

Dear Dr. Akhilesh Chandra Mishra,

With reference to your above-mentioned proposal, we are pleased to inform that your proposal has been approved by BIRAC at a total cost of **Rs. 1600.00 Lakhs** with Industry-Academia Collaborative Mission For Accelerating Discovery Research To Early Development For Biopharmaceuticals - "Innovate in India (i3) Empowering biotech entrepreneurs & accelerating inclusive innovation" support of **Rs. 1250.00 Lakhs** and company contribution of **Rs. 350.00 Lakhs** for **48 Months** as per the terms of the Grant-in-aid Letter Agreement (GLA) enclosed.

If you are in acceptance with the terms of funding support as mentioned in the GLA, the following documents should be executed within a time period of ***TWO WEEKS*** from the date of issue of this communication.

- Grant-in-aid Letter Agreement (GLA) including all the Schedules: All pages to be clearly initialled and stamped by the Fund Recipient and the Institute should affix the official seal on the signature page to the GLA.
- Authority Letter from the Institute in the prescribed format of BIRAC.
- Saving Account details on the KYC format to be submitted by the Institute with regard to specific project account in the prescribed format of BIRAC (*A copy of cancelled cheque to be submitted along with executed GLA*).

The Grant-in-aid Letter agreement has been executed by BIRAC. Kindly take a colour printout of this GLA and the schedules and execute the same from your end.

The first instalment of fund release will be made only after completion of all these formalities and upon submission of above mentioned documents as per norms.

For Biotechnology Industry Research Assistance Council


Dr. Kavita Singh
(Mission Director-National Biopharma Mission)



Private and Confidential

Dr Vidya Arankalle
Sr Scientist
School for Health Affairs
Bharati Vidyapeeth Deemed University
Pune – 411 043

E-mail: grants@indiaalliance.org
Tel: Hyderabad:+91 40 4018 9445
New Delhi:+91 11 4100 8403

Our Ref: IA/E/17/1/503651

27 December 2018

Dear Dr Arankalle

The Wellcome Trust/DBT India Alliance has agreed to award **Dr Harshad Patil** an Early (Basic) Fellowship for 60 months for his study entitled, **“Development of potent adjuvanted respiratory syncytial virus vaccine for mucosal delivery”**, under your sponsorship.

The India Alliance reserves the right to amend any terms and conditions in this Award Letter.

In the event of any conflict between the provisions of this Award Letter and of the Award Conditions, the provisions of the Award Conditions shall take precedence.

An award of up to ₹ 1,68,93,888.00 has been provided to the Interactive Research School for Health Affairs (hereinafter referred to as ‘Host Institution’) for this purpose.

The grant has been given a start date of **01 January 2019** and is intended to provide support as follows:

RING-FENCED FUNDS:

Post 1: EARLY CAREER FELLOW	Total (₹)
India Alliance’s contribution towards Dr Harshad Patil’s personal support (top-up)	15,98,700.00
Reserve funds (Refer to the clause 2.1.1.1)	35,85,300.00
Overseas Allowance	
Subsistence for 06 months (\$3000/month at a conversion rate of \$1=₹65)	11,70,000.00
Travel	1,50,000.00
Contribution towards Institutional Overheads	15,35,808.00
Sub Total(A)	80,39,808.00

TRANSFERABLE FUNDS:

	Total (₹)
Salaries For Support Staff	
Post 2 – Technician	16,53,600.00

Mailing Address, Hyderabad
The Wellcome Trust/DBT India Alliance
8-2- 684/3K/19, Kaushik Society, Road No. 12,
Banjara Hills, Hyderabad-500 034
☎ +91 040 40189445/6/7 📠 +91 40 4018 9449

Mailing Address, Delhi
The Wellcome Trust/DBT India Alliance
526, DLF Tower A, Jasola District Centre
Mathura Road, New Delhi-110025
☎ +91-11 41008402 , 41008403

Regd. Office:
The Wellcome Trust/DBT India Alliance
Department of Biotechnology, C.G.O Complex,
Block 2, Lodhi Road, New Delhi-110 003

Flexible Funding Allowance	2,50,000.00
Travel To Meetings	
Dr Harshad Patil	7,50,000.00
Materials & Consumables	48,05,000.00
Equipment	
Tissue Dissociator	5,00,000.00
Tissue grinder	1,00,000.00
Animal: Mice Balb/c female mice	
Animal Purchase: 954 mice @ ₹ 500	4,77,000.00
Animal Maintenance: 954 mice for 80 weeks @ ₹ 2 each/week	1,52,640.00
Animal Experimental Procedures	10,840.00
Animal Associated Costs: Animal environment, training and enrichment	15,000.00
Miscellaneous	
Graphpad Prism Software	1,40,000.00
Sub Total(B)	88,54,080.00
GRAND TOTAL(A+B)	1,68,93,888.00

The following details along with the enclosed **Award Conditions**, outline the framework in which the Fellowship will operate.

- 1 **Terms**
- 2 **Costs**
 - 2.1 **Ring-Fenced Funds**
 - 2.2 **Transferable Funds**
- 3 **Acceptance**
- 4 **Payment**
- 5 **Reports**
 - 6.1 **Annual**
 - 6.2 **End-of-Fellowship**
- 6 **Fellows' Title**
- 7 **Publications from Fellowship**
- 8 **Mid-term Review Process**
- 9 **Mentorship Requirement**
- 10 **IP arising from the Fellowship**
- 11 **Award Extension**

- 12 Other Fellowships and Grants
- 13 Variation and Termination of Fellowship
- 14 Statement on Equality and Diversity
- 15 Managing reputational risks
- 16 Fellows' Meetings
- 17 Application Reviews
- 18 Contact

1 Terms of the awards

1.1 Terms for the activation of the Award

This award must be activated no later than **01 January 2019**.

a) Mentorship requirement

The India Alliance recognizes the value of good mentorship for its Fellows. Therefore, each Fellow is required to identify a suitable mentor. This is a mandatory requirement for the Early Career Fellowship. A letter of agreement from the mentor will be required for initiating the award, which must reach the Office before the start date of the Fellowship. (See Award Condition 8).

The Office has received a letter from Professor A L W Huckriede of University Medical center Groningen. She has agreed to be a mentor on Dr Harshad Patil's Early Career Fellowship award. Since mentor's role is carefully scrutinized during the tenure of the Fellowship, Dr Harshad Patil is expected to update the status of mentor on annual basis.

b) Ethics Approvals

The India Alliance has noted that Dr Harshad Patil's studies would require human PBMC or PBMC-derived cells and also noted that the procedures to be carried out Balb/c female mice.

It is important that appropriate ethical approvals are obtained before any experiments requiring stem cells/animals/Human samples/Human participation are initiated.

We have received an undertaking from the Sponsor confirming that Dr Harshad Patil will not undertake any human and animal experiments unless he submits documentary proof of all the ethics approval to the India Alliance.

It is expected that once the appropriate approvals are obtained, the Fellow would provide a copy to the office in required format. For further details on submission of the approvals, please refer to Fellow's Corner.

Please note that the India Alliance office withholds the right to release funds based on the documentation received in this matter.

c) Indemnification

The Fellow shall, at all times, keep indemnified the India Alliance against any losses, liability damages or compensation (including legal costs) payable as direct or indirect consequences of any accident, death or injury involving their employees or any other third party, and

resulting directly or indirectly from or by any act, omission or operation conducted by or on its behalf. Further, applicants shall, at all times, indemnify and keep indemnified India Alliance against all liability, losses or, damages, compensation, etc. payable as a result of any infringement of any Intellectual Property Rights (IPR) of any third party while carrying out its responsibilities/work in relation to the Project and this Agreement.

1.2 Terms for monitoring and evaluation of the progress made on the award

The India Alliance will evaluate the Fellow's progress during the tenure of their India Alliance Fellowship. Consequently, continuation of the India Alliance funding after third year of the Fellowship will be contingent upon a satisfactory review of the progress made during the first half of the Fellowship (**See Award Condition 7**).

1.3 Terms for using the overseas allowance approved on the award

It is a mandatory requirement for *Dr Harshad Patil* to keep the India Alliance informed of their Work Outside Host Institution duration and location. He will be required to submit the following documents in order to utilize the overseas allowance approved on their Fellowship award.

- a) The India Alliance must be informed of the duration and location of the visit before moving to the External Sponsor's lab.
- b) An email confirmation from the External Sponsor from her official email address clearly indicating the duration of Dr Harshad Patil's stay i.e. start date and end date. This can be emailed to grants@indiaalliance.org.
- c) India Alliance must be informed in writing regarding completion of the overseas visit to the External Sponsor's lab after returning to the Host Institution in India.
- d) Utilization certificate (of funds transferred to the External Sponsor's institution for overseas project work) from the Finance department of the overseas institution, within 2 weeks of completion of the trip.
- e) Financial support for the overseas travel: It is expected that the Fellow would receive their personal support from the Host Institution and India Alliance and overseas allowance from India Alliance during such visits. In case the Fellow receives any other remuneration for such visits, the Office reserves the right to adjust the overseas allowance accordingly. A self-declaration from the Fellow indicating the support received during these overseas visits would be required by the Office.

Dr Harshad Patil will be required to furnish this information for every overseas visit that he will undertake during the tenure of the India Alliance Fellowship award.

It is a condition that the Host Institution will administer the Fellowship in accordance with the purposes for which it has been awarded and under the terms set forth in the India Alliance's **Award Conditions (enclosed)**, subject to any modifications made thereto from time to time. An updated version of the Award Conditions is also available on our website.

It is incumbent on the Host Institution and the Fellow to be familiar with our Award Conditions and policies, and comply with them during the tenure of the award.

2 Costs on the Award

This award provides funding for directly incurred costs on the Fellowship, including its associated research project. Directly incurred costs are actual costs; that are explicitly identifiable as arising from the conduct of a project (e.g. staff salaries, equipment, materials, travel). These costs are charged as the cash value actually spent, and are supported by an auditable record. The award is cash-limited; supplementary funding will only be provided in exceptional and specific circumstances.

The award is divided into two primary types of funds: (1) ring-fenced and (2) transferable. Ring-fenced funds may be used only for the purpose(s) as indicated in this letter.

2.1 Ring-Fenced Funds

2.1.1 Personal Support for the Fellow

The India Alliance's contribution to personal support is determined as follows.

Each Fellowship has a set level of personal support as detailed on our website.

The level set for the India Alliance's Early Career Fellows is currently, ₹ 10,36,800 per annum. This level has been calculated as follows: a basic salary of ₹ 5,40,000 per annum, allowances amounting to 60% of this salary and an additional Fellowship enhancement of 20%.

If the Fellow does not have a salaried position at the host institution, the India Alliance will pay the entire sum to the level set for the requisite Fellowship.

If the Fellow has a position at the host institution that provides a salary, the India Alliance will provide a top-up to meet the requisite level. The amount of top-up is calculated based on the salary certificate or contract of employment provided by the Fellow. **Please note that the salary will be revised for each installment based on the April salary pay slip or latest pay slip for the same financial year and will be fixed for the financial year.** No interim adjustments will be made to the salary during the financial year. Any revisions in salary at the Host Institution during the financial year will only be considered for the next installment in the next financial year.

If the Host Institution's contributions to the Fellows personal support exceeds the India Alliance's set level, no personal support will be provided.

Based on our understanding, Dr Harshad Patil currently receives salary support from the Host Institution. The India Alliance's contribution therefore, was calculated based on the documentation provided by the Host Institution.

2.1.1.1 Reserve Funds

During application processing, full support from IA Fellowship was considered.

Post-award, from the latest documentation provided (salary slip), it is our understanding that Dr Harshad Patil currently receives salary support from the Host Institution. Based, on these

documentation, the India Alliance's contribution towards Dr Harshad Patil's personal support was calculated. The remaining ring-fenced funds (difference between the personal support indicated during application process and post-award) can be claimed by the Fellow towards research cost by providing a scientific justification, subject to review and approval by the Chair of the Selection Committee. This option may be exercised by the Fellow in the penultimate year of the Fellowship so that the funds if approved can be released in the last installment. Justified request in this regard should be received by the Office at least 4 months before the end of the penultimate financial year of the Fellowship. The total funds released on an award shall not exceed the sanctioned amount mentioned in the award letter. The India Alliance expects the Host Institution to ensure that personal support for the Fellow is paid as specified in this award. It is for the Host Institution and the Fellow to determine how their personal support would be presented for tax purposes in India or overseas, as applicable. Please note that the India Alliance would not expect a Fellow's total personal support to exceed the level that has been set for the respective Fellowship.

The India Alliance reserves the right periodically to review and revise its provision for the Fellow's personal support. If there are any changes to the personal support received by the Fellow from the Host Institution, the India Alliance must be informed in a timely manner.

2.1.2 Contribution towards Institutional Overheads

A contribution towards institutional overheads has been provided in this award and is calculated as 10% of the total funds. These costs should be applied in such a way that they support the Fellow's research, e.g. by contributing to costs for laboratory infrastructure, utilities, or administrative support relating to the research. It is expected that charges made against this heading must be based on the actual expenditure incurred on the research funds on the fellowship and not on the allocations described on the payment profile and at no point should exceed the amount provided for this purpose. The interest earned by the Host Institution on the India Alliance funds will be adjusted annually from the institutional overheads.

2.1.3 Overseas Allowances when working outside the Host Institution

Where Fellows have requested to undertake their research outside their Host Institution, they are provided with a subsistence allowance (\$ 3000/month; revised as per the prevailing conversion rate at the time of release of funds; fluctuations in the currency conversion rates will not be accommodated once funds are released) and travel allowance (₹ 1,50,000). The total amount specified in this ring-fenced category may be used flexibly, at the Fellow's discretion, to cover any reasonable costs associated with relocating and working overseas. Transfer of funds for overseas activities would have to be undertaken by the Fellow's Host Institution.

2.2 Transferable Funds

Budgets detailed under 'Transferable funds' are indicative only and movement of funds between budget headings is allowed. Fellows are provided the flexibility to use 'Transferable Funds' as required for the pursuit of their Fellowship research goals. There are two exceptions:

- a) Funds may not be used to purchase, maintain or perform procedures on animals not included in the award letter. Permission from the India Alliance office must be obtained prior to implementation of any changes.
- b) Fellows may not support any additional posts without prior permission from the India Alliance.

2.2.1 Research Staff

It is expected that the contract of employment of any staff associated with the award should not extend beyond the end of the Fellowship. The administration of these funds must be carried out within the rules of the Host Institution.

2.2.2 Flexible Funding Allowance

The Flexible Funding Allowance (FFA) is intended to increase financial flexibility available to Fellows, and to simplify Fellowship administration. The FFA can be used to meet unanticipated directly incurred costs that would assist in meeting the goals of the Fellowship research. This includes, but is not limited to, publication costs, travel and training fees for research staff, and other miscellaneous costs.

2.2.3 Travel to Meetings

These funds are for attendance to scientific meetings, or for short working visits to other laboratories, for the Fellow and any staff employed on the Fellowship. It is a matter for the Fellow to decide as and when the funds should be used. Visits to the India Alliance office and for India Alliance events are expected to be funded from this budget.

2.2.4 Materials & Consumables, Equipment and Animals

Funds provided for materials, consumables, equipment and animals are also transferable. Animals purchased, maintained and/or used for the research purposes cannot exceed the number requested in the Fellowship.

3 Acceptance

To accept this award and activate the Fellowship, a completed **Grant Start Certificate** (attached) must be submitted to the India Alliance Office by **31 December 2018**. The Fellowship cannot be activated until this confirmation has been received. The India Alliance will not accept liability for any expenses incurred on the Fellowship until a signed Grant Start Certificate has been returned.

When accepting this Award of Fellowship, the Host Institution recognizes that the undertakings given by the Institution and others at the time of signing the Full Application Form are "conditions precedent" and the Host Institution will ensure that they, their agents, employees and students will continue to abide by the undertakings given throughout the lifetime of the Fellowship.

Copies of this letter and the notes should be forwarded to all the relevant persons in the Host Institution.

4 Payment

All payments on the award will be made electronically via bank transfer. A **Payment Details Form** (attached) should be filled by the Host Institution and returned to the India Alliance Office by **31 December 2018**.

The India Alliance will provide funds pro-rata on a yearly basis following the financial year (1 Apr – 31 Mar) cycle. Equipment cost will be released in equal payments in the first two installments, unless specified by the Fellow. All other ring-fenced and transferable funds will be released in yearly installments. A provisional payment profile of the disbursements will be released by our Finance department, at the time of release of payments.

2% of total transferable funds and overheads are withheld from the last but one installment. Release is subject to receipt of the End-of-Fellowship Research Report and Spend Report. (See 6.2)

The first two installments will be released in whole, regardless of the amount spent by the Fellow. From the third installment onwards, if any amount from the previous year is unspent, this will be carried forward and the balance will be adjusted against the next installment.

5 Reports

The India Alliance requires Research and Spend Reports from the Fellow and the Host Institution, annually and at the end of the Fellowship.

5.1 Annual

Research Report: To monitor research progress made during the year; to be submitted by the Fellow and to be received by 30 November, unless specified otherwise by the India Alliance Office. A communication specifying the format of the report will be sent by the Office.

Spend Report: To enable the release of next installment of payment; to be submitted by the Host Institution. A form will be sent by our Finance team towards the end of the financial year. This report must be received latest by 31 May and should detail all the expenditure undertaken on the Fellowship up to 31 March. The Annual Spend Reports would also have to include a pay slip indicating gross salary of the Fellow for the preceding financial year.

Funds for the next installment will not be released until a complete 'Spend Report' is received by the India Alliance. The India Alliance will not be responsible for any delays in the release of funds if the Spend Report is not submitted in time.

5.2 End-of-Fellowship

Research Report: To highlight research milestones and other accomplishments during the tenure of the Fellowship; to be submitted by the Fellow.

Audited Spend Report: To indicate all the expenditures incurred on the Fellowship during its tenure; to be submitted by the Host Institution.

A detailed email highlighting the closure process and documents required towards successful closure of the award would be shared with Fellow soon after the Fellowship end period. The India Alliance will not release the eligible retained funds (based on actual expenditure incurred) unless these reports reach the office within three months of the end of Fellowship. The Fellow and the Host Institution would be informed about the formats for the final reports. [Also see Award Conditions 2, 4 and 6 and addendum to award conditions]

- 6 Fellows' Title: See Award Condition 1**
- 7 Publications from Fellowship: See Award Condition 6**
- 8 Mid-term review process: See Award Condition 7**
- 9 Mentorship Requirement: See Award Condition 8**
- 10 IP arising from the Fellowship: See Award Condition 9**
- 11 Award Extension: See Award Condition 11**
- 12 Other Fellowships and Grants: See Award Condition 12**
- 13 Limitation of Liability: See Award Condition 13**
- 14 Variation and Termination of Fellowship: See Award Condition 14**
- 15 Statement on Equality and Diversity: See Award Condition 15**
- 16 Managing reputational risks: See Award Condition 16**
- 17 Fellows' Meetings**

The India Alliance will periodically organize meetings for all its Fellows. Information on the meetings will be made available well in advance and attendance by the Fellow is mandatory.

18 Application Reviews

The India Alliance application process relies on the co-operation of the scientific community in providing referees' comments on proposals, and the Fellow's success with this application is partly due to the goodwill of scientists in providing comments. As a holder of an India Alliance Fellowship, the Fellow is, therefore, expected to undertake review of research proposals submitted to the India Alliance upon request.

19 Contact

The India Alliance staff would be glad to meet with the Fellows at any time, either at their laboratory or at the India Alliance offices in Hyderabad or Delhi. These visits would be to ensure that a good working relationship is built between the India Alliance, Fellow and the Host Institution.

For further clarifications regarding the Fellowship, please write to: grants@indiaalliance.org.

Yours sincerely



Dr Sachin Sharma
Grants Adviser

cc Dr Harshad Patil

The Wellcome Trust / DBT India Alliance

Mr Nataraj Bollam (Finance Manager)

Dr Suveera Dhup (Grants Manager)

Encl Award Conditions
Payment Details Form
Grant Start Certificate
Ethical Approval Certification Template

Applicant's Name : **Dr.Harshad Patil**

Type of Grant : **EARLY CAREER** **Basic**

Host Institute Name : **IRSHA, Pune**

IA Reference No : **IA/E/17/1/503651**

Host Institute Ref. No: **BVDU/IRSHA/2018-19/776**

Award Letter Date: **27-12-2018**

Grant Start Date: **01-01-2019**

Grant End Date: **31-12-2023**

Grant Award Amt. ₹ **1,68,93,888**

Bank Account Details :

SBI/SB#30808434608

Note: ***(FS) Fixed till 'MARCH' Only, for current FY** Equipment Cost (E) **6,00,000** Removable Exp.(R) **-** Inst. Sal Actg Period **Apr - Mar**

F&A Contact Details :

Mr.Gavade Vijaychand Pandurang , Accountant email: vijay.irsha@gmail.com

Work Outside Host. Inst. (OA)		Year (FY)		IA Fellow Personal Support Details		
6 Months pm @ (+) Travel ₹1.50 L	\$3,000			Estimated FIXED Personal Support (FS)* p.m. (will be revised every year at beginning of FY)		
Exchange Rate	No. of Months			IA Salary Cap	HI Salary	Top-up / IA PS
		2018-19		86400	59755	26,645
		2019-20		86400	71014	15,386
		2020-21		86400	73148	13,252
65	0	2021-22		86400	66520	19,880
65	6	2022-23		86400	66520	19,880
		2023-24		86400	66520	19,880
(+) O Travel (₹)		1,50,000				0

Particulars	No. of Months	AWARD AMT.								RETENTION (R)	Adjustment	NET AWARD
		AWARD AMT.	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25			
Ring-fenced Funds (R-f)												
Revised Fellow Salary (FS)		15,98,700	79,935	1,84,632	1,59,024	2,38,560	2,38,560	1,78,920	0		-5,19,069	10,79,631
Adj. of Unspent/DISALLOWED / Reduction in Top-up of (FS)			0	-33,777	-19,206	-19,206	0	0	0		-72,189	-72,189
Net Release of (FS) (a)		15,98,700	79,935	1,50,855	1,39,818	2,19,354	2,38,560	1,78,920	0	0	-5,91,258	10,07,442
Overseas All. (Work outside Host Inst.) (OA)		13,20,000	0	0	0	0	13,20,000	0	0	0	0	13,20,000
Adj. of Unspent / Reduction in (OA)		0	0	0	0	0	0	0	0	0	0	0
Net Release of (OA) (b)		13,20,000	0	0	0	0	13,20,000	0	0	0	0	13,20,000
Reserve Fund		35,85,300						35,85,300			0	35,85,300
Adj. of Unspent/DISALLOWED												
Net Release of (RF) (c)		35,85,300	0	0	0	0	0	35,85,300	0	0	0	35,85,300
Net R-f Fund (C =a+b)		65,04,000	79,935	1,50,855	1,39,818	2,19,354	15,58,560	37,64,220	0	0	-5,91,258	59,12,742
Add: Institutional O.H. Cont. @10%												
OH on R-f Fund (c)		6,50,400	7,994	15,086	13,982	21,935	1,55,856	3,76,422	0	0	-59,126	5,91,275
OH on T-Fund (g)		8,85,408	71,270	1,95,082	1,65,082	1,63,645	1,47,373	1,23,811	0	17,708	-1,436	8,83,972
Adjustment of Interest Earned on IA Funds			0	-186	-48,074	-23,619	0	0	0	0	-71,879	-71,879
Less: Retention Amt. on OH							-3,03,229			3,03,229		
Total Institutional O.H. Cont. (d)		15,35,808	79,264	2,09,982	1,30,990	1,61,961	0	5,00,233	0	3,20,937	-1,32,441	14,03,368
Total - Ring-fenced Funds (RF) (e=c+d)		80,39,808	1,59,199	3,60,837	2,70,808	3,81,315	15,58,560	42,64,453	0	3,20,937	-7,23,699	73,16,110
Transferable Funds (TF)		88,54,080	7,12,704	19,50,816	16,50,816	16,50,816	16,50,816	12,38,112			0	88,54,080
Adj: Other Adjustments +/-											0	0
Adj. of Excess/Un Spent TF Funds +/-		0				-14,362					-14,362	-14,362
Net Transferable Funds		88,54,080	7,12,704	19,50,816	16,50,816	16,36,454	16,50,816	12,38,112	0	0	-14,362	88,39,718
Less: Retention Amt. @2% on TF (R)							-1,77,082			1,77,082	0	0
Net Release of (TF) (g)		88,54,080	7,12,704	19,50,816	16,50,816	16,36,454	14,73,734	12,38,112	0	1,77,082	-14,362	88,39,718
Grand Total (GT) ₹		1,68,93,888	8,71,903	23,11,653	19,21,624	20,17,769	30,32,294	55,02,565	0	4,98,019	-7,38,061	1,61,55,828

ADD: SUPPLEMENTARY FUNDS:

TOTAL - SUPPLEMENTARY FUNDS (SF) (₹)												Award Plus Suppl ₹	1,68,22,009
--------------------------------------	--	--	--	--	--	--	--	--	--	--	--	--------------------	-------------

Interest Earned on Grant Received from IA	71,879	186	48,074	23,619								Total Grant Amt. ₹	1,68,93,888
---	--------	-----	--------	--------	--	--	--	--	--	--	--	--------------------	-------------

ADI: REVISION / (PERMANENT REDUCTION - (PR)

Revision / (PR) in Fellow Salary (FS)	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25	REVISION AWARD ₹	
Revision / (PR) in Overseas Allowance (OA)	-	-	-	-	-	-	-	-	-
Revision / (PR) in Transferable Funds (TF)	-	-	-	-	-	-	-	-	-
Institutional O.H. @ 10% on above (FS+OA+TF)	(71,879)	(186)	(48,074)	(23,619)	-	-	-	-	-
TOTAL - REVISION / (PR) (₹)	(71,879)	(186)	(48,074)	(23,619)	-	-	-	-	-

SPENT DETAILS	TOTAL SPENT	1	2	3	4	5	6	7	TOTAL UNSPENT	TOTAL RECEIPT (GT)
Fellow Salary (FS)	3,51,402	46,158	1,65,426	1,39,818					19,206	3,70,608
Overseas All. (Work outside Host Inst.) (OA)	-	-	-	-	-	-	-	-	-	-
Transferable Funds (TF)	41,22,608		26,59,777	14,62,831					1,91,728	43,14,336
Institutional O.H. @ 10% on above (FS+OA+TF)	4,47,401	4,616	2,82,520	1,60,265	-	-	-	-	(27,165)	4,20,236
TOTAL AMOUNT ₹	49,21,411	50,774	31,07,723	17,62,914	-	-	-	-	1,83,769	51,05,180
Unspent Amount (₹)	1,83,769	8,21,129	(7,96,070)	1,58,710	-	-	-	-	1,83,769	2,55,648
Committed Amount Provision ₹ (CP)	1,77,366		48,380	1,28,986					1,95,103	1,95,103
Unspent after Commitment Prov ₹	6,403	8,21,129	(8,44,450)	29,724	-	-	-	-	(11,334)	60,545
UNSPENT / (EXCESS) SPENT - (FS)	72,189	33,777	19,206	19,206	-	-	-	-	79,408	
UNSPENT / (EXCESS) SPENT - (OA)	-	-	-	-	-	-	-	-	-	95,206
UNSPENT / (EXCESS) SPENT - (TF)	14,362	7,12,704	(7,57,341)	58,999	-	-	-	-	15,798	

Cumulative Total Payment	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25		
Current Liability (CL) (Unspent Adjusted Payable)	15,799	-	-	15,799					
Expenditure (GT+R+CL)	1,61,71,626	8,71,903	23,11,653	19,21,624	20,33,568	35,30,313	55,02,565	-	-
Deferred Liability (DL)		1,60,21,985	1,37,10,146	1,17,40,448	96,83,261	61,52,948	6,50,383	6,50,383	6,50,383

Please Note:
1. Payment of yearly installment will be made subject to submission of (a) Ledger Copy/ R&P/ I&E/ Stmt. of A/c of Fellows Project, (b) Latest Pay Slip AND Salary Certificate for the previous FY, (c) Ethical Approval / Certificate from Sponsor (If appl.), (d) Signed Grant Spend Report for the previous year, (e) Fellows Research Report, (f) Latest Audited & Unaudited Financial Statements and Annual Report of the Institute.
2. UNSPENT TF & OA amounts will be adjusted from 3rd installment, it will be released upon submission of Spend Report and Future requirements.

FILE NO. ECR/2017/000391
SCIENCE & ENGINEERING RESEARCH BOARD(SERB)
(a statutory body of the Department of Science & Technology, government of India)

5 & 5A, Lower Ground Floor
Vasant Square Mall
Plot No. A, Community Centre
Sector-B, Pocket-5, Vasant Kunj
New Delhi-110070

Dated: 08-May-2018

ORDER

Subject: Financial Sanction of the research project titled "**Evaluation of different adjuvants for development of potent chikungunya vaccine**" under the guidance of Dr. Harshad Padmanabh Patil, Communicable Diseases, Interactive Research School for Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive research school for health affairs (irsha), bharati vidyapeeth deemed university, pune satara road, pune, maharashtra, Pune, Maharashtra-411043 - Release of 1st grant.

Sanction of Science and Engineering Research Board (SERB) is hereby accorded to the above mentioned project at a total cost of Rs. 3222474/- (Rs. Thirty Two Lakh Twenty Two Thousand Four Hundred and Seventy Four Only) with break-up of Rs. 412722/- under Capital (Non-recurring) head and Rs.2809752/- under General (Recurring) head for a duration of 36 months. The items of expenditure for which the total allocation of Rs. 3222474/- has been approved are given below: The following budget may be considered for **Interactive Research School For Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive Research School For Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune Satara Road, Pune, Maharashtra**

S. No	Head	Total (in Rs.)
A	Non-recurring	
1	Equipment -> Ice flaking machine -> Stepper Pipette -> Electronic Adjustable Tip Spacing Multichannel Equalizer Pipettes -> Electronic Multichannel Pipettes	412722
A'	Total (Non-Recurring)	412722
B	Recurring Items	
1	Recurring - I : (Manpower) Recurring - II : (Consumables, Travel, Contingencies)	1216800 1300000
2	Recurring - III : (Overhead Charges)	292952
B'	Total (Recurring)	2809752
C	Total cost of the project (A' + B')	3222474

2. Sanction of the SERB is also accorded to the payment of

- Rs. 412722/- (Rupees Four Lakh Twelve Thousand Seven Hundred and Twenty Two only) under 'Grants for creation of capital assets' and Rs. 936578/- (Rupees Nine Lakh Thirty Six Thousand Five Hundred and Seventy Eight only) under 'Grants-in-aid General' to **Director, Interactive Research School For Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive Research School For Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune Satara Road, Pune, Maharashtra**

being the first installment of the grant for the year 2018-2019 for implementation of the said research project.

3. The expenditure involved is debit to **Fund for Science & Engineering Research (FSER)**

This release is being made under Early Career Research Award. (EC Life Sciences)

4. The Sanction has been issued to Interactive Research School For Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive Research School For Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune Satara Road, Pune, Maharashtra with the approval of the competent authority under delegated powers on **25 April, 2018** and vide Diary No. **SERB/F/160/2018-2019** dated **07 May, 2018**

5. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at website (www.serb.gov.in).

6. Overhead expenses are meant for the host Institute towards the cost for providing infrastructural facilities and general administrative support etc. including benefits to the staff employed in the project.

7. While providing operational flexibility among various subheads under head Recurring-II, it should be ensured that not more than Rs. 1.5 lakh each should be spent for travel and contingency.

8. As per rule 211 of GFR, the accounts of project shall be open to inspection by sanctioning authority/audit whenever the institute is called upon to do so.

9. The sanctioned equipment would be procured as per GFR and its disposal of the same would be done with prior approval of SERB

10. The release amount of Rs. 1349300/- (Rupees Thirteen Lakh Forty Nine Thousand Three Hundred only) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

Account Name	The Director Interactive Research School for Health Affairs IRSHA
Account Number	30808434608
Bank Name & Branch	State Bank of India Katraj Branch, S.No. 133/2, Near Bharati Vidyapeeth, Pune Satara Road, Katraj, Pune 411 046. Tel. No. 020 24371861
IFSC/RTGS Code	SBIN0008752
Email id of A/C Holder	director.irsha@bharatividyaapeeth.edu
Email id of PI	mailharshadpatil@gmail.com

11. The institute will furnish to the SERB, New Delhi, separate Utilization certificate(UCs) financial year wise to the SERB for Recurring (Grants-in-aid General) & Non-Recurring (Grants for creation of capital assets) and an audited statement of accounts pertaining to the grant immediately after the end of each financial year.

12. The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.

13. The project File no. ECR/2017/000391 may also be mentioned in all research communications arising from the above project with due acknowledgement of SERB.


14. The manpower sanctioned in the project, if any is co-terminus with the duration of the project and SERB will have no liability to meet the fellowship and salary of supporting staff if any. beyond the duration of the project

15. As this is the first grant being released for the project, no previous U/C is required.

16. The institute may refund any unspent balance to SERB by means of a Demand Draft favoring "FUND FOR SCIENCE AND ENGINEERING RESEARCH" payable at New Delhi.

17. The organization/institute/university should ensure that the technical support/financial assistance provided to them by the Science & Engineering Research Board, a statutory body of the Department of Science & Technology (DST), Government of India should invariably be highlighted/ acknowledged in their media releases as well as in bold letters in the opening paragraphs of their Annual Report.


18. In addition, the investigator/host institute must also acknowledge the support provided to them in all publications, patents and any other output emanating out of the project/program funded by the Science & Engineering Research Board, a statutory body of Department of Science & Technology (DST), Government of India.


(Dr. Thangaradjou T)
Scientist E
msls@serb.gov.in

To,
Under Secretary
SERB, New Delhi

Copy forwarded for information and necessary action to: -

1.	The Principal Director of Audit, A.G.C.R.Building, IIIrd Floor I.P. Estate, Delhi-110002
2.	Sanction Folder, SERB , New Delhi.
3.	File Copy
4.	Dr. Harshad Padmanabh Patil Communicable Diseases Interactive Research School for Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University , Interactive research school for health affairs (irsha), bharati vidyapeeth deemed university, pune satara road, pune, maharashtra, Pune, Maharashtra-411043 Email: mailharshadpatil@gmail.com Mobile: 919130551560 (Start date of the project may be intimated by name to the undersigned. For guidance, terms & Conditions etc. Please visit www.serb.gov.in .)
5.	Director, Interactive Research School For Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive Research School For Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune Satara Road, Pune, Maharashtra (Receipt of Grant may be intimated by name to the undersigned)


(Dr. Thangaradjou T)
Scientist E
msls@serb.gov.in

SERB India

Science and Engineering Research Board

(Statutory Body Established Through an Act of Parliament : SERB Act 2008)

Department of Science and Technology, Government of India

FILE NO. ECR/2017/000391

SCIENCE & ENGINEERING RESEARCH BOARD(SERB)

(a statutory body of the Department of Science & Technology, government of India)

5 & 5A, Lower Ground Floor
Vasant Square Mall
Plot No. A, Community Centre
Sector-B, Pocket-5, Vasant Kunj
New Delhi-110070

Dated: 18-Jun-2020

ORDER

Subject: Research project entitled "**Evaluation of different adjuvants for development of potent chikungunya vaccine**" under the guidance of Dr. Harshad Padmanabh Patil, Communicable Diseases, Interactive Research School for Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive research school for health affairs (irsha), bharati vidyapeeth deemed university, pune satara road, pune, maharashtra, Pune, Maharashtra-411043.

1. This is in continuation of SERB's sanction order No. "ECR/2017/000391" dated "08 May, 2018 " of **Science and Engineering Research Board (SERB)**.

2. Sanction of the competent authority is hereby accorded to the payment of a sum of **Rs. 750000/-** (Rupees Seven Lakh Fifty Thousand only) under 'Grants-in-aid General' to **Director, Interactive Research School For Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive Research School For Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune Satara Road, Pune, Maharashtra** being the 3rd grant for the financial year 2020-2021 for implementation of the above said project.

3. Sanction of the competent authority is also accorded to the carry forward of unspent balance of **Rs. 61949/-** (Rupees Sixty One Thousand Nine Hundred and Forty Nine only) (Recurring Rs. 57465 and Non-Recurring Rs. 4484) to Interactive Research School for Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune Satara Road, Pune, Maharashtra from FY 2019-2020 to FY 2020-2021 for the same purpose for which it was sanctioned.

4. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at the website (www.serb.gov.in).

5. It is certified that provision of GFR 212 relating to Utilization Certificates (Ucs) for the funds released under the grant have been satisfied and the UC/s is/are enclosed herewith.

6. The expenditure involved is debitable to **Fund for Science & Engineering Research (FSER)**

This release is being made under Early Career Research Award. (EC Life Sciences) (GEN).

7. The Sanction has been issued to Interactive Research School For Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive Research School For Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune Satara Road, Pune, Maharashtra with the approval of the competent authority under delegated powers on **17 June, 2020** and vide Diary No. **SERB/F/526/2020-2021** dated **18 June, 2020**

8. The release amount of **Rs. 750000/-** (Rupees Seven Lakh Fifty Thousand only) (Recurring Rs. 750000 and Non-Recurring Rs. 0) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

PFMS Unique Code	IRSHABVU
Account Name	BVDU Interactive Research School for Health Affairs

Account Number	3265101003835
Bank Name & Branch	Canara Bank Dhankawadi Branch, S.No. 29, Plot No. 47, Omkar Chambers, Near Foot Bridge, Satara Road, Dhankawadi, Pune - 411 043. (Maharashtra)
IFSC/RTGS Code	CNRB0003265
Email id of A/C Holder	<u>director.irsha@gmail.com</u>
Email id of PI	<u>mailharshadpatil@gmail.com</u>

9. The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.

10. As per rule 211 of GFR the accounts of Grantee Institution shall be open to inspection by the sanctioning authority / audit whenever the institute is called upon to do so.

11. The institute will furnish to the SERB, Utilization certificate(separate for Recurring & Non-Recurring) and an audited statement of accounts pertaining to the grant immediately after the end of each financial year.

12. After completion of the project unspent balance if any should be returned as Demand Draft drawn in favour of "Fund for Science and Engineering Research" payable at New Delhi.

13. The organization/institute/university should ensure that the technical support/financial assistance provided to them by the Science & Engineering Research Board, a statutory body of the Department of Science & Technology (DST), Government of India should invariably be highlighted/ acknowledged in their media releases as well as in bold letters in the opening paragraphs of their Annual Report.

14. In addition, the investigator/host institute must also acknowledge the support provided to them in all publications, patents and any other output emanating out of the project/program funded by the Science & Engineering Research Board, a statutory body of Department of Science & Technology (DST), Government of India.

(Dr. Thangaradjou T)

Scientist E

msls@serb.gov.in

To,

Under Secretary

SERB, New Delhi

Copy forwarded for information and necessary action to: -

1.	The Principal Director of Audit, A.G.C.R.Building, IIIrd Floor I.P. Estate, Delhi-110002
-----------	--

2.	Sanction Folder, SERB , New Delhi.
3.	File Copy
4.	Dr. Harshad Padmanabh Patil Communicable Diseases Interactive Research School for Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University , Interactive research school for health affairs (irsha), bharati vidyapeeth deemed university, pune satara road, pune, maharashtra, Pune, Maharashtra-411043 Email: mailharshadpatil@gmail.com Mobile: 919130551560
5.	Director, Interactive Research School For Health Affairs (IRSHA), Bhaarti Vidyapeeth Deemed University, Interactive Research School For Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune Satara Road, Pune, Maharashtra

(Dr. Thangaradjou T)

Scientist E

msls@serb.gov.in

F.No.3-64/2019-CCRUM/Tech.
CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE
Ministry of AYUSH, Government of India

Jawahar Lal Nehru Anusandhan Bhawan
61-65, Institutional Area, opp. D-Block,
Janakpuri, New Delhi- 110058
Dated: 11.03.2020


SANCTION ORDER

With the approval of the Competent Authority, sanction of the Director General, CCRUM is hereby accorded to collaborative project entitled "**Phytochemical standardization and evaluation of anti-cancer and immunomodulatory activity of Unani formulation, Itrifal ghudadi**" submitted by Dr. Ruchika Kaul Ghanekar, Scientist and Head, Cell and Translational Research Division, Interactive Research School for Health Affairs (IRSHA), Bharati Vidya Peeth University, Pune with a total cost of Rs. 43, 57,750/- (Rupees forty three lakh fifty seven thousand seven hundred fifty only) for a period of three years. The head-wise break-up of expenditure approved are as under:-

Head	I year (Rs.)	II year (Rs.)	III year (Rs.)	Total (Rs.)
Salary: 01 JRF (Life Sciences)	3,90,000/-	3,90,000/-	3,90,000/-	11,70,000/-
Books	5,000/-	5,000/-	-	10,000/-
Other Non-Recurring Expenditure	1,00,000/-	-	-	1,00,000/-
Recurring Expenditure	11,00,000/-	9,00,000/-	6,00,000/-	26,00,000/-
Travel	20,000/-	50,000/-	50,000/-	1,20,000/-
Institutional Support (5%)	79,000/-	70,500/-	55,250/-	2,04,750/-
Miscellaneous expenses	65,000/-	65,000/-	65,000/-	1,95,000/-
Total	17,38,000/-	14,70,000/-	11,49,750/-	43,57,750/-

Sanction of the Director General, CCRUM is accorded for payment of **Rs. 5, 21,400/- (Rupees five lakh twenty one thousand four hundred only)** as 30% of Grant- in -aid for the year 2019-20 from the total amount of first year grant i.e. Rs.17,38,000/-. The expenditure will be chargeable out of the head "**Research Activities**" for the year 2019-20.

This issues with the approval of the Director General, CCRUM.


(Devanand)

Assistant Director (Admn.)
for Director General

- Account Officer, CCRUM Headquarters, New Delhi for payment to The Director, IRSHA, Bharati Vidya Peeth University, Pune, STATE BANK OF INDIA, Katraj Branch, Satara Road-Pune (Account Number- 30808434608 & IFSC Code- SBIN0008752)
- Dr. Ruchika Kaul Ghanekar, Principal Investigator, Cell and Translational Research Division, Interactive Research School for Health Affairs (IRSHA), Bharati Vidya Peeth University, Pune for information.
- File concerned

FILE NO. EMR/2017/001208
SCIENCE & ENGINEERING RESEARCH BOARD(SERB)
(a statutory body of the Department of Science & Technology, government of India)

5 & 5A, Lower Ground Floor
Vasant Square Mall
Plot No. A, Community Centre
Sector-B, Pocket-5, Vasant Kunj
New Delhi-110070

Dated: 16-Oct-2018

ORDER

Subject: Financial Sanction of the research project titled "Evaluating the effect of Alpha linolenic acid (ALA), an omega 3 fatty acid, on modulation of epigenetic markers in cervical cancer cell lines" under the guidance of Dr. Ruchika Kaul Shanekar, Cancer Research Lab, Bharati Vidyapeeth, Bharati vidyapeeth campus, Dhankawadi, pune, mh, Pune, Maharashtra-411043 - Release of 1st grant.

Sanction of Science and Engineering Research Board (SERB) is hereby accorded to the above mentioned project at a total cost of Rs. 3316800/- (Rs. Thirty Three Lakh Sixteen Thousand Eight Hundred Only) with break-up of Rs. 0/- under Capital (Non-recurring) head and Rs. 3316800/- under General (Recurring) head for a duration of 36 months. The items of expenditure for which the total allocation of Rs. 3316800/- has been approved are given below:
The following budget may be considered for Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH

S. No	Head	Total (in Rs.)
A	Non-recurring	
1	Equipment	0
A'	Total (Non-Recurring)	0
B	Recurring Items	
1	Recurring - I : (Manpower)	1216800
	Recurring - II : (Consumables, Travel, Contingencies)	1800000
2	Recurring - III : (Overhead Charges)	300000
B'	Total (Recurring)	3316800
C	Total cost of the project (A' + B')	3316800

Sanction of the SERB is also accorded to the payment of Rs. 1105000/- (Rupees Eleven Lakh Five Thousand only) under 'Grants-in-aid General' to Director, Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH being the first installment of the grant for the year 2018-2019 for implementation of the said research project. The expenditure involved is debitable to Fund for Science & Engineering Research (FSER) and its release is being made under Core Research Grant. (PAC Health Sciences)

The Sanction has been issued to Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH with the approval of the competent authority under delegated powers on 15 October, 2018 and vide Diary No. SERB/F/8154/2018-19 dated 16 October, 2018

Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at website (www.serb.gov.in).

Overhead expenses are meant for the host Institute towards the cost for providing infrastructural facilities and general administrative support etc. including benefits to the staff employed in the project.

While providing operational flexibility among various subheads under head Recurring-II, it should be ensured that not more than Rs. 1.5 lakh each should be spent for travel and contingency.

As per rule 211 of GFR, the accounts of project shall be open to inspection by sanctioning authority/audit whenever the institute is called upon to do so.

The sanctioned equipment would be procured as per GFR and its disposal of the same would be done with prior approval of SERB.

The release amount of Rs. 1105000/- (Rupees Eleven Lakh Five Thousand only) will be drawn by the Under Secretary the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

Account Name	Interactive Research School for Health Affairs (IRSHA)
--------------	--

Account Number	30808434608
Bank Name & Branch	State Bank of India KATRAJ BRANCH, S.No. 133/2, NEAR BHARATI VIDYAPEETH UNIVERSITY, PUNE-SATARA RD, KATRAJ, PIN - 411046
IFSC/RTGS Code	SBIN0008752
Email id of A/C Holder	director.irsha@bharatividyaapeeth.edu
Email id of PI	ruchika.kaulghanekar@gmail.com

11. The institute will furnish to the SERB, New Delhi, separate Utilization certificate(UCs) financial year wise to the SERB for Recurring (Grants-in-aid General) & Non-Recurring (Grants for creation of capital assets) and an audited statement of accounts pertaining to the grant immediately after the end of each financial year.

12. The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.

13. The project File no. EMR/2017/001208 may also be mentioned in all research communications arising from the above project with due acknowledgement of SERB.


14. The manpower sanctioned in the project, if any is co-terminus with the duration of the project and SERB will have no liability to meet the fellowship and salary of supporting staff if any, beyond the duration of the project

15. As this is the first grant being released for the project, no previous U/C is required.

16. The institute may refund any unspent balance to SERB by means of a Demand Draft favoring "FUND FOR SCIENCE AND ENGINEERING RESEARCH" payable at New Delhi.

17. The organization/institute/university should ensure that the technical support/financial assistance provided to them by the Science & Engineering Research Board, a statutory body of the Department of Science & Technology (DST), Government of India should invariably be highlighted/ acknowledged in their media releases as well as in bold letters in the opening paragraphs of their Annual Report.


18. In addition, the investigator/host institute must also acknowledge the support provided to them in all publications, patents and any other output emanating out of the project/program funded by the Science & Engineering Research Board, a statutory body of Department of Science & Technology (DST), Government of India.


 (Dr. Balachandar Venkatesan)
 Scientist E
 ms_hs@serbonline.in

To,
 Under Secretary
 SERB, New Delhi

Copy forwarded for information and necessary action to :-

1.	The Principal Director of Audit, A.G.C.R. Building, IIIrd Floor I P Estate, Delhi-110002
2.	Sanction Folder, SERB, New Delhi.
3.	File Copy
4.	Dr. Ruchika Kaul Ghanekar Cancer Research Lab Bharati Vidyapeeth, Bharati vidyapeeth campus, Dhankawadi, pune, mh, Pune, Maharashtra-411043 Email: ruchika.kaulghanekar@gmail.com Mobile: 919860200826 (Start date of the project may be intimated by name to the undersigned. For guidance, terms & Conditions etc. Please visit www.serb.gov.in)
5.	Director, Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH (Receipt of Grant may be intimated by name to the undersigned)


 (Dr. Balachandar Venkatesan)
 Scientist E
 ms_hs@serbonline.in

FILE NO. EMR/2017/001208
SCIENCE & ENGINEERING RESEARCH BOARD(SERB)
(a statutory body of the Department of Science & Technology, government of India)

5 & 5A, Lower Ground Floor
Vasant Square Mall
Plot No. A, Community Centre
Sector-B, Pocket-5, Vasant Kunj
New Delhi-110070

Dated: 17-Feb-2020

ORDER

Subject: Research project entitled "Evaluating the effect of Alpha linolenic acid (ALA), an omega 3 fatty acid, on modulation of epigenetic markers in cervical cancer cell lines" under the guidance of Dr. Ruchika Kaul Ghanekar, Cancer Research Lab, Bharati Vidyapeeth, Bharati vidyapeeth campus, Dhankawadi, pune, mh, Pune, Maharashtra-411043.

1. This is in continuation of SERB's sanction order No. "EMR/2017/001208" dated "16 October, 2018 " of Science and Engineering Research Board (SERB).
2. Sanction of the competent authority is hereby accorded to the payment of a sum of Rs. 600000/- (Rupees Six Lakh only) under 'Grants-in-aid General' to Director, Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH being the 2nd grant for the financial year 2019-2020 for implementation of the above said project.
3. Sanction of the competent authority is also accorded to the carry forward of unspent balance of Rs. 559091/- (Rupees Five Lakh Fifty Nine Thousand and Ninety One only) (Recurring Rs. 559091 and Non-Recurring Rs. 0) to Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH from FY 2018-2019 to FY 2019-2020 for the same purpose for which it was sanctioned.
4. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at the website (www.serb.gov.in).
5. It is certified that provision of GFR 212 relating to Utilization Certificates (Ucs) for the funds released under the grant have been satisfied and the UC/s is/are enclosed herewith.
6. The expenditure involved is debitable to Fund for Science & Engineering Research (FSER) This release is being made under Core Research Grant. (PAC Health Sciences)
7. The Sanction has been issued to Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH with the approval of the competent authority under delegated powers on 14 February, 2020 and vide Diary No. SERB/F/10282/2019-2020 dated 17 February, 2020
8. The release amount of Rs. 600000/- (Rupees Six Lakh only) (Recurring Rs. 600000 and Non-Recurring Rs. 0) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

PFMS Unique Code	NA
Account Name	Interactive Research School for Health Affairs (IRSHA)
Account Number	30808434608
Bank Name & Branch	State Bank of India KATRAJ BRANCH, S.No. 133/2, NEAR BHARATI VIDYAPEETH UNIVERSITY, PUNE-SATARA RD, KATRAJ, PIN - 411046
IFSC/RTGS Code	SBIN0008752
Email id of A/C Holder	director.irsha@bharatividyaapeeth.edu
Email id of PI	ruchika.kaulghanekar@gmail.com

sanctioned letter 2

9. The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.


10. As per rule 211 of GFR the accounts of Grantee Institution shall be open to inspection by the sanctioning authority / audit whenever the institute is called upon to do so.

11. The institute will furnish to the SERB, Utilization certificate(separate for Recurring & Non-Recurring) and an audited statement of accounts pertaining to the grant immediately after the end of each financial year.

12. After completion of the project unspent balance if any should be returned as Demand Draft drawn in favour of "Fund for Science and Engineering Research" payable at New Delhi.

13. The organization/institute/university should ensure that the technical support/financial assistance provided to them by the Science & Engineering Research Board, a statutory body of the Department of Science & Technology (DST), Government of India should invariably be highlighted/ acknowledged in their media releases as well as in bold letters in the opening paragraphs of their Annual Report.


14. In addition, the investigator/host institute must also acknowledge the support provided to them in all publications, patents and any other output emanating out of the project/program funded by the Science & Engineering Research Board, a statutory body of Department of Science & Technology (DST), Government of India.


(Dr. Balachandar Venkatesan)
Scientist E
ms_hs@serbonline.in

To,
Under Secretary
SERB, New Delhi

Copy forwarded for information and necessary action to: -

1.	The Principal Director of Audit, A.G.C.R.Building, IIIrd Floor I.P. Estate, Delhi-110002
2.	Sanction Folder, SERB , New Delhi.
3.	File Copy
4.	Dr. Ruchika Kaul Ghanekar Cancer Research Lab Bharati Vidyapeeth , Bharati vidyapeeth campus,Dhankawadi, pune, mh, Pune, Maharashtra-411043 Email: ruchika.kaulghanekar@gmail.com Mobile: 919860200825
5.	Director, Bharati Vidyapeeth, Bharati Vidyapeeth Campus,Dhankawadi, Pune, MH


(Dr. Balachandar Venkatesan)
Scientist E
ms_hs@serbonline.in

FILE NO. EMR/2017/001208
SCIENCE & ENGINEERING RESEARCH BOARD(SERB)
(a statutory body of the Department of Science & Technology, government of India)

5 & 5A, Lower Ground Floor
Vasant Square Mall
Plot No. A, Community Centre
Sector-B, Pocket-5, Vasant Kunj
New Delhi-110070

Dated: 10-Sep-2020

ORDER

Subject Research project entitled "Evaluating the effect of Alpha linolenic acid (ALA), an omega 3 fatty acid, on modulation of epigenetic markers in cervical cancer cell lines" under the guidance of Dr. Ruchika Kaul Ghanekar, Cancer Research Lab, Bharati Vidyapeeth, Bharati vidyapeeth campus, Dhankawadi, pune, mh, Pune, Maharashtra-411043.

- This is in continuation of SERB's sanction order No. "EMR/2017/001208" dated "16 October, 2018" of Science and Engineering Research Board (SERB).
- Sanction of the competent authority is hereby accorded to the payment of a sum of **Rs. 1000000/-** (Rupees Ten Lakh only) under 'Grants-in-aid General' to **Director, Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH** being the 3rd grant for the financial year 2020-2021 for implementation of the above said project.
- Sanction of the competent authority is also accorded to the carry forward of unspent balance of **Rs. 50594/-** (Rupees Fifty Thousand Five Hundred and Ninety Four only) (Recurring Rs. 50594 and Non-Recurring Rs. 0) to Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH from FY 2019-2020 to FY 2020-2021 for the same purpose for which it was sanctioned.
- Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at the website (www.serb.gov.in).
- It is certified that provision of GFR 212 relating to Utilization Certificates (UCs) for the funds released under the grant have been satisfied and the UC/s is/are enclosed herewith.
- The expenditure involved is debitable to **Fund for Science & Engineering Research (FSER)**
This release is being made under Core Research Grant. (PAC Health Sciences)
- The Sanction has been issued to Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH with the approval of the competent authority under delegated powers on **09 September, 2020** and vide Diary No. **SERB/F/3257/2020-2021** dated **10 September, 2020**
- The release amount of **Rs. 1000000/-** (Rupees Ten Lakh only) (Recurring Rs. 1000000 and Non-Recurring Rs. 0) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

PFMS Unique Code	NA
Account Name	Interactive Research School for Health Affairs (IRSHA)
Account Number	30808434608
Bank Name & Branch	State Bank of India KATRAJ BRANCH, S.No. 133/2, NEAR BHARATI VIDYAPEETH UNIVERSITY, PUNE-SATARA RD, KATRAJ, PIN - 411046
IFSC/RTGS Code	SBIN0008752
Email id of A/C Holder	director.irsha@bharatividyaapeeth.edu
Email id of PI	ruchika.kaulghanekar@gmail.com
- The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.
- As per rule 211 of GFR the accounts of Grantee Institution shall be open to inspection by the sanctioning authority / audit whenever the institute is called upon to do so.
- The institute will furnish to the SERB, Utilization certificate (separate for Recurring & Non-Recurring) and an audited statement of accounts pertaining to the grant immediately after the end of each financial year

sanctioned letter 3

FILE NO. EMR/2017/001208
SCIENCE & ENGINEERING RESEARCH BOARD(SERB)
(a statutory body of the Department of Science & Technology, government of India)

5 & 5A, Lower Ground Floor
Vasant Square Mall
Plot No. A, Community Centre
Sector-B, Pocket-5, Vasant Kunj
New Delhi-110070

Dated: 10-Sep-2020

ORDER

Subject: Research project entitled "Evaluating the effect of Alpha linolenic acid (ALA), an omega 3 fatty acid, on modulation of epigenetic markers in cervical cancer cell lines" under the guidance of Dr. Ruchika Kaul Ghanekar, Cancer Research Lab, Bharati Vidyapeeth, Bharati vidyapeeth campus, Dhankawadi, pune, mh, Pune, Maharashtra-411043.

1. This is in continuation of SERB's sanction order No. "EMR/2017/001208" dated "16 October, 2018 " of Science and Engineering Research Board (SERB).
2. Sanction of the competent authority is hereby accorded to the payment of a sum of **Rs. 1000000/-** (Rupees Ten Lakh only) under 'Grants-in-aid General' to **Director, Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH** being the 3rd grant for the financial year 2020-2021 for implementation of the above said project.
3. Sanction of the competent authority is also accorded to the carry forward of unspent balance of **Rs. 50594/-** (Rupees Fifty Thousand Five Hundred and Ninety Four only) (Recurring Rs. 50594 and Non-Recurring Rs. 0) to Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH from FY 2019-2020 to FY 2020-2021 for the same purpose for which it was sanctioned.
4. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at the website (www.serb.gov.in).
5. It is certified that provision of GFR 212 relating to Utilization Certificates (UCs) for the funds released under the grant have been satisfied and the UC/s is/are enclosed herewith.
6. The expenditure involved is debitable to **Fund for Science & Engineering Research (FSER)**
This release is being made under Core Research Grant. (PAC Health Sciences)
7. The Sanction has been issued to Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH with the approval of the competent authority under delegated powers on **09 September, 2020** and vide Diary No. SERB/F/3257/2020-2021 dated **10 September, 2020**
8. The release amount of **Rs. 1000000/-** (Rupees Ten Lakh only) (Recurring Rs. 1000000 and Non-Recurring Rs. 0) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

PFMS Unique Code	NA
Account Name	Interactive Research School for Health Affairs (IRSHA)
Account Number	30808434608
Bank Name & Branch	State Bank of India KATRAJ BRANCH, S.No. 133/2, NEAR BHARATI VIDYAPEETH UNIVERSITY, PUNE-SATARA RD, KATRAJ, PIN - 411046
IFSC/RTGS Code	SBIN0008752
Email id of A/C Holder	director.irsha@bharatividyaapeeth.edu
Email id of PI	ruchika.kaulghanekar@gmail.com

9. The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.
10. As per rule 211 of GFR the accounts of Grantee Institution shall be open to inspection by the sanctioning authority / audit whenever the institute is called upon to do so.
11. The institute will furnish to the SERB, Utilization certificate (separate for Recurring & Non-Recurring) and an audited statement of accounts pertaining to the grant immediately after the end of each financial year.

No.SR/WOS-A/LS-205/2017 (G)
Government of India
Ministry of Science & Technology
Department of Science & Technology
KIRAN DIVISION

Technology Bhawan
New Mehrauli Road
New Delhi-110016
Dated 06.09.2018

ORDER

Sub: Financial approval of the project under Women Scientist Scheme A (WOS-A) entitled "Comparing vaginal microflora diversity between healthy and cervical cancer women for identifying isolates having probiotic and anticancer potential."

PI Dr. Ashwini Laxman Kamble, Cancer Lab, Interactive Research School for Health Affairs (IRSHA), Pune-Satara Road, Katraj-Dhankawadi, Pune-411043, Maharashtra.

Sanction of the President is hereby accorded to the above mentioned project at a total cost of Rs. 32,06,000/- (Rupees Thirty Two Lac Six Thousand only) for a duration of three years. The items of expenditure for which the total allocation of Rs 32,06,000/- (recurring) has been approved for three years are given below.

Sl. No.	Heads	1 st Year	2 nd Year	3 rd Year	Total
A.	Non-Recurring (Capital Items)				
	Equipments: Nil	-----	-----	-----	-----
B.	Recurring(General)				
	Fellowship for Ph.D@ Rs. 55,000/-	6,60,000/-	6,60,000/-	6,60,000/-	19,80,000/-
	Consumables	2,90,000/-	2,80,000/-	2,80,000/-	8,50,000/-
	Contingencies	20,000/-	20,000/-	20,000/-	60,000/-
	Travel	10,000/-	10,000/-	10,000/-	30,000/-
C.	Overhead	96,000/-	95,000/-	95,000/-	2,86,000/-
D.	Total of Recurring Grant (B+C)	10,76,000/-	10,65,000/-	10,65,000/-	32,06,000/-
E.	GRAND TOTAL (A+D)	10,76,000/-	10,65,000/-	10,65,000/-	32,06,000/-

2 Sanction of the grant is subject to the conditions as detailed in website www.online-wosa.gov.in

3 The sanction of the President is also accorded to the release of Rs. 10,76,000/- (Rupees Ten Lakh Seventy Six Thousand only) under "General Component" to The **Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra** being the first installment of the grant for the year 2018-2019 for implementation of the above mentioned project.

4 This sanction is subject to the condition that the grantee organization will furnish to the Department of Science & technology, financial year wise Utilization Certificate (UC) in the proforma prescribed as per GFR 2017 and audited statement of expenditure (SE) along with up to date progress report at the end of each financial year duly reflecting the interest earned / accrued on the grants received under the project. This is also subject to the condition of submission of the final statement of expenditure, utilization certificate and project completion report within one year from the scheduled date of completion of the project.

5 The grantee organization will have to enter & upload the Utilization Certificate in the PFMS portal besides sending it in physical form to this Division. The subsequent/final installment will be released only after confirmation of the acceptance of the UC by the Division and entry of previous Utilization Certificate in the PFMS.

6 If the grant has been released under capital head through separate sanction order under the same project for purchase of equipment(s), separate SE/UC has to be furnished for the released Capital head grant.

7 The grant-in-aid being released is subject to the condition that

(a) A transparent procurement procedure in line with the Provisions of General Financial Rules 2017 will be followed by the Institute/ Organization under the appropriate rules of the grantee organization while procuring capital assets sanctioned for the above mentioned project and a certificate to this effect will be submitted by the Grantee organization immediately on receipt of the grant.

(b) While submitting Utilization Certificate/Statement of Expenditure, the organization has to ensure submission of supporting documentary evidences with regard to purchase of equipment/capital assets as per the provisions of GFR 2017. Subsequent release of grant under the project shall be considered only on receipt of the said documents.

Contd. p/-2

8. The Grantee Institute (GI) will maintain separate audited as per GFR 2017 Rule 230 (B) account for the project and the entire amount of grant will be kept in an interest bearing bank account. For Grants released during FY 2017-2018 and onwards interest and other earnings, against released Grant shall be remitted to Consolidated Fund of India, immediately after finalization of accounts, as it shall not be adjusted towards future release of Grant. A certificate to this effect shall have to be submitted along with statement of expenditure/utilization certificate for considering subsequent release of grant/closure of project accounts. GI should also follow Rule 230 (17) of GFR 2017.

9. DST reserves sole rights on the assets created out of grants. Assets acquired wholly or substantially out of government grants (except those declared as obsolete and unserviceable or condemned in accordance with the procedure laid down in GFR 2017), shall not be disposed of without obtaining the prior approval of DST.

10. The Principal Investigator under Women Scientist Scheme is not permitted to withdraw any emoluments/ salary/fellowship from any other project either supported by DST or by any other funding agency.

11. The account of the grantee organization shall be open to inspection by the sanctioning authority and audit (both by C& AG of India and Internal Audit by the Principal Accounts Office of the DST), whenever the organization is called upon to do so, as laid down under Rule 236(1) of General Financial Rules 2017.

12. Due acknowledgement of technical support / financial assistance resulting from this project grant should mandatorily be highlighted by the grantee organization in bold letters in all publications / media releases as well as in the opening paragraphs of their Annual Reports during and after the completion of the project.

13. Failure to comply with the terms and conditions of the Bond will entail full refund with interest in terms of Rule 231 (2) of GFR 2017.

14. The expenditure involved is debit to Demand No.84 Department of Science & Technology for the year 2018-19:

3425 Other Scientific Research (Major Head)
60 Others (Sub-Major Head)
60.200 Assistance to other Scientific Bodies (Minor Head)
68 Science and Technology Institutional and Human Capacity Building (Sub Head)
01 Disha Programme for Women in Science
68.01.31 **Grants-in-aid General for the year 2018-2019 (Voted)**
(Previous Disha Programme for Women in Science 3425.60.200.55.01.31)


15. The amount of **Rs. 10,76,000/-** (Rupees Ten Lakh Seventy Six Thousand only) will be drawn by the Drawing and Disbursing Officer DST and will be disbursed to The **Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra**. The bank details for electronic transfer of funds through RTGS are given below -

Institute name	: Interactive Research School for Health Affairs (IRSHA), Pune
Bank Name	: State Bank of India
Account No	: 30808434608
Branch	: Katraj, Near Bharati Vidyapeeth, Pune
IFSC code	: SBIN008752

16. Unique Id of the Organization under NGO DARPAN Portal is **MH/2017/0153828**.


17. As per Rule 234 of GFR 2017, this sanction has been entered at S. No. 262 in the register of grants maintained in the KIRAN Division for scheme (KIRAN: WOS-A).

18. This issues with the concurrence of IFD Vide their Concurrence Dy No/1486/2018-19 dated 28.07.2018


(Vandana Singh)
Scientist-E

Copy for information and necessary action to:-

1. The Director of Audit (CW & M-II), AGCR Building, IP Estate, New Delhi-110 002.
2. Copy with two spare copies of the sanction to the Drawing & Disbursing Officer, DST, Cash Section.
3. The Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra.
4. Dr. Ruchika Kau-Ghanekar, Associate Prof. and Head, Cancer Lab, Interactive Research School for Health Affairs (IRSHA), Pune-Satara Road, Katraj-Dhankawadi, Pune-411043, Maharashtra.
5. Dr. Ashwini Laxman Kamble, Cancer Lab, Interactive Research School for Health Affairs (IRSHA), Pune-Satara Road, Katraj-Dhankawadi, Pune-411043, Maharashtra.
6. Pay & Accounts Officer, DST, New Delhi.
7. IFD, DST, New Delhi.
8. Sanction Folder


(Vandana Singh)
Scientist-E

No. SR/WOS-A/LS-205/2017
Government of India
Ministry of Science & Technology
Department of Science & Technology
(KIRAN DIVISION)

Technology Bhawan
New Mehrauli Road
New Delhi-110016
Dated- 16/06/2020

ORDER

Sub: Financial approval of the project under Women Scientist Scheme A (WOS-A) entitled "*Comparing vaginal microflora diversity between healthy and cervical cancer women for identifying isolates having probiotic and anticancer potential*" under the guidance of Dr. Ashwini Laxman Kamble, Cancer Lab, Interactive Research School for Health Affairs (IRSHA), Pune-Satara Road, Katraj-Dhankawadi, Pune-411043, Maharashtra.

In continuation of this Department's sanction letter of even number dated 06.09.2018, sanction of the President is hereby accorded to the payment of **Rs.10,55,000/-** (Rupees Ten Lakh Fifty Five Thousand only) as Second installment to the **Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra** for implementation of the said project during the current financial year.

2. Sanction of the President is also hereby accorded to carry forward the remaining unspent balance of **Rs. 138/-** from the financial year 2018-19 to 2019-20 for utilization for the same purpose for which it was sanctioned.
3. The revised fellowship (w.e.f. 01.04.2019) of PI shall be released from the sanctioned budget under fellowship head.
4. This sanction is subject to the condition that the grantee organisation will furnish to the Department of Science & technology, financial year wise Utilization Certificate (UC) in the proforma prescribed as per GFR 2017 and audited statement of expenditure (SE) along with up to date progress report at the end of each financial year duly reflecting the interest earned / accrued on the grants received under the project. This is also subject to the condition of submission of the final statement of expenditure, utilization certificate and project completion report within one year from the scheduled date of completion of the project.
5. The grantee organisation will have to enter & upload the Utilization Certificate in the PFMS portal besides sending it in physical form to this Division. The subsequent/final installment will be released only after confirmation of the acceptance of the UC by the Division and entry of previous Utilization Certificate in the PFMS.
6. The Grantee Institute (GI) will maintain separate audited as per GFR 2017 Rule 230 (8) account for the project and the entire amount of grant will be kept in an interest bearing bank account. For Grants released during FY 2020-21 and onwards interest and other earnings, against released Grant shall be remitted to Consolidated Fund of India, immediately after finalization of accounts, as it shall not be adjusted towards future release of Grant. A certificate to this effect shall have to be submitted along with statement of expenditure/utilization certificate for considering subsequent release of grant/closure of project accounts. GI should also follow Rule 230(17) of GFR 2017 concerning to reservation of SC/ST/OBC, if applicable.
7. DST reserves sole rights on the assets created out of grants. Assets acquired wholly or substantially out of government grants (except those declared as obsolete and unserviceable or condemned in accordance with the procedure laid down in GFR 2017), shall not be disposed of without obtaining the prior approval of DST.
8. Principal investigator under Women Scientist Scheme is not permitted to withdraw any emoluments/ salary/fellowship from any other project either supported by DST or by any other funding agency.
9. The account of the grantee organisation shall be open to inspection by the sanctioning authority and audit (both by C& AG of India and Internal Audit by the Principal Accounts Office of the DST), whenever the organisation is called upon to do so, as laid down under Rule 236(1) of General Financial Rules 2017.
10. Due acknowledgement of technical support / financial assistance resulting from this project grant should mandatorily be highlighted by the grantee organisation in bold letters in all publications / media releases as well as in the opening paragraphs of their Annual Reports during and after the completion of the project.
11. Principal Investigator (PI) is directed to acknowledge "research grant" in all publications emerging out of this particular project. For example, "author acknowledge Department of Science & Technology, Government of India for financial support vide reference no.....under Women Scientist Scheme to carry out this work". Also she is advised to be either 'first' or 'corresponding' author in all publications.

Contd..p/-

12. The expenditure involved is debitable to Demand No.87, Department of Science & Technology for the year 2020-21:

3425 Other Scientific Research (Major Head)
60 Others (Sub-Major Head)
60.200 Assistance to other Scientific Bodies (Minor Head)
68 Science and Technology Institutional and Human Capacity Building (Sub Head)
01 Disha Programme for Women in Science
68.01.31 Grants-in-aid General for the year 2020-21 (Voted)
(Previous: Disha Programme for Women in Science 3425.60.200.55.01.31)

13. The amount of Rs.10,55,000/- (Rupees Ten Lakh Fifty Five Thousand only) will be drawn by the Drawing and Disbursing Officer, DST and will be disbursed to the Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra. The bank details for electronic transfer of funds through RTGS are given below:


Institute name : Interactive Research School for Health Affairs (IRSHA)
Bank Name : State Bank of India
Account Number : 30808434608
Branch : Katraj, Near Bharati Vidyapeeth, Pune
IFSC code : SBIN0008752

14. Host Institute is registered under NGO Darpan Portal & unique ID-MH/2017/0153828.

15. Goods (consumables/equipment) available in GeM portal are to be procured mandatorily online through Gem only.


16. As per Rule 234 of GFR 2017, this sanction has been entered at S. No. 98 in the register of grants maintained in the Division for scheme (KIRAN: WOS-A).

17. This issues with the concurrence of IFD Vide their Concurrence Dy.No.C/699/IFD/2020-21 dated. 16/06/2020


(Vandana Singh)
Scientist-E

Copy forwarded for information and necessary action to:-

1. The Director of Audit (CW & M-II), AGCR Building, IP Estate, New Delhi-110 002.
2. Copy with two spare copies of the sanction to the Drawing & Disbursing Officer, DST, Cash Section.
3. The Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra.
4. Dr. Ashwini Laxman Kamble, Cancer Lab, Interactive Research School for Health Affairs (IRSHA), Pune-Satara Road, Katraj-Dhankawadi, Pune-411043, Maharashtra.
5. Pay & Accounts Officer, DST, New Delhi
6. IFD, DST, New Delhi.
7. Sanction Folder.


(Vandana Singh)
Scientist-E

No. SR/WOS-A/LS-205/2017
Government of India
Ministry of Science & Technology
Department of Science & Technology
(WISE-KIRAN DIVISION)

Technology Bhawan
New Mehrauli Road
New Delhi-110016
Dated 18.06.2021

ORDER

Sub: Financial approval of the project under Women Scientist Scheme A (WOS-A) entitled "*Comparing vaginal microflora diversity between healthy and cervical cancer women for identifying isolates having probiotic and anticancer potential*" under the guidance of Dr. Ashwini Laxman Kamble, Cancer Lab, Interactive Research School for Health Affairs (IRSHA), Pune-Satara Road, Katraj-Dhankawadi, Pune-411043, Maharashtra

In continuation of this Department's sanction letter of even number dated 06.09.2018, sanction of the President is hereby accorded to the payment of Rs. 10,00,000/- (Rupees Ten Lakh only) as Third installment to the Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra for implementation of the said project during the current financial year.

2. Sanction of the President is also hereby accorded to carry forward the remaining unspent balance of Rs. 401/- from the financial year 2020-21 to 2021-22 for utilization for the same purpose for which it was sanctioned.

3. This sanction is subject to the condition that the grantee organisation will furnish to the Department of Science & Technology, financial year wise Utilization Certificate (UC) in the proforma prescribed as per GFR 2017 and audited statement of expenditure (SE) along with up to date progress report at the end of each financial year duly reflecting the interest earned / accrued on the grants received under the project. This is also subject to the condition of submission of the final statement of expenditure, utilization certificate and project completion report within one year from the scheduled date of completion of the project.

4. The grantee organisation will have to enter & upload the Utilization Certificate in the PFMS portal besides sending it in physical form to this Division. The subsequent/final installment will be released only after confirmation of the acceptance of the UC by the Division and entry of previous Utilization Certificate in the PFMS.

5. The Grantee Institute (GI) will maintain separate audited as per GFR 2017 Rule 230 (8) account for the project and the entire amount of grant will be kept in an interest bearing bank account. For Grants released during F/Y 2021-22 and onwards interest and other earnings, against released Grant shall be remitted to Consolidated Fund of India, immediately after finalization of accounts, as it shall not be adjusted towards future release of Grant. A certificate to this effect shall have to be submitted along with statement of expenditure/utilization certificate for considering subsequent release of grant/closure of project accounts. GI should also follow Rule 230(17) of GFR 2017 concerning to reservation of SC/ST/OBC, if applicable.

6. DST reserves sole rights on the assets created out of grants. Assets acquired wholly or substantially out of government grants (except those declared as obsolete and unserviceable or condemned in accordance with the procedure laid down in GFR 2017), shall not be disposed of without obtaining the prior approval of DST.

7. Principal investigator under Women Scientist Scheme is not permitted to withdraw any emoluments/salary/fellowship from any other project either supported by DST or by any other funding agency.

8. The account of the grantee organisation shall be open to inspection by the sanctioning authority and audit (both by C & AG of India and Internal Audit by the Principal Accounts Office of the DST) whenever the organisation is called upon to do so, as laid down under Rule 236(1) of General Financial Rules 2017.

9. Due acknowledgement of technical support / financial assistance resulting from this project grant should mandatorily be highlighted by the grantee organisation in bold letters in all publications / media releases as well as in the opening paragraphs of their Annual Reports during and after the completion of the project.

10. Principal Investigator (PI) is directed to acknowledge "research grant" in all publications emerging out of this particular project. For example, "author acknowledge Department of Science & Technology, Government of India for financial support vide reference no. under Women Scientist Scheme to carry out this work". Also she is advised to be either 'first' or 'corresponding' author in all publications.

Contd. p/-

Keep this doc in DST WOS-A file. ① 3rd year sanctioned letter ② UC

11. The expenditure involved is debitable to Demand No.88, Department of Science & Technology for the year 2021-22

3425 Other Scientific Research (Major Head)
60 Others (Sub-Major Head)
60.200 Assistance to other Scientific Bodies (Minor Head)
68 Science and Technology Institutional and Human Capacity Building (Sub Head)
01 Disha Programme for Women in Science
68.01.31 Grants-in-aid General for the year 2021-22 (Voted)
(Previous: Disha Programme for Women in Science 3425 60.200.55.01.31)

12. The amount of Rs. 10,00,000/- (Rupees Ten Lakh only) will be drawn by the Drawing and Disbursing Officer, DST and will be disbursed to the Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra. The bank details for electronic transfer of funds through RTGS are given below:

Institute Name : Interactive Research School for Health Affairs (IRSHA)
Bank Name : State Bank of India
Account Number : 30808434608
Branch : Katraj, Near Bharati Vidyapeeth, Pune
IFSC Code : SBIN0008752


13. Host Institute is registered under NGO Darpan Portal & unique ID-MH/2017/0153828.

14. Goods (consumables/equipment) available in GeM portal are to be procured mandatorily online through Gem only

15. The project continuation beyond 31.03.2021 will be subject to appraisal and approval of the continuation of the Schemes under which these project are funded as approved by DoE vide OM No. 42(02)/PF-II/2014 dated 06.08.2020.


16. As per Rule 234 of GFR 2017, this sanction has been entered at S. No. 103 in the register of grants maintained in the Division for scheme (WISE-KIRAN: WOS-A).

17. This issues with the concurrence of IFD Vide their Concurrence Dy.No C/588/IFD/2021-22 dated 17.06.2021


(Vandana Singh)
Scientist-E

Copy forwarded for information and necessary action to -

1. The Director of Audit (CW & M-II), AGCR Building, IP Estate, New Delhi-110 002
2. Copy with two spare copies of the sanction to the Drawing & Disbursing Officer, DST, Cash Section
3. The Director, Interactive Research School for Health Affairs (IRSHA), Pune-411043, Maharashtra
4. Dr. Ashwini Laxman Kamble, Cancer Lab, Interactive Research School for Health Affairs (IRSHA), Pune-Satara Road, Katraj-Dhankawadi, Pune-411043, Maharashtra.
5. Pay & Accounts Officer, DST, New Delhi
6. IFD, DST, New Delhi.
7. Sanction Folder.


(Vandana Singh)
Scientist-E

DST/SATYAM/2017/85
Government of India
Ministry of Science & Technology
Department of Science & Technology
(KIRAN DIVISION)

Technology Bhawan
New Mehrauli Road
New Delhi-110016
Dated-16.12.2020

ORDER

Sub: Financial approval of the project under Science and Technology of Yoga and Meditation (SATYAM) entitled "***Effect of yoga intervention on skeletal muscle linked glucose homeostasis in pre-dibetic individuals***" under the guidance of Dr. Supriya Bhalerao, Associate Professor, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India.

In continuation of this Department's sanction letter of even number dated 06.03.2019, sanction of the President is hereby accorded to the payment of **Rs. 13,00,000/-** (Rupees Thirteen Lakh only) as Second installment to the **Director, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India** for implementation of the said project during the current financial year.

2. Sanction of the President is also hereby accorded to carry forward the remaining unspent balance of **Rs. 2,24,317/-** from the financial year 2019-20 to 2020-21 for utilization for the same purpose for which it was sanctioned.

3. The revised fellowship/HRA (w.e.f. 01.01.2019) of manpower recruited shall be released from the sanctioned budget under manpower head.

4. This sanction is subject to the condition that the grantee organisation will furnish to the Department of Science & technology, financial year wise Utilization Certificate (UC) in the proforma prescribed as per GFR 2017 and audited statement of expenditure (SE) along with up to date progress report at the end of each financial year duly reflecting the interest earned / accrued on the grants received under the project. This is also subject to the condition of submission of the final statement of expenditure, utilization certificate and project completion report within one year from the scheduled date of completion of the project.

5. The grantee organisation will have to enter & upload the Utilization Certificate in the PFMS portal besides sending it in physical form to this Division. The subsequent/final installment will be released only after confirmation of the acceptance of the UC by the Division and entry of previous Utilization Certificate in the PFMS.

6. The Grantee Institute (GI) will maintain separate audited as per GFR 2017 Rule 230 (8) account for the project and the entire amount of grant will be kept in an interest bearing bank account. For Grants released during F/Y 2020-21 and onwards interest and other earnings, against released Grant shall be remitted to Consolidated Fund of India, immediately after finalization of accounts, as it shall not be adjusted towards future release of Grant. A certificate to this effect shall have to be submitted along with statement of expenditure/utilization certificate for considering subsequent release of grant/closure of project accounts. GI should also follow Rule 230(17) of GFR 2017 concerning to reservation of SC/ST/OBC, if applicable.

7. DST reserves sole rights on the assets created out of grants. Assets acquired wholly or substantially out of government grants (except those declared as obsolete and unserviceable or condemned in accordance with the procedure laid down in GFR 2017), shall not be disposed of without obtaining the prior approval of DST.

8. Principal investigator under Women Scientist Scheme is not permitted to withdraw any emoluments/salary/fellowship from any other project either supported by DST or by any other funding agency.

9. The account of the grantee organisation shall be open to inspection by the sanctioning authority and audit (both by C & AG of India and Internal Audit by the Principal Accounts Office of the DST), whenever the organisation is called upon to do so, as laid down under Rule 236(1) of General Financial Rules 2017.

10. Due acknowledgement of technical support / financial assistance resulting from this project grant should mandatorily be highlighted by the grantee organisation in bold letters in all publications / media releases as well as in the opening paragraphs of their Annual Reports during and after the completion of the project.

11. Principal Investigator (PI) is directed to acknowledge "research grant" in all publications emerging out of this particular project. For example, "author acknowledge Department of Science & Technology, Government of India for financial support vide reference no.....under Women Scientist Scheme to carry out this work". Also she is advised to be either 'first' or 'corresponding' author in all publications.

12. The expenditure involved is debitable to Demand No.87, Department of Science & Technology for the year 2020-21:

3425	Other Scientific Research (Major Head)
60	Others (Sub-Major Head)
60.200	Assistance to other Scientific Bodies (Minor Head)
68	Science and Technology Institutional and Human Capacity Building (Sub Head)
04	Other Programmes
68.04.31	Grants-in-aid General for the year 2020-2021 (Voted)

This release is being made **Research & Development** Scheme.

(Previous: Research & Development Support 3425.60.200.25.01.31)

13. The amount of **Rs. 13,00,000/-** (Rupees Thirteen Lakh only) will be drawn by the Drawing and Disbursing Officer, DST and will be disbursed to the **Director, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India**. The bank details for electronic transfer of funds through RTGS are given below:

Institute Name: Bharati Vidyapeeth Deemed to be University, Pune
Bank Name: State Bank of India
Account No: 30808434608
Branch: Pune
IFSC Code: SBIN0008752
Unique Code: MH/2017/0153828

14. Goods (consumables/equipment) available in **GeM** portal are to be procured mandatorily online through Gem only and PI will also follow DoE's guidelines for incurring expenditure under the different sub-head.

15. As per Rule 234 of GFR 2017, this sanction has been entered at S. No. **62** in the register of grants maintained in the **Research & Development**.

16. This issues with the concurrence of IFD Vide their Concurrence Dy.No.C/**3762**/IFD/2020-21 dated 15.12.2020.

17. The project continuation beyond 31.03.2021 will be subject to appraisal and approval of the continuation of the Schemes under which these project are funded as approved by DoE vide OM No. 42(02)/PF-II/2014 dated 06.08.2020.



(Vandana Singh)
Scientist-E

Copy forwarded for information and necessary action to:-

1. The Director of Audit (CW & M-II), AGCR Building, IP Estate, New Delhi-110 002.
2. Copy with two spare copies of the sanction to the Drawing & Disbursing Officer, DST, Cash Section.
3. The Director, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India.
4. Dr. Supriya Bhalerao, Associate Professor, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India.
5. Pay & Accounts Officer, DST, New Delhi.
6. IFD, DST, New Delhi.
7. Sanction Folder.



(Vandana Singh)
Scientist-E

DST/SATYAM/2017/85
Government of India
Ministry of Science & Technology
Department of Science & Technology
(KIRAN DIVISION)

Technology Bhawan
New Mehrauli Road
New Delhi-110016
Dated-16.12.2020

ORDER

Sub: Financial approval of the project under Science and Technology of Yoga and Meditation (SATYAM) entitled "***Effect of yoga intervention on skeletal muscle linked glucose homeostasis in pre-dibetic individuals***" under the guidance of Dr. Supriya Bhalerao, Associate Professor, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India.

In continuation of this Department's sanction letter of even number dated 06.03.2019, sanction of the President is hereby accorded to the payment of **Rs. 13,00,000/-** (Rupees Thirteen Lakh only) as Second installment to the **Director, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India** for implementation of the said project during the current financial year.

2. Sanction of the President is also hereby accorded to carry forward the remaining unspent balance of **Rs. 2,24,317/-** from the financial year 2019-20 to 2020-21 for utilization for the same purpose for which it was sanctioned.

3. The revised fellowship/HRA (w.e.f. 01.01.2019) of manpower recruited shall be released from the sanctioned budget under manpower head.

4. This sanction is subject to the condition that the grantee organisation will furnish to the Department of Science & technology, financial year wise Utilization Certificate (UC) in the proforma prescribed as per GFR 2017 and audited statement of expenditure (SE) along with up to date progress report at the end of each financial year duly reflecting the interest earned / accrued on the grants received under the project. This is also subject to the condition of submission of the final statement of expenditure, utilization certificate and project completion report within one year from the scheduled date of completion of the project.

5. The grantee organisation will have to enter & upload the Utilization Certificate in the PFMS portal besides sending it in physical form to this Division. The subsequent/final installment will be released only after confirmation of the acceptance of the UC by the Division and entry of previous Utilization Certificate in the PFMS.

6. The Grantee Institute (GI) will maintain separate audited as per GFR 2017 Rule 230 (8) account for the project and the entire amount of grant will be kept in an interest bearing bank account. For Grants released during F/Y 2020-21 and onwards interest and other earnings, against released Grant shall be remitted to Consolidated Fund of India, immediately after finalization of accounts, as it shall not be adjusted towards future release of Grant. A certificate to this effect shall have to be submitted along with statement of expenditure/utilization certificate for considering subsequent release of grant/closure of project accounts. GI should also follow Rule 230(17) of GFR 2017 concerning to reservation of SC/ST/OBC, if applicable.

7. DST reserves sole rights on the assets created out of grants. Assets acquired wholly or substantially out of government grants (except those declared as obsolete and unserviceable or condemned in accordance with the procedure laid down in GFR 2017), shall not be disposed of without obtaining the prior approval of DST.

8. Principal investigator under Women Scientist Scheme is not permitted to withdraw any emoluments/salary/fellowship from any other project either supported by DST or by any other funding agency.

9. The account of the grantee organisation shall be open to inspection by the sanctioning authority and audit (both by C & AG of India and Internal Audit by the Principal Accounts Office of the DST), whenever the organisation is called upon to do so, as laid down under Rule 236(1) of General Financial Rules 2017.

10. Due acknowledgement of technical support / financial assistance resulting from this project grant should mandatorily be highlighted by the grantee organisation in bold letters in all publications / media releases as well as in the opening paragraphs of their Annual Reports during and after the completion of the project.

11. Principal Investigator (PI) is directed to acknowledge "research grant" in all publications emerging out of this particular project. For example, "author acknowledge Department of Science & Technology, Government of India for financial support vide reference no.....under Women Scientist Scheme to carry out this work". Also she is advised to be either 'first' or 'corresponding' author in all publications.

12. The expenditure involved is debit to Demand No.87, Department of Science & Technology for the year 2020-21:

3425	Other Scientific Research (Major Head)
60	Others (Sub-Major Head)
60.200	Assistance to other Scientific Bodies (Minor Head)
68	Science and Technology Institutional and Human Capacity Building (Sub Head)
04	Other Programmes
68.04.31	Grants-in-aid General for the year 2020-2021 (Voted)

This release is being made **Research & Development** Scheme.

(Previous: Research & Development Support 3425.60.200.25.01.31)

13. The amount of **Rs. 13,00,000/-** (Rupees Thirteen Lakh only) will be drawn by the Drawing and Disbursing Officer, DST and will be disbursed to the **Director, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India**. The bank details for electronic transfer of funds through RTGS are given below:

Institute Name: Bharati Vidyapeeth Deemed to be University, Pune
Bank Name: State Bank of India
Account No: 30808434608
Branch: Pune
IFSC Code: SBIN0008752
Unique Code: MH/2017/0153828

14. Goods (consumables/equipment) available in **GeM** portal are to be procured mandatorily online through Gem only and PI will also follow DoE's guidelines for incurring expenditure under the different sub-head.

15. As per Rule 234 of GFR 2017, this sanction has been entered at S. No. **62** in the register of grants maintained in the **Research & Development**.

16. This issues with the concurrence of IFD Vide their Concurrence Dy.No.C/**3762**/IFD/2020-21 dated 15.12.2020.

17. The project continuation beyond 31.03.2021 will be subject to appraisal and approval of the continuation of the Schemes under which these project are funded as approved by DoE vide OM No. 42(02)/PF-II/2014 dated 06.08.2020.



(Vandana Singh)
Scientist-E

Copy forwarded for information and necessary action to:-

1. The Director of Audit (CW & M-II), AGCR Building, IP Estate, New Delhi-110 002.
2. Copy with two spare copies of the sanction to the Drawing & Disbursing Officer, DST, Cash Section.
3. The Director, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India.
4. Dr. Supriya Bhalerao, Associate Professor, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed to be University, Pune-411043, Maharashtra, India.
5. Pay & Accounts Officer, DST, New Delhi.
6. IFD, DST, New Delhi.
7. Sanction Folder.



(Vandana Singh)
Scientist-E

2020-21 All Release

Details of Approved RE 2020-21 and remittances made to your Bank A/c through RTGS/PFMS during 2020-21

**HEAD WISE BREAK-UP OF GRANTS FOR 2020-21
(ICAR SHARE ONLY)**

Sl. No	Name of the Centre	RE for 2020-21	P & A	T A	RC	Total	Date of remittance made through RTGS/NEFT
1	AICRP on Linseed, Pune	Approved grants as per RE	13,13,500	12,600	2,40,300	15,66,400	
2	Closing Balance of AUC for 2019-20 as per SAU		12,31,256	--	--	12,31,256	
3	I Inst of Grants released		2,98,200	3,500	42,000	3,43,700	08.06.2020
4	II Inst of Grants released		2,00,000	--	30,000	2,30,000	24.08.2020
5	III Inst of Grants released		2,23,700	--	46,500	2,70,200	01.10.2020
6	IV Inst of Grants released		--	9,100	32,400	41,500	28.11.2020
7	V Inst of Grants released		--	--	89,400	89,400	11.02.2021
8	VI Inst of Grants released		3,99,800	--	--	3,99,800	24.02.2021
9	VII Inst of Grants released		1,91,800	--	--	1,91,800	20.03.2021
	TOTAL GRANTS RELEASED FOR 2020-21		13,13,500	12,600	2,40,300	15,66,400	

NOTE: Regarding the details for release of funds under AICRP on Linseed, please visit IIOR website <http://www.iior-icar.org.in>

May please submit the UC/AUC and S.O.E. Head-Wise along with 1st Half Demand in the prescribed proforma latest by 30/04/2021.

Yours faithfully,


FINANCE & ACCOUNTS OFFICER

Copy to:

1. The Assistant Director General (O&P), ICAR, Krishi Bhawan, New Delhi – 110 001.
2. Project Incharge, Linseed Value Addition Center, BVDU, IRSHA, Dhankawadi, Pune – 411 046.
3. Dr. P.Ratna Kumar, I/C AICRP on Linseed, IIOR, Hyderabad.
4. AUC File.



भारत अनुप- भारतीय तिलहन अनुसंधान संस्थान
ICAR-Indian Institute of Oilseeds Research

राजेंद्रनगर, हैदराबाद-500 030, तेलंगाना राज्य, भारत
Rajendranagar, Hyderabad-500 030, Telangana State, India

Fax: + 91-040-24017969 Web: <http://www.icar-iior.org.in>

ISO 9001:2008 Certified Institute



F.No.10-3/AICRP/Rel-Lin/BVDU/17-18

1544
REGD-POST

Dt. 28.04.2018

To
Register & Finance Officer,
BVDU (CINH), IRSHA,
Medical College Campus, Pune-Satara Road,
Pune -411043

Sub: Release of grants in instalments in respect of AICRP on Linseed at Pune, BVDU, Pune for the year 2017-18 – Regarding.

Ref: 1) F.No.1 (1)/2018-Budget, dated. 6th February, 2018 from ICAR. – regarding revised RE for 2017-18.

Sir,

As per RE 2017-18 communicated vide ICAR letter referred above, the AICRP centre on Linseed at Pune - BVDU is provided with approved budgetary grant of Rs.14.35 lakhs (ICAR Share only) for the year 2017-18 as per the break-up given sub-head wise on Page-2. Releases are made on monthly basis taking into consideration of the available plus/minus closing balance of AUC with the centre as on 31.03.17. **Remittance of Rs.14,35,000/- has already been made directly to your Bank Account No.051110100014432 (BKID) at Pune, through RTGS/PFMS and remittance details are placed in IIOR website for ready reference. The releases made are subject to the following terms and conditions:**

1. The project will continue as per sanctions made in SFC 2017-20.
2. The expenditure during 2017-18 may be restricted to the ceiling indicated under each sub-head including additional allocations under Pay & Allowances in the above statement of costs.
3. **The requisite UC/AUC be submitted to this office on or before 30-05-2018, strictly as per the format already circulated. Otherwise release of funds for the year 2018-19 cannot be processed.**

Contd....2

Details of Approved RE 2017-18 and remittances made to your Bank A/c through RTGS/PFMS during 2017-18


**HEAD WISE BREAK-UP OF GRANTS FOR 2017-18
(ICAR SHARE ONLY)**

Sl. No	Name of the Centre	RE for 2017-18	P & A	T A	RC	Total	Date of remittance made through RTGS/NEFT
1	AICRP on Linseed, Pune	Approved grants as per RE	13,30,000	30,000	75,000	14,35,000	
2	Closing Balance of AUC for 2016-17 as per SAU		3,00,837	--	--	3,00,837	
3	I Inst of Grants released		1,60,000	--	--	1,60,000	22.06.2017
4	II Inst of Grants released		85,830	--	--	85,830	16.08.2017
5	III Inst of Grants released		6,74,170	--	--	6,74,170	29.09.2017
6	IV Inst of Grants released		3,10,000	--	--	3,10,000	13.11.2017
7	V Inst of Grants released		1,00,000	--	25,000	1,25,000	03.03.2018
8	VI Inst of Grants released		--	30,000	50,000	80,000	28.03.2018
	TOTAL GRANTS RELEASED FOR 2017-18		13,30,000	30,000	75,000	14,35,000	

NOTE: Regarding the details for release of funds under AICRP on Linseed, please visit IIOR website <http://www.iior-icar.org.in>

May please submit the UC/AUC along with 1st Half Demand in the prescribed proforma latest by 30/05/2018.

Yours faithfully,


FINANCE & ACCOUNTS OFFICER

Finance & Accounts Officer
भाकूअनुप-भारतीय तिलहन अनुसंधान संस्थान
ICAR-Indian Institute of Oilseeds Research
राजेन्द्रनगर/Rajendranagar, हैदराबाद/Hyderabad-30.(TS)

Copy to:

1. The Assistant Director General (O&P), ICAR, Krishi Bhawan, New Delhi – 110 001.
2. Incharge, Linseed Value Addition Centre, BVDU, IRSHA, Dhankawadi, Pune – 411046.
3. AUC File.

FINANCE & ACCOUNTS OFFICER
वित्त एवं लेखा अधिकारी

Finance & Accounts Officer
भाकूअनुप-भारतीय तिलहन अनुसंधान संस्थान
ICAR-Indian Institute of Oilseeds Research
राजेन्द्रनगर/Rajendranagar, हैदराबाद/Hyderabad-30.(TS)



भाकृअनुप- भारतीय तिलहन अनुसंधान संस्थान
ICAR-Indian Institute of Oilseeds Research

राजेंद्रनगर, हैदराबाद-500 030, तेलंगाना राज्य, भारत
Rajendranagar, Hyderabad-500 030, Telangana State, India
Fax: +91-040-24017969 Web: <http://www.icar-iior.org.in>
ISO 9001:2008 Certified Institute



F.No.10-3/AICRP/Rel-Lin/BVDU/18-19

Dt. 15.05.2019

REGD-POST

To
✓ Registrar & Finance Officer,
BVDU (CINHD), IRSHA,
Medical College Campus,
Pune - Satara Road,
Pune - 411041.

Sub: Release of grants in respect of AICRP on Linseed at Pune, BVDU, Pune for the year 2018-19 – Regarding.

Ref: 1) Communicated vide E-mail dated 29th March, 2019, of Sri V. K. Sharma, Deputy Secretary (CS), ICAR, New Delhi – regarding revised RE for 2018-19.

Sir,

As per RE 2018-19 communicated vide ICAR letters referred above, the AICRP center on Linseed at Pune - BVDU is provided with approved budgetary grant of **Rs.28.47 lakhs** (ICAR Share only) for the year 2018-19 as per the break-up given sub-head wise on Page-2. Releases are made on monthly basis taking into consideration of the available plus/minus closing balance of AUC with the center as on 31.03.18. **Remittance of Rs.28,47,500/- has already been made directly to your Bank Account No.051110100014432 (BKID) at Pune, through RTGS/PFMS** and remittance details are placed in IIOR website for ready reference. The releases made are subject to the following terms and conditions:

1. The project will continue as per sanctions made in SFC 2017-20.
2. The expenditure during 2018-19 may be restricted to the ceiling indicated under each sub-head including additional allocations under TA & RC as shown in the above statement of costs.
3. **The requisite UC/AUC be submitted to this office on or before 31-05-2019, strictly as per the format already circulated. Otherwise release of funds for the year 2019-20 cannot be processed.**

{ 2 }

Details of Approved RE 2018-19 and remittances made to your Bank A/c through RTGS/NEFT during 2018-19


**HEAD WISE BREAK-UP OF GRANTS FOR 2018-19
(ICAR SHARE ONLY)**

Sl. No	Name of the Centre	RE for 2018-19	P & A	T A	RC	Total	Date of remittance made through RTGS/NEFT
1	AICRP on Linseed, Pune	Approved grants as per RE	25,00,000	70,000	2,77,500	28,47,500	
2	Closing Balance of AUC for 2017-18 as per SAU		3,77,430	--	--	3,77,430	
3	I Inst of Grants released		5,00,000	18,750	50,000	5,68,750	11.07.18
4	II Inst of Grants released		5,00,000	18,750	50,000	5,68,750	31.08.18
5	III Inst of Grants released		6,66,600	7,500	1,02,500	7,76,600	09.11.18
6	IV Inst of Grants released		8,33,400	--	--	8,33,400	25.03.19
7	Additional grants released		--	25,000	75,000	1,00,000	28.03.19
	TOTAL GRANTS RELEASED FOR 2018-19		25,00,000	70,000	2,77,500	28,47,500	

NOTE: Regarding the details for release of funds under AICRP on Linseed, please visit IIOR website <http://www.iior-icar.org.in>

May please submit the UC/AUC along with 1st Half Demand in the prescribed proforma latest by 31/05/2019.

Yours faithfully,


FINANCE & ACCOUNTS OFFICER

वित्त एवं लेखा अधिकारी

Finance & Accounts Officer

भाकृअनुप-भारतीय तिलहन अनुसंधान संस्थान
ICAR-Indian Institute of Oilseeds Research

राजेन्द्रनगर/Rajendranagar, हैदराबाद/Hyderabad-30.(TS)

Copy to:

1. The Assistant Director General (O&P), ICAR, Krishi Bhawan, New Delhi - 110001.
2. Incharge, Linseed Value Addition centre, BVDU, IRSHA, Dhankawadi, Pune - 411046.
3. AUC File.



भाकृअनुप-भारतीय तिलहन अनुसंधान संस्थान ICAR-Indian Institute of Oilseeds Research

राजेंद्रनगर, हैदराबाद-500 030, तेलंगाना राज्य, भारत
Rajendranagar, Hyderabad-500 030, Telangana State, India

Tel: +91-040-24017969 Web: <http://www.icar-iior.org.in>
Fax: +91-040-24017969



भारतीय
IICOR

ISO 9001:2008 Certified Institute
AICRP ON LINSEED 2019 - 20

Sl. No.	CENTRE	Positions sanctioned	Allocation as per Final RE 2019-20						TOTAL	Total releases from Apr. 2019 to March 2020						TOTAL						
			PA	TA	R.C	NRC	TSP (Gen)	TSP (Cap)		PA	TA	R.C	NRC	TSP (Gen)	TSP (Cap)							
A	Linseed	0	454000	1300000				1754000	0	454000	1300000				0	454000	1300000				1754000	
1	IIPR, Kanpur	0							5666573	1980891	1490000	1460000	3000000	90000	3000000	0	1980891	1490000	1460000	3000000	90000	3211891
2	Nagpur, PDKV	3	3654585	1000000	4340000	75000	3000000	4653585	1866615	3654585	1000000	4340000	75000	3000000	3000000	3654585	1000000	4340000	75000	3000000	3000000	4653585
3	Sagar, JNKV	2	9151171	1980000	5950000	75000	3000000	10409171	1247229	9151171	1980000	5950000	75000	3000000	3000000	9151171	1980000	5950000	75000	3000000	3000000	10409171
4	Raipur, IGKVV	4	2722516	990000	4340000			3255516	2401684	2722516	990000	4340000			3000000	2722516	990000	4340000			3000000	3255516
5	Palampur, HPKV	2	301600	500000	2690000			620600	4026614	301600	500000	2690000			3000000	301600	500000	2690000			3000000	620600
6	Kota, AU	1	603200	1000000	4340000	1000000	3000000	1627200	4491221	603200	1000000	4340000	1000000	3000000	90000	603200	1000000	4340000	1000000	3000000	90000	1627200
7	Keonjhar, OUAT	2	5710980	1490000	5060000			6365980	2454820	5710980	1490000	5060000			3000000	5710980	1490000	5060000			3000000	6365980
8	Kanpur, CSAUA&T	3	2278355	1000000	4340000			2812355	4131845	2278355	1000000	4340000			3000000	2278355	1000000	4340000			3000000	2812355
9	Kanke, BAU	2	2891266	1490000	4460000			3486266	2847534	2891266	1490000	4460000			3000000	2891266	1490000	4460000			3000000	3486266
10	Mauranpur, BUA&T	3	3082428	1490000	4460000			3677428	2664372	3082428	1490000	4460000			3000000	3082428	1490000	4460000			3000000	3677428
11	Raichur, UAS	3	2828135	1490000	4460000			3423135	3235665	2828135	1490000	4460000			3000000	2828135	1490000	4460000			3000000	3423135
12	Bikramganj, BAU	3	933198	660000	1980000			1197198	1614402	933198	660000	1980000			3000000	933198	660000	1980000			3000000	1197198
13	Pune, BYDJ	1	36138325	1912000	6488000	3960000	1200000	46494325		36138325	1912000	6488000	3960000	1200000	3600000	36138325	1912000	6488000	3960000	1200000	3600000	46494325
B																						
14	Shillongani AAU(NEH)	2	4252100	700000	1800000	1040000	450000	7306100	-221586	4252100	700000	1800000	1040000	450000	0	4252100	700000	1800000	1040000	450000	0	7306100
15	Medsiphermita, NU(NEH)	2	1854575	724000	1776000		350000	4704575	644025	1854575	724000	1776000		350000	0	1854575	724000	1776000		350000	0	4704575
	TOTAL (B)	4	6106675	1424000	3576000	1040000	800000	12010675		6106675	1424000	3576000	1040000	800000	0	6106675	1424000	3576000	1040000	800000	0	12010675
	GRAND TOTAL (A + B)	33	42245000	3336000	10084000	5000000	2000000	58505000		42245000	3336000	10084000	5000000	2000000	3600000	42245000	3336000	10084000	5000000	2000000	3600000	58505000

The unspent balances available with the centers as on 01-04-2019, may be utilized during the current F Y. 2019-20

ICAR IICOR
FINANCE & ACCOUNTS OFFICER
Finance & Accounts Officer
भाकृअनुप-भारतीय तिलहन अनुसंधान संस्थान
ICAR-Indian Institute of Oilseeds Research
राजेंद्रनगर, हैदराबाद, तेलंगाना-500030



Anand Zanwar <anandzanwar10@gmail.com>

SERB-Notification

1 message

SERB_Administrator@serbonline.in <SERB_Administrator@serbonline.in>

Thu, Mar 11, 2021 at 2:19

PM

To: serbinfo1@gmail.com



Science and Engineering Research Board

(Statutory Body Established Through an Act of Parliament : SERB Act 2008)
Department of Science and Technology, Government of India

FILE NO. ECR/2016/002024

SCIENCE & ENGINEERING RESEARCH BOARD(SERB)

(A statutory body of the Department of Science & Technology, Government of India)

5 & 5A, Lower Ground Floor
Vasant Square Mall
Plot No. A, Community Centre
Sector-B, Pocket-5, Vasant Kunj
New Delhi-110070

Dated: 23-Feb-2021

ORDER

Subject: Financial Sanction of the research project titled "**Evaluation of efficacy of novel stabilized omega-3-fatty acid and antioxidants formulation for the prevention and treatment of metabolic syndrome**" under the guidance of Dr. Anand A Zanwar, Centre for Innovation in Nutrition Health Disease, Interactive Research School For Health Affairs, Bharati Vidyapeeth , Bharati vidyapeeth campus,Dhankawadi, pune, mh, Pune, Maharashtra-411043 - Release of final installment.

Sanction of **Science and Engineering Research Board (SERB)** is hereby accorded to the above mentioned project at a total cost of **Rs. 3846201/- (Rs. Thirty Eight Lakh Forty Six Thousand Two Hundred and One Only)** with break-up of **Rs. 1172634/- under Capital (Non-recurring) head** and **Rs.2673567/- under General (Recurring) head** for a duration of 39 months.

In continuation of the sanction order of even no dated "16 June, 2017 ". The sanction of **Science and Engineering Research Board (SERB)** is hereby accorded to the above mentioned project at a revised cost as defined below:

The following budget may be considered for **Bharati Vidyapeeth, Bharati Vidyapeeth Campus,Dhankawadi, Pune, MH**

S. No	Head	Total (in Rs.)

A	Non-recurring	
1	Equipment -> Clinical Chemistry Analyzer -> Deep Freezer (-80 degree) -> ELISA Microplate reader	1172634
A'	<i>Total (Non-Recurring)</i>	1172634
B	Recurring Items	
1	Recurring - I : (Manpower)	1141573
	Recurring - II : (Consumables, Travel, Contingencies)	1165021
	Recurring - III : Scientific Social Responsibility	0
2	Recurring - IV : (Overhead Charges)	366973
B'	<i>Total (Recurring)</i>	2673567
C	Total cost of the project (A' + B')	3846201

2. Sanction of the **SERB** is also accorded to the payment of **Rs. 353745/-** (Rupees Three Lakh Fifty Three Thousand Seven Hundred and Forty Five only) under 'Grants-in-aid General' to **Director CINHD-IRSHA, Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH** being the last and final installment of the grant for implementation of the said research project.

3. The expenditure involved is debitable to **Fund for Science & Engineering Research (FSER)**

This release is being made under Early Career Research Award. (EC Life Sciences)

4. The Sanction has been issued to Bharati Vidyapeeth, Bharati Vidyapeeth Campus, Dhankawadi, Pune, MH with the approval of the competent authority under delegated powers on **22 February, 2021** and vide Diary No. **SERB/F/7761/2020-2021** dated **22 February, 2021**

5. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at website (www.serb.gov.in).

6. As per rule 211 of GFR, the accounts of project shall be open to inspection by sanctioning authority/audit whenever the institute is called upon to do so.

7. The sanctioned equipment would be procured as per GFR and its disposal of the same would be done with prior approval of SERB.

8. The release amount of **Rs. 353745/-** (Rupees Three Lakh Fifty Three Thousand Seven Hundred and Forty Five only) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

PFMS Unique Code	BVU
Account Name	Bharati Vidyapeeth Deemed to be University
Account Number	3265101003833
Bank Name & Branch	Canara Bank Sr. No. 29, Plot no. 47, Omkar Chambers, Near Foot Bridge, Satara Road, Dhankawadi, Pune - 411043, Maharashtra State.
IFSC/RTGS Code	CNRB0003265
Email id of A/C Holder	bvdufinance@gmail.com
Email id of PI	anandzanwar10@gmail.com

9. The institute will furnish to the SERB, separate Utilization certificate(UCs) to the SERB for Recurring (Grants-in-aid General) & Non-Recurring (Grants for creation of capital assets) and an audited statement of accounts pertaining to the grant immediately after the receipt of the grant.

10. The institute will maintain separate audited accounts for the project.

11. The project File no. ECR/2016/002024 may also be mentioned in all research communications arising from the above project with due acknowledgement of SERB.

12. The manpower sanctioned in the project, if any is co-terminus with the duration of the project and SERB will have no liability to meet the fellowship and salary of supporting staff if any. beyond the duration of the project.

13. The institute may refund any unspent balance to SERB by means of a Demand Draft favoring "FUND FOR SCIENCE AND ENGINEERING RESEARCH" payable at New Delhi.

14. The organization/institute/university should ensure that the technical support/financial assistance provided to them by the Science & Engineering Research Board should invariably be highlighted/ acknowledged in their media releases as well as in bold letters in the opening paragraphs of their Annual Report.

15. In addition, the investigator/host institute must also acknowledge the support provided to them in all publications, patents and any other output emanating out of the project/program funded by the Science & Engineering Research Board.

(Dr. Thangaradjou T)

Scientist E

msls@serb.gov.in

To,

Under Secretary

SERB, New Delhi

Copy forwarded for information and necessary action to: -

1.	The Principal Director of Audit, A.G.C.R.Building, IIIrd Floor I.P. Estate, Delhi-110002
2.	Sanction Folder, SERB , New Delhi.
3.	File Copy
4.	<p>Dr. Anand A Zanwar Centre for Innovation in Nutrition Health Disease, Interactive Research School For Health Affairs Bharati Vidyapeeth , Bharati vidyapeeth campus,Dhankawadi, pune, mh, Pune, Maharashtra-411043 Email: anandzanwar10@gmail.com Mobile: 918379915982</p> <p>(Start date of the project may be intimated by name to the undersigned. For guidance, terms & Conditions etc. Please visit www.serb.gov.in.)</p>
5.	<p>Director CINHD-IRSHA, Bharati Vidyapeeth, Bharati Vidyapeeth Campus,Dhankawadi, Pune, MH</p> <p>(Receipt of Grant may be intimated by name to the undersigned)</p>

(Dr. Thangaradjou T)

Scientist E

msls@serb.gov.in

***** LEGAL DISCLAIMER *****

Please do not reply to this mail !![SERB is now on Social-Media. Kindly follow us on Twitter: @serbonline <https://www.twitter.com/serbonline>]

This is a system generated information and does not require any signature. This E-Mail may contain Confidential and/or legally privileged Information and is meant for the intended recipient(s) only. If you have received this e-mail in error and are not the intended recipient/s, kindly notify us at info@serbonline.in and then delete this e-mail immediately from your system. Any unauthorized review, use, disclosure, dissemination, forwarding, printing or

copying of this email or any action taken in reliance on this e-mail is strictly prohibited and may be unlawful. Internet communications cannot be guaranteed to be timely,secure, error or virus-free. The sender does not accept any liability for any errors, omissions, viruses or computer problems experienced by any recipient as a result of this e-mail.

'SAVE PAPER - THINK BEFORE YOU PRINT!'

* Don't want to receive such notification anymore?[Click here to send a mail to unsubscribe](#)

1.BVDU IMED,PUNE-MBA (2021-22)

ERANDWANE PUNE

IMPRESS GRANTS

Group Summary

1-Apr-2019 to 31-Mar-2021

Page 1

	Opening Balance	Transactions		Closing Balance
		Debit	Credit	
CONTINGENCY (IMPRESS)		17,830.00	17,830.00	
EQUIPMENT & STUDY MATERAIL (IMPRESS)		82,800.00	82,800.00	
FIELDWORK (IMPRESS GRANT)		39,234.00	39,234.00	
RESEARCH STAFF(IMPRESS)		2,49,230.00	2,49,230.00	
Grand Total		3,89,094.00	3,89,094.00	



Indian Council of Social Science Research

(Ministry of Education)

JNU Institutional Area, Aruna Asaf Ali Marg

New Delhi - 110067

E-mail: impress201819@gmail.com

Website: www.icssr.org

Pushkar Pathak
Systems Analyst
IMPRESS
011-26741449

F.No. IMPRESS/P2511 /182/2018-19/ICSSR

The Registrar

Bharti Vidyapeeth,
Institute of Management & Entrepreneurship Development,
Pune, Maharashtra
Pune-411038

Dated: 22-06-2021

Subject: Research Project entitled **"Technology Addiction among Children & Youth - A Study of Related Behavioral Impact"**.

Dear Sir,

In continuation of the Council's letter of even number dated 20/03/2019 on the above subject, I am directed to convey that ICSSR has sanctioned the Grant-in-Aid bill for the payment of **Rs1,10,000** /- as the **third** installment for the research project mentioned above. This brings to the total amount released so far to **Rs. 495000/-** against the total sanctioned grant of **Rs.550000/-**.

A copy of the grant-in-aid bill for release of **Rs.1,10,000/-** as the **third** installment is enclosed. It is requested that the bill may be filled in and returned to the Council to enable us to release the grant.

The grant-in-aid is subject to all the conditions laid down in our letter referred above.

The expenditure on this account is debitable to the Budget Head Impress (Research Projects).



Yours faithfully,

Pathak

(For Member Secretary)

Copy to:

Dr. Keerti Gupta

Professor

Bharti Vidyapeeth,

Institute of Management & Entrepreneurship Development,

Pune, Maharashtra

Pune-411038

FA&CAO, ICSSR, New Delhi

Pathak

(For Member Secretary)

Handwritten notes in red ink:
- Inward No. 65
- Date: 5/7/2021
- File No. 182/2018-19/ICSSR
- "copy of the bill" (with arrow pointing to the stamp)
- "all documents to show me file" (with arrow pointing to the stamp)
- "copy of the bill" (with arrow pointing to the stamp)
- "5/7/21" (with arrow pointing to the date in the stamp)

ICSSR Project File

5/7/21

Handwritten signature/initials at the bottom left.



Indian Council of Social Science Research

(Ministry of Human Resource Development)

JNU Institutional Area, Aruna Asaf Ali Marg

New Delhi - 110067

E-mail: impress201819@gmail.com

Website: www.icssr.org

Pushkar Pathak
System Analyst
IMPRESS
Tel 011-26741459

F.No. IMPRESS/P2511 /182/2018-19/ICSSR

Dated: 26 /08 /2020

The Registrar

Institute of
Management &
Entrepreneurship
Development, Pune,
Maharashtra - 411038

Subject: Research Project entitled "**Technology Addiction among Children & Youth - A Study of Related Behavioral Impact**".

Dear Sir,

In continuation of the Council's letter of even number dated / /2019 on the above subject, I am directed to convey that ICSSR has sanctioned the Grant-in-Aid bill for the payment of **Rs165000 /-** as the **second** installment for the research project mentioned above. This brings to the total amount released so far to **Rs. 385000/-** against the total sanctioned grant of **Rs.550000/-**.

A copy of the grant-in-aid bill for release of **Rs.165000/-** as the **second** installment is enclosed. It is requested that the bill may be filled in and returned to the Council to enable us to release the grant.

The grant-in-aid is subject to all the conditions laid down in our letter referred above.

The expenditure on this account is debitable to the Budget Head Impress (Research Projects).

Yours faithfully,

[Signature]
(For Member Secretary)

ICSSR Project Bill


OC
26/8/2020

Copy to:

Dr.Kirti Gupta,
Professor,
Bharati Vidyapeeth,
Institute of Management & Entrepreneurship Development,
Pune-411038

[Handwritten signature]

[Signature]
(For Member Secretary)



[Handwritten signature]
OC / 30/9/2020

ICSSR, New Delhi



Indian Council of Social Science Research

(Ministry of Human Resource Development)

JNU Institutional Area, Aruna Asaf Ali Marg

New Delhi - 110067

E-mail: impress201819@gmail.com

Website: www.icssr.org

Pushkar Pathak
System Analyst
IMPRESS
Tel 011-26741459

F.No. IMPRESS/P2511 /182/2018-19/ICSSR

Dated: 26 /08 /2020

The Registrar

Institute of
Management &
Entrepreneurship
Development, Pune,
Maharashtra - 411038

Subject: Research Project entitled "**Technology Addiction among Children & Youth - A Study of Related Behavioral Impact**".

Dear Sir,

In continuation of the Council's letter of even number dated / /2019 on the above subject, I am directed to convey that ICSSR has sanctioned the Grant-in-Aid bill for the payment of **Rs165000 /-** as the **second** installment for the research project mentioned above. This brings to the total amount released so far to **Rs. 385000/-** against the total sanctioned grant of **Rs.550000/-**.

A copy of the grant-in-aid bill for release of **Rs.165000/-** as the **second** installment is enclosed. It is requested that the bill may be filled in and returned to the Council to enable us to release the grant.

The grant-in-aid is subject to all the conditions laid down in our letter referred above.

The expenditure on this account is debitable to the Budget Head Impress (Research Projects).

Yours faithfully,

(For Member Secretary)

Copy to:

Dr.Kirti Gupta,
Professor,
Bharati Vidyapeeth,
Institute of Management & Entrepreneurship Development,
Pune-411038

FA&CAO, ICSSR, New Delhi

(For Member Secretary)




ICSSR
Project File
26/8/2020


[Handwritten signature]
[Handwritten signature]
[Handwritten signature]


Project Progress Report -December 2019

- Ms. Aradhana - Joined as a research staff on 3rd December 2019.
- Carried review of literature, noting down the factors for study along with some case studies
- Field visit for a pilot survey and incorporating in questionnaire.
- Field visit to various colleges for collection of data and data entry in to online forms for the purpose of analysis.
- Field work for collection of data from parents, college students and children in school, colleges, cafes and malls.
- Reporting the Project Director about the progression of the project on daily basis.
- Daily entry of data in Google forms and designed structure of analysis from the data collected.

Date:	Field work / Data collection from
5.12.2019	SPPU, Pune
6.12.2019	Fergusson College
9.12.2019	FTII, ILS, Symbiosis
14.12.2019	Westend Mall, Aundh
18.12.2019	Felix High School
19.12.2019	Felix Jr. College
19.12.2019	Wadia College
23.12.2019	Kothrud


Mrinal Khosla
Field Investigator
(ICSSR-IMPRESS)


Aradhana Shukla
Research assistant
(ICSSR-IMPRESS)



Dr. Kirti Gupta
Project Director

To
Accounts dept
IMED.

Please draw salary sheet for research staff
as follows

December 2019

- 1) Mrinal Khosla - 29 days @ 15000 pm
- 2) Aradhana Shukla - 27 days @ 20000 pm


7/1/2020



Bharati Vidyapeeth (Deemed to be University) Pune, India.

Founder Chancellor : Dr. Patangrao Kadam

Prof. Dr. Shivajirao Kadam
M.Sc., Ph.D.
Chancellor

★ Accredited with 'A+' Grade (2017) by NAAC ★
★ Category-I University Status by UGC ★
★ NIRF Ranking - 66 ★

Prof. Dr. M. M. Salunkhe
M.Sc., Ph.D., F.R.S.C.
Vice Chancellor

"Social Transformation Through Dynamic Education"



Dr. Vishwajeet Kadam
B.Tech., M.B.A., Ph.D.
Pro Vice Chancellor

G. Jayakumar
M.Com., Dip.Pub.Admn.
Registrar

Ref : BVDU:A5:2019-20/ 3378

November 29, 2019

APPOINTMENT LETTER

Dear Madam,

With reference to your application and subsequent interview held on 25th September, 2019, I am pleased to offer you the post of Research Assistant for the ICSSR-IMPRESS Sponsored Research Project titled "Technology Addiction Among Children and Youth – A Study of Related Behavioral Impact" at the Institute of Management & Entrepreneurship Development, Pune.


1. The appointment is purely temporary for a period of six months and renewable subject to your performance till the completion of the project.
2. You will be paid a consolidated Salary of Rs. 20,000/- per month.
3. You will not be entitled for any other privileges/benefits/allowances.
4. In unforeseen circumstances, if the project is terminated or closed prematurely, your appointment will automatically be terminated.
5. You will not disclose any official information to anyone without the knowledge of the Project Director.
6. You will be working under the supervision and guidance of the Project Director.
7. You will not have claim for any permanent appointment either in Bharati Vidyapeeth or Bharati Vidyapeeth (Deemed to be University) or in any of its institution.

If you agree to the above terms and conditions of the offer, you may report for duty on or before 10th December, 2019 and submit the duplicate copy of the offer letter duly signed by you as a token of acceptance alongwith the joining report.

Yours sincerely,
G. Jayakumar
(G. Jayakumar)
Registrar

To,

Ms. Aradhana Shukla,
Flat No. 16, 'B' Wing,
Moti Villa,
Sanewadi, Aundh,
Pune 411 007



Copy to

1. The Director, BVDU IMED, Pune
2. Dr. Kirti Gupta, Project Director, BVDU IMED, Pune
3. The Accounts & Finance Officer, BVDU, Pune

ICSSR
IMPRESS

Project Ric.
Dr. Kirti Gupta Madam

jj/ar/databack18.8.2014/1/ar/18/2019

Date: 15.11.2019

Report of Duties carried out by Research Staff under ICSSR-IMPRESS Project

Name : Ms. Hema Manisha D'Silva


Project : ICSSR-IMPRESS , P2511

Project Director : Prof. Dr. Kirti Gupta


Designation: Research Assistant

The following is the details of the work carried out by Ms. Hema Manisha during the month of October till date

- Joined as a research assistant on 1st of October 2019
- Assisted in carrying out the review of literature, planning of different aspects of the project like listing the equipments, study materials etc. required for the research study
- Work related to opening a bank account, and collecting quotations for equipments
- Commenced the field work for in the month of October



Dr. Kirti Gupta
Project Director, IMED



RIC
SRS
15/11/19

Dr. Jaydeep
Dr. Swapan
[Handwritten signature]

Bharati Vidyapeeth (Deemed To Be University), Pune
Institute of Management & Entrepreneurship Development, Pune

BVU/IMED/655/2019-20

Date-12/11/2019

ICSSR - IMPRESS PFMS Scheme


Registration Mandate Form

PFMS Unique ID	BVU
Name of the institution	Bharati Vidyapeeth University
Address	Bharati Vidyapeeth Bhavan, L.B.S. Road, Pune - 411030
State	Maharashtra.
District	Pune
Pin code	411 030
Contact Person	Registrar, Bharati Vidyapeeth University
Designation	Registrar
Phone No. (with STD Code)	020 - 24325701
Mobile No.	9850392324
Email Address	bvdufinance@gmail.com
Name of Bank	Bank of Maharashtra
Account No.	60344375755
Branch Details	Paud Phata
Agency Name in Bank	Institute of Management & Entrepreneurship Development, Pune

Dated: 12/11/2019.

Signature: _____

(of Authorized person with seal)



DIRECTOR
Bharati Vidyapeeth
Deemed to be University Pune India
Institute of Management and
Entrepreneurship Development
Pune - 411 038



ICSSR-IMPRESS PFMS Scheme

Registration Mandate Form

PFMS Unique ID	BVU
Name of the Institution	Bharati Vidyapeeth University
Address	Bharati Vidyapeeth Bhavan L.B.S Road, Pune - 411 030.
State	Maharashtra.
District	PUNE
Pin code	411 030.
Contact Person	Registrar, Bharati Vidyapeeth University
Designation	Registrar.
Phone No (with STD Code)	020 - 24325701
Mobile No.	9850392324
Email Address	bvdufinance@gmail.com
Name of Bank	Bank of Maharashtra
Account No.	60344375755
Branch Details	Paud Phata
Agency Name in Bank	Institute of Management & Entrepreneurship Development, Pune.

Dated: 12/11/2019.

[Handwritten initials]



[Handwritten signature]
Signature: _____

(of Authorized person with seal)

DIRECTOR
Bharati Vidyapeeth
Deemed to be University Pune India
Institute of Management and
Entrepreneurship Development
Pune - 411 038

Digital Literacy Workshop Result

Financial Assistance For Digital literacy Workshop- 2019-20 Division - Mumbai (Dist - Mumbai)			
Sr. No.	Name	Title	Remark
1	The Board of Education Society Kandivali, Mumbai	Digital And Media Literacy.	Selected. Same organisation is applied twice should conduct together.
2	Akar Samajik Sanstha, Malad (West), Mumbai - 400095.	Workshop on Digital Literacy to the Slum, Minority Women in Malwani, Mumbai.	Selectd (Malvani Malad)
3	MES'S Pillai College of Education & Research,Chembur,Mumbai - 400071.	Accelerate Digital Literacy Using Mobile Internet.	Selected-
4	Mauli Aadhar Mahila Udyog Sanstha,Mumbai - 400051.	Digital Literacy Program foe Women.	Selected
5	Adhunik Stree Vikas Pratisthan,Mumbai - 83.	Digital Literacy to the Slum,Minority women in Vikroli.	Selected(Vikroli Slum)
6	Berojgar Swarup Seva Sahakari Sanstha,Mumbai.	Introducing Govt.Apps And Social Media.	Selected-
7	Ujjwala Audyogik Utpadak Sahakari Sanstha,Mumbai.	Mobile Literacy.	Rejected- Similar as proposal which Is selected Title Should Focus on Digital Literacy, All The Topics Should be Covered In One training Not In Separate
8	Berojgar Akshada Seva Sahakari Sanstha,Mumbai.	E - Marketing.	Rejected- Similar as proposal which Is selected Title Should Focus on Digital Literacy, All The Topics Should be Covered In One training Not In Separate

11	Rupshri Mahila Vikas Sanstha Dist. Pune	Digital Literacy Workshop For Women.	Selected(Junner)
12	Gajba Research And Training Institute Pvt Ltd Dist. Pune	Digital Literacy Workshop For Women. And Awareness Program On Helth And Mental Issue in Working Women In field Of I.T.	Rejected- Objective are not Specified no as per the Noms/ Incomplite Proposal
13	Om Gramanye Institute For Educational Excellence Dist. Pune	Digital Literacy Awareness of Women Workshop.	Rejected- Not Satisfactory Proposal, Incomplite Proposal
14	All India Institute Of Local Slf Government, Dist. Pune	Special Traing On Awareness About Helth And Hygiene For Prerikas- Adolescent Girls In Ashram School	Rejected- Objective Not AS Per Scheme, Proposal On Helth.
15	Malganga Andha Apanga Seva Sanstha Dist. Pune	Legala Awareness Camp For Women	Rejected- Objective Not AS Per Scheme, Proposal On legal Awareness
16	Yash Education Society Dist. Pune	Digital Literacy Workshop For Women	Selected(Purandar)
17	Janhvi Foundation Dist. Pune	Digital Literacy Workshop For Women	Selected(Pune Rural,Urban)
18	Human Resources Development Organization Dist. Pune	Women Health Program, Education Mahila, Beffedgut Sadifery Paid C Maintain H B % Blood	Rejected- Objective Not AS Per Scheme, Proposal On Women Helth.
19	Stree Adhar Kendra (SAK) Dist. Pune	Digital Literacy Workshop For Women	Selected(Take at Thane & Pune)
20	Institute Of Management & Entrepreneurship Development IMED ,Dist. Pune	Digital Literacy Workshop For Women	Selected
21	Oasis Foundation Dist. Pune	Digital Literacy Workshop For Women	Selected
22	Navchetana Yuva Manch Va Gramin Vikas Sanstha Dist. Pune	Digital Literacy Workshop For Women	Selected(Mulshi)
23	Sarthi Guide Foundation Dist. Pune	Digital Literacy Workshop For Women	Selected(Pune Rural)
24	Dr. D. Y. Patil Arts, Commerce & Science College, Dist. Pune	Digital Literacy Workshop For Women	Rejected
25	Dr. D. Y. Patil Acs College Dist. Pune	Digital Literacy Workshop For Women	Rejected- Similar Collage is Giving Same Proposal For Same Area.
26	Shri Maulikrupa Dnyanadan Annadan Sanstha	Legala Awareness Camp For Women	Rejected- Objective Not AS Per Scheme, Proposal On legal Awareness
27	Agriculture Development Trust Dist. Pune	Digital Literacy Workshop For Women	Selected(Baramati or Dound)



Bharati Vidyapeeth

(Deemed to be University) Pune, India.

Founder Chancellor : Dr. Patangrao Kadam

★ Accredited with 'A+' Grade (2017) by NAAC ★ Category - I University Status by UGC ★

INSTITUTE OF MANAGEMENT AND ENTREPRENEURSHIP DEVELOPMENT

★ Ranked 55th among top 75 B-Schools in India by NIRF, MHRD, Govt. of India

Erandawane, Paud Road, PUNE : 411038 Maharashtra, INDIA

"Social Transformation Through Dynamic Education"

Chancellor
Prof. Dr. Shivajirao Kadam
M.Sc., Ph.D.

Vice-Chancellor
Prof. Dr. Manikrao Salunkhe
M.Sc., Ph.D., F.R.S.C.

Pro-Vice Chancellor
Dr. Vishwajeet Kadam
B.E.(Comp.), M.B.A., Ph.D

Dean & Director
Prof. Dr. Sachin Vernekar
MBA., LL.B.(Gen.), Ph.D., FIMA, FICA


BVDU / IMED / 578 / 2019

Date : 25-9-2019

Letter of Authority

This is to certify that Dr. Kirti Gupta is working as a FULL TIME PROFESSOR in this institute. We hereby authorize her to conduct the formalities for the Seminar/Workshop grant on the behalf of the institute.




Dr. Sachin S. Vernekar

Dean - FMS & Director -IMED

DIRECTOR
Bharati Vidyapeeth
Deemed to be University Pune India
Institute of Management and
Entrepreneurship Development
Pune - 411 038



भारती सहकारी बँक लिमिटेड, पुणे
BHARATI SAHAKARI BANK LIMITED, PUNE
 (Multi-State Scheduled Bank)

ERANDWANE KOTHRUD: S.No.94, Plot No.4,
 Shiv Sagar Co-Op Housing Society Ltd. Right Bhusari Colony
 IFS Code: SVCB0010020

"Valid for 3 months from the date of issue"

D	D	M	M	Y	Y	Y	Y		

29 Aug 15 12:39:33 PM
 ARJUN 201104
 DDIP - CTS 2010

Pay

or-Bearer

Rupees रुपये

अदा करें।



Savings at Par A/c. No.: 202003130000042

For INSTITUTE OF MANAGEMENT (I M E D)

Authorized Sign

Payable at all our CBS Branches

Please sign above

⑈ 1 2 1 7 1 5 ⑈ 4 1 1 3 5 5 0 0 7 ⑈ 0 0 0 0 4 2 ⑈ 3 1

Receipt

Received with thanks from **Maharashtra State Commission for Women, Mumbai** the sum of
Rs. 27,500 (Rs. Twenty Seven Thousand Five Hundred only)
by Cheque No. _____ Dtd. _____ in payment for
Research/conference which Financial Assistance Granted.

Rs.: 27,500/-

Date: 26/9/15.



PROFESSOR
Bharat V. [Signature] th University
Institute of Management and
Entrepreneurship Development
Pune-411 038.

Name of Acceptance: DR. KIRTI GUPTA

Contact/Mobile No.: 9860442165

Address: IMED, ERANDWANE EDUCATIONAL COMPLEX
PAUD ROAD, PUNE-38.

Stamp of the N.G.O./Institute/Collage



Account

Revathy Vishwanath
Deputy Director
RP Division Incharge
Tel #011-26716690
E-mail: impress201819@gmail.com

Indian Council of Social Science Research
(Ministry of Human Resource Development)
JNU Institutional Area, Aruna Asaf Ali Marg
New Delhi – 110067
Website: www.icssr.org

SANCTION ORDER

F.No. IMPRESS/P2511/182/2018-19/ICSSR

Dated: 20-03-2019


**The Director,
Bharati Vidyapeeth,
Institute of Management & Entrepreneurship Development,
Pune – 411038**

Subject: Sanction of Impactful Policy Research in Social Science (IMPRESS) Research Project entitled "**Technology Addiction among Children & Youth - A Study of Related Behavioral Impact**" under domain Social Media and Technology to Dr. Kirti Gupta

Dear Sir,

1. The Indian Council of Social Science Research (ICSSR) considered the above Impactful Policy Research in Social Science (IMPRESS) research project submitted by Dr. Kirti Gupta, Professor, Institute of Management & Entrepreneurship Development, Bharati Vidyapeeth (Deemed to be University), Pune – 411038. Co-Project Directors of the study are: NIL.
2. The study, as proposed by the researcher, is to be located at and financially administered by your institution as per the guidelines of this award.
3. The ICSSR has sanctioned a grant-in-aid of Rs. **5,50,000/-** (Rupees Five lakhs Fifty Thousand only) for the above research project and the grant will be released as follows:

First instalment	:Rs. 2,20,000/-
Second instalment	:Rs. 1,65,000/-
Third instalment	:Rs. 1,10,000/-
Fourth Instalment	:Rs. 27,500/-
Publication cost*	:Rs. 27,500/-
<u>Total</u>	<u>:Rs. 5,50,000/-</u>
Overhead charges over and above 5% or maximum Rs.1,00,000	: Rs. 27,500/-**



* ICSSR would publish it subject to recommendation by the expert and relevant Committees for the purpose, from the overall budget, so to be retained by the ICSSR .
**will be released on successful completion of project after evaluation.

(The breakup budget approved by the ICSSR of Rs.5,50,000/- is enclosed.)

4. The First installment of the approved grant-in-aid will be released after receiving the grant-in-aid bill duly filled in, stamped and signed by the Project Director as well as the affiliating organization. (GIB already received).
5. In case, the study involves survey research, the finalized schedules/questionnaires (2 copies) designed to elicit information should be sent to the ICSSR as per the following schedule:
 - a) If the schedule /questionnaire for eliciting information is as per standard questionnaire, these will have to be sent to ICSSR immediately,


*Account
MHRD
ICSSR
Kirti Gupta*

3/5/19

Revathy

16. The Project Director will ensure that the expenditure incurred by him conforms to the approved budget heads. The grant-in-aid is subject to all the conditions laid down in the IMPRESS (Impactful Policy Research in Social Science) Research Projects available in the IMPRESS website www.impress-icssr.res.in
17. The expenditure on this account is debatable to the Budget Head-IMPRESS (Scheme Code 3615); OH 31.01 Research Projects.
18. The bank details in respect of the affiliating institution with regard to the Project Director is:
Bank Name: Bharati Sahakari Bank Limited, Erandwane, Kothrud, Pune, Beneficiary Name: Bharati Vidyapeeth (deemed to be University), Pune, India . Account No.: 202003130000042
IFSC Code: SVCB0010020
19. As per MHRD instruction, the amount of grant sanctioned herein is to be utilized by the end of the project duration. Any amount of the grant remaining unspent shall be refunded to the ICSSR immediately after the expiry of the duration of the project. If the grantee fails to utilize the grant for the purpose for which the same has been sanctioned/or fails to submit the audited statement of expenditure within the stipulated period, the grantee will be required to refund the amount of the grant with interest thereon @ 10% per annum.

Yours faithfully,



(Revathy Vishwanath)
For MEMBER-SECRETARY

Encl: as above.

Copy to:

1. Dr. Kirti Gupta
Professor,
Bharati Vidyapeeth,
Institute of Management & Entrepreneurship Development,
Pune - 411038
2. Finance Branch, ICSSR, New Delhi
3. Record file



(Revathy Vishwanath)
For MEMBER-SECRETARY

PROJECT BUDGET

Title **Technology Addiction among Children & Youth - A Study of Related Behavioral Impact**

By: Dr. Kirti Gupta

S.No	Expenditure Head	Percentage Allocation to Total Budget of the Study	Actual Value as per the Study (In Rs.)
1	Research Staff Full time/Part-time/Hired Services	Not exceeding 45% of the total budget.	2,47,500
2	Fieldwork Travel/Logistics/Boarding, etc. Including Books/Journals	Not exceeding 35%	1,92,500
3	Equipment and Study Material Computer, printer etc. Source Material/Software and Data Sets, etc.	Not exceeding 10%	55,000
4	Contingency	Not exceeding 5%	27,500
5	Publication of Report*	5%	27,500
6	Total	100%	5,50,000
	Overhead Charges(over and above the total cost of the project)	5% or maximum Rs.1,00,000/- whichever is less	27,500


*The five percent (5%) publication amount will be kept by the ICSSR for publication of the final report based on the recommendations of the Expert Committee constituted by the ICSSR.

➤ **Remuneration and Emoluments of Project Staff**

a) Project staff could be engaged by the Project Director on a full/ part-time basis during the research work and the duration/consolidated monthly emoluments of their employment may be decided by the project director within the limits of the sanctioned financial allocation and as per the ICSSR rules. b) Research Associate @Rs.25, 000/- p.m. (Qualification – Post graduate in any social science discipline with minimum 55% marks and NET/SLET /M.Phil/Ph.D) c) Research Assistant @Rs.20, 000/- p.m. (Qualification-Ph.D./M.Phil./ Post graduate in social science discipline with minimum 55% marks d) Field Investigator @ Rs.15, 000/-p.m. (not exceeding 6 months) (Qualification-M.A with minimum 55% marks). e) Retrospective payment for work already done is not permissible

➤ **Re-appropriation:** The Project Investigator may with the permission of the Institution may re-appropriate expenditure from one sub-head to another (except publication of report) subject to a maximum of 10 % of the head which is being increased. If the study necessitates re-appropriation of beyond 10%, it may be done only after the approval of the ICSSR➤ **Selection of Research Staff** should be done through an advertisement and a selection committee consisting of (1) Project Director; (2) One outside Expert (other than the institute where the project is located); (3) a nominee of the Vice Chancellor/Head of the Institution and (4) Head of the Department)/Dean of relevant faculty duly approved by the competent authority.➤ **For all field work related expenses** of Project Director, Co-Director and project personnel, rules pertaining to affiliating institutes shall be followed.➤ **All equipment and books** purchased out of the project fund shall be the property of the affiliating institutions. On completion of the study, the Project Director shall submit an undertaking in this regard. The ICSSR, however, reserves the right to take charge of equipment and books, if it thinks it fit in a case.

➤ Purchase of equipment/ assets for the research Project is permissible only if it is originally proposed and approved by the ICSSR and does not exceed the permissible amount.



IMPACTFUL POLICY RESEARCH IN SOCIAL SCIENCE

Proposal Details

Proposal Reference Number : P2511

Proposal Status : Applied

Domain : Social Media and Technology

Sub Domain : Social Media, Networks and Society

Project Title : Technology Addiction among Children & Youth - A Study of Related Behavioral Impact

Project Summary : Children and youth today have become far more dependent upon connectivity for studying, playing, communicating, and socializing etc. Smart phones, smart TVs. Video games are just a few of the many gadgets that have mesmerized people. Access to technology is available in various forms - right from parents' smart phone, to laptops, PCs, tablets, ipad, consoles and so on. This technology many a times becomes an addiction to the children giving rise to multiple problems and challenges. Already countries like the US and China are worried about the problem of Internet Addiction and are on a lookout for solutions. India is not far behind. Mobile-de-addiction centers will be a common thing in India in times to come. This project is focused upon exploring the different dimensions of technology addiction among children and youth and the behavioral impact it has on their social, professional, personal, group and ethical spaces.

Duration of Project
in Months : 18

Proposal Budget : 5,50,000.0

Introduction of the
proposed study :

It is often said that "Use Social Media not to Impress but to create an impact". People today have become far more dependent upon connectivity for studying, playing, communicating, and socializing. A survey in the US has found that a person, on an average, clicks 2657 times in a day on his cell phone! "Internet addiction" refers to excessive and compulsive technology-related behaviors resulting in negative outcomes. On one hand the advent of internet, internet of things, smart phones, cloud etc have changed the way industries function, but on the other hand, it is proving to be a hindrance for the normal growth of individuals and leading people to swim more in the cyber space and interact less and less in the physical space and surroundings. Technology has fuelled the innovations in the way people communicate and this has been possible through the Social Media. Social media like facebook, Whataspp, Pinterest, Linkedin and the like along with games that can be played on the go, by

Major existing research works reviewed :

International :

Cash et al. (2012) have studied the problematic computer use which is under debate globally. They have identified the complications, disturbances and the problems posed by the addiction to computer. Researchers have termed it as Internet Addiction Disorder(IAD) and studies based on definition, classification have been carried out. A survey in the US has found that a person, on an average, clicks 2657 times in a day on his cell phone! Weinstein et. Al. (2010) studied incidence of addiction of internet use and found very low (0.8%), while prevalence rates as high as 18% have been reported in the UK Beard(2005). A recent review of more than 103 studies of the phenomenon found that over 12% of male students and 5% of female students in China showed signs of Internet addiction. O'Brian(2010) in a study on Taiwanese university women, found that students who scored high on a test of mobile phone addiction showed more social extraversion and anxiety, and somewhat lower self-esteem. Teen technology addiction is also studied by researchers and the threats associated with it are found to be very dangerous. Zach and Christy(2014) explored role of self esteem in the problematic use of social networking. Goldberg(1995), O'Reily(1996) and Young(1996) were among the first few researchers who studied the phenomenon of internet addiction while Goldberg coined the term Internet Addiction Disorder(IAD). Atwood et al(2017) thoroughly explored the relationship between adolescents" use of

National :

On the national front, review of literature suggests that: □
 Very few studies have actually being conducted on the Internet addiction or misgivings of social media in the Indian context. □
 Most studies also focus on the psychological aspects and relevant topics. Deogade et al(2018) conducted a cross sectional study to determine the associations between adverse health effects and unhealthy behaviors with social networking usage among dental students. They found evidence of problems such as avoiding answer calls, isolation from family members and society, headache, pain, and eye irritation. Sachdeva(2015) studied the impact of playing games and mobile access. Raina and Malgorzata(2018) studied the preoccupation of children with mobile phones leading to lack of human interactions and absence of emotions in individuals. With the rise in the young population in 2020, this issue will help to come up with some concrete suggestions that will guide the policy makers.

Identification of Research gap :

The review of literature reveals that - Some studies have been conducted on internet addiction and disorders among children during the nineties, but they were mostly out of India - In Indian context, a study of students in dental discipline has been conducted but this is a very limited sample. - Most of the studies are on the psychology discipline - Every researcher has concluded with the fact that internet or technology addiction is looming problem, and a matter of concern Research Gaps: - Research on the Indian population are few - Extensive studies covering the different stakeholders like parents, organizations, doctors, schools etc have not been undertaken so far. - There are few studies which aim at suggesting to the policy makers, the different steps needed to be taken. The objectives of the study are: •To assess the different forms of technology addiction in children and youth •To study the extent of technology addiction among children and youth.

Framework and methods proposed for research :

The following framework is suggested: Phase I : Extensive review of literature and problem formulation Phase II: Formalizing the research design Phase III: Collection of Data and analysis Phase IV: Report writing Research Design: Exploratory and Descriptive Sampling design: Sampling technique : Non-probability Judgment Sampling Sample size : The different units in the sample will be represented in the following manner (approximately) Children 500, Youth 500, Parents 200, Teachers / Professors-50, Principals -15, Doctors 40, Employers / HR Heads 20, Data Collection techniques: Interviews, Semi Structured questionnaires, Observation Interaction meetings with parents, teachers, principals, professors, doctors, organization officials, and youth populations will be conducted to get a deeper insight into the topic of study

Innovativeness in the proposed research :

This study will be a blend of technological, management, social dimensions and aims to be holistic in nature so as to uncover the dimensions of technology addiction This will be helpful for society and have implications at all levels of the economy

Expected Outputs such as papers, report, book, document, dataset:

It is expected that this study will actually be able to bring out the extent and nature of damage being done by the addiction to technology in youth. There is sufficient scope for consultancy to parents, schools and organizations based upon the results of the study which will be beneficial for the betterment of mankind and society

Relevance of the proposed study for policy-making :

It will help to draft policy for - organizations - to avoid loss of productive hours - schools and parents - to avoid child getting addicted to technology - society - on the impact of technology and ways of harnessing technology and social media for betterment of society - individuals - to understand the ill effects of misuse of technology. There is sufficient scope for consultancy to parents, schools and organizations based upon the results of the study which will be beneficial for the betterment of mankind and society

Relevance of the proposed study for society :

This topic is very much relevant in the current scenario when the youth are addicted to the technology in its various forms and it is affecting the society and individuals alike. This area needs to be carefully studied and remedial measures explored so as to be well armed for tackling the issue. The study will be significant for the development and contribution to the betterment of society today.

Proposal Budget :

Heads of Expenditure	Number	Months	Rate/Month	Amount
1. Research Staff				4,00,000.0
(a) Research Associate	1	8	20000	1,60,000.0
(b) Research Assistant	2	6	15000	1,80,000.0

BHARATI VIDYAPEETH (DEEMED TO BE UNIVERSITY), PUNE
Institute of Management & Entrepreneurship Development, Pune

BV/IMED/442/2019-20

9th August 2019

To,
The Registrar,
Bharati Vidyapeeth (Deemed To Be University), Pune

Subject: Opening of Bank Account for research grant from ICSSR

Dear Sir,

1. One of our faculty Dr. Kirti Gupta has been awarded research project grants of Rs. 5,50,000 from the ICSSR, New Delhi. In this connection it is required to open a separate bank account for management of the funds to be received from ICSSR. We request you to kindly permit us to open a bank account in the Bank having the following details :


Name of the account - BVDU-IMED (ICSSR-0877)

Operated by : 1) Registrar, BVDU, Pune **OR** Dr. Sachin S. Vernekar, Director –
→ IMED and Dr. Kirti Gupta, Professor, IMED

2. The draft for advertisement for the staff for project is enclosed herewith, which may be released from STEPS communication with minimum budget in a local newspaper.

Thanking You,

Yours Sincerely


Dr. Sachin S. Vernekar.
Dean-FMS & Director IMED

c.c: Shri Vasant Rao Mane, Head, Record Section, BVDU, Pune
Encl: Letter from ICSSR

BHARATI VIDYAPEETH (DEEMED TO BE UNIVERSITY), PUNE

Advertisement for the post of Research Associate/Research Assistant/ Field Investigator

Applications are invited from the meritorious and interested candidates for the position of Research Staff (Research Associate / Research Assistant / Field Investigator) on purely temporary basis for the Indian Council of Social Science Research (ICSSR) funded IMPRESS (Impactful Policy Research in Social Science) Project.

Project: "Technology Addiction Among Children and Youth – A Study of Related Behavioral Impact."

Project Director (PD) – Dr. Kirti Gupta, Professor – IMED, Pune

Qualifications and Remuneration of Staff: As per ICSSR Rules

Sr No.	Research Staff	Remuneration (Consolidated)	Qualification	Tenure
1.	Research Associate	Rs. 25,000/- p.m.	Post graduate in any Social Science discipline/ Statistics / Management with minimum 55% marks. and NET/SLET/M. Phil. /Ph. D.	Six months
2.	Research Assistant	Rs. 20,000/- p.m.	Ph.D./ M.Phil / Post graduate in any Social Science discipline/ Statistics with minimum 55% marks.	Nine months
3	Field Investigator	Rs. 15,000/- p.m.	Masters Degree in Social Sciences with minimum 55% marks.	Six months

Interested candidates may apply for the position by sending their detailed curriculum vitae through e-mail (with the specified subject "**Research Associate / Research Assistant / Field Investigator Position**") to Dr. Kirti Gupta at kirti_gupta2004@yahoo.co.in or by post to Dr. Kirti Gupta, Professor, Institute of Management & Entrepreneurship Development, Erandwane Campus, Pune 411038. (Maharashtra) by 16th August 2019. Candidates will be shortlisted initially based on qualification and work experience, and only the shortlisted candidates will be called for interview.

The position is purely temporary and co-terminus with the ICSSR project. **No TA or DA will be paid for the shortlisted candidates for attending the interview.**

Registrar

Bharati Vidyapeeth (Deemed To Be University), Pune



Phone : 011-26131577 - 78, 80
011-29581000
Website : www.aicte-india.org



अखिल भारतीय तकनीकी शिक्षा परिषद्
(भारत सरकार का एक सांविधिक निकाय)
(मानव संसाधन विकास मंत्रालय, भारत सरकार)
नेल्सन मंडेला मार्ग, वसंत कुंज, नई दिल्ली-110070

ALL INDIA COUNCIL FOR TECHNICAL EDUCATION
(A Statutory Body of the Govt. of India)
(Ministry of Human Resource Development, Govt. of India)
Nelson Mandela Marg, Vasant Kunj, New Delhi-110070

Prof. Dileep N. Malkhede
Advisor (RIFD)

F.No. 67-25/RIFD/GOC/POLICY-1/2017-18
Dated: 02.07.2019

To,

The Principal/Director/Registrar
Institute of Management and Entrepreneursip
Development-MCA Programme, Bharati Vidyapeeth
Educational Complex, Paud Road, Erandawane,
Maharashtra-411038


Sub: Clarification regarding utilization of released fund under Grant for Organizing Conference (GOC) scheme -2017-18 reg.

Sir/Madam,

With reference to the grant sanctioned to your institute to conduct the conference vide this office sanction order of even No. 67-25/RIFD/GOC/POLICY-1/2017-18 dated- 25.02.2019, it is further informed that following may be complied with to conduct the conference.

1. No payment is permissible against the conference already conducted, if any, in anticipation of the grant that was expected from AICTE. Institutions are liable to refund the grant if received after the conduct of conference and have no plan of conducting conference.
2. Six months additional time period is accorded in addition to the stipulated time period of six months to conduct the conference as mentioned in the sanction letter. In other words, conference can be organized within 12 months of receipt of sanction letter or receipt of money from AICTE whichever is later.
3. The financial assistance from AICTE may be considered as Rs. 5 Lakhs or 1/3rd of total expenditure incurred for organizing the Conference, whichever is lesser.
4. It is reiterated that, if the institution is not in a position to conduct the conference for any reason, the sanctioned/released fund may be refunded to the council **within thirty days of receipt of this letter.**


The above conditions may be strictly complied with.

Yours Sincerely

(Dileep N. Malkhede)

Copy forwarded for information and necessary action to:-

Dr. Baljeet Kaur
(Co-ordinator)

Institute of Management and Entrepreneursip
Development-MCA Programme, Bharati Vidyapeeth
Educational Complex, Paud Road, Erandawane,
Maharashtra-411038






Phone : 011-26131577 - 78, 80
011-29581000
Website : www.aicte-india.org



सत्यमेव जयते



अखिल भारतीय तकनीकी शिक्षा परिषद्

(भारत सरकार का एक सांविधिक निकाय)

(मानव संसाधन विकास मंत्रालय, भारत सरकार)
नेल्सन मंडेला मार्ग, वसंत कुंज, नई दिल्ली-110070

ALL INDIA COUNCIL FOR TECHNICAL EDUCATION

(A Statutory Body of the Govt. of India)

(Ministry of Human Resource Development, Govt. of India)
Nelson Mandela Marg, Vasant Kunj, New Delhi-110070

Prof. Dileep N. Malkhede
Advisor (RIFD)

F. No. 67-25/RIFD/GOC/POL-1/2017-18

Dated: 03.09.2019

To,

The Principal

Institute of Management and Entrepreneurship
Development-MCA Programme, Bharati Vidyapeeth
Educational Complex, Paud Road, Erandawane,
Maharashtra-411038

Sub: - Approval of proposed date/coordinator/title of Conference.

Ref: - Your letter No. BVDU/IMED/380/2019-20 dated-25.07.2019.

Sir/Madam,

With reference to your letter under reference, it is to inform with a pleasure that the approval is accorded to conduct the "National Conference on Emerging Trends, Challenges and Opportunities in Data Mining And Information Security NTCOMIS-2019" on 17th & 18th January, 2020 as requested by your institute.

It is pertinent to mention, that the grant from AICTE may be considered as "Rs. 5 Lakhs or 1/3rd of total expenditure incurred for organizing the Conference, whichever is less". It may be noted that, the utilization of the "grant for conference" will be audited by AICTE on total expenses incurred on organizing conference and not only the share of AICTE grant. You are, therefore, requested to submit to AICTE the total account of expenses incurred on organizing the conference within 7 days after the conference is held.

Further, we anticipate the event of high standards.

Yours sincerely

(Dileep N. Malkhede)

Copy forwarded for information and necessary action to:-

1. **Dr. Baljit Kaur**

(Co-ordinator)

Institute of Management and Entrepreneurship
Development-MCA Programme, Bharati Vidyapeeth
Educational Complex, Paud Road, Erandawane,
Maharashtra-411038

Received mail


from AICTE abt. We
are working on it.

dit



सूचना का
अधिकार

Handwritten notes in red ink:
In case of any
issue
contact
Principal
or
Coordinator





Phone : 011-26131577 - 78, 80
011-29581000
Website : www.aicte-india.org



सत्यमेव जयते

अखिल भारतीय तकनीकी शिक्षा परिषद्

(भारत सरकार का एक सांविधिक निकाय)
(मानव संसाधन विकास मंत्रालय, भारत सरकार)
नेल्सन मंडेला मार्ग, वसंत कुंज, नई दिल्ली-110070

ALL INDIA COUNCIL FOR TECHNICAL EDUCATION

(A Statutory Body of the Govt. of India)
(Ministry of Human Resource Development, Govt. of India)
Nelson Mandela Marg, Vasant Kunj, New Delhi-110070

Dr. Uma Raghunathan
Director (RIFD)

F. No.67-25/RIFD/GOC/Policy-1/2017-18
Dated-22.04.2019

To

The Principal,
Institute of Management and Entrepreneursip
Development-MCA Programme, Bharati Vidyapeeth
Educational Complex, Paud Road, Erandawane,
Maharashtra-411038

Sub: Submission of undertaking -reg.

Sir/Madam,

Consequent upon recommendation of your proposal of 2017-18 a sum of Rs. 5,00,000/- (Rupees Five lakhs only) has been sanctioned and released to your institute to organize the proposed conference.


In this regard, you are to submit within fifteen days of receipt of this letter an undertaking regarding the acceptance of Terms and Conditions laid in the Sanction Order apprising the proposed date/title of the conference.

Further, the conference should be organized within six months of receipt of the sanction order, failing which institute would be liable to refund the released fund along with interest accrued thereon.

Once the Conference is conducted the institute has to submit an Utilization certificate of complete fund [i.e (5)+ (5)+(5) lacs (as given in guideline of the scheme)] to the Council.

Yours Sincerely

(Uma Raghunathan)
22/4/19



All India Council for Technical Education

(A Statutory body under Ministry of HRD, Govt. of India)

Nelson Mandela Marg, Vasant Kunj, New Delhi-110070 Website: www.aicte-india.org



GOC - Sanction Letter

To
The Drawing and Disbursing Officer
All India Council for Technical Education
Nelson Mandela Marg, Vasant Kunj,
New Delhi-110070

Sub: Release of a sum of Rs. 500000/- for conduct of Conference (GOC).-reg.

Sir,

This is to convey the sanction of the Council for payment of Rs. 500000/- (Rupees Five Lakh only) for conduct of Conference on National Conference on Emerging Trends, Challenges and Opportunities In Data Mining And Information Security NTCOMIS-2018 to INSTITUTE OF MANAGEMENT AND ENTREPRENEURSHIP DEVELOPMENT - MCA PROGRAMME, BHARATI VIDYAPEETH EDUCATIONAL COMPLEX, PAUD ROAD, ERANDAWANE, PUNE PIN NO. - 411038 Maharashtra, under the scheme of **GRANT FOR ORGANIZING CONFERENCE (GOC)**.

1. The amount of the Grant shall be drawn by the Drawing and Disbursing Officer, All India Council for Technical Education on the grant-in-aid bill and shall be disbursed to and credited to the Registrar/Director/Principal of the institute through RTGS.
2. This grant-in-aid is being released in conformity with the terms & conditions as well as norms of the scheme as already communicated and also being communicated in this letter.
3. The sanctioned amount is debitible to the Major Head 601.8 (a) Gen. of the Scheme of Grant for Organizing Conference (GOC) and is valid for payment during the financial year 2018-19.

The instructions/guidelines to be followed by University/Institution

I. Release of funds and maintenance of accounts

- a. The Principal of the institute and the Coordinator of the program are requested to verify the correctness of the under mentioned bank account/ RTGS details submitted by them along with the Proposal, in which the grant is being released :-


Institute PAN No.	Bank Name	Bank Branch Name	Bank Branch Address	Account Holder Name	Account Type	Account Number	IFSC Code
AAATB1 836D	BHARATIS AHAKARI BANK LTD. PUNE	ERANDAWANE , KOTHRUD	SHOP NO- 1,2,3,4, SURVEY NO- 94, SHIVSAGAR HOUSING SOCIETY LTD. KOTHRUD PUNE	DIRECTOR /REGISTRAR	Saving Account	20200313000 0042	SVCB00 10020

In case of any omission the same should be reported to AICTE immediately.

withdrawn.

- f. The assets acquired wholly or substantially of the All India Council for Technical Education's grants shall not be disposed or encumbered or utilized for the purposes other than those for which it was given without proper sanction of the Council and should, at any time the Institution ceased to function, such assets shall revert to the All India Council for Technical Education.
- g. Title of event - National Conference on Emerging Trends, Challenges and Opportunities In Data Mining And Information Security NTCOMIS-2018
- h. Date of Event - 04-05-2018
- i. **GOI GFR rules** (@<https://doe.gov.in/order-circular/general-financial-rules2017-0>) should be followed during utilization of grant.
- j. This Sanction Order may be treated as Offer Letter for all purposes.

Yours sincerely,


Dileep N. Malkhede
Advisor (RIFD)
28/2/19

Copy forwarded for information and necessary action to: -

1. Name and Address of the Coordinator

Dr. BALJEET KAUR
INSTITUTE OF MANAGEMENT AND ENTREPRENEURSHIP DEVELOPMENT - MCA PROGRAMME
BHARATI VIDYAPEETH EDUCATIONAL COMPLEX,
PAUD ROAD,
ERANDAWANE, PUNE
PUNE - 411038

2. The Registrar / Director / Principal

✓ Dr. Ajit More
INSTITUTE OF MANAGEMENT AND ENTREPRENEURSHIP DEVELOPMENT - MCA PROGRAMME
BHARATI VIDYAPEETH EDUCATIONAL COMPLEX,
PAUD ROAD,
ERANDAWANE, PUNE
PUNE - 411038

3. Guard File

Grant for Organizing Conference (GOC)

Utilization Certificate

for the financial year : _____

Name of Institute: _____

Name of the Scheme under which Grant was sanction: _____

AICTE Sanction Order No. & Date under which Grant was sanctioned	Amount Sanction (Rs.)	CERTIFICATE
	Rs. _____ Rs. _____ (for Non-recurring) Rs. _____ (for Recurring)	Certified that out of the grant-in-aid of Rs. _____ (in words) sanctioned by the AICTE during the Financial Year _____ as per letter mentioned in the margin, Rs. _____ on account of unspent balance of previous year + Rs. _____ on account of Interest, a sum of Rs. _____ has been utilized for the purpose for which it was sanctioned, and the balance of Rs. _____ remained unutilized at the end of the year _____.

Certified that I have satisfied myself that the conditions on which the grant-in-aid was sanctioned have been duly fulfilled and that I have exercised the following checks to see that the money was actually utilized for the purpose for which it was sanctioned.

Kinds of checks exercised:

1. Audited Annual Accounts of the Institute
2. Receipt & Payment Account of the Institute
3. Periodical Progress Report of the Institute

[Signature of Chartered Accountant

Name of CA : _____

Membership No. : _____

Full Address : _____

[with seal]

(mandatory for self financing institutes)

[Signature of Head of the Institute]

Name : _____

Designation : _____

Full Address : _____

[with seal]

[Signature of the Finance Officer]

Name : _____

Designation : _____

Full Address : _____

[with seal]

(Govt./Govt.Aided/University & whatever applicable)

Place : _____

Date : _____

STATEMENT OF EXPENDITURE

AICTE File No. :

Title of the Conference :

Name of the Co-ordinator :

Sanction Order No. & Date	Grant Sanctioned	Details of expenditure Incurred Item wise		No.of Participants	Exact Date(s) of event
			Rs.		
		Total Expenditure			
		Grant Received			
		Balance is to be Received			

(1) _____
Signature of Co-ordinator
with Seal

(2) _____
Name and Signature of
Head of Institution with Seal

(3) _____
Signature (with Seal) of the Finance Officer/
Auditor/Accounts Officer
(If it is Govt./Govt. Aided Institute)

(4) _____
Signature of Chartered Accountant:
Name of Chartered Accountant:
Membership No:
Rubber stamp:
Full Address of CA :

Date:

Note:-If it is more than one page, each page must be signed & Stamped in all annexure

FEED BACK FORM

SCHEME – Grant for organizing Conference (GOC)

1. AICTE's Offer Letter No. & Date
2. Name of the Convener / Coordinator
3. Name and Address of the Institution
4. Details of events.
5. Dates of event from _____ to _____
6. Venue
7. Total no. of participants.
8. Total amount sanctioned : Rs.

9.

AICTE's Sanction Order No.	Date	Grant Released

07. Total expenditure incurred in conducting the scheme.
08. Grant received from various agencies other than AICTE for the scheme.

Sl. No.	Name of Agency	Grant Received
	Total	

Contd.....2/-

All India Council for Technical Education

(A Statutory body under Ministry of HRD, Govt. of India)

Nelson Mandela Marg, Vasant Kunj, New Delhi-110070 Website: www.aicte-india.org



GOC - Sanction Letter

To

The Drawing and Disbursing Officer
All India Council for Technical Education
Nelson Mandela Marg, Vasant Kunj,
New Delhi-110070

Sub: Release of a sum of Rs. 500000/- for conduct of Conference (GOC).-reg.

Sir,

This is to convey the sanction of the Council for payment of Rs. 500000/- (Rupees Five Lakh only) for conduct of Conference on National Conference on Emerging Trends, Challenges and Opportunities In Data Mining And Information Security NTCOMIS-2018 to INSTITUTE OF MANAGEMENT AND ENTREPRENEURSHIP DEVELOPMENT - MCA PROGRAMME, BHARATI VIDYAPEETH EDUCATIONAL COMPLEX, PAUD ROAD, ERANDAWANE, PUNE PIN NO. - 411038 Maharashtra, under the scheme of **GRANT FOR ORGANIZING CONFERENCE (GOC)**.

1. The amount of the Grant shall be drawn by the Drawing and Disbursing Officer, All India Council for Technical Education on the grant-in-aid bill and shall be disbursed to and credited to the Registrar/Director/Principal of the institute through RTGS.
2. This grant-in-aid is being released in conformity with the terms & conditions as well as norms of the scheme as already communicated and also being communicated in this letter.
3. The sanctioned amount is debitible to the Major Head 601.8 (a) Gen. of the Scheme of Grant for Organizing Conference (GOC) and is valid for payment during the financial year 2018-19.

The instructions/guidelines to be followed by University/Institution

I. Release of funds and maintenance of accounts

- a. The Principal of the institute and the Coordinator of the program are requested to verify the correctness of the under mentioned bank account/ RTGS details submitted by them along with the Proposal, in which the grant is being released :-


Institute PAN No.	Bank Name	Bank Branch Name	Bank Branch Address	Account Holder Name	Account Type	Account Number	IFSC Code
AAATB1 836D	BHARATIS AHAKARI BANK LTD. PUNE	ERANDAWANE , KOTHRUD	SHOP NO- 1,2,3,4, SURVEY NO- 94, SHIVSAGAR HOUSING SOCIETY LTD. KOTHRUD PUNE	DIRECTOR /REGISTRAR	Saving Account	20200313000 0042	SVCB00 10020

In case of any omission the same should be reported to AICTE immediately.

withdrawn.

- f. The assets acquired wholly or substantially of the All India Council for Technical Education's grants shall not be disposed or encumbered or utilized for the purposes other than those for which it was given without proper sanction of the Council and should, at any time the Institution ceased to function, such assets shall revert to the All India Council for Technical Education.
- g. Title of event - National Conference on Emerging Trends, Challenges and Opportunities In Data Mining And Information Security NTCOMIS-2018
- h. Date of Event - 04-05-2018
- i. **GOI GFR rules** (@<https://doe.gov.in/order-circular/general-financial-rules2017-0>) should be followed during utilization of grant.
- j. This Sanction Order may be treated as Offer Letter for all purposes.

Yours sincerely,


Dileep N. Malkhede
Advisor (RIFD)
28/2/19

Copy forwarded for information and necessary action to: -

1. **Name and Address of the Coordinator**

✓
Dr. BALJEET KAUR
INSTITUTE OF MANAGEMENT AND ENTREPRENEURSHIP DEVELOPMENT - MCA PROGRAMME
BHARATI VIDYAPEETH EDUCATIONAL COMPLEX,
PAUD ROAD,
ERANDAWANE, PUNE
PUNE - 411038

2. **The Registrar / Director / Principal**

Dr. Ajit More
INSTITUTE OF MANAGEMENT AND ENTREPRENEURSHIP DEVELOPMENT - MCA PROGRAMME
BHARATI VIDYAPEETH EDUCATIONAL COMPLEX,
PAUD ROAD,
ERANDAWANE, PUNE
PUNE - 411038

3. **Guard File**



Phone : 011-26131577 - 78, 80
011-29581000

Website : www.aicte-india.org



सत्यमेव जयते

अखिल भारतीय तकनीकी शिक्षा परिषद्
(भारत सरकार का एक सांविधिक निकाय)
(मानव संसाधन विकास मंत्रालय, भारत सरकार)
नेल्सन मंडेला मार्ग, वसंत कुंज, नई दिल्ली-110070

ALL INDIA COUNCIL FOR TECHNICAL EDUCATION
(A Statutory Body of the Govt. of India)
(Ministry of Human Resource Development, Govt. of India)
Nelson Mandela Marg, Vasant Kunj, New Delhi-110070

Prof. Dileep N. Malkhede
Advisor (RIFD)

F.No. 67-25/RIFD/GOC/POLICY-1/2017-18
Dated: 02.07.2019

To,

The Principal/Director/Registrar
Institute of Management and Entrepreneursip
Development-MCA Programme, Bharati Vidyapeeth
Educational Complex, Paud Road, Erandawane,
Maharashtra-411038

Sub: Clarification regarding utilization of released fund under Grant for Organizing Conference (GOC) scheme -2017-18 reg.

Sir/Madam,

With reference to the grant sanctioned to your institute to conduct the conference vide this office sanction order of even No. 67-25/RIFD/GOC/POLICY-1/2017-18 dated- 25.02.2019, it is further informed that following may be complied with to conduct the conference.

1. No payment is permissible against the conference already conducted, if any, in anticipation of the grant that was expected from AICTE. Institutions are liable to refund the grant if received after the conduct of conference and have no plan of conducting conference.
2. Six months additional time period is accorded in addition to the stipulated time period of six months to conduct the conference as mentioned in the sanction letter. In other words, conference can be organized within 12 months of receipt of sanction letter or receipt of money from AICTE whichever is later.
3. The financial assistance from AICTE may be considered as Rs. 5 Lakhs or 1/3rd of total expenditure incurred for organizing the Conference, whichever is lesser.
4. It is reiterated that, if, the institution is not in a position to conduct the conference for any reason, the sanctioned/released fund may be refunded to the council **within thirty days of receipt of this letter.**


✓ The above conditions may be strictly complied with.

Yours Sincerely

(Dileep N. Malkhede)

Copy forwarded for information and necessary action to:-

Dr. Baljeet Kaur
(Co-ordinator)
Institute of Management and Entrepreneursip
Development-MCA Programme, Bharati Vidyapeeth
Educational Complex, Paud Road, Erandawane,
Maharashtra-411038



1.BVDU IMED,PUNE-MBA (2021-22)
ERANDWANE PUNE

IMPRESS GRANTS (KIRTI GUPTA)

Ledger Account

1-Apr-2019 to 8-Sep-2021

Page 1

Date	Particulars	Vch Type	Vch No.	Debit	Credit
29-11-2019	Cr CASH <i>NEW ACCOUNT OPEN FOR ICSE</i>	Payment	462	1,500.00	
	Dr Bank of Maharashtra Ac No-60344375755	Receipt	451		2,20,000.00
	Cash 29-11-2019 2,20,000.00 Dr <i>BEING GRANT RECVD</i>				
31-3-2020	Dr Bank of Maharashtra Ac No-60344375755	Receipt	572		2,00,000.00
	Cheque/DD 31-3-2020 2,00,000.00 Dr <i>BEING GRANT RECVD</i>				
	Cr (as per details)	Journal	68	2,02,121.00	
	EQUIPMENT & STUDY MATERAIL (IMPRESS) 29,900.00 Cr				
	FIELDWORK (IMPRESS GRANT) 31,057.00 Cr				
	RESEARCH STAFF(IMPRESS) 1,41,164.00 Cr				
	<i>IMPRESS GRANTS- KIRTI GUPTA UTILIZED, DURING THE YEAR 2019-20</i>				
	Dr Bank of Maharashtra Ac No-60344375755	Receipt	577		1,500.00
	Cheque 31-3-2020 1,500.00 Dr <i>being account opening balnce transfer</i>				
	Cr Closing Balance			2,03,621.00	4,21,500.00
				2,17,879.00	
				4,21,500.00	4,21,500.00
1-4-2020	Dr Opening Balance				2,17,879.00
31-3-2021	Dr Bank of Maharashtra Ac No-60344375755	Receipt	933		1,65,000.00
	Cheque/DD 31-3-2021 1,65,000.00 Dr <i>BEING AMOUNT RECIEVED GRANT</i>				
	Dr Bank of Maharashtra Ac No-60344375755	Receipt	934		2,00,000.00
	Cheque/DD 31-3-2021 2,00,000.00 Dr				
	Cr Bank of Maharashtra Ac No-60344375755	Payment	472	4,00,000.00	
	<i>two time amount return asper bank statement 09/07/2020 & 13/07 /2020</i>				
	Cr (as per details)	Journal	48	1,74,073.00	
	CONTINGENCY (IMPRESS) 17,830.00 Cr				
	FIELDWORK (IMPRESS GRANT) 8,177.00 Cr				
	RESEARCH STAFF(IMPRESS) 1,08,066.00 Cr				
	EQUIPMENT & STUDY MATERAIL (IMPRESS) 40,000.00 Cr				
	<i>Impress Grants- Dr Kirti Gupta Utilized for Recurring & Non -Recurring Expenditure, during the year 2020-21</i>				
	Carried Over			5,74,073.00	5,82,879.00

continued ...

1.BVDU IMED,PUNE-MBA (2021-22)

IMPRESS GRANTS (KIRTI GUPTA)

Ledger Account : 1-Apr-2019 to 8-Sep-2021

Page 2

Date	Particulars	Vch Type	Vch No.	Debit	Credit
	Brought Forward			5,74,073.00	5,82,879.00
				<hr/>	<hr/>
				5,74,073.00	5,82,879.00
Cr	Closing Balance			8,806.00	
				<hr/>	<hr/>
				5,82,879.00	5,82,879.00

No. BT/PR30540/BIC/101/1090/2018
GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY

Block 2, (6-8th Floors)
CGO Complex, Lodhi Road,
New Delhi- 110 003
Date: 30-06-2021

RELEASE ORDER

In continuation of this Department's sanction order of even number dated 30-08-2019, sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rule, 1978, for the release of Rs. **1518262.00** (Rupees Fifteen Lakhs Eighteen Thousand Two Hundred and Sixty-Two Only) being the second year release for the project entitled "**Platelet derived exosomes and their role in endothelial dysfunction in dengue infection**", being implemented by:


Dr. Shubham Shrivastava, Interactive Research School for Health Affairs,, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be) University, Pune-Satara Road, Dhankawadi, Katraj, Pune 411043, Pune - 411043, Maharashtra

The detailed break-up is as given below:

SN	Institute Name	Recurring						Total Release Amount (Rs)
		Manpower	Consumable	Travel	Contingency	Others	Overhead	
1	Interactive Research School for Health Affairs, Pune	529113.00	800321.00	50000.00	48778.00	0.00	90050.00	1518262.00
The interest earned of 17,469/- in 2019-20 and Rs. 2309/- in 2020-21; and unspent balance under NT head, Rs. 1056/- has been deposited to Bharatkosh. Carry forward of Rs. 56,933/- from FY 2020-21 to FY 2021-22 permitted.								

2. The amount of Rs. **1518262.00** /-(Rupees **Fifteen Lakhs Eighteen Thousand Two Hundred and Sixty-Two Only**) will be directly credited by the Pay & Accounts Officer, DBT in the account as detailed below:

The The Director, Interactive Research School for Health Affairs,, Satara Road, Katraj- Dhankawadi, Pune, Pune - 411043, Maharashtra


डॉ. अभिशेक कुमार मेहता / Dr. Abhishek Kumar Mehta
वैज्ञानिक 'सी' / Scientist 'C'
बायोटेक्नोलॉजी विभाग / Department of Biotechnology
विज्ञान और प्रौद्योगिकी मंत्रालय
Ministry of Science & Technology
भारत सरकार / Govt. of India
सी.जी.ओ. कॉम्प्लेक्स, लोधी रोड, नई दिल्ली-110003
C.G.O. Complex, Lodhi Road, New Delhi-110003

Bank Name : State Bank of India
Branch Name : Katraj
A/c No. : 30808434608
IFSC Code : SBIN0008752
MICR Code : 411002018

3. The expenditure involved is debit to:

Demand No. 89	Department of Biotechnology
3425	Other Scientific Research 2021-2022
3425.60	Others (Sub Major Head)
3425.60.200	Assistance to other Scientific Bodies (Minor Head)
3425.60.200.29	Biotechnology Research and Development
3425.60.200.29.17	Assistance to Research and Development
3425.60.200.29.17.31	Grants -in-Aid General

- The Director, Interactive Research School for Health Affairs,, Pune, Maharashtra will submit audited utilization certificates and statements of expenditure in respect of the above-mentioned amount.
- As per Rule 236 (1) of GFR 2017, the accounts of all Grantee Institutions or Organisations shall be open to inspection by the sanctioning authority and audit, both by the Comptroller and Auditor General of India under the provision of CAG(DPC) Act 1971 and internal audit by the Principal Accounts Office of the Ministry or Department, whenever the Institution or Organisation is called upon to do so.
- No International Travel will be undertaken from the sanctioned project grant unless specified otherwise.
- The Institute/Agency will keep the whole of the grant in a Bank Account earning interest, and the interest so earned should be reported to DBT in the Utilisation Certificate and Statement of Expenditure. The Interest so earned shall be remitted to Consolidated Fund of India (Bharatkosh) at end of each financial year.
- The other terms and conditions governing the financial sanction will remain unaltered.
- The utilization certificate for the financial year **2020-21** is enclosed herewith.
- This issues under the powers delegated to this Department and with the concurrence of IFD, DBT, vide their SAN No. **352/2021-22** dated **30-06-2021**.
- This sanction order has been noted at serial no.11 (2021-22) in the Register of Grants.

To,

(Dr. Abhishek Kumar Mehta)

Scientist - C
डॉ. अभिषेक कुमार मेहता / Dr. Abhishek Kumar Mehta
वैज्ञानिक 'सी' / Scientist 'C'
बायोटेक्नोलॉजी विभाग / Department of Biotechnology
विज्ञान और प्रौद्योगिकी मंत्रालय
Ministry of Science & Technology
भारत सरकार / Govt. of India
सी.जी.ओ. कॉम्प्लेक्स, लोधी रोड, नई दिल्ली-110003
C.G.O. Complex, Lodhi Road, New Delhi-110003

The Pay & Accounts Officer,
Department of Biotechnology,
New Delhi – 110 003.

Copy to:

- 1 The Principal Director of Audit (Scientific Departments), DACR Building, New Delhi- 110 002.
- 2 Dr. Shubham Shrivastava(Project Co-ordinator), Pune-Satara road, Dhankawadi Katraj, Pune 411043
- 3 The The Director, Interactive Research School for Health Affairs,, Satara Road, Katraj- Dhankawadi, Pune, Pune - 411043, Maharashtra
- 4 Dr. Deepak Govind Bhosle, Professor, Medicine, Bharati Vidyapeeth University Medical College, Pune, pune-satara road Katraj, Pune - 411043, Maharashtra
- 5 Dr. Shubham Shrivastava, PI, Communicable Diseases, Interactive Research School for Health Affairs,, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be) University, Pune-Satara Road, Dhankawadi, Katraj, Pune 411043, Pune - 411043, Maharashtra
- 6 Cash Section, DBT (2 copies).
- 7 Sanction Folder.
- 8 File Copy.



(Dr. Abhishek Kumar Mehta)
Scientist-C

डॉ. अभिषेक कुमार मेहता / Dr. Abhishek Kumar Mehta
वैज्ञानिक 'सी' / Scientist 'C'
बायोटेक्नोलॉजी विभाग / Department of Biotechnology
विज्ञान और प्रौद्योगिकी मंत्रालय
Ministry of Science & Technology
भारत सरकार / Govt. of India
सी.जी.ओ. कॉम्प्लेक्स, लोधी रोड, नई दिल्ली-110003
C.G.O. Complex, Lodhi Road, New Delhi-110003